alendronate has been researched along with Bone Loss, Perimenopausal in 1002 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this randomized, controlled trial, sequential therapy with once-weekly subcutaneous injection of teriparatide for 72 weeks, followed by alendronate for 48 weeks resulted in a significantly lower incidence of morphometric vertebral fracture than monotherapy with alendronate for 120 weeks in women with osteoporosis at high risk of fracture." | 9.69 | Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05. ( Hagino, H; Mitomo, Y; Mori, S; Nakamura, T; Soen, S; Sone, T; Sugimoto, T; Takahashi, K; Tanaka, S, 2023) |
| "The efficacy of generic teriparatide in improving BMD at lumbar spine in patients with osteoporosis was similar to that of alendronate." | 9.51 | Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study. ( Chao, A; Cheng, Q; Dong, J; Gao, X; Hu, J; Jin, X; Li, M; Li, P; Li, Q; Lin, H; Shen, L; Shi, R; Tang, H; Xia, W; Xiong, X; Xue, Q; You, L; Yu, W; Zhang, Y; Zhang, Z; Zheng, S, 2022) |
| "This systematic review and meta-analysis aimed to reveal the efficacy and safety of zoledronic acid compared with alendronate in patients with primary osteoporosis." | 9.41 | Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis. ( Ai, W; Wang, Q; Yu, Q; Zeng, P, 2023) |
| "In this randomized, controlled trial, treatment with once-weekly subcutaneous injection of teriparatide for 72 weeks was found to be associated with a significant reduction in the incidence of morphometric vertebral fractures compared with alendronate in women with primary osteoporosis who were at high risk of fracture." | 9.41 | A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. ( Hagino, H; Mori, S; Nakamura, T; Sasaki, K; Soen, S; Sone, T; Sugimoto, T; Tanaka, S, 2021) |
| "A total of 140 postmenopausal women or men aged older than 50 years who met the indications for osteoporosis treatment were randomized to receive either generic (Bonmax®) or brand alendronate (Fosamax®) 70 mg/week over a 12-month period during the May 2014 to June 2015 study period." | 9.24 | Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment. ( Jarusriwanna, A; Songcharoen, P; Unnanuntana, A, 2017) |
| " The aim of this study was to perform a meta-analysis of the effects of alendronate combined with atorvastatin compared with alendronate alone in the treatment of osteoporosis in diabetes mellitus." | 9.22 | Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus. ( Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C, 2022) |
| "To evaluate and compare the efficacy of alendronate sodium (ALN) and raloxifene (RLX) for the management of primary hyperparathyroidism (PHPT) in postmenopausal female patients (pts) with osteoporosis." | 9.17 | Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism. ( Akbaba, G; Ates Tutuncu, Y; Berker, D; Guler, S; Isik, S; Ozuguz, U, 2013) |
| "The effects of teriparatide versus alendronate were compared by gender and menopausal status in patients with glucocorticoid-induced osteoporosis." | 9.14 | Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. ( Dobnig, H; Krohn, K; Langdahl, BL; Maricic, M; Marin, F; See, K; Shane, E; Warner, MR; Zanchetta, JR, 2009) |
| "The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy." | 9.12 | Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. ( Hiligsmann, M; Maggi, S; Reginster, JY; Sartori, L; Veronese, N, 2021) |
| "In osteoporosis patients who avoided sunlight and vitamin D supplements, this once-weekly tablet containing alendronate and cholecalciferol provided equivalent antiresorptive efficacy, reduced the risk of low serum 25OHD, improved vitamin D status over 15 weeks, and was not associated with hypercalcemia, hypercalciuria or other adverse findings, versus alendronate alone." | 9.12 | Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. ( Benhamou, L; Delmas, PD; Emkey, R; Felsenberg, D; Hawkins, F; He, W; Lippuner, K; Lips, P; Recker, R; Rosen, C; Salzmann, G; Santora, AC, 2006) |
| "To determine whether secondary hyperparathyroidism (HPTH) due to hypovitaminosis D affects bone mineral density (BMD) response to alendronate (ALN) in elderly women with osteoporosis." | 9.12 | Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. ( Barone, A; Bianchi, G; Girasole, G; Giusti, A; Palummeri, E; Pioli, G; Pizzonia, M; Razzano, M, 2007) |
| "The purpose of this study was to investigate the effect of alendronate on metacarpal and lumbar bone mineral density (BMD), bone resorption, and chronic back pain in postmenopausal women with osteoporosis." | 9.11 | Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2004) |
| "The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids." | 9.11 | The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. ( Alatas, O; Armagan, O; Colak, O; Oner, C; Tascioglu, F, 2005) |
| "Exercise may enhance the effect of alendronate on bone mineral density (BMD) and reduce chronic back pain in elderly women with osteoporosis." | 9.11 | Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate. ( Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2005) |
| " The study enrolled 450 postmenopausal women and men with osteoporosis (224 took alendronate, 226 took placebo) who were ambulatory and community dwelling at 48 outpatient study centers in the United States." | 9.10 | Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. ( de Papp, AE; Field-Munves, E; Greenspan, S; Palmisano, J; Petruschke, R; Smith, M; Tonino, R; Wang, L; Yates, J, 2002) |
| "Alendronate effectively increases bone mass and has greater antiresorptive power than etidronate in patients with primary biliary cirrhosis, and is associated with minor or no side effects." | 9.10 | Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. ( Alvarez, L; Caballería, L; Guañabens, N; Martínez de Osaba, MJ; Monegal, A; Parés, A; Peris, P; Pons, F; Roca, M; Rodés, J; Ros, I, 2003) |
| "To determine the effect of alendronate therapy on days affected by back pain in postmenopausal women with existing vertebral fractures." | 9.09 | Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. ( Black, DM; Cummings, SR; Ensrud, K; Nevitt, MC; Rubin, SR; Thompson, DE; Yates, AJ, 2000) |
| "Alendronate has been reported to increase bone mineral density (BMD) and reduce fracture risk in women with osteoporosis." | 9.09 | Effects of alendronate on bone density in men with primary and secondary osteoporosis. ( Frauman, AG; Ho, YV; Seeman, E; Thomson, W, 2000) |
| " Here we describe a case with macular edema, which is the first reported case observed after long-term alendronate tolerance." | 8.93 | Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report. ( Liu, L; Lu, Q; Ma, C; Tian, Y; Wang, R; Yin, F, 2016) |
| "The purpose of this paper is to discuss the effects of antifracture drugs on postmenopausal, male and glucocorticoid-induced osteoporosis, focussing on the efficacy and safety of alendronate and risedronate." | 8.84 | Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate. ( Iwamoto, J; Sato, Y; Takeda, T, 2007) |
| "In osteoporosis, both the bisphosphonate alendronate and parathyroid hormone (1-34) (PTH (1-34) ) have been shown to reduce the incidence of fractures." | 8.82 | Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis? ( Doggrell, SA, 2004) |
| "Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy." | 8.81 | Role of alendronate and risedronate in preventing and treating osteoporosis. ( Leonard, M; Licata, AA; Peters, ML, 2001) |
| "We describe three patients who had severe esophagitis shortly after starting to take alendronate and also analyze adverse esophageal effects reported to Merck, the manufacturer, through postmarketing surveillance." | 8.79 | Esophagitis associated with the use of alendronate. ( Daifotis, A; de Groen, PC; Freedholm, D; Hirsch, LJ; Lubbe, DF; Pinkas, H; Pryor-Tillotson, S; Seleznick, MJ; Stephenson, W; Wang, KK, 1996) |
| "Two cases of esophagitis associated with the use of alendronate are described." | 8.79 | [Alendronate-induced esophagitis. A report of 2 cases]. ( Girelli, CM; Reguzzoni, G; Rocca, F, 1997) |
| "From January 2018 to January 2020, we recruited 165 female osteoporosis patients after percutaneous vertebroplasty who were assigned into sequential treatment of teriparatide followed by alendronate group (TPTD + ALN group) and alendronate alone group (ALN group)." | 8.31 | Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study. ( Han, W; Huang, K; Long, Y; Tan, J; Wang, M; Yang, D; Yi, W; Zeng, S; Zhu, S, 2023) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 8.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| "Both teriparatide and alendronate were used in the treatment of osteoporosis after renal transplantation." | 8.02 | Analysis of the Efficacy and Safety of Teriparatide and Alendronate in the Treatment of Osteoporosis After Renal Transplantation. ( Deng, J; Lin, C; Qiu, Z; Wu, M; Zhang, Y, 2021) |
| "After 5 years of alendronate treatment, younger postmenopausal women (ages 50-70) with osteoporosis would likely benefit from a drug holiday, whereas older women (age 80) are likely to benefit from treatment for 10 years before a drug holiday." | 7.96 | Cost-effectiveness of five versus ten years of alendronate treatment prior to drug holiday for women with osteoporosis. ( Greenspan, SL; Nayak, S, 2020) |
| "Osteoporosis adversely affects disc degeneration cascades, and prophylactic alendronate (ALN) helps delay intervertebral disc degeneration (IDD) in ovariectomized (OVX) rats." | 7.85 | Effects of alendronate on lumbar intervertebral disc degeneration with bone loss in ovariectomized rats. ( Dai, M; Li, S; Luo, Y; Shen, Y; Song, H; Wang, W; Yang, K; Zhang, L; Zhang, Y, 2017) |
| " We present a case of acute polyarthritis after administration of alendronate and risedronate in a 52-year-old woman." | 7.83 | Alendronate- and risedronate-induced acute polyarthritis. ( Uğurlar, M, 2016) |
| "To describe the distribution of serum 25-hydroxyvitamin D (25-[OH] D) in Canadian men and postmenopausal women with osteoporosis taking 400 IU or less of vitamin D daily and to evaluate the safety, tolerability, and impact of vitamin D(3) supplementation 400 IU daily taken concurrently with alendronate sodium 70 mg weekly." | 7.77 | Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis. ( Chouha, F; Djandji, M; Hanley, DA; Karaplis, AC; Sampalis, JS, 2011) |
| " Recent reports have demonstrated the association between long-term alendronate therapy with low-energy subtrochanteric fracture or diaphyseal femoral fractures in a small number of patients." | 7.76 | Bilateral atypical femoral fractures after long-term alendronate therapy: a case report. ( Bamrungsong, T; Pongchaiyakul, C, 2010) |
| "We describe 7 cases of synovitis or arthritis occurring after commencement of alendronate for treatment of osteoporosis." | 7.74 | Alendronate-induced synovitis. ( Gwynne Jones, DP; Highton, J; Savage, RL, 2008) |
| "The study was designed to evaluate the relationship of menopause, hormone replacement therapy (HRT), alendronate (ALN), and calcium supplements on salivary flow rate, saliva pH, and electrolytes." | 7.73 | The effect of menopause, hormone replacement therapy (HRT), alendronate (ALN), and calcium supplements on saliva. ( Gurgan, S; Gurgan, T; Yalçin, F, 2005) |
| "To report a case of corneal graft rejection precipitated by severe uveitis secondary to alendronate therapy and to review the literature of relevance to this case." | 7.73 | Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy. ( Richards, JC; Wiffen, SJ, 2006) |
| "Alendronate sodium, an aminobiphosphonate used primarily to treat osteoporosis in postmenopausal women, is known to cause esophagitis." | 7.70 | Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features. ( Kelsey, P; Mueller, PR; Ryan, BM; Ryan, JM, 1998) |
| " The aim of the present study was to evaluate the effects of treatment with alendronate in patients affected by hyperthyroidism and osteoporosis." | 7.69 | Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. ( Affinito, P; Arlotta, F; Cascone, E; Di Carlo, C; Lupoli, G; Nappi, C; Nuzzo, V; Vitale, G; Vollery, M, 1996) |
| "Osteoporosis resulting in bone fractures is a complication in patients with primary biliary cirrhosis (PBC)." | 6.78 | Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. ( Cerdá, D; Gifre, L; Guañabens, N; Monegal, A; Muxí, Á; Parés, A; Peris, P, 2013) |
| " To determine whether a lower dosage in oral form combined with calcitriol can effectively manage AI-induced bone loss, we performed a randomized, double-blind, prospective, placebo-controlled 24-week trial with a combination of alendronate and 0." | 6.78 | Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. ( Lim, SK; Park, BW; Park, HS; Park, S; Rhee, Y; Song, K, 2013) |
| "Treatment with alendronate, a potent and specific inhibitor of bone resorption, is known to significantly reduce fracture risk among women with postmenopausal osteoporosis." | 6.43 | Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. ( Hochberg, MC; Liberman, UA; Papapoulos, SE; Quandt, SA; Thompson, DE, 2005) |
| "Postmenopausal women compliance to alendronate therapy is suboptimal due to the complex dosing requirements." | 5.72 | Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine. ( Elaraj, J; Fatayer, D; Hamad, A; Jarar, B; Johar, A; Radwan, A; Shraim, N; Zriqah, A, 2022) |
| " The two groups were similar at baseline in underlying disease, age, duration of RA, duration of alendronate use, laboratory findings, and rheumatoid arthritis drugs." | 5.69 | Efficacy of Raloxifene as Add-on Therapy on Disease Activity of Postmenopausal Women with Rheumatoid Arthritis: A Double-blind, Randomized, Placebo-controlled Clinical Trial. ( Esmaily, H; Mehrnaz Aghili, S; Saeidi, S; Sahebari, M; Salari, M; Sarafraz Yazdi, M, 2023) |
| "In this randomized, controlled trial, sequential therapy with once-weekly subcutaneous injection of teriparatide for 72 weeks, followed by alendronate for 48 weeks resulted in a significantly lower incidence of morphometric vertebral fracture than monotherapy with alendronate for 120 weeks in women with osteoporosis at high risk of fracture." | 5.69 | Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05. ( Hagino, H; Mitomo, Y; Mori, S; Nakamura, T; Soen, S; Sone, T; Sugimoto, T; Takahashi, K; Tanaka, S, 2023) |
| "The efficacy of generic teriparatide in improving BMD at lumbar spine in patients with osteoporosis was similar to that of alendronate." | 5.51 | Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study. ( Chao, A; Cheng, Q; Dong, J; Gao, X; Hu, J; Jin, X; Li, M; Li, P; Li, Q; Lin, H; Shen, L; Shi, R; Tang, H; Xia, W; Xiong, X; Xue, Q; You, L; Yu, W; Zhang, Y; Zhang, Z; Zheng, S, 2022) |
| "This systematic review and meta-analysis aimed to reveal the efficacy and safety of zoledronic acid compared with alendronate in patients with primary osteoporosis." | 5.41 | Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis. ( Ai, W; Wang, Q; Yu, Q; Zeng, P, 2023) |
| "Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab, followed by alendronate, reduce clinical fractures in postmenopausal females with osteoporosis." | 5.41 | Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. ( Ayers, C; Fu, R; Harrod, C; Kansagara, D; Kwon, A; Lazur, B, 2023) |
| "This study evaluated the cost effectiveness of denosumab versus alendronate for secondary prevention of osteoporotic fractures among post-menopausal women in China." | 5.41 | Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis. ( Jiang, S; Jiang, Y; Li, L; Li, M; Shi, S; Si, L, 2023) |
| " The primary measures of romosozumab efficacy used in this study were vertebral, non-vertebral, and clinical fracture events, and secondary outcomes were bone mineral density (BMD) changes at the lumbar spine, total hip, and femoral neck and the incidence of adverse events (AEs), RESULTS: Nine RCTs including 12 796 participants were included in the analysis, and romosozumab was compared with placebo, alendronate, and teriparatide in the treatment of osteoporosis in postmenopausal women." | 5.41 | Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J). ( Guo, S; Huang, W; Nagao, M; Nishizaki, Y; Tanigawa, T; Yonemoto, N, 2023) |
| "To assess the effectiveness and safety of denosumab (Prolia®) compared to bisphosphonates (alendronate, ibandronate, risedronate, zoledronate), selective estrogen receptor modulators (SERMs; bazedoxifene, raloxifene) or placebo, for the treatment of osteoporosis in postmenopausal women (PMW)." | 5.41 | The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis. ( Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T, 2023) |
| "In this randomized, controlled trial, treatment with once-weekly subcutaneous injection of teriparatide for 72 weeks was found to be associated with a significant reduction in the incidence of morphometric vertebral fractures compared with alendronate in women with primary osteoporosis who were at high risk of fracture." | 5.41 | A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. ( Hagino, H; Mori, S; Nakamura, T; Sasaki, K; Soen, S; Sone, T; Sugimoto, T; Tanaka, S, 2021) |
| " Among patients with osteoporosis in Taiwan who had experienced a fracture and had started alendronate therapy, compliance with the dosage regimen was suboptimal." | 5.37 | Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. ( Lin, SJ; Lin, TC; Yang, CY; Yang, YH, 2011) |
| " The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate." | 5.34 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007) |
| "Alendronate is a bisphosphonate used in treating osteoporosis." | 5.33 | Alendronate-induced chemical laryngitis. ( Bhutta, MF; Gillett, D; Rance, M; Weighill, JS, 2005) |
| "Esophagitis is one of the adverse effects (AE) associated to its use." | 5.31 | [Esophagitis associated with use of alendronate in 5 postmenopausic patients]. ( Fay, M; Luciani, J; Naves, A; Pedrana, R; Pigatto, V; Piola, JC; Prada, DB; Silvestre Begnis, M, 2001) |
| "A total of 140 postmenopausal women or men aged older than 50 years who met the indications for osteoporosis treatment were randomized to receive either generic (Bonmax®) or brand alendronate (Fosamax®) 70 mg/week over a 12-month period during the May 2014 to June 2015 study period." | 5.24 | Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment. ( Jarusriwanna, A; Songcharoen, P; Unnanuntana, A, 2017) |
| " The aim of this study was to perform a meta-analysis of the effects of alendronate combined with atorvastatin compared with alendronate alone in the treatment of osteoporosis in diabetes mellitus." | 5.22 | Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus. ( Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C, 2022) |
| "To evaluate and compare the efficacy of alendronate sodium (ALN) and raloxifene (RLX) for the management of primary hyperparathyroidism (PHPT) in postmenopausal female patients (pts) with osteoporosis." | 5.17 | Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism. ( Akbaba, G; Ates Tutuncu, Y; Berker, D; Guler, S; Isik, S; Ozuguz, U, 2013) |
| "The aim of this study was to assess the effects of the antiresorptive treatments of alendronate (ALN), risedronate (RIS) and raloxifene (RLX) on the response of bone to endogenous parathyroid hormone (PTH) induced by acute hypocalcemia." | 5.14 | Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone. ( Stepan, JJ; Zikan, V, 2009) |
| "The effects of teriparatide versus alendronate were compared by gender and menopausal status in patients with glucocorticoid-induced osteoporosis." | 5.14 | Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. ( Dobnig, H; Krohn, K; Langdahl, BL; Maricic, M; Marin, F; See, K; Shane, E; Warner, MR; Zanchetta, JR, 2009) |
| "Postmenopausal women with breast cancer were randomly assigned to receive alendronate or placebo for 1 year within 3 months after withdrawal of tamoxifen therapy." | 5.13 | Prevention of bone loss after withdrawal of tamoxifen. ( Brown, IN; Cohen, A; Fleischer, JB; Hershman, DL; Joe, AK; Johnson, MK; McMahon, DJ; Silverberg, SJ, 2008) |
| "The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy." | 5.12 | Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. ( Hiligsmann, M; Maggi, S; Reginster, JY; Sartori, L; Veronese, N, 2021) |
| " The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD." | 5.12 | Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. ( Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K, 2006) |
| "In osteoporosis patients who avoided sunlight and vitamin D supplements, this once-weekly tablet containing alendronate and cholecalciferol provided equivalent antiresorptive efficacy, reduced the risk of low serum 25OHD, improved vitamin D status over 15 weeks, and was not associated with hypercalcemia, hypercalciuria or other adverse findings, versus alendronate alone." | 5.12 | Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. ( Benhamou, L; Delmas, PD; Emkey, R; Felsenberg, D; Hawkins, F; He, W; Lippuner, K; Lips, P; Recker, R; Rosen, C; Salzmann, G; Santora, AC, 2006) |
| "To determine whether secondary hyperparathyroidism (HPTH) due to hypovitaminosis D affects bone mineral density (BMD) response to alendronate (ALN) in elderly women with osteoporosis." | 5.12 | Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. ( Barone, A; Bianchi, G; Girasole, G; Giusti, A; Palummeri, E; Pioli, G; Pizzonia, M; Razzano, M, 2007) |
| "The purpose of this study was to investigate the effect of alendronate on metacarpal and lumbar bone mineral density (BMD), bone resorption, and chronic back pain in postmenopausal women with osteoporosis." | 5.11 | Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2004) |
| "The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids." | 5.11 | The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. ( Alatas, O; Armagan, O; Colak, O; Oner, C; Tascioglu, F, 2005) |
| "Exercise may enhance the effect of alendronate on bone mineral density (BMD) and reduce chronic back pain in elderly women with osteoporosis." | 5.11 | Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate. ( Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2005) |
| "The purpose of this open-labeled prospective study was to compare the treatment effects of cyclical etidronate and alendronate on the lumbar bone mineral density (BMD), bone resorption, and back pain in elderly women with osteoporosis." | 5.11 | Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2005) |
| " This study compared the incidence of gastric ulcers after treatment with risedronate, a pyridinyl bisphosphonate, or alendronate, a primary amino bisphosphonate, in healthy postmenopausal women stratified by Helicobacter pylori status." | 5.10 | 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. ( Blank, MA; Hunt, RH; Lanza, FL; Li, Z; Marshall, JK; Provenza, JM; Royer, MG; Thomson, AB, 2002) |
| " The study enrolled 450 postmenopausal women and men with osteoporosis (224 took alendronate, 226 took placebo) who were ambulatory and community dwelling at 48 outpatient study centers in the United States." | 5.10 | Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. ( de Papp, AE; Field-Munves, E; Greenspan, S; Palmisano, J; Petruschke, R; Smith, M; Tonino, R; Wang, L; Yates, J, 2002) |
| "The purpose of the present study was to examine the early response of lumbar bone mineral density (BMD), bone resorption, and back pain to alendronate after treatment with cyclical etidronate in postmenopausal women with osteoporosis." | 5.10 | Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis. ( Ichimura, S; Iwamoto, J; Takeda, T; Uzawa, M, 2003) |
| "Alendronate effectively increases bone mass and has greater antiresorptive power than etidronate in patients with primary biliary cirrhosis, and is associated with minor or no side effects." | 5.10 | Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. ( Alvarez, L; Caballería, L; Guañabens, N; Martínez de Osaba, MJ; Monegal, A; Parés, A; Peris, P; Pons, F; Roca, M; Rodés, J; Ros, I, 2003) |
| "To determine the effect of alendronate therapy on days affected by back pain in postmenopausal women with existing vertebral fractures." | 5.09 | Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. ( Black, DM; Cummings, SR; Ensrud, K; Nevitt, MC; Rubin, SR; Thompson, DE; Yates, AJ, 2000) |
| " We conducted a 1-year, single-center, prospective, randomized, double-blind study to determine whether bone loss would occur in the distal radius after a Colles' fracture and whether this loss could be prevented using an antiresorptive drug (alendronate)." | 5.09 | The effect of alendronate on bone mass after distal forearm fracture. ( Haarman, H; Lips, P; Patka, P; van der Poest Clement, E; Vandormael, K, 2000) |
| "Alendronate has been reported to increase bone mineral density (BMD) and reduce fracture risk in women with osteoporosis." | 5.09 | Effects of alendronate on bone density in men with primary and secondary osteoporosis. ( Frauman, AG; Ho, YV; Seeman, E; Thomson, W, 2000) |
| " This study compared the incidence of gastric ulcers after treatment with risedronate, a pyridinyl bisphosphonate, and alendronate, a primary amino bisphosphonate." | 5.09 | Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. ( Blank, MA; Hunt, RH; Lanza, FL; Provenza, JM; Thomson, AB, 2000) |
| "The present study was planned to assess the safety, tolerability and efficacy on bone mineral density (BMD), pain, quality of life and fracture risk of alendronate, calcitonin and calcium treatments." | 5.09 | Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. ( Dursun, E; Dursun, N; Yalçin, S, 2001) |
| " The pivotal phase 3 trial ACTIVE and its extension (ACTIVExtend) demonstrated the efficacy of initial treatment with ABL for 18 months followed by sequential treatment with alendronate (ALN) for an additional 24 months to reduce the risk of vertebral, nonvertebral, clinical, and major osteoporotic fractures and to increase BMD in postmenopausal women with osteoporosis." | 5.05 | Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. ( Bilezikian, JP; Bone, HG; Cosman, F; Fitzpatrick, LA; McCloskey, EV; Miller, PD; Mitlak, B, 2020) |
| " Here we describe a case with macular edema, which is the first reported case observed after long-term alendronate tolerance." | 4.93 | Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report. ( Liu, L; Lu, Q; Ma, C; Tian, Y; Wang, R; Yin, F, 2016) |
| "Alendronate is a second generation bisphosphonate which has been widely used in medical practice for two decades to treat osteoporosis and prevent fragility fractures both in elderly people and in younger patients." | 4.90 | Alendronate: new formulations of an old and effective drug to improve adherence avoiding upper gastrointestinal side effects. ( Auriemma, R; Migliore, A; Neglia, C; Piscitelli, P, 2014) |
| "The purpose of this paper is to discuss the effects of antifracture drugs on postmenopausal, male and glucocorticoid-induced osteoporosis, focussing on the efficacy and safety of alendronate and risedronate." | 4.84 | Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate. ( Iwamoto, J; Sato, Y; Takeda, T, 2007) |
| " Alendronate and risedronate are the two most widely used compounds in the treatment of postmenopausal osteoporosis." | 4.83 | Bisphosphonates. ( Botsis, D; Christodoulakos, G; Lambrinoudaki, I, 2006) |
| " We studied 1588 patients over the age of 50 yr who were started on cyclic etidronate (1119) or alendronate (469) in the CANDOO (Canadian Database for Osteoporosis and Osteopenia Patients) Study." | 4.82 | What predicts early fracture or bone loss on bisphosphonate therapy? ( Adachi, JD; Brown, JP; Goldsmith, CH; Hanley, DA; Ioannidis, G; Josse, R; Murray, T; Olszynski, WP; Papaioannou, A; Petrie, A; Sawka, AM; Sebaldt, RJ; Tenenhouse, A, 2003) |
| "In osteoporosis, both the bisphosphonate alendronate and parathyroid hormone (1-34) (PTH (1-34) ) have been shown to reduce the incidence of fractures." | 4.82 | Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis? ( Doggrell, SA, 2004) |
| "According to the data of a fracture intervention trial, in women aged 55-80 years with vertebral fractures or osteoporosis diagnosed by bone mineral density measurement, treatment with the bisphosphonate alendronate prevented hip fractures with numbers-needed-to-treat within 5 years of treatment of 46 and 66, respectively." | 4.81 | [Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures]. ( Netelenbos, JC, 2001) |
| "Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy." | 4.81 | Role of alendronate and risedronate in preventing and treating osteoporosis. ( Leonard, M; Licata, AA; Peters, ML, 2001) |
| "Our results demonstrate that alendronate reduces the risk of vertebral, non vertebral and hip fractures in postmenopausal women with low bone mass." | 4.80 | [Effect of alendronate on bone mineral density and incidence of fractures in postmenopausal women with osteoporosis. A meta-analysis of published studies]. ( Arboleya, LR; Fiter, J; Morales, A, 2000) |
| "We describe three patients who had severe esophagitis shortly after starting to take alendronate and also analyze adverse esophageal effects reported to Merck, the manufacturer, through postmarketing surveillance." | 4.79 | Esophagitis associated with the use of alendronate. ( Daifotis, A; de Groen, PC; Freedholm, D; Hirsch, LJ; Lubbe, DF; Pinkas, H; Pryor-Tillotson, S; Seleznick, MJ; Stephenson, W; Wang, KK, 1996) |
| " The parent compound, etidronate, was first used in multicentered trials for the treatment of primary osteoporosis and showed some success in increasing bone density and perhaps controlling fracture rates." | 4.79 | Bisphosphonate therapy. ( Licata, AA, 1997) |
| "Two cases of esophagitis associated with the use of alendronate are described." | 4.79 | [Alendronate-induced esophagitis. A report of 2 cases]. ( Girelli, CM; Reguzzoni, G; Rocca, F, 1997) |
| "5 μg/kg body weight/day), ovariectomized practicing moderate exercise training, ovariectomized estradiol-treated and practiced a moderate exercise training, and ovariectomized alendronate-treated (OVX + Alen) (OVX + Alen rats were treated orally with alendronate 3 mg/kg body weight/week) groups." | 4.31 | The potential anti-osteoporotic effect of exercise-induced increased preptin level in ovariectomized rats. ( Abdelfattah Abulfadle, K; Mohammed, NA; Osama Mohammed, H; Refaat Abdelkader Atia, R; Saad Ramadan, R, 2023) |
| "From January 2018 to January 2020, we recruited 165 female osteoporosis patients after percutaneous vertebroplasty who were assigned into sequential treatment of teriparatide followed by alendronate group (TPTD + ALN group) and alendronate alone group (ALN group)." | 4.31 | Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study. ( Han, W; Huang, K; Long, Y; Tan, J; Wang, M; Yang, D; Yi, W; Zeng, S; Zhu, S, 2023) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 4.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| "Abaloparatide (ABL) significantly increases bone mineral density in men with osteoporosis similar to what was reported in postmenopausal women with osteoporosis." | 4.31 | Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States. ( Caminis, J; Hiligsmann, M; Mathew, J; Pearman, L; Reginster, JY; Silverman, SS; Singer, AJ; Wang, Y, 2023) |
| " This retrospective study assessed the comparability of postmenopausal women, treated with osteoporosis medications with various mechanisms of action such as denosumab (receptor activator of nuclear factor κB ligand [RANKL] inhibitor), zoledronic acid (bisphosphonate derivative), or oral bisphosphonates including alendronate." | 4.31 | Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States. ( Arora, T; Balasubramanian, A; Bradbury, BD; Curtis, JR; Kim, M; Lin, TC; O'Kelly, J; Spangler, L; Stad, RK; Zhao, H, 2023) |
| "To evaluate the cost-effectiveness of four anti-osteoporosis medications (denosumab, zoledronate, teriparatide, and alendronate) for postmenopausal osteoporotic women in mainland China, using a stratified treatment strategy recommended by the American Association of Clinical Endocrinologists and the American College of Endocrinology (AACE/ACE)." | 4.31 | Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis. ( Li, YF; Luo, C; Qu, XL; Sheng, ZF; Tian, L; Wang, QY; Xu, LL; Yang, YY; Yue, C, 2023) |
| "Bisphosphonate medications, including alendronate, ibandronate and risedronate administered orally and zoledronate, administered intravenously, are commonly prescribed for the treatment of osteoporosis based on evidence that, correctly taken, bisphosphonates can improve bone strength and lead to a reduction in the risk of fragility fractures." | 4.31 | Clinicians' views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study. ( Bastounis, A; Bishop, S; Corp, N; Gittoes, N; Griffin, J; Langley, T; Leonardi-Bee, J; Narayanasamy, MJ; Paskins, Z; Sahota, O, 2023) |
| "This work aimed to examine the risk of community-acquired pneumonia in individuals receiving denosumab compared to those receiving alendronate." | 4.12 | Denosumab and Risk of Community-acquired Pneumonia: A Population-based Cohort Study. ( Lei, G; Li, H; Li, J; Li, X; Lyu, H; Wang, Y; Wei, J; Xie, D; Zeng, C; Zhao, S, 2022) |
| "Both teriparatide and alendronate were used in the treatment of osteoporosis after renal transplantation." | 4.02 | Analysis of the Efficacy and Safety of Teriparatide and Alendronate in the Treatment of Osteoporosis After Renal Transplantation. ( Deng, J; Lin, C; Qiu, Z; Wu, M; Zhang, Y, 2021) |
| " This health economic analysis indicates that sequential romosozumab-to-alendronate can be a cost-effective treatment option for postmenopausal women with severe osteoporosis at high risk of fracture." | 4.02 | Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. ( Åkesson, KE; Berling, P; Borgström, F; Kanis, JA; Lindberg, I; Lorentzon, M; Söreskog, E; Ström, O; Willems, D, 2021) |
| "We believe that the continuous use of alendronate and risedronate for 10 years could be an option for the treatment of postmenopausal osteoporosis patients." | 3.96 | Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients. ( Iba, K; Sonoda, T; Takada, J; Yamashita, T, 2020) |
| "After 5 years of alendronate treatment, younger postmenopausal women (ages 50-70) with osteoporosis would likely benefit from a drug holiday, whereas older women (age 80) are likely to benefit from treatment for 10 years before a drug holiday." | 3.96 | Cost-effectiveness of five versus ten years of alendronate treatment prior to drug holiday for women with osteoporosis. ( Greenspan, SL; Nayak, S, 2020) |
| "Osteoporosis adversely affects disc degeneration cascades, and prophylactic alendronate (ALN) helps delay intervertebral disc degeneration (IDD) in ovariectomized (OVX) rats." | 3.85 | Effects of alendronate on lumbar intervertebral disc degeneration with bone loss in ovariectomized rats. ( Dai, M; Li, S; Luo, Y; Shen, Y; Song, H; Wang, W; Yang, K; Zhang, L; Zhang, Y, 2017) |
| "Retrospective single-center cohort study of osteoporosis patients treated with alendronate or risedronate for at least 2 years and then discontinued their bisphosphonate for a drug holiday." | 3.83 | Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. ( Adams-Huet, B; Maalouf, NM; Poindexter, JR; Xu, LH, 2016) |
| " Assuming a willingness to pay (WTP) of €32,000 per quality-adjusted life years (QALYs), treatment with generic alendronate is cost effective for men and women aged 50 years or more, with 10-year probabilities for major osteoporotic fractures and hip above 8." | 3.83 | Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal. ( Borgström, F; da Silva, JA; Kanis, JA; Lourenço, Ó; Marques, A; Ortsäter, G, 2016) |
| " We present a case of acute polyarthritis after administration of alendronate and risedronate in a 52-year-old woman." | 3.83 | Alendronate- and risedronate-induced acute polyarthritis. ( Uğurlar, M, 2016) |
| "Compared with use of alendronate/risedronate, use of strontium was not associated with significantly increased risk of acute coronary syndrome (rate per 1000 person-years 5." | 3.80 | Use of strontium ranelate and risk of acute coronary syndrome: cohort study. ( Hviid, A; Pasternak, B; Svanström, H, 2014) |
| "The aims of this study were to assess changes in muscle mass and strength according to changes in bone mineral density (BMD) after alendronate-calcitriol therapy and to assess subsequent changes in common biomarkers for osteoporosis and sarcopenia to establish a common strategy against these coexisting conditions." | 3.79 | Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women. ( Cho, S; Choi, YS; Lee, BS; Park, HS; Park, JH; Park, KH; Seo, SK, 2013) |
| "Patients treated with alendronate and raloxifene had similar adjusted fracture rates in up to 8 years of adherent treatment, and raloxifene patients had lower breast cancer rates." | 3.79 | Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. ( Burge, R; Chu, BC; Curkendall, S; Diakun, DR; Foster, SA; Krege, JH; Shi, N; Stock, J, 2013) |
| " The population was predominantly composed of women aged 60-69 years old, who had started treatment in 2000, resident in the Southeast of Brazil, who had previously suffered osteoporotic fractures, and Alendronate sodium was the drug most commonly used at baseline." | 3.79 | [Public spending on drugs for the treatment of osteoporosis in post-menopause]. ( Acurcio, Fde A; Andrade, EI; Brandão, CM; Cherchiglia, ML; Ferré, F; Guerra, AA; Machado, GP, 2013) |
| "We aimed to evaluate the clinical efficacy of monotherapy with alendronate and combined therapy with alendronate and menatetrenone (vitamin K2 [VitK2]) in postmenopausal rheumatoid arthritis (RA) patients with osteoporosis or osteopenia." | 3.79 | Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK₂) in postmenopausal RA patients. ( Fukushima, Y; Hamada, M; Nakase, T; Suzuki, K; Tomita, T; Tsuji, S; Yoshikawa, H, 2013) |
| "To describe the distribution of serum 25-hydroxyvitamin D (25-[OH] D) in Canadian men and postmenopausal women with osteoporosis taking 400 IU or less of vitamin D daily and to evaluate the safety, tolerability, and impact of vitamin D(3) supplementation 400 IU daily taken concurrently with alendronate sodium 70 mg weekly." | 3.77 | Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis. ( Chouha, F; Djandji, M; Hanley, DA; Karaplis, AC; Sampalis, JS, 2011) |
| " Recent reports have demonstrated the association between long-term alendronate therapy with low-energy subtrochanteric fracture or diaphyseal femoral fractures in a small number of patients." | 3.76 | Bilateral atypical femoral fractures after long-term alendronate therapy: a case report. ( Bamrungsong, T; Pongchaiyakul, C, 2010) |
| " The aim of this study was to evaluate the effect of antibone resorptive agents, in particular alendronate (ALN) on BMD in postmenopausal osteoporotic women with thyroid carcinoma who were receiving long-term thyrotropin (TSH)-suppressive therapy with thyroxine." | 3.75 | Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate. ( Assante, R; Fonderico, F; Lupoli, G; Lupoli, GA; Marciello, F; Martinelli, A; Panico, A, 2009) |
| "We studied 26,636 new users of an osteoporosis medication (alendronate, calcitonin, estrogen, raloxifene, or risedronate) who were age 65 or older and had an extended lapse in refill compliance, defined as a period of at least 60 days after the completion of one prescription in which no refill for any osteoporosis medication was obtained." | 3.74 | Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. ( Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH, 2007) |
| "A simulation model adopting a health system perspective showed population-based screening with DXA, followed by alendronate treatment of persons with osteoporosis, or with anamnestic fracture and osteopenia, to be cost-effective in Swiss postmenopausal women from age 70, but not in men." | 3.74 | Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. ( Lippuner, K; Schwenkglenks, M, 2007) |
| "We describe 7 cases of synovitis or arthritis occurring after commencement of alendronate for treatment of osteoporosis." | 3.74 | Alendronate-induced synovitis. ( Gwynne Jones, DP; Highton, J; Savage, RL, 2008) |
| "The study was designed to evaluate the relationship of menopause, hormone replacement therapy (HRT), alendronate (ALN), and calcium supplements on salivary flow rate, saliva pH, and electrolytes." | 3.73 | The effect of menopause, hormone replacement therapy (HRT), alendronate (ALN), and calcium supplements on saliva. ( Gurgan, S; Gurgan, T; Yalçin, F, 2005) |
| "To report a case of corneal graft rejection precipitated by severe uveitis secondary to alendronate therapy and to review the literature of relevance to this case." | 3.73 | Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy. ( Richards, JC; Wiffen, SJ, 2006) |
| "Alendronate sodium is an aminobiphosphonate, an analog of inorganic pyrophosphate, indicated for the treatment of osteoporosis in post-menopausal women." | 3.72 | Pharmacovigilance study of alendronate in England. ( Biswas, PN; Shakir, SA; Wilton, LV, 2003) |
| "Alendronate sodium, an aminobiphosphonate used primarily to treat osteoporosis in postmenopausal women, is known to cause esophagitis." | 3.70 | Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features. ( Kelsey, P; Mueller, PR; Ryan, BM; Ryan, JM, 1998) |
| "Alendronate is indicated for the treatment of osteoporosis in post-menopausal women." | 3.70 | United Kingdom experience with alendronate and oesophageal reactions. ( Freemantle, SN; Mackay, FJ; Mann, RD; Pearce, GL; Wilton, LV, 1998) |
| "We developed a decision analytic Markov model to compare the effects of alendronate therapy, raloxifene therapy, and HRT on risks of hip fracture, coronary heart disease (CHD), breast cancer, and life expectancy." | 3.70 | Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. ( Col, NF; Eckman, MH; Goldberg, RJ; Orr, RK; Pauker, SG; Ross, EM; Wong, JB, 1999) |
| "Ingestion of alendronate sodium (Fosamax) by osteoporotic patients can be associated with esophagitis and esophageal ulcer." | 3.70 | Alendronate-associated esophageal injury: pathologic and endoscopic features. ( Abraham, SC; Cruz-Correa, M; Lee, LA; Wu, TT; Yardley, JH, 1999) |
| " The aim of the present study was to evaluate the effects of treatment with alendronate in patients affected by hyperthyroidism and osteoporosis." | 3.69 | Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. ( Affinito, P; Arlotta, F; Cascone, E; Di Carlo, C; Lupoli, G; Nappi, C; Nuzzo, V; Vitale, G; Vollery, M, 1996) |
| " Incidences of adverse events, asymptomatic decreases in serum calcium, and evolution of kidney function during the studies were similar across all baseline kidney function groups." | 3.11 | Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. ( Adachi, JD; Albergaria, BH; Cheung, AM; Chines, AA; Gielen, E; Langdahl, BL; Miller, PD; Miyauchi, A; Oates, M; Reid, IR; Santiago, NR; Vanderkelen, M; Wang, Z; Yu, Z, 2022) |
| " Benefits of long-term use of BPs: Large and important trials (Fracture Intervention Trial Long-term Extension and Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly-Pivotal Fracture Trial) with extended use of alendronate (up to 10 years) and zoledronate (up to 6 years) evidenced significant gain of bone mineral density (BMD) and vertebral fracture risk reduction." | 3.01 | Long-term consequences of osteoporosis therapy with bisphosphonates. ( Alves Coelho, MC; Brasil d'Alva, C; Gehrke, B; Madeira, M, 2023) |
| "Postmenopausal osteoporosis is characterised by increased bone turnover and an imbalance between bone resorption and formation." | 2.94 | The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study. ( Eastell, R; Gossiel, F; McCloskey, EV; Naylor, KE; Paggiosi, MA; Peel, N; Walsh, J, 2020) |
| "In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO)." | 2.87 | ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. ( Bilezikian, JP; Bone, HG; Cosman, F; Dore, RK; Fitzpatrick, LA; Hattersley, G; Hu, MY; Miller, PD; Mitlak, B; Papapoulos, S; Rizzoli, R; Saag, KG; Williams, GC, 2018) |
| "This study showed that ESWT could efficiently improve the local BMD; relatively, the high dosage was effective." | 2.84 | Short-term effects of extracorporeal shock wave therapy on bone mineral density in postmenopausal osteoporotic patients. ( Cheng, L; Gao, F; Guo, W; Li, Z; Shi, L; Sun, W; Wang, B; Wang, W, 2017) |
| "Co-treatment with calcitriol (10(-8)M) partially reversed this zoledronate-induced inhibition." | 2.80 | The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells. ( Edwards, S; Elford, C; Evans, BA; Fogelman, I; Frost, ML; Hampson, G; Ishtiaq, S; Sankaralingam, A, 2015) |
| "Whether denosumab fully inhibits bone resorption when challenged by a higher dose of teriparatide is unknown." | 2.80 | Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate. ( Burnett-Bowie, SA; Foley, K; Leder, BZ; Lee, H; Neer, RM; Tsai, JN; Zhu, Y, 2015) |
| "However, their relative effects on bone resorption and formation, and how quickly the effects resolve after treatment cessation, are uncertain." | 2.79 | Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. ( Boonen, S; Deacon, S; Eastell, R; Kuwayama, T; Nagase, S; Ohyama, M; Small, M; Spector, T, 2014) |
| ") ibandronate versus oral alendronate, (2) a correlation exists between adherence and persistence to medication and drug efficacy, and (3) any unexpected adverse events/serious adverse events (AEs/SAEs) may occur." | 2.79 | The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. ( Amling, M; Felsenberg, D; Hadji, P; Hofbauer, LC; Kandenwein, JA; Kurth, A, 2014) |
| " Overall and serious adverse events were similar between groups." | 2.79 | Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. ( Brown, JP; Fahrleitner-Pammer, A; Ferreira, I; Hawkins, F; Ho, PR; Hofbauer, LC; Micaelo, M; Minisola, S; Papaioannou, N; Roux, C; Siddhanti, S; Stone, M; Wagman, RB; Wark, JD; Zillikens, MC, 2014) |
| "Osteoporosis and atherosclerosis are the two most common diseases in postmenopausal women." | 2.79 | Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis. ( Igase, M; Kohara, K; Miki, T; Ochi, M; Ohara, M; Okada, Y; Tabara, Y; Takita, R, 2014) |
| "The alendronate-treated cases had a reduced eroded surface (ES/BS, p<0." | 2.79 | Effects of long-term alendronate treatment on bone mineralisation, resorption parameters and biomechanics of single human vertebral trabeculae. ( Amling, M; Breer, S; Busse, B; Glueer, CC; Hahn, M; Hapfelmeier, A; Kornet, J; Krause, M; Morlock, M; Püschel, K; Soltau, M; Wulff, B; Zimmermann, EA, 2014) |
| "Osteoporosis resulting in bone fractures is a complication in patients with primary biliary cirrhosis (PBC)." | 2.78 | Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. ( Cerdá, D; Gifre, L; Guañabens, N; Monegal, A; Muxí, Á; Parés, A; Peris, P, 2013) |
| "Odanacatib (ODN) is a selective cathepsin K inhibitor being developed to treat osteoporosis." | 2.78 | Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial. ( Bonnick, S; Chapurlat, R; DaSilva, C; De Villiers, T; Gurner, D; Le Bailly De Tilleghem, C; Leung, AT; Odio, A; Palacios, S; Scott, BB, 2013) |
| " To determine whether a lower dosage in oral form combined with calcitriol can effectively manage AI-induced bone loss, we performed a randomized, double-blind, prospective, placebo-controlled 24-week trial with a combination of alendronate and 0." | 2.78 | Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. ( Lim, SK; Park, BW; Park, HS; Park, S; Rhee, Y; Song, K, 2013) |
| " No serious adverse events were observed in either group and safety profiles were similar." | 2.76 | The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in chinese post-menopausal women at risk of osteoporosis. ( Chen, JY; Chen, L; Pan, L; Sheng, ZY; You, L, 2011) |
| " However, the use of daily regimen of alendronate in women at risk for osteoporosis has been relatively low in China because of its dosing inconvenience." | 2.74 | The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis. ( Li, F; Li, M; Liu, J; Luo, B; Wang, W; Xie, H; Yan, Y; Zhang, G; Zhu, H, 2009) |
| "Alendronate was randomly prescribed for 41 patients and risedronate were prescribed for 43 patients." | 2.73 | Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients. ( Iizuka, T; Matsukawa, M, 2008) |
| "Alendronate treatment decreased urinary NTX level by 39." | 2.73 | Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2007) |
| "Treatment with alendronate reduced the risk of clinical fractures to a similar degree in those with (OR: 0." | 2.73 | Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. ( Bauer, DC; Cauley, JA; Cummings, SR; Ensrud, KE; Hochberg, M; Ishani, A; Jamal, SA, 2007) |
| " Inconvenient dosing was reported as a primary reason for discontinuation due to stopping or changing treatment in 19 (6." | 2.73 | Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. ( Chen, SH; Chen, YJ; Hall, BJ; Khan, MA; Kung, AW; Mirasol, R; Pasion, EG; Shah, GA; Sivananthan, SK; Tam, F; Tay, BK; Thiebaud, D, 2007) |
| "Osteoporosis affects mostly postmenopausal women, leading to deterioration of the microarchitectural bone structure and low bone mass, with an increased fracture risk with associated disability, morbidity and mortality." | 2.72 | Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. ( Betsch, M; Colarossi, G; Eschweiler, J; Maffulli, N; Migliorini, F; Tingart, M, 2021) |
| " A dosage of 2." | 2.72 | Assessment of DNA damage in postmenopausal women under osteoporosis therapy. ( Bayram, M; Kadioglu, E; Sardas, S; Soyer, C, 2006) |
| "Treatment with alendronate plus HRT resulted in a 10." | 2.72 | Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women. ( Ho, ES; Hu, CC; Kao, CH; Lan, HH; Sheu, WH; Tseng, LN, 2006) |
| " Bone mineral density increases at other skeletal sites and effects on bone turnover were also virtually identical for the two dosing regimens." | 2.71 | Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. ( Bone, HG; Daifotis, AG; Davie, MW; de Villiers, TJ; Gilchrist, N; Luckey, MM; Orloff, JJ; Santora, AC; Wu, M, 2003) |
| "Alendronate was superior to hormone replacement, and combination therapy was superior to either therapy alone." | 2.71 | Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. ( Greenspan, SL; Parker, RA; Resnick, NM, 2003) |
| "Alendronate has no effect on vascular markers or sex hormone-binding globulin." | 2.71 | Effects of hormone therapy and alendronate on C-reactive protein, E-selectin, and sex hormone-binding globulin in osteoporotic women. ( Eviö, S; Tiitinen, A; Välimäki, M; Ylikorkala, O, 2003) |
| "To compare the effects of alendronate (ALN) 70 mg once weekly (OW) and risedronate (RIS) 5 mg daily between-meal dosing on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal women with osteoporosis." | 2.71 | Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. ( Adami, S; Andia, JC; Benhamou, L; Felsenberg, D; Hosking, D; Petruschke, RA; Reginster, JY; Rybak-Feglin, A; Santora, AC; Välimäki, M; Yacik, C; Zaru, L, 2003) |
| "Alendronate has been shown to reduce bone turnover and increase bone mass." | 2.71 | Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. ( Alexandersen, P; Bagger, YZ; Christiansen, C; Ravn, P; Tankó, LB, 2003) |
| "Alendronate has recently been approved for the prevention and treatment of postmenopausal osteoporosis, and its efficacy has been demonstrated in many Western countries." | 2.71 | Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. ( Chailurkit, LO; Jongjaroenprasert, W; Ongphiphadhanakul, B; Rajatanavin, R; Rungbunnapun, S; Sae-tung, S, 2003) |
| "Once weekly dosing of alendronate has been shown to provide equivalent efficacy to once daily dosing for treatment of osteoporosis in postmenopausal women." | 2.71 | Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. ( Fuleihan, Gel-H; Gaines, KA; González González, JG; Kendler, D; Kung, AW; Melton, ME; Verbruggen, N, 2004) |
| "With the demise of oestrogen treatment for postmenopausal osteoporosis, it is useful that strontium ranelate is emerging as a promising drug in this condition." | 2.71 | Recent important clinical trials of drugs in osteoporosis. ( Doggrell, SA, 2004) |
| "All patients with postmenopausal osteoporosis (PMOP) in this clinical trial had been allocated into 4 groups: placebo therapy group, vitamin D addition calcium therapy group, hormone replacement treatment (HRT) therapy group, and risedronate therapy group." | 2.71 | [Quality of life in the treatment assessment of postmenopausal osteoporosis]. ( Hu, YF; Sun, ZQ, 2005) |
| "Treatment with alendronate 70 mg once weekly for one year resulted in significant BMD improvement of 6." | 2.71 | Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women. ( Ho, AY; Kung, AW, 2005) |
| "Significantly more women with postmenopausal osteoporosis preferred once-monthly ibandronate therapy to once-weekly alendronate therapy, and found the once-monthly regimen to be more convenient." | 2.71 | Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). ( Beusterien, K; Devas, V; Emkey, R; Kivitz, A; Koltun, W; Masanauskaite, D; Seidman, L, 2005) |
| "In contrast, bisphosphonates reduce bone resorption and increase BMD." | 2.70 | A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. ( Body, JJ; Correa-Rotter, R; Cumming, DC; Dore, RK; Gaich, GA; Hodsman, AB; Kulkarni, PM; Miller, PD; Papaioannou, A; Peretz, A; Scheele, WH, 2002) |
| "The aim of this study was to provide confirmation that once-weekly dosing with 70 mg of alendronate (seven times the daily oral dose) and twice-weekly dosing with 35 mg is equivalent to the 10-mg once-daily regimen and to gain more extensive safety experience with this new dosing regimen." | 2.70 | Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. ( Adami, S; Bone, G; Foldes, AJ; Greenspan, SL; Kaur, A; Levine, MA; Orloff, JJ; Peverly, CA; Rizzoli, R; Roux, C; Santora, AC; Schnitzer, TJ; Uebelhart, B; Watts, NB, 2002) |
| "This study aimed to determine patient preference for once-weekly versus once-daily dosing with alendronate, and to determine which treatment regimen the patients believed was more convenient and would be easier to comply with for a long period." | 2.70 | Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. ( Lewiecki, EM; Palmisano, JJ; Petruschke, RA; Simon, JA; Smith, ME; Wang, L, 2002) |
| "For subjects with postmenopausal osteoporosis, receiver-operating characteristic curve analysis yielded areas under the curve of 0." | 2.70 | Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease. ( Baylink, D; Drinkwater, B; Farley, S; Kleerekoper, M; Lang, R; Lappe, J; Licata, A; McClung, M; Miller, P; Nattrass, S; Powell, H; Recker, R; Sarno, L; Sarno, M; Schwartz, EN; Tjersland, G; Tucci, JR; Warnick, GR; Wolf, S, 2001) |
| "Etidronate was given cyclically (14-day courses in a dosage of 400 mg/d separated by 76-day intervals with calcium and vitamin D supplementation) and alendronate was given daily in a dosage of 10 mg/d." | 2.70 | Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy. ( Béra-Louville, A; Cortet, B; Delcambre, B; Gauthier, A; Gauthier, P; Marchandise, X, 2001) |
| "Eighty women suffering from postmenopausal osteoporosis were included in the study." | 2.70 | Effect of two forms of alendronate administration upon bone mass after two years of treatment. ( Betancor, P; de la Peña, E; Gómez, A; Hernández, D; Segarra, MC; Sosa, M, 2002) |
| "In women with postmenopausal osteoporosis (PMO), response to therapy with bisphosphonates is conventionally monitored using central-site (hip and spine) bone mineral density (BMD), but more convenient alternatives are desirable." | 2.70 | Use of phalangeal bone mineral density and multi-site speed of sound conduction to monitor therapy with alendronate in postmenopausal women. ( Banville, C; Brown, JP; Drake, WM; Kendler, DL, 2002) |
| "Alendronate was revealed to be well tolerated, with a good safety profile; a dose of 10 mg daily offers the best risk:benefit ratio and appears to be the optimal dosage for the treatment of established postmenopausal osteoporosis." | 2.69 | Alendronate in the treatment of postmenopausal osteoporosis. ( Favus, M; Hosking, DJ; Yates, AJ, 1999) |
| "Alendronate did not increase bone mineral density of the forearm, but it slowed the loss." | 2.69 | Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. ( Balske, A; Chilvers, CE; Christiansen, C; Daley, M; Hosking, D; McClung, M; Ravn, P; Ross, P; Thompson, D; Wasnich, R; Yates, AJ, 1998) |
| "Alendronate seems to be a safe and effective nonhormonal option for prevention of postmenopausal bone loss." | 2.69 | Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. ( Clemmesen, B; Daifotis, A; Eisman, J; Gilchrist, NL; McClung, M; Ravn, P; Reda, C; Weinstein, RS; Yates, AJ, 1998) |
| " The present results indicate that alendronate effectively decreases bone turnover in a dose-related manner and increases lumbar BMD at a dosage of 2." | 2.69 | A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. ( Fukunaga, M; Inoue, T; Kaneda, K; Kishimoto, H; Kushida, K; Minaguchi, H; Nagata, Y; Nakashima, M; Orimo, H; Shiraki, M; Tomita, A, 1998) |
| "Twenty-five women with postmenopausal osteoporosis (mean +/- SD: 65." | 2.69 | Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate. ( Becker, P; Watts, NB, 1999) |
| "Sensitivity and specificity were used to assess the accuracy of change from baseline at month 6 in the biochemical markers for predicting prevention of bone loss in the spine over 2 years." | 2.69 | Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. ( Christiansen, C; Clemmesen, B; Ravn, P, 1999) |
| "Alendronate is an antiresorptive therapy for osteoporosis and results in a decrease in bone turnover." | 2.69 | Monitoring alendronate therapy for osteoporosis. ( Braga de Castro Machado, A; Eastell, R; Hannon, R, 1999) |
| "In conclusion, thinness is an important risk factor for low bone mass and increased bone loss in postmenopausal women." | 2.69 | Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. ( Bjarnason, NH; Christiansen, C; Cizza, G; Daley, M; Hosking, D; McClung, M; Ravn, P; Thompson, D; Wasnich, RD; Yates, AJ, 1999) |
| "Alendronate has been shown to increase bone density among early postmenopausal women." | 2.69 | Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women. ( Cizza, G; Ross, PD; Thompson, DE; Wasnich, RD; Yates, AJ, 1999) |
| "Alendronate plus calcium treatment led to a significant reduction in total alkaline phosphatase and hydroxy prolinuria as well as to a significant increase in lumbar and femoral bone density." | 2.69 | Calcitriol and alendronate combination treatment in menopausal women with low bone mass. ( Gnudi, S; Malavolta, N; Ripamonti, C; Veronesi, M; Zanardi, M, 1999) |
| "Alendronate treatment increased the bone mineral density in the femoral neck, the trochanter, the Ward's triangle and the total hip by +3." | 2.69 | [The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungary of an international multicenter clinical study)]. ( Balogh, A; Bettembuk, P, 1999) |
| "Alendronate use was not associated with a significant increase in upper GI tract events among women at increased risk for these events (those aged > or =75 years with previous upper GI tract disease or using nonsteroidal anti-inflammatory drugs)." | 2.69 | Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. ( Bauer, DC; Black, D; Ensrud, K; Freedholm, D; Hochberg, M; Musliner, T; Nevitt, M; Thompson, D, 2000) |
| "Alendronate does not cause predictable esophageal, gastric, or duodenal mucosal damage when used as directed." | 2.69 | Upper gastrointestinal toxicity of alendronate. ( Depew, WT; Lowe, CE; Meddings, JB; Paterson, WG; Vanner, SJ, 2000) |
| " Less frequent dosing with any medication may enhance compliance, thereby maximizing the effectiveness of therapy." | 2.69 | Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. ( Adami, S; Bone, HG; Crepaldi, G; Emkey, R; Felsenberg, D; Foldes, AJ; Greenspan, SL; Kaur, A; Kiel, D; Levine, MA; McClung, M; Orloff, JJ; Pinchera, A; Recker, RR; Roux, C; Santora, AC; Schnitzer, T; Thompson, DE; Tonino, RP; Yates, J, 2000) |
| "Free deoxypyridinoline (f-DPD) was measured in fasting urine specimens." | 2.69 | Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. ( Adami, S; Braga, V; Fracassi, E; Gatti, D; Gerardi, D; Guidi, G, 2000) |
| "Alendronate treatment for 1 year resulted in significant improvement in BMD at all sites measured when compared with placebo." | 2.69 | The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study. ( Chu, LW; Kung, AW; Yeung, SS, 2000) |
| "Alendronate was found to be more effective than HRT and could have a very beneficial effect when added to the HRT regimen in patients with postmenopausal osteoporosis." | 2.69 | Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study. ( Daya, S; Noyan, V; Tiraş, MB; Yildirim, M; Yildiz, A, 2000) |
| "The alendronate-treated group gained more bone at both the spine (p < 0." | 2.69 | Alendronate prevents bone loss in Chinese women with osteoporosis. ( Chan, YH; Griffith, J; Lau, EM; Woo, J, 2000) |
| "Postmenopausal osteoporosis is a serious health problem, and additional treatments are needed." | 2.68 | Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. ( Bell, NH; Bröll, J; Dequeker, J; Downs, RW; Favus, M; Liberman, UA; Minne, HW; Quan, H; Rodriguez-Portales, J; Weiss, SR, 1995) |
| "Clinical studies were performed to examine the oral bioavailability of alendronate (4-amino-1-hydroxy-butylidene-1,1-bisphosphonate monosodium)." | 2.68 | Studies of the oral bioavailability of alendronate. ( Freeman, A; Gertz, BJ; Holland, SD; Kline, WF; Lasseter, KC; Matuszewski, BK; Mucklow, JC; Porras, AG; Quan, H, 1995) |
| " BMD continued to increase over the entire 3-year study duration in the ALN-treated groups and, compared with the other dosage groups, 10 mg ALN produced the largest gains in BMD during the 3rd year." | 2.68 | Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. ( Broll, H; Correa-Rotter, R; Cumming, DC; De Deuxchaisnes, CN; Devogelaer, JP; Geusens, P; Hirsch, LJ; Hosking, D; Jaeger, P; Kaufman, JM; Leite, M; Leon, J; Liberman, U; Lombardi, A; Menkes, CJ; Meunier, PJ; Plezia, K; Reid, I; Rodriguez, J; Romanowicz, A; Santora, AC; Seeman, E; Vermeulen, A; Yates, AJ; Yuan, W, 1996) |
| "Oral alendronate sodium is a potent, specific inhibitor of osteoclast-mediated bone resorption." | 2.68 | Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. ( Emkey, RD; Kher, U; Peverly, CA; Santora, AC; Tonino, RP; Tucci, JR, 1996) |
| "Alendronate (ALN) is an aminobisphosphonate employed as an antiresorptive agent in the treatment of osteoporosis." | 2.68 | Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. ( Bone, HG; Downs, RW; Gertz, BJ; Hale, E; Harris, ST; Kimmel, DB; Licata, AA; McClung, MR; Polvino, WJ; Tucci, JR; Weinstein, RS, 1997) |
| "Alendronate sodium (ALN) is a potent amino bisphosphonate which specifically inhibits osteoclastic bone resorption and has been found to reverse bone loss in several animal models." | 2.67 | Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. ( Adami, S; Baroni, MC; Broggini, M; Carratelli, L; Caruso, I; Gnessi, L; Laurenzi, M; Lombardi, A; Norbiato, G; Ortolani, S, 1993) |
| "Alendronate was the most prescribed drug (more than 30% over the observation period); however, vDCa was seldom prescribed." | 2.66 | Cumulative network meta-analyses, practice guidelines, and actual prescriptions for postmenopausal osteoporosis: a meta-epidemiological study. ( Chaimani, A; Cipriani, A; Furukawa, TA; Kataoka, Y; Kimachi, M; Li, T; Luo, Y; Murad, MH; Onishi, A; Tsujimoto, Y, 2020) |
| "In women with osteopenia or osteoporosis, 6 years of zoledronic acid reduced clinical fractures (HR, 0." | 2.61 | Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. ( Brasure, M; Butler, M; Ensrud, KE; Fink, HA; Forte, ML; MacDonald, R; Nelson, VA; Olson, CM; Rosebush, CE; Schousboe, JT; Taylor, BC; Ullman, K; Wilt, TJ, 2019) |
| "A network meta-analysis was conducted to compare the short-term efficacy and adverse events of different drugs for the treatment of postmenopausal osteoporosis (PMO), providing a more effective treatment for PMO." | 2.58 | A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis. ( Liu, GF; Liu, L; Miao, YY; Wang, ZQ; Yu, SN; Zhang, BT, 2018) |
| "The data on gastrointestinal side effects (47 trials) indicated that alendronate, risedronate etidronate, and zolendronate have similar rates of the adverse effects; application of Bayesian network meta-analysis showed that equivalence was demonstrated according to margins around ±10%." | 2.52 | Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference. ( Fadda, V; Maratea, D; Messori, A; Trippoli, S, 2015) |
| "A meta-analysis of spine BMD dose-response relationships for alendronate, risedronate, and ibandronate was performed." | 2.49 | A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. ( Yates, J, 2013) |
| "Inhibition of bone resorption is fully reversible following discontinuation." | 2.49 | Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis. ( Josse, R; Khan, A; Ngui, D; Shapiro, M, 2013) |
| " And adverse events (AEs), including incidence of neoplasms and infections, were considered as secondary outcomes." | 2.48 | Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. ( Cai, XZ; Guo, C; Lin, T; Shi, MM; Wang, C; Yan, SG; Ying, ZM; Yuan, FZ; Zhao, X, 2012) |
| "Postmenopausal osteoporosis is a chronic disease requiring treatment that balances long-term fracture efficacy against risk." | 2.48 | Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). ( Cooper, C; Cortet, B; Diaz-Curiel, M; Kanis, JA; Lorenc, RS; Reginster, JY; Rizzoli, R, 2012) |
| " Although less frequent dosing is preferred, other factors such as perceived efficacy, side effects, medication cost, availability of patient support programmes and route of delivery are equally important." | 2.47 | Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. ( Glendenning, P; Inderjeeth, CA; Lee, S, 2011) |
| "Alendronate effects were also prospectively assessed in 33 patients with postmenopausal osteoporosis who were treated with alendronate at a dose of 5 mg/day for 18 months." | 2.47 | Vertebral fracture risk and alendronate effects on osteoporosis assessed by a computed tomography-based nonlinear finite element method. ( Imai, K, 2011) |
| " A once monthly 150 mg regimen produced greater increases in lumbar spine, total hip, femoral neck, and trochanter BMD than daily treatment, with a similar incidence of adverse events between the groups." | 2.47 | Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. ( Lee, YH; Song, GG, 2011) |
| " Also reviewed are results of "bridging" studies designed to demonstrate the comparable efficacy of less frequent dosing regimens to increase bone mineral density and to reduce bone turnover." | 2.45 | Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. ( Bilezikian, JP, 2009) |
| " A once-weekly regimen of alendronate administration provides better patient compliance and persistence with the treatment than the once-daily dosing regimen, leading to greater efficacy against hip fractures." | 2.44 | Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T, 2008) |
| "etidronate) have been associated with acute renal failure." | 2.44 | Safety considerations with bisphosphonates for the treatment of osteoporosis. ( Civitelli, R; Emkey, R; Strampel, W, 2007) |
| "Alendronate treatment after PTH therapy can maintain gains in BMD at lumbar spine and hip as well." | 2.44 | [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis]. ( Nakamura, T, 2007) |
| " In order to improve the efficacy of antiresorptive drugs, fewer demands on patients and better adherence were obtained with less frequent dosing schedule." | 2.44 | [Alendronate and vitamin D (Fosavance): persistence, adherence and importance of vitamin D]. ( Grazio, S; Morović-Vergles, J, 2007) |
| "Treatment with alendronate, a potent and specific inhibitor of bone resorption, is known to significantly reduce fracture risk among women with postmenopausal osteoporosis." | 2.43 | Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. ( Hochberg, MC; Liberman, UA; Papapoulos, SE; Quandt, SA; Thompson, DE, 2005) |
| "Osteoporosis affects postmenopausal women and patients on glucocorticoid therapy." | 2.43 | Rapid prevention of vertebral fractures associated with osteoporosis. ( Wallace, DJ, 2005) |
| "The alendronate was discontinued, and, with the administration of prednisone, the symptoms of scleritis fully resolved." | 2.43 | Bisphosphonate-associated scleritis: a case report and review. ( Ashar, BH; Leung, S; Miller, RG, 2005) |
| "Oral daily bisphosphonates carry a potential for gastrointestinal (GI) adverse events, which has been partly addressed by introducing once-weekly regimens." | 2.43 | Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. ( Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM, 2006) |
| " RCTs have demonstrated that the incidence of gastrointestinal tract adverse events in postmenopausal osteoporotic women treated with bisphosphonates and placebo are similar, and also the long-term efficacy and safety of alendronate and risedronate." | 2.43 | Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T, 2006) |
| "The main goal of postmenopausal osteoporosis treatment is to reduce the risk of fragility fractures." | 2.43 | [Osteoporosis: Optimizing treatment strategy]. ( Thomas, T, 2006) |
| "Osteopenia is a progressive condition that places patients at risk for increased morbidity and mortality if untreated." | 2.42 | Identifying the osteopenic patient and preventing worsening of the disease. ( Derman, R, 2003) |
| "Alendronate has demonstrated significant reductions in vertebral and nonvertebral fracture risk after 3 years." | 2.42 | An approach to postmenopausal osteoporosis treatment: a case study review. ( Kessenich, C, 2003) |
| "Selection of appropriate drug for treatment of postmenopausal osteoporosis should take into account the long-term effect of the antiresorptive agent on bone." | 2.42 | Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. ( Alenfeld, F; Boivin, G; Feyen, JH; Lakatos, P; Stepan, JJ, 2003) |
| "Bisphosphonates suppress bone resorption and bone turnover by a mechanism that depends on their structure." | 2.42 | Postmenopausal osteoporosis and alendronate. ( Pérez-López, FR, 2004) |
| "The objective of this review is to present the clinical profiles of the once-weekly and once-daily dosing formulations of alendronate and risedronate, the 2 bisphosphonates currently available in the United States for the prevention and treatment of postmenopausal osteoporosis." | 2.42 | Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. ( Emkey, R, 2004) |
| " Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis." | 2.42 | Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2004) |
| "Alendronate has been approved for treatment of osteoporosis in men, and other treatments for men are under evaluation." | 2.41 | Osteoporosis in elderly: prevention and treatment. ( Deal, C; Srivastava, M, 2002) |
| " Clinical trials often underestimate the rate of adverse events in clinical practice, and ethics prohibit direct evaluation of toxicity in high-risk patients." | 2.41 | The gastrointestinal tolerability and safety of oral bisphosphonates. ( Marshall, JK, 2002) |
| "Alendronate has the greatest positive effect on BMD and reduces the incidence of vertebral and nonvertebral fractures." | 2.41 | Prevention and treatment of osteoporosis in women with breast cancer. ( Mincey, BA; Moraghan, TJ; Perez, EA, 2000) |
| "Alendronate is a potent bisphosphonate that is effective in preventing osteoporotic fractures." | 2.40 | The clinical tolerability profile of alendronate. ( Daifotis, A; Freedholm, D; Watts, N, 1999) |
| "Alendronate is an aminobisphosphonate which appears to attenuate, rather than completely inhibiting bone turnover, by suppressing the activity of osteoclasts." | 2.40 | Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. ( Barradell, LB; Jeal, W; McTavish, D, 1997) |
| " In addition, alendronate was shown to have no adverse effects on bone mineralization or microstructure." | 2.40 | Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy. ( Adachi, JD, 1998) |
| "Alendronate treatment results in an early and dose-dependent inhibition of skeletal resorption, which can be followed clinically with biochemical markers, and which ultimately reaches a plateau and is slowly reversible upon discontinuation of the drug." | 2.40 | Pharmacokinetics of alendronate. ( Gertz, BJ; Holland, SD; Porras, AG, 1999) |
| "Many new agents for the treatment of osteoporosis are being examined." | 2.39 | Osteoporosis prevention and treatment. ( Bellantoni, MF, 1996) |
| "She had been treated for postmenopausal osteoporosis with 70 mg of alendronate weekly for 2 years." | 1.91 | A Case Report of Oral Bisphosphonate Treatment for Osteoporosis Leading to Atypical Femoral Fracture and Pathologic Mandibular Fracture. ( Fernandes, TL; Franco, GCN; Jitumori, C; Viezzer Fernandes, B, 2023) |
| " Administration of risedronate gastric-resistant does not require fasting, and this more convenient dosing administration may explain its improved efficacy." | 1.72 | Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. ( Alam, A; Boolell, M; Gauthier, G; Palacios, S; Thomasius, F; Vekeman, F, 2022) |
| "Postmenopausal women compliance to alendronate therapy is suboptimal due to the complex dosing requirements." | 1.72 | Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine. ( Elaraj, J; Fatayer, D; Hamad, A; Jarar, B; Johar, A; Radwan, A; Shraim, N; Zriqah, A, 2022) |
| "Alendronate was the most common initial therapy." | 1.72 | Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience. ( Baim, S; Bedrose, S; Casagrande, A; Go, MT; Goel, M; Hanna, M; Husni, H; Li, D; Mahrous, P; Morkos, M, 2022) |
| "Osteoporosis is common in older adults leading to fragility fractures at enormous individual and economic cost." | 1.72 | Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults. ( Bishop, S; Gittoes, N; Langley, T; Narayanasamy, M; Paskins, Z; Sahota, O, 2022) |
| " This, together with the need for less frequent administration of zoledronate, supports its wider use in clinical practice, particularly if longer dosing intervals than those currently recommended are shown to be effective." | 1.56 | Practical guidance for the use of bisphosphonates in osteoporosis. ( Compston, J, 2020) |
| "Alendronate was synthesized in 1970s in a search for inhibitors of calcification." | 1.56 | History of alendronate. ( Black, DM; Cummings, SR; Russell, RGG; Santora, AC, 2020) |
| "Alendronate was ineffective to avoid spontaneous clinical vertebral fractures." | 1.51 | Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports. ( Aguado, P; Aubry-Rozier, B; Benavent-Núñez, D; Fernández-Fernández, E; Gonzalez-Rodriguez, E; Lamy, O; Monjo-Henry, I; Stoll, D, 2019) |
| "Serum markers of bone formation, bone resorption, as well as bone mineral density (BMD) were serially measured." | 1.51 | Effects of Intermittent Parathyroid Hormone 1-34 Administration on Circulating Mesenchymal Stem Cells in Postmenopausal Osteoporotic Women. ( Hao, C; Kang, L; Su, Z; Sun, Q; Tang, Y; Xia, H; Xue, Y, 2019) |
| "The use of gastro-resistant risedronate, a convenient dosing regimen for oral bisphosphonate therapy, seems a cost-effective strategy compared with weekly alendronate, generic risedronate, and no treatment for the treatment of postmenopausal women with osteoporosis in France." | 1.51 | Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. ( Hiligsmann, M; Reginster, JY, 2019) |
| "Resultant osteoporotic fractures are a significant contributor of economic and social burden among elderly osteoporosis patients." | 1.48 | Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review. ( Baidya, S; Barron, R; Fujiwara, S; Hamaya, E; Miyauchi, A; Nicholls, RJ; Pinto, L; Takada, J; Weston, A, 2018) |
| "Even if postmenopausal osteoporosis is accompanied by diabetes in this animal model, both alendronate and raloxifene seem to show antiresorptive effects, decreased bone turnover rates, and improved bone mechanical strength." | 1.48 | Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model. ( Cho, DC; Gupta, R; Han, I; Kim, CH; Kim, KT; Kwon, JT; Lee, YS; Park, EK; Seo, YJ; Seu, SY; Sung, JK, 2018) |
| " rhPTH (1-34) and ALN were safe in the treatment of postmenopausal osteoporosis." | 1.48 | Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis. ( Deng, J; Feng, Z; Li, Q; Li, Y; Pan, T; Zhao, C, 2018) |
| "The frequency distribution of the bone resorption marker urinary deoxypyridinoline crosslinks (uDPD), was obtained retrospectively from 211 osteoporotic women attended at an academic hospital endocrine clinic, treated for >2 years with oral bisphosphonates." | 1.46 | BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD. ( Liel, Y; Plakht, Y; Tailakh, MA, 2017) |
| "Postmenopausal osteoporosis is often treated with bisphosphonates (eg, alendronate, [ALN]), but oversuppression of bone turnover by long-term bisphosphonate treatment may decrease bone tissue heterogeneity." | 1.46 | Intermittent Parathyroid Hormone After Prolonged Alendronate Treatment Induces Substantial New Bone Formation and Increases Bone Tissue Heterogeneity in Ovariectomized Rats. ( Altman-Singles, AR; de Bakker, CM; Han, L; Jeong, Y; Kim, DG; Liu, XS; Lott, C; Qin, L; Robberts, J; Tseng, WJ; Zhao, H, 2017) |
| " These results led us to hypothesize a mode of action by which presence of a linker is crucial in facilitating the anabolic effects of EP4a when dosed as a prodrug with ALN." | 1.43 | In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss. ( Chen, G; Grynpas, MD; Hu, S; Liu, CC; Willett, T; Young, RN, 2016) |
| " During the last decade, the occurrence of atypical fractures, mostly subtrochanteric and diaphyseal femoral fractures, has been acknowledged in patients with long-term use of bisphosphonates." | 1.43 | Bilateral distal fibula fractures in a woman on long-term bisphosphonate therapy. ( Audet, MC; Bédard, M; Michou, L; Murray, JC, 2016) |
| "To elucidate the efficacy and adverse events of alendronate (Aldren70) after 12 months of treatment in 50 to 70 years old postmenopausal women." | 1.40 | A prospective analytical study of the effects and adverse events of alendronate (Aldren70) treatment in Thai postmenopausal women. ( Jaruwangsanti, N; Tienboon, P, 2014) |
| "Rosiglitazone (RSG) is an antidiabetic drug that has been associated with increased peripheral fractures, primarily in postmenopausal women." | 1.39 | The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate. ( Fitzpatrick, LA; Guldberg, RE; Hoffman, SJ; Jolette, J; Kumar, S; Mansell, P; Samadfam, R; Smith, SY, 2013) |
| "We observed three cohorts of women aged 65 years and older who initiated once-a-week dosing of bisphosphonate therapy; (1) patients adherent to alendronate (n = 21,615), (2) patients adherent to risedronate (n = 12,215), or (3) patients filling only a single bisphosphonate prescription (n = 5,390) as a referent population." | 1.39 | Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2013) |
| "The authors describe a femoral pseudoarthrosis of an atypical fracture treated with intramedullary nailing in a female after prolonged alendronate therapy." | 1.39 | Pseudoarthrosis in atypical femoral fracture: case report. ( Bottai, V; De Paola, G; Dell'Osso, G; Ghilardi, M; Giannotti, S; Guido, G, 2013) |
| "Patients with a diagnosis of postmenopausal osteoporosis, bisphosphonate usage of at least 5 years and prodromal pain prior to fracture were included the study." | 1.39 | Bilateral low-energy sequential femoral shaft fractures in patients on long-term bisphosphonate therapy. ( Çakmak, S; Erdik, B; Keklikçi, K; Mahiroğulları, M; Rodop, O; Sarı, E, 2013) |
| " During her most recent gynecology visit, she expressed concern about unusual femoral fractures being linked to long-term use of alendronate." | 1.39 | Menopause practitioner perspective on the American Society of Bone and Mineral Research Task Force report on atypical femoral fracture. ( Ettinger, B; Schnatz, PF; Stuenkel, CA, 2013) |
| "We report a case of bilateral ulna stress fractures following bilateral femoral fractures associated with long-term bisphosphonate use." | 1.39 | Bilateral ulna fractures associated with bisphosphonate therapy. ( Ang, BF; Howe, TS; Koh, JS; Ng, AC, 2013) |
| "Many postmenopausal women have osteopenia, a condition characterized by loss of bone mineral density (BMD) that is not as severe as in osteoporosis." | 1.39 | Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. ( Fukagawa, M; Inoue, H; Komaba, H; Moriwaki, K; Noto, S; Takahashi, HE; Takiguchi, T; Toujo, T; Yanagisawa, S, 2013) |
| "Chronic obstructive pulmonary disease (COPD) and systemic glucocorticoid exposure are well-known risk factors of osteoporosis." | 1.39 | Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids. ( Abrahamsen, B; Brask-Lindemann, D; Eiken, P; Eskildsen, P, 2013) |
| "Alendronate treatment appeared to have a similar effect on surrogate markers in postmenopausal osteoporotic Japanese women with or without RD." | 1.38 | Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without renal dysfunction: a retrospective study. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M, 2012) |
| "The main outcome measure was colorectal cancers incidence and post-diagnosis survival in patients taking oral alendronate for osteoporosis." | 1.38 | Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study. ( Abrahamsen, B; Eastell, R; Eiken, PA; Pazianas, M; Russell, RG, 2012) |
| "Alendronate use was not associated with increased risk of cancer development in women with osteoporosis (adjusted hazard ratio, 1." | 1.38 | Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study. ( Chan, WL; Chen, JW; Chen, TJ; Chiang, CH; Chung, CM; Huang, CC; Huang, PH; Leu, HB; Lin, SJ, 2012) |
| " Intravenous ibandronate suppressed serum CTX levels to a significantly greater degree at 7 days after the second dosing (0." | 1.38 | Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates. ( Bae, SJ; Kim, BJ; Kim, GS; Kim, HK; Koh, JM; Lee, SH; Lim, KH, 2012) |
| "Alendronate was administered at 100 μg/kg, orally, once a day." | 1.38 | Downregulation of the inflammatory response by CORM-3 results in protective effects in a model of postmenopausal arthritis. ( Alcaraz, MJ; Caeiro, JR; Ferrándiz, ML; Guede, D; Ibáñez, L; Maicas, N; Motterlini, R, 2012) |
| " Long-term use of bisphosphonates may lead to low-energy femoral subtrochanteric or shaft fractures in a very few patients." | 1.38 | Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report. ( Chen, CH; Chen, JC; Cheng, YM; Fu, YC; Hsieh, CH; Huang, HT; Huang, PJ; Kang, L; Lin, SY, 2012) |
| "Alendronate treatment increased BMD and reduced the level of bone turnover markers." | 1.37 | Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis. ( Alimanovic-Alagić, R; Brković, A; Hadžović-Džuvo, A; Kučukalić-Selimović, E; Skopljak-Beganović, A; Valjevac, A, 2011) |
| " Among patients with osteoporosis in Taiwan who had experienced a fracture and had started alendronate therapy, compliance with the dosage regimen was suboptimal." | 1.37 | Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. ( Lin, SJ; Lin, TC; Yang, CY; Yang, YH, 2011) |
| " In two trials involving 1189 and 504 women, the incidence of clinical fractures, recorded as simple adverse effects, did not differ significantly between the groups." | 1.37 | Denosumab. Limited efficacy in fracture prevention, too many adverse effects. ( , 2011) |
| "A rise in gastrointestinal (GI) adverse events (AEs) and a decline in bone mineral density (BMD) was observed in patients previously tolerant to brand alendronate shortly after generic versions were introduced in July 2005 to the Canadian market." | 1.36 | Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study. ( Adachi, JD; Airia, P; Grima, DT; Ioannidis, G; Papaioannou, A, 2010) |
| "Treatment with alendronate could lead to a significant reduction in fracture risk in MGUS patients with skeletal fragility." | 1.35 | The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance. ( Fassino, V; Mascia, ML; Minisola, S; Pepe, J; Petrucci, MT; Piemonte, S; Romagnoli, E, 2008) |
| "We studied 1515 women with postmenopausal osteoporosis under treatment with anti-resorbing agents (alendronate, risedronate, raloxifene) for 13." | 1.35 | Vitamin D status and response to treatment in post-menopausal osteoporosis. ( Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L, 2009) |
| "Alendronate effects were detected at 3 months, and marked bone density increases were noted in juxta-cortical areas compared to inner trabecular areas." | 1.35 | Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. ( Imai, K; Matsumoto, T; Nakamura, K; Ohnishi, I; Yamamoto, S, 2009) |
| "Bisphosphonates are widely used for treatment of postmenopausal osteoporosis." | 1.35 | Case reports: two femoral insufficiency fractures after long-term alendronate therapy. ( Sayed-Noor, AS; Sjödén, GO, 2009) |
| "The objective of this study was to compare the changes on bone mineral density, and the effects on persistence and adverse events in patients treated for postmenopausal osteoporosis with generic alendronate or with branded alendronate (Fosamax®) or branded risedronate (Actonel®) once weekly." | 1.35 | Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. ( Möller, G; Ringe, JD, 2009) |
| "Alendronate is a bisphosphonate that inhibits bone resorption, thereby increasing bone mineral density (BMD), while also reducing bone formation closely coupled with bone resorption." | 1.35 | Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption. ( Aonuma, H; Hongo, M; Kasukawa, Y; Miyakoshi, N; Shimada, Y, 2009) |
| "Alendronate treatment decreased urinary cross-linked N-terminal telopeptides of type I collagen and serum alkaline phosphatase levels, and maintained metacarpal bone mineral density in postmenopausal Japanese women with osteoporosis." | 1.35 | Factors affecting discontinuation of alendronate treatment in postmenopausal Japanese women with osteoporosis. ( Iwamoto, J; Matsumoto, H; Miyata, A; Sato, Y; Takeda, T, 2009) |
| "Subtrochanteric insufficiency fractures in post-menopausal patients have not been commonly reported in the literature." | 1.35 | An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? ( Goh, SK; Howe, TS; Koh, JS; Kwek, EB; Png, MA, 2008) |
| " The effect of patient age, prescriber, initial dosing regimen, gastrointestinal adverse events, co-medication and fractures on non-compliance was investigated." | 1.35 | Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. ( Erkens, JA; Herings, RM; Olson, M; Penning-van Beest, FJ, 2008) |
| "Alendronate was the reference category in all analyses." | 1.35 | Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. ( Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T, 2008) |
| " The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate." | 1.34 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007) |
| " Hepatotoxicity due to alendronate therapy is a rare but possible adverse effect." | 1.34 | Hepatotoxicity induced by alendronate therapy. ( Atalar, H; Turkay, C; Yanik, B, 2007) |
| "Treatment with alendronate (Fosamax) has been shown to significantly reduce the risk of fragility fractures." | 1.34 | Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial. ( Boonen, S; Borgström, F; Haentjens, P; Johnell, O; Kanis, JA; Sen, SS; Ström, O, 2007) |
| " We believe that this finding is important and indicates the need for caution in the long-term use of alendronate in the treatment of osteoporosis." | 1.34 | Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. ( Chua, DT; Chua, SY; Goh, SK; Howe, TS; Koh, JS; Wong, MK; Yang, KY, 2007) |
| " 10 years), dosing frequency (monthly vs." | 1.34 | Osteoporosis medication profile preference: results from the PREFER-US study. ( McHorney, CA; Weiss, TW, 2007) |
| "Alendronate is a bisphosphonate used in treating osteoporosis." | 1.33 | Alendronate-induced chemical laryngitis. ( Bhutta, MF; Gillett, D; Rance, M; Weighill, JS, 2005) |
| "Alendronate was assumed to reduce the fracture risk by 50%." | 1.33 | Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. ( Brixen, K; Christensen, PM; Gyrd-Hansen, D; Kristiansen, IS, 2005) |
| "Alendronate OW was well tolerated; only 2." | 1.33 | Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. ( Cohen, YC; Foldes, AJ; Ish-Shalom, S; Shamir-Elron, Y; Vered, I; Weiss, M, 2005) |
| "In the field of postmenopausal osteoporosis, the quality of bone has gained more attention than the quantity, so the most important part of anti-osteoporotic efficacy of an agent translates its capacity to reduce osteoporotic fractures." | 1.33 | Are we treating women with postmenopausal osteoporosis for their low BMD or high fracture risk? ( Api, M, 2005) |
| "To investigate the cost-effectiveness of universal bone densitometry in women aged 65 and older combined with alendronate treatment for those diagnosed with osteoporosis (femoral neck T-score < or = -2." | 1.33 | Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. ( Ensrud, KE; Kane, RL; Melton, LJ; Nyman, JA; Schousboe, JT, 2005) |
| " Reducing oral bisphosphonate dosing frequency is one measure available to increase therapy convenience and practicality, with the hope of improving compliance and persistence." | 1.33 | Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. ( Altman, R; Amonkar, MM; Cramer, JA; Hebborn, A, 2005) |
| " Current reports have focused on therapy-resistant osteonecrosis of the jaws as a possible side effect of bisphosphonates." | 1.33 | [Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates]. ( Eufinger, H; Hoefert, S, 2005) |
| "A total of 1,041 postmenopausal osteoporosis cases were classified into 4 categories, Young controls (n = 165) and Old controls (n = 95) (Control group), Young (n = 309) and Old osteoporosis (n = 110) treated with alendronate (ALN group), and Young (n = 238) and Old osteoporosis (n = 124) treated with vitamins D3 or K2 (VDK group)." | 1.33 | [Very old patients with osteoporosis should be treated with alendronate]. ( Shiraki, M, 2006) |
| "Systemic mastocytosis is a rare and occasionally aggressive condition that raises major diagnostic challenges." | 1.32 | Aggressive systemic mastocytosis. ( Bertin, P; Inaoui, R; Jaccard, A; Petit, B; Trèves, R, 2003) |
| " At least 12 (n = 12) dosage units were tested for each product (except Fosmin, n = 10)." | 1.32 | Disintegration/dissolution profiles of copies of Fosamax (alendronate). ( Chow, J; Cryer, B; Epstein, S; Johnson, MA; Leyes, AE; Ragi, S; Walliser, J; Zanchetta, JR, 2003) |
| "Alendronate has been proven to be effective in the prevention and treatment of postmenopausal osteoporosis with the recommended daily dose of 10 mg." | 1.32 | Efficacy of intermittent low dose alendronate in Thai postmenopausal osteoporosis. ( Aunphongpuwanart, S; Chailurkit, LO; Jongjaroenprasert, W; Ongphiphadhanakul, B; Rajatanavin, R; Sae-tung, S, 2004) |
| "Alendronate was significantly more effective than risedronate, calcitonin, estrogen, etidronate, and raloxifene (Relative Risks: 0." | 1.32 | Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. ( Hochberg, MC; Hosking, D; Wehren, LE, 2004) |
| "Hip fractures are the most costly and best-documented complication of osteoporosis." | 1.32 | Health-economic comparison of three recommended drugs for the treatment of osteoporosis. ( Brecht, JG; Huppertz, E; Kruse, HP; Möhrke, W; Oestreich, A, 2004) |
| "A case review of postmenopausal osteoporosis is presented in the context of recent literature in the field." | 1.31 | Osteoporotic fractures in older women. ( Elliott, ME, 2002) |
| "Because on bone marker measurement bone resorption was increased and bone formation was decreased from baseline, treatment was switched to oral alendronate (5 mg/day, daily)." | 1.31 | Insufficiency fracture of the femoral neck during osteoporosis treatment: a case report. ( Iwamoto, J; Takeda, T, 2002) |
| "Up to 80-90% of patients with treatment-requiring osteoporosis are not receiving specific treatment." | 1.31 | [Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. ( Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W, 2002) |
| "Alendronate is an aminobisphosphonate, a selective inhibitor of osteoclast-mediated bone resorption." | 1.31 | [Prediction of changes in bone density during alendronate treatment in postmenopausal women]. ( Letkovská, A; Masaryk, P; Rovenský, J; Stancíková, M, 2002) |
| "One class of agents used to treat osteoporosis is the bisphosphonates, which inhibit bone resorption, cause an increase in bone mineral density and reduce the risk of future fractures caused by aging, estrogen deficiency and corticosteroid use." | 1.31 | Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. ( Bone, H; Greenspan, SL; Harris, ST; Miller, PD; Orwoll, ES; Rosen, CJ; Watts, NB, 2000) |
| " The bisphosphonate alendronate was recently approved for once-a-week dosing for the prevention and treatment of postmenopausal osteoporosis." | 1.31 | Osteoporosis. Efficacy and safety of a bisphosphonate dosed once weekly. ( Baran, D, 2001) |
| "Esophagitis is one of the adverse effects (AE) associated to its use." | 1.31 | [Esophagitis associated with use of alendronate in 5 postmenopausic patients]. ( Fay, M; Luciani, J; Naves, A; Pedrana, R; Pigatto, V; Piola, JC; Prada, DB; Silvestre Begnis, M, 2001) |
| "Based on evidence that the increased bone resorption after estrogen loss is due to an increase in osteoclastogenesis, we hypothesized that estrogen loss also stimulates osteoblastogenesis." | 1.30 | Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. ( Jilka, RL; Manolagas, SC; Munshi, M; Roberson, PK; Takahashi, K; Williams, DC, 1998) |
| " The drug should be absorbed after an overnight fast to improve its bioavailability and with a big glass of plain water to reduce the risk of oesophageal ulcerations." | 1.30 | [Drug clinics. The drug of the month. Alendronate (Fosamax)]. ( Scheen, AJ, 1998) |
| "In a woman with postmenopausal osteoporosis, the infusion of alendronate (7." | 1.29 | The effect of alendronate on renal tubular reabsorption of phosphate. ( Gertz, B; Kahn, S; Kanis, JA; McCloskey, EV; O'Doherty, DP; Vasikaran, SD, 1994) |
| " When taken after an overnight fast, 2 h before breakfast, the oral bioavailability of alendronate averages approximately 0." | 1.29 | Clinical pharmacology of alendronate sodium. ( Gertz, BJ; Holland, SD; Kline, WF; Matuszewski, BK; Porras, AG, 1993) |
| "Alendronate is a drug with considerable potential." | 1.29 | Alendronate: a new bisphosphonate for the treatment of osteoporosis. ( Keen, RW; Spector, TD, 1996) |
| "Bone loss associated with postmenopausal osteoporosis can be reduced by treatment with antiresorptive agents such as estrogen or bisphosphonates." | 1.29 | Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. ( Black, EC; Bryant, HU; Chandrasekhar, S; Frolik, CA; Magee, DE, 1996) |
| "Alendronate 7." | 1.29 | Sustained response to intravenous alendronate in postmenopausal osteoporosis. ( Kanis, JA; Khan, S; McCloskey, EV; Vasikaran, SD, 1995) |
| "Alendronate treatment maintained all parameters of bone turnover at control (nonovariectomized) levels and prevented the bone loss in a dose-dependent manner." | 1.28 | The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. ( Clair, J; Davidson, J; Fioravanti, C; Frankenfield, D; Jackson, R; Klein, H; Quartuccio, H; Seedor, JG; Solomon, H; Thompson, DD, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 157 (15.67) | 18.2507 |
| 2000's | 493 (49.20) | 29.6817 |
| 2010's | 265 (26.45) | 24.3611 |
| 2020's | 87 (8.68) | 2.80 |
| Authors | Studies |
|---|---|
| Thomasius, F | 2 |
| Palacios, S | 3 |
| Alam, A | 1 |
| Boolell, M | 3 |
| Vekeman, F | 2 |
| Gauthier, G | 1 |
| Asadullah, M | 1 |
| Sarfaraz, S | 1 |
| Tanzil, S | 1 |
| Ikram, R | 1 |
| Kamil, N | 1 |
| Qiu, Z | 1 |
| Lin, C | 2 |
| Zhang, Y | 3 |
| Deng, J | 2 |
| Wu, M | 6 |
| Hayes, KN | 1 |
| Brown, KA | 1 |
| Cheung, AM | 2 |
| Kim, SA | 1 |
| Juurlink, DN | 1 |
| Cadarette, SM | 2 |
| Feng, P | 1 |
| Shu, S | 1 |
| Zhao, F | 1 |
| Cosman, F | 19 |
| Kendler, DL | 8 |
| Langdahl, BL | 5 |
| Leder, BZ | 6 |
| Lewiecki, EM | 9 |
| Miyauchi, A | 3 |
| Rojeski, M | 2 |
| McDermott, M | 1 |
| Oates, MK | 2 |
| Milmont, CE | 1 |
| Libanati, C | 5 |
| Ferrari, S | 2 |
| Xiong, Z | 1 |
| Yi, P | 1 |
| Tang, X | 1 |
| Shu, L | 1 |
| Zhang, C | 2 |
| Radwan, A | 1 |
| Shraim, N | 1 |
| Elaraj, J | 1 |
| Hamad, A | 1 |
| Fatayer, D | 1 |
| Jarar, B | 1 |
| Johar, A | 1 |
| Zriqah, A | 1 |
| Miller, PD | 15 |
| Adachi, JD | 12 |
| Albergaria, BH | 1 |
| Chines, AA | 1 |
| Gielen, E | 1 |
| Oates, M | 1 |
| Reid, IR | 2 |
| Santiago, NR | 1 |
| Vanderkelen, M | 1 |
| Wang, Z | 3 |
| Yu, Z | 1 |
| Goeree, R | 3 |
| Burke, N | 1 |
| Jobin, M | 1 |
| Brown, JP | 6 |
| Lawrence, D | 1 |
| Stollenwerk, B | 2 |
| Willems, D | 2 |
| Johnson, B | 2 |
| Abdelfattah Abulfadle, K | 1 |
| Refaat Abdelkader Atia, R | 1 |
| Osama Mohammed, H | 1 |
| Saad Ramadan, R | 1 |
| Mohammed, NA | 1 |
| Lyu, H | 1 |
| Zhao, S | 1 |
| Li, J | 5 |
| Li, X | 1 |
| Wang, Y | 6 |
| Xie, D | 2 |
| Zeng, C | 1 |
| Lei, G | 1 |
| Wei, J | 1 |
| Li, H | 3 |
| Sahebari, M | 1 |
| Sarafraz Yazdi, M | 1 |
| Mehrnaz Aghili, S | 1 |
| Esmaily, H | 1 |
| Saeidi, S | 1 |
| Salari, M | 1 |
| Choo, YW | 1 |
| Mohd Tahir, NA | 1 |
| Mohamed Said, MS | 1 |
| Li, SC | 1 |
| Makmor Bakry, M | 1 |
| González Macías, J | 1 |
| Olmos Martínez, JM | 1 |
| Morkos, M | 1 |
| Mahrous, P | 1 |
| Casagrande, A | 1 |
| Go, MT | 1 |
| Husni, H | 1 |
| Hanna, M | 1 |
| Goel, M | 1 |
| Bedrose, S | 1 |
| Li, D | 1 |
| Baim, S | 2 |
| Li, M | 9 |
| Zhang, Z | 2 |
| Xue, Q | 1 |
| Li, Q | 2 |
| Jin, X | 1 |
| Dong, J | 1 |
| Cheng, Q | 4 |
| You, L | 5 |
| Lin, H | 4 |
| Tang, H | 4 |
| Shen, L | 2 |
| Gao, X | 1 |
| Hu, J | 2 |
| Chao, A | 1 |
| Li, P | 1 |
| Shi, R | 1 |
| Zheng, S | 1 |
| Xiong, X | 1 |
| Yu, W | 2 |
| Xia, W | 3 |
| Haider, IT | 1 |
| Sawatsky, A | 1 |
| Zhu, Y | 2 |
| Page, R | 1 |
| Kostenuik, PJ | 1 |
| Boyd, SK | 1 |
| Edwards, WB | 1 |
| Pluskiewicz, W | 1 |
| Adamczyk, P | 1 |
| Drozdzowska, B | 1 |
| Mori, S | 2 |
| Hagino, H | 6 |
| Sugimoto, T | 3 |
| Tanaka, S | 3 |
| Mitomo, Y | 1 |
| Takahashi, K | 2 |
| Sone, T | 4 |
| Nakamura, T | 8 |
| Soen, S | 2 |
| Ganapathy, A | 3 |
| Nieves, JW | 5 |
| Keaveny, TM | 7 |
| Narayanasamy, M | 3 |
| Bishop, S | 4 |
| Sahota, O | 6 |
| Paskins, Z | 4 |
| Gittoes, N | 4 |
| Langley, T | 4 |
| Wang, Q | 3 |
| Yu, Q | 3 |
| Zeng, P | 3 |
| Ai, W | 3 |
| Larrañaga-Vera, A | 2 |
| Toti, KS | 2 |
| Flatow, JS | 2 |
| Haraczy, AJ | 2 |
| Warnick, E | 2 |
| Rao, H | 2 |
| Gao, ZG | 2 |
| Sussman, SM | 2 |
| Mediero, A | 2 |
| Leucht, P | 2 |
| Jacobson, KA | 2 |
| Cronstein, BN | 2 |
| Ayers, C | 1 |
| Kansagara, D | 1 |
| Lazur, B | 1 |
| Fu, R | 1 |
| Kwon, A | 1 |
| Harrod, C | 1 |
| Tutaworn, T | 1 |
| Levin, JE | 1 |
| Yoo, JE | 1 |
| Lane, JM | 2 |
| Jiang, Y | 6 |
| Jiang, S | 1 |
| Li, L | 2 |
| Shi, S | 1 |
| Si, L | 1 |
| Pedersen, AB | 1 |
| Risbo, N | 1 |
| Kafatos, G | 1 |
| Neasham, D | 1 |
| O'Kelly, J | 2 |
| Ehrenstein, V | 1 |
| Huang, W | 1 |
| Nagao, M | 1 |
| Yonemoto, N | 1 |
| Guo, S | 1 |
| Tanigawa, T | 1 |
| Nishizaki, Y | 1 |
| Yang, D | 1 |
| Tan, J | 1 |
| Long, Y | 1 |
| Huang, K | 1 |
| Han, W | 1 |
| Wang, M | 1 |
| Zhu, S | 1 |
| Zeng, S | 1 |
| Yi, W | 1 |
| Mendes, D | 1 |
| Penedones, A | 1 |
| Alves, C | 1 |
| Oliveira, T | 1 |
| Donato, A | 1 |
| Batel-Marques, F | 1 |
| Eisman, JA | 2 |
| Cortet, B | 5 |
| Ionescu-Ittu, R | 1 |
| Heroux, J | 1 |
| Moshi, MR | 1 |
| Nicolopoulos, K | 1 |
| Stringer, D | 1 |
| Ma, N | 1 |
| Jenal, M | 1 |
| Vreugdenburg, T | 1 |
| Hiligsmann, M | 3 |
| Silverman, SS | 1 |
| Singer, AJ | 1 |
| Pearman, L | 1 |
| Mathew, J | 1 |
| Caminis, J | 1 |
| Reginster, JY | 16 |
| Kim, M | 2 |
| Lin, TC | 3 |
| Arora, T | 1 |
| Zhao, H | 2 |
| Balasubramanian, A | 1 |
| Stad, RK | 2 |
| Spangler, L | 1 |
| Bradbury, BD | 1 |
| Curtis, JR | 2 |
| Tan, EH | 1 |
| Robinson, DE | 1 |
| Jödicke, AM | 1 |
| Mosseveld, M | 1 |
| Bødkergaard, K | 1 |
| Reyes, C | 2 |
| Moayyeri, A | 1 |
| Voss, A | 1 |
| Marconi, E | 1 |
| Lapi, F | 1 |
| Reinold, J | 1 |
| Verhamme, KMC | 1 |
| Pedersen, L | 1 |
| Braitmaier, M | 1 |
| de Wilde, M | 1 |
| Ruiz, MF | 1 |
| Aragón, M | 1 |
| Bosco-Levy, P | 1 |
| Lassalle, R | 1 |
| Prieto-Alhambra, D | 2 |
| Sanchez-Santos, MT | 1 |
| Tian, L | 1 |
| Luo, C | 1 |
| Li, YF | 1 |
| Wang, QY | 1 |
| Qu, XL | 1 |
| Yue, C | 1 |
| Xu, LL | 1 |
| Yang, YY | 1 |
| Sheng, ZF | 2 |
| Everts-Graber, J | 1 |
| Bonel, H | 1 |
| Lehmann, D | 1 |
| Gahl, B | 1 |
| Häuselmann, H | 1 |
| Studer, U | 1 |
| Ziswiler, HR | 1 |
| Reichenbach, S | 1 |
| Lehmann, T | 1 |
| Casado, E | 1 |
| Rosas, J | 1 |
| Rubio-Terrés, C | 1 |
| Rubio-Rodríguez, D | 1 |
| Arístegui, I | 1 |
| Narayanasamy, MJ | 1 |
| Corp, N | 1 |
| Bastounis, A | 1 |
| Griffin, J | 1 |
| Leonardi-Bee, J | 1 |
| Hikmet, R | 1 |
| Harsløf, T | 3 |
| Fernandes, TL | 1 |
| Viezzer Fernandes, B | 1 |
| Jitumori, C | 1 |
| Franco, GCN | 1 |
| Gehrke, B | 1 |
| Alves Coelho, MC | 1 |
| Brasil d'Alva, C | 1 |
| Madeira, M | 1 |
| Koiwai, H | 1 |
| Kamimura, M | 2 |
| Takahashi, J | 1 |
| Nakamura, Y | 2 |
| Kato, H | 2 |
| Uemura, Y | 2 |
| Taguri, M | 1 |
| Kawahara, T | 1 |
| Chiba, Y | 1 |
| Kendler, D | 5 |
| Chines, A | 2 |
| Clark, P | 1 |
| Ebeling, PR | 2 |
| McClung, M | 18 |
| Rhee, Y | 3 |
| Huang, S | 1 |
| Iba, K | 4 |
| Takada, J | 5 |
| Sonoda, T | 1 |
| Yamashita, T | 4 |
| Mitlak, B | 5 |
| Hu, MY | 3 |
| Hattersley, G | 4 |
| Bockman, RS | 1 |
| Duckworth, AD | 1 |
| McQueen, MM | 1 |
| Tuck, CE | 1 |
| Tobias, JH | 1 |
| Wilkinson, JM | 1 |
| Biant, LC | 1 |
| Pulford, EC | 1 |
| Aldridge, S | 1 |
| Edwards, C | 1 |
| Roberts, CP | 1 |
| Ramachandran, M | 1 |
| McAndrew, AR | 1 |
| Cheng, KCK | 1 |
| Johnston, P | 1 |
| Shah, NH | 1 |
| Mathew, P | 1 |
| Harvie, J | 1 |
| Hanusch, BC | 1 |
| Harkess, R | 1 |
| Rodriguez, A | 1 |
| Murray, GD | 1 |
| Ralston, SH | 4 |
| Ha, J | 1 |
| Lee, JM | 1 |
| Lim, Y | 1 |
| Kim, MK | 1 |
| Kwon, HS | 1 |
| Song, KH | 1 |
| Jeon, HM | 1 |
| Kang, MI | 1 |
| Baek, KH | 1 |
| Gossiel, F | 3 |
| Paggiosi, MA | 3 |
| Naylor, KE | 3 |
| McCloskey, EV | 7 |
| Walsh, J | 1 |
| Peel, N | 2 |
| Eastell, R | 13 |
| Horne, AM | 1 |
| Mihov, B | 1 |
| Stewart, A | 2 |
| Bastin, S | 1 |
| Gamble, GD | 1 |
| Giampà, E | 2 |
| Di Bonito, M | 2 |
| Ferretti, V | 2 |
| Nuvoli, G | 2 |
| Paoletti, F | 2 |
| Piazzini, M | 2 |
| Ranieri, M | 2 |
| Tuveri, MA | 2 |
| Vinicola, V | 2 |
| Nayak, S | 1 |
| Greenspan, SL | 19 |
| Lau, EMC | 1 |
| Dinavahi, R | 1 |
| Woo, YC | 1 |
| Wu, CH | 1 |
| Guan, J | 1 |
| Maddox, J | 3 |
| Tolman, C | 1 |
| Yang, W | 2 |
| Shin, CS | 3 |
| Pongchaiyakul, C | 2 |
| Nanagara, R | 1 |
| Songpatanasilp, T | 1 |
| Unnanuntana, A | 3 |
| Kataoka, Y | 1 |
| Luo, Y | 2 |
| Chaimani, A | 1 |
| Onishi, A | 1 |
| Kimachi, M | 1 |
| Tsujimoto, Y | 1 |
| Murad, MH | 1 |
| Li, T | 1 |
| Cipriani, A | 1 |
| Furukawa, TA | 1 |
| Karakousis, VA | 1 |
| Liouliou, D | 1 |
| Loula, A | 1 |
| Kagianni, N | 1 |
| Dietrich, EM | 1 |
| Meditskou, S | 1 |
| Sioga, A | 1 |
| Papamitsou, T | 1 |
| Compston, J | 1 |
| Fontalis, A | 1 |
| Cummings, SR | 19 |
| McCulloch, C | 1 |
| McClung, MR | 14 |
| Ebetino, FH | 1 |
| Lesclous, P | 1 |
| Cloitre, A | 1 |
| Catros, S | 1 |
| Devoize, L | 1 |
| Louvet, B | 1 |
| Châtel, C | 1 |
| Foissac, F | 1 |
| Roux, C | 9 |
| Santora, AC | 20 |
| Black, DM | 25 |
| Russell, RGG | 1 |
| Hesse, E | 1 |
| Napoli, N | 2 |
| Matsumoto, T | 4 |
| Crittenden, DB | 1 |
| Fitzpatrick, LA | 7 |
| Harvey, NC | 1 |
| Deal, C | 2 |
| Wu, J | 1 |
| Wang, C | 5 |
| Li, GF | 1 |
| Tang, ET | 2 |
| Zheng, Q | 1 |
| Suzuki, T | 1 |
| Harada, A | 3 |
| Shimada, H | 1 |
| Hosoi, T | 2 |
| Kawata, Y | 1 |
| Inoue, T | 3 |
| Saito, H | 1 |
| Bandeira, F | 2 |
| Dantas, W | 1 |
| Bilezikian, JP | 15 |
| Paik, J | 1 |
| Scott, LJ | 1 |
| Watts, NB | 13 |
| Dore, RK | 3 |
| Rozental, TD | 1 |
| LeBoff, MS | 2 |
| Bone, HG | 14 |
| Itoi, E | 1 |
| Ohta, H | 1 |
| Fukunaga, M | 4 |
| Orimo, H | 4 |
| Shiraki, M | 6 |
| Söreskog, E | 1 |
| Lindberg, I | 1 |
| Kanis, JA | 10 |
| Åkesson, KE | 1 |
| Lorentzon, M | 3 |
| Ström, O | 6 |
| Berling, P | 1 |
| Borgström, F | 5 |
| Sølling, AS | 2 |
| Christensen, DH | 1 |
| Darvalics, B | 1 |
| Thomsen, RW | 1 |
| Langdahl, B | 3 |
| Maggi, S | 1 |
| Veronese, N | 1 |
| Sartori, L | 2 |
| Giusti, A | 3 |
| Bianchi, G | 4 |
| Barone, A | 3 |
| Zheng, WB | 1 |
| Dai, Y | 1 |
| Zhao, DC | 1 |
| Wang, O | 3 |
| Xia, WB | 7 |
| Xing, XP | 3 |
| Bruun, NH | 1 |
| Ouyang, Y | 1 |
| Chen, S | 1 |
| Wan, T | 1 |
| Zheng, G | 1 |
| Sun, G | 1 |
| Ma, R | 1 |
| Li, Y | 5 |
| Wang, J | 4 |
| Yang, P | 1 |
| Chen, Y | 1 |
| Wang, W | 4 |
| Song, J | 2 |
| Wang, K | 1 |
| Tanaka, K | 1 |
| Silverman, S | 1 |
| Gandra, SR | 1 |
| Charokopou, M | 1 |
| Adachi, K | 1 |
| Mori, T | 3 |
| Crandall, CJ | 3 |
| Fujii, T | 2 |
| Ganz, DA | 3 |
| Sasaki, K | 1 |
| Catalano, A | 2 |
| Bellone, F | 1 |
| Santoro, D | 1 |
| Schwarz, P | 1 |
| Gaudio, A | 1 |
| Basile, G | 1 |
| Sottile, MC | 1 |
| Stoian, SA | 1 |
| Corica, F | 1 |
| Morabito, N | 1 |
| Cromer, SJ | 1 |
| D'Silva, KM | 1 |
| Yu, EW | 1 |
| Landon, J | 1 |
| Desai, RJ | 2 |
| Kim, SC | 2 |
| Engelke, K | 1 |
| Chapurlat, R | 4 |
| Foldes, AJ | 4 |
| Nogues, X | 1 |
| Civitelli, R | 2 |
| De Villiers, T | 2 |
| Massari, F | 1 |
| Zerbini, CAF | 1 |
| Recknor, C | 3 |
| Falgayrac, G | 1 |
| Farlay, D | 2 |
| Ponçon, C | 1 |
| Béhal, H | 1 |
| Gardegaront, M | 1 |
| Ammann, P | 1 |
| Boivin, G | 7 |
| Migliorini, F | 1 |
| Maffulli, N | 1 |
| Colarossi, G | 1 |
| Eschweiler, J | 1 |
| Tingart, M | 1 |
| Betsch, M | 1 |
| Albert, SG | 1 |
| Reddy, S | 1 |
| Liel, Y | 1 |
| Plakht, Y | 1 |
| Tailakh, MA | 1 |
| Altman-Singles, AR | 1 |
| Jeong, Y | 1 |
| Tseng, WJ | 1 |
| de Bakker, CM | 1 |
| Lott, C | 1 |
| Robberts, J | 1 |
| Qin, L | 1 |
| Han, L | 1 |
| Kim, DG | 1 |
| Liu, XS | 1 |
| Yoon, BK | 2 |
| Lee, DY | 2 |
| Park, MC | 1 |
| Cho, SH | 1 |
| Park, HM | 2 |
| Choi, YM | 1 |
| Wang, YK | 1 |
| Qin, SQ | 1 |
| Ma, T | 1 |
| Song, W | 1 |
| Jiang, RQ | 1 |
| Guo, JB | 1 |
| Li, K | 1 |
| Zhang, YM | 1 |
| Jarusriwanna, A | 1 |
| Songcharoen, P | 1 |
| Shi, L | 1 |
| Gao, F | 1 |
| Sun, W | 1 |
| Wang, B | 1 |
| Guo, W | 1 |
| Cheng, L | 1 |
| Li, Z | 3 |
| Tebe, C | 1 |
| Martinez-Laguna, D | 1 |
| Ali, MS | 1 |
| Soria-Castro, A | 1 |
| Carbonell, C | 1 |
| Granchi, D | 1 |
| Torreggiani, E | 1 |
| Massa, A | 1 |
| Caudarella, R | 1 |
| Di Pompo, G | 1 |
| Baldini, N | 1 |
| Pan, WL | 1 |
| Chen, PL | 1 |
| Lin, CY | 1 |
| Pan, YC | 1 |
| Ju, YR | 1 |
| Chan, CP | 1 |
| Hsu, RW | 1 |
| Misof, BM | 3 |
| Blouin, S | 2 |
| Lueger, S | 1 |
| Paschalis, EP | 5 |
| Recker, RR | 4 |
| Phipps, R | 2 |
| Klaushofer, K | 6 |
| Roschger, P | 3 |
| Saag, KG | 4 |
| Petersen, J | 2 |
| Brandi, ML | 3 |
| Karaplis, AC | 2 |
| Thomas, T | 8 |
| Fan, M | 1 |
| Meisner, PD | 1 |
| Grauer, A | 3 |
| Karlsson, L | 1 |
| Mesterton, J | 1 |
| Tepie, MF | 1 |
| Intorcia, M | 1 |
| Overbeek, J | 1 |
| Roh, YH | 1 |
| Noh, JH | 1 |
| Gong, HS | 1 |
| Baek, GH | 1 |
| Franklin, JM | 1 |
| Axelsson, KF | 1 |
| Nilsson, AG | 1 |
| Boskey, AL | 1 |
| Spevak, L | 1 |
| Ma, Y | 1 |
| Wang, H | 3 |
| Bauer, DC | 14 |
| Schwartz, AV | 9 |
| Liu, GF | 1 |
| Wang, ZQ | 1 |
| Liu, L | 2 |
| Zhang, BT | 1 |
| Miao, YY | 1 |
| Yu, SN | 1 |
| Al Daghri, N | 1 |
| Kaufman, JM | 2 |
| Bruyère, O | 1 |
| Hirsch, C | 1 |
| Steurer, J | 1 |
| Kajihara, Y | 1 |
| Bradburn, M | 1 |
| Peel, NFA | 1 |
| Walsh, JS | 3 |
| Fujiwara, S | 1 |
| Hamaya, E | 1 |
| Nicholls, RJ | 1 |
| Weston, A | 1 |
| Baidya, S | 1 |
| Pinto, L | 1 |
| Barron, R | 1 |
| Anastasilakis, AD | 2 |
| Polyzos, SA | 2 |
| Makras, P | 1 |
| Lee, YS | 1 |
| Gupta, R | 1 |
| Kwon, JT | 1 |
| Cho, DC | 1 |
| Seo, YJ | 1 |
| Seu, SY | 1 |
| Park, EK | 1 |
| Han, I | 1 |
| Kim, CH | 1 |
| Sung, JK | 1 |
| Kim, KT | 1 |
| Williams, GC | 2 |
| Papapoulos, S | 2 |
| Rizzoli, R | 7 |
| Burns, RB | 1 |
| Rosen, H | 1 |
| Berry, S | 1 |
| Smetana, GW | 1 |
| Liao, EY | 4 |
| Zhang, ZL | 6 |
| Wang, L | 6 |
| Hao, YQ | 3 |
| Chen, DC | 4 |
| Peng, YD | 2 |
| He, L | 3 |
| Hu, ZH | 3 |
| Song, CL | 3 |
| Wei, F | 3 |
| Zhang, L | 4 |
| Ayyoub, S | 1 |
| Coyne, C | 1 |
| Yoshizawa, T | 1 |
| Nishino, T | 1 |
| Okubo, I | 1 |
| Yamazaki, M | 1 |
| Le, QA | 1 |
| Hay, JW | 1 |
| Becker, R | 1 |
| Khanizadeh, F | 1 |
| Rahmani, A | 1 |
| Asadollahi, K | 1 |
| Ahmadi, MRH | 1 |
| Jia, G | 1 |
| Kong, X | 1 |
| Zhang, W | 1 |
| Meng, C | 1 |
| Feng, Z | 1 |
| Pan, T | 1 |
| Zhao, C | 1 |
| Moriwaki, K | 4 |
| Fukuda, H | 1 |
| Lamy, O | 3 |
| Fernández-Fernández, E | 1 |
| Monjo-Henry, I | 1 |
| Stoll, D | 1 |
| Aubry-Rozier, B | 1 |
| Benavent-Núñez, D | 1 |
| Aguado, P | 1 |
| Gonzalez-Rodriguez, E | 1 |
| Tang, Y | 1 |
| Xia, H | 1 |
| Kang, L | 2 |
| Sun, Q | 1 |
| Su, Z | 1 |
| Hao, C | 1 |
| Xue, Y | 1 |
| Torres, G | 1 |
| Bandeira, E | 1 |
| Duarte, MB | 1 |
| Nóbrega, AM | 1 |
| Bandeira, L | 1 |
| Horikawa, A | 1 |
| Miyakoshi, N | 2 |
| Hongo, M | 2 |
| Kasukawa, Y | 2 |
| Kodama, H | 1 |
| Shimada, Y | 2 |
| Beattie, JR | 1 |
| Sophocleous, A | 1 |
| Caraher, MC | 1 |
| O'Driscoll, O | 1 |
| Cummins, NM | 1 |
| Bell, SEJ | 1 |
| Towler, M | 1 |
| Rahimnejad Yazdi, A | 1 |
| Idris, AI | 1 |
| Fink, HA | 2 |
| MacDonald, R | 1 |
| Forte, ML | 1 |
| Rosebush, CE | 1 |
| Ensrud, KE | 15 |
| Schousboe, JT | 4 |
| Nelson, VA | 1 |
| Ullman, K | 1 |
| Butler, M | 1 |
| Olson, CM | 1 |
| Taylor, BC | 1 |
| Brasure, M | 1 |
| Wilt, TJ | 1 |
| Pepe, J | 3 |
| Cipriani, C | 2 |
| Cecchetti, V | 1 |
| Ferrara, C | 1 |
| Della Grotta, G | 1 |
| Danese, V | 1 |
| Colangelo, L | 1 |
| Minisola, S | 6 |
| Min, YK | 2 |
| Choi, SJ | 1 |
| Kim, JH | 1 |
| Choi, D | 1 |
| McNabb, BL | 1 |
| Vittinghoff, E | 5 |
| Ensrud, K | 10 |
| Rosenberg, E | 5 |
| Santora, A | 4 |
| Barrett-Connor, E | 6 |
| Von Schacht, E | 1 |
| Dambacher, MA | 1 |
| Ringe, JD | 7 |
| Dukas, L | 1 |
| Kumar, S | 1 |
| Hoffman, SJ | 1 |
| Samadfam, R | 1 |
| Mansell, P | 1 |
| Jolette, J | 1 |
| Smith, SY | 1 |
| Guldberg, RE | 1 |
| Chiu, WY | 1 |
| Lee, JJ | 1 |
| Tsai, KS | 2 |
| Park, JH | 1 |
| Park, KH | 1 |
| Cho, S | 2 |
| Choi, YS | 2 |
| Seo, SK | 2 |
| Lee, BS | 2 |
| Park, HS | 2 |
| Foster, SA | 1 |
| Shi, N | 1 |
| Curkendall, S | 1 |
| Stock, J | 2 |
| Chu, BC | 1 |
| Burge, R | 2 |
| Diakun, DR | 1 |
| Krege, JH | 6 |
| Lindsay, R | 8 |
| Lange, JL | 4 |
| Delmas, PD | 14 |
| Silverman, SL | 4 |
| Terpos, E | 1 |
| Giannotti, S | 1 |
| Bottai, V | 1 |
| Dell'Osso, G | 1 |
| De Paola, G | 1 |
| Ghilardi, M | 1 |
| Guido, G | 1 |
| Chung, YS | 2 |
| Choi, YJ | 1 |
| Kim, SH | 2 |
| Guañabens, N | 2 |
| Monegal, A | 2 |
| Cerdá, D | 1 |
| Muxí, Á | 1 |
| Gifre, L | 1 |
| Peris, P | 2 |
| Parés, A | 2 |
| Çakmak, S | 1 |
| Mahiroğulları, M | 1 |
| Keklikçi, K | 1 |
| Sarı, E | 1 |
| Erdik, B | 1 |
| Rodop, O | 1 |
| Di Fede, O | 1 |
| Fusco, V | 1 |
| Matranga, D | 1 |
| Solazzo, L | 1 |
| Gabriele, M | 1 |
| Gaeta, GM | 1 |
| Favia, G | 1 |
| Sprini, D | 1 |
| Peluso, F | 1 |
| Colella, G | 1 |
| Vescovi, P | 1 |
| Campisi, G | 1 |
| Jiang, Q | 1 |
| Snapinn, S | 1 |
| Parthan, A | 1 |
| Kruse, M | 1 |
| Yurgin, N | 1 |
| Huang, J | 1 |
| Viswanathan, HN | 1 |
| Taylor, D | 1 |
| Nagase, S | 1 |
| Small, M | 1 |
| Boonen, S | 6 |
| Spector, T | 1 |
| Ohyama, M | 1 |
| Kuwayama, T | 1 |
| Deacon, S | 1 |
| Prada García, C | 1 |
| Rodríguez Prieto, MÁ | 1 |
| Wan, X | 3 |
| Zhao, Y | 2 |
| Boroujerdi, MA | 1 |
| Schmidt, S | 1 |
| Binkley, N | 4 |
| Kiel, DP | 4 |
| Regnister, JY | 1 |
| Pong, A | 1 |
| Lindtner, RA | 1 |
| Tiaden, AN | 1 |
| Genelin, K | 1 |
| Ebner, HL | 1 |
| Manzl, C | 1 |
| Klawitter, M | 1 |
| Sitte, I | 1 |
| von Rechenberg, B | 1 |
| Blauth, M | 1 |
| Richards, PJ | 1 |
| Gallagher, JC | 3 |
| Tella, SH | 2 |
| Brandão, CM | 2 |
| Ferré, F | 1 |
| Machado, GP | 1 |
| Guerra, AA | 2 |
| Andrade, EI | 1 |
| Cherchiglia, ML | 1 |
| Acurcio, Fde A | 2 |
| Ettinger, B | 4 |
| Stuenkel, CA | 1 |
| Schnatz, PF | 1 |
| Serrano, AJ | 1 |
| Begoña, L | 1 |
| Anitua, E | 1 |
| Cobos, R | 1 |
| Orive, G | 1 |
| Bonnick, S | 3 |
| Odio, A | 1 |
| DaSilva, C | 1 |
| Scott, BB | 1 |
| Le Bailly De Tilleghem, C | 1 |
| Leung, AT | 1 |
| Gurner, D | 1 |
| Akbaba, G | 1 |
| Isik, S | 1 |
| Ates Tutuncu, Y | 1 |
| Ozuguz, U | 1 |
| Berker, D | 1 |
| Guler, S | 1 |
| Yang, CY | 2 |
| Yang, YH | 2 |
| Lin, SJ | 3 |
| Hadji, P | 5 |
| Felsenberg, D | 9 |
| Amling, M | 2 |
| Hofbauer, LC | 2 |
| Kandenwein, JA | 1 |
| Kurth, A | 1 |
| Ho, PR | 1 |
| Wark, JD | 3 |
| Zillikens, MC | 1 |
| Fahrleitner-Pammer, A | 7 |
| Hawkins, F | 2 |
| Micaelo, M | 1 |
| Papaioannou, N | 1 |
| Stone, M | 1 |
| Ferreira, I | 1 |
| Siddhanti, S | 6 |
| Wagman, RB | 3 |
| Diab, DL | 1 |
| Drampalos, E | 1 |
| Skarpas, G | 1 |
| Barbounakis, N | 1 |
| Michos, I | 1 |
| van den Bergh, JP | 1 |
| Bouts, ME | 1 |
| van der Veer, E | 1 |
| van der Velde, RY | 1 |
| Janssen, MJ | 1 |
| Geusens, PP | 1 |
| Winkens, B | 1 |
| Oldenhof, NJ | 1 |
| van Geel, TA | 1 |
| Ma, YL | 2 |
| Zeng, QQ | 1 |
| Chiang, AY | 1 |
| Burr, D | 2 |
| Dobnig, H | 6 |
| Michalská, D | 4 |
| Marin, F | 3 |
| Pavo, I | 8 |
| Stepan, JJ | 8 |
| McLendon, AN | 1 |
| Woodis, CB | 1 |
| Bolognese, MA | 5 |
| Diez-Perez, A | 2 |
| Zanchetta, JR | 5 |
| Wasserman, SM | 1 |
| Katz, L | 1 |
| Yang, YC | 2 |
| Cairoli, E | 1 |
| Eller-Vainicher, C | 1 |
| Ulivieri, FM | 1 |
| Zhukouskaya, VV | 1 |
| Palmieri, S | 1 |
| Morelli, V | 1 |
| Beck-Peccoz, P | 1 |
| Chiodini, I | 1 |
| Liu, Y | 5 |
| Liu, H | 2 |
| Zhou, P | 1 |
| Xing, X | 2 |
| Liao, E | 1 |
| Chen, D | 1 |
| Liu, J | 3 |
| Tao, T | 1 |
| Wu, W | 2 |
| Xu, L | 3 |
| Gopal, GK | 1 |
| Tam, KL | 1 |
| Krishnan, SP | 1 |
| Maddern, IL | 1 |
| Igase, M | 1 |
| Kohara, K | 1 |
| Tabara, Y | 1 |
| Ohara, M | 1 |
| Takita, R | 1 |
| Ochi, M | 1 |
| Okada, Y | 1 |
| Miki, T | 2 |
| Yilmaz, F | 1 |
| Doğu, B | 1 |
| Sahin, F | 1 |
| Sirzai, H | 1 |
| Kuran, B | 1 |
| Muschitz, C | 2 |
| Kocijan, R | 1 |
| Haschka, J | 1 |
| Schima, W | 1 |
| Kapiotis, S | 1 |
| Resch, H | 2 |
| Gorai, I | 2 |
| Yoshikawa, H | 3 |
| Tanaka, Y | 1 |
| Nakano, T | 2 |
| Ito, M | 2 |
| Matsui, S | 1 |
| Yoneda, T | 1 |
| Takami, H | 1 |
| Watanabe, K | 1 |
| Osakabe, T | 1 |
| Svanström, H | 1 |
| Pasternak, B | 1 |
| Hviid, A | 1 |
| Kim, KJ | 1 |
| Koh, JM | 2 |
| Kim, KM | 1 |
| Byun, DW | 1 |
| Kim, IJ | 1 |
| Kim, SS | 1 |
| Min, KW | 1 |
| Han, KO | 1 |
| Choi, SH | 1 |
| Park, JS | 1 |
| Chung, DJ | 1 |
| Mok, JO | 1 |
| Baek, HS | 1 |
| Moon, SH | 1 |
| Kim, YS | 1 |
| Lim, SK | 3 |
| Ottaway, ZV | 1 |
| Hammond, C | 1 |
| Merritt, S | 1 |
| Yang, L | 2 |
| Wu, Y | 1 |
| He, C | 1 |
| Chiang, GS | 1 |
| Grace, CS | 1 |
| Koh, KW | 1 |
| Kelvin, KW | 1 |
| Chong, TW | 1 |
| Wei, CT | 1 |
| Tan, BY | 1 |
| Yeow, TB | 1 |
| Osada, R | 1 |
| Zukawa, M | 1 |
| Kimura, T | 1 |
| Messori, A | 2 |
| Fadda, V | 2 |
| Maratea, D | 2 |
| Trippoli, S | 2 |
| Marinai, C | 1 |
| Hofstetter, B | 2 |
| Gamsjaeger, S | 3 |
| Varga, F | 1 |
| Petto, H | 4 |
| McCloskey, E | 1 |
| Fabiny, A | 1 |
| McNabb, B | 1 |
| Tienboon, P | 1 |
| Jaruwangsanti, N | 1 |
| Acerbo, AS | 1 |
| Kwaczala, AT | 1 |
| Judex, S | 1 |
| Miller, LM | 1 |
| Krause, M | 1 |
| Soltau, M | 1 |
| Zimmermann, EA | 1 |
| Hahn, M | 1 |
| Kornet, J | 1 |
| Hapfelmeier, A | 1 |
| Breer, S | 1 |
| Morlock, M | 1 |
| Wulff, B | 1 |
| Püschel, K | 1 |
| Glueer, CC | 1 |
| Busse, B | 1 |
| Hassler, N | 1 |
| Brozek, W | 1 |
| Stuckey, BG | 1 |
| Sallie, R | 1 |
| Casiano, V | 1 |
| Kalish, VB | 1 |
| Unwin, B | 1 |
| Ishtiaq, S | 1 |
| Edwards, S | 1 |
| Sankaralingam, A | 1 |
| Evans, BA | 1 |
| Elford, C | 1 |
| Frost, ML | 2 |
| Fogelman, I | 3 |
| Hampson, G | 1 |
| Cesareo, R | 2 |
| Di Stasio, E | 1 |
| Vescini, F | 1 |
| Campagna, G | 1 |
| Cianni, R | 1 |
| Pasqualini, V | 1 |
| Romitelli, F | 1 |
| Grimaldi, F | 1 |
| Manfrini, S | 1 |
| Palermo, A | 1 |
| Mukaiyama, K | 1 |
| Uchiyama, S | 1 |
| Ikegami, S | 1 |
| Piscitelli, P | 1 |
| Auriemma, R | 1 |
| Neglia, C | 1 |
| Migliore, A | 1 |
| Skoglund, K | 1 |
| Hjortdal, O | 1 |
| De Peng, Y | 1 |
| Tsai, JN | 2 |
| Foley, K | 1 |
| Lee, H | 3 |
| Burnett-Bowie, SA | 1 |
| Neer, RM | 2 |
| Zion, M | 2 |
| Garrett, P | 1 |
| Neubort, S | 1 |
| Dempster, D | 1 |
| Jacques, RM | 1 |
| Paggiosi, M | 1 |
| Peel, NF | 1 |
| Tallarico, M | 1 |
| Canullo, L | 1 |
| Xhanari, E | 1 |
| Meloni, SM | 1 |
| Hu, S | 1 |
| Liu, CC | 1 |
| Chen, G | 1 |
| Willett, T | 1 |
| Young, RN | 1 |
| Grynpas, MD | 1 |
| Gatti, D | 5 |
| Adami, S | 17 |
| Viapiana, O | 2 |
| Rossini, M | 5 |
| Zheng, H | 1 |
| He, JW | 2 |
| Fu, WZ | 1 |
| Eiken, P | 2 |
| Vestergaard, P | 3 |
| Lengfeld, J | 1 |
| Buder-Bakhaya, K | 1 |
| Goebeler, M | 1 |
| Wobser, M | 1 |
| Ribeiro, NR | 1 |
| Silva, Lde F | 1 |
| Santana, DM | 1 |
| Nogueira, RL | 1 |
| Ebina, K | 1 |
| Noguchi, T | 1 |
| Hirao, M | 1 |
| Hashimoto, J | 2 |
| Kaneshiro, S | 1 |
| Yukioka, M | 1 |
| Rugpolmuang, L | 1 |
| Waikakul, S | 1 |
| Murray, JC | 1 |
| Audet, MC | 1 |
| Bédard, M | 1 |
| Michou, L | 1 |
| Xu, LH | 1 |
| Adams-Huet, B | 1 |
| Poindexter, JR | 1 |
| Maalouf, NM | 1 |
| Cho, PG | 1 |
| Ji, GY | 1 |
| Shin, DA | 1 |
| Ha, Y | 1 |
| Yoon, DH | 1 |
| Kim, KN | 1 |
| Wang, JY | 1 |
| Zhou, PR | 1 |
| Xu, XJ | 2 |
| Ma, DD | 2 |
| Lee, MY | 1 |
| Kim, HY | 1 |
| Singh, D | 1 |
| Yeo, SH | 1 |
| Baek, SY | 1 |
| Park, YK | 1 |
| Lee, CH | 1 |
| Tian, Y | 1 |
| Wang, R | 1 |
| Ma, C | 1 |
| Lu, Q | 1 |
| Yin, F | 1 |
| van de Glind, EM | 1 |
| Willems, HC | 1 |
| Eslami, S | 1 |
| Abu-Hanna, A | 1 |
| Lems, WF | 2 |
| Hooft, L | 1 |
| de Rooij, SE | 1 |
| van Munster, BC | 1 |
| Paccou, J | 1 |
| Marques, A | 1 |
| Lourenço, Ó | 1 |
| Ortsäter, G | 1 |
| da Silva, JA | 1 |
| Uğurlar, M | 1 |
| Tan, W | 1 |
| Sun, J | 1 |
| Zhou, L | 1 |
| Wu, X | 1 |
| Yoshimura, M | 1 |
| Noto, S | 2 |
| Takiguchi, T | 2 |
| Sánchez, A | 1 |
| Blanco, R | 1 |
| Berkhout, J | 1 |
| Stone, JA | 1 |
| Verhamme, KM | 1 |
| Danhof, M | 1 |
| Post, TM | 1 |
| Han, LW | 1 |
| Lü, F | 1 |
| Valter, I | 1 |
| Riis, BJ | 1 |
| Christiansen, C | 9 |
| Black, D | 9 |
| Mouri, M | 1 |
| Jiang, LA | 1 |
| Song, H | 1 |
| Li, S | 1 |
| Yang, K | 1 |
| Dai, M | 1 |
| Shen, Y | 1 |
| Petrucci, MT | 1 |
| Mascia, ML | 1 |
| Piemonte, S | 2 |
| Fassino, V | 1 |
| Romagnoli, E | 2 |
| Giannini, S | 1 |
| Sinigaglia, L | 2 |
| Di Munno, O | 1 |
| Fiore, CE | 1 |
| Choi, HJ | 1 |
| Im, JA | 1 |
| Iizuka, T | 1 |
| Matsukawa, M | 1 |
| Buduneli, N | 1 |
| Saygan, BH | 1 |
| Karaduman, U | 1 |
| Saraç, F | 1 |
| Karaduman, M | 1 |
| Ayçelik, N | 1 |
| Luckey, M | 2 |
| Adachi, J | 3 |
| Saag, K | 1 |
| Seeman, E | 8 |
| Meeves, S | 1 |
| Lang, TF | 3 |
| Sayed-Noor, AS | 2 |
| Sjödén, GO | 2 |
| Tosteson, AN | 1 |
| Burge, RT | 1 |
| Marshall, DA | 1 |
| Holder, KK | 1 |
| Kerley, SS | 1 |
| Lima, MG | 1 |
| Silva, AL | 1 |
| Silva, GD | 1 |
| Imai, K | 2 |
| Ohnishi, I | 1 |
| Yamamoto, S | 2 |
| Nakamura, K | 2 |
| Nabhan, AF | 1 |
| Rabie, NH | 1 |
| Rabenda, V | 2 |
| Vanoverloop, J | 2 |
| Fabri, V | 2 |
| Mertens, R | 2 |
| Sumkay, F | 2 |
| Vannecke, C | 2 |
| Deswaef, A | 2 |
| Verpooten, GA | 2 |
| Bonnick, SL | 2 |
| Beck, TJ | 2 |
| Hochberg, MC | 9 |
| de Papp, AE | 6 |
| Hatakeyama, N | 1 |
| Ozasa, Y | 1 |
| Wada, T | 1 |
| Husek, P | 1 |
| Svagera, Z | 1 |
| Vsianský, F | 1 |
| Franeková, J | 1 |
| Simek, P | 1 |
| Guido, NM | 1 |
| Elia, C | 1 |
| Liuzzo, CC | 1 |
| Mario, C | 1 |
| de Terlizzi, F | 1 |
| Ruggiero, G | 1 |
| Verhaar, HJ | 1 |
| Iwamoto, J | 17 |
| Sato, Y | 15 |
| Takeda, T | 16 |
| Matsumoto, H | 6 |
| Sheehy, O | 1 |
| Kindundu, CM | 1 |
| Barbeau, M | 1 |
| LeLorier, J | 1 |
| Antoniucci, DM | 2 |
| Palermo, L | 12 |
| Sellmeyer, DE | 5 |
| Pioli, G | 3 |
| Girasole, G | 3 |
| Siccardi, V | 1 |
| Palummeri, E | 3 |
| Trevisani, VF | 1 |
| Riera, R | 1 |
| Imoto, AM | 1 |
| Saconato, H | 1 |
| Atallah, AN | 1 |
| Sedghizadeh, PP | 1 |
| Stanley, K | 1 |
| Caligiuri, M | 1 |
| Hofkes, S | 1 |
| Lowry, B | 1 |
| Shuler, CF | 1 |
| Barrow, SY | 1 |
| Zikan, V | 1 |
| Bize, R | 1 |
| Peytremann-Bridevaux, I | 1 |
| Thomas, MV | 1 |
| Straus, SE | 1 |
| Mueller, D | 1 |
| Gandjour, A | 1 |
| Geusens, P | 5 |
| Isik, A | 1 |
| Uras, I | 1 |
| Uyar, ME | 1 |
| Karakurt, F | 1 |
| Kaftan, O | 1 |
| Kasai, T | 1 |
| Pogrel, MA | 1 |
| Hossaini, M | 1 |
| Nishizawa, Y | 1 |
| Morii, H | 2 |
| Taketani, Y | 1 |
| Itabashi, A | 1 |
| Mizunuma, H | 1 |
| Ohashi, Y | 1 |
| Minamide, T | 1 |
| Eiken, PA | 3 |
| Abrahamsen, B | 3 |
| Yan, Y | 1 |
| Zhu, H | 1 |
| Luo, B | 1 |
| Xie, H | 1 |
| Zhang, G | 1 |
| Li, F | 1 |
| Shane, E | 1 |
| Maricic, M | 2 |
| Krohn, K | 2 |
| See, K | 1 |
| Warner, MR | 1 |
| Martens, MG | 1 |
| Derman, RJ | 1 |
| Greenwald, M | 2 |
| Kohles, JD | 1 |
| Bachmann, GA | 1 |
| Zahrowski, JJ | 1 |
| Panico, A | 2 |
| Lupoli, GA | 2 |
| Fonderico, F | 1 |
| Marciello, F | 2 |
| Martinelli, A | 2 |
| Assante, R | 1 |
| Lupoli, G | 3 |
| Kwon, YD | 1 |
| Kim, YR | 1 |
| Choi, BJ | 1 |
| Lee, DW | 1 |
| Kim, DY | 1 |
| Möller, G | 1 |
| Emkey, R | 8 |
| Bolognese, M | 2 |
| Borges, JL | 1 |
| Ragi-Eis, S | 1 |
| Zerbini, CA | 1 |
| Neate, C | 1 |
| Sedarati, F | 2 |
| Epstein, S | 4 |
| Studd, J | 1 |
| Robb-Nicholson, C | 3 |
| Aonuma, H | 1 |
| Lombardi, A | 8 |
| Maier, G | 1 |
| Fratzl-Zelman, N | 2 |
| Fratzl, P | 1 |
| Wermers, RA | 3 |
| Mauck, KF | 1 |
| Xie, L | 2 |
| Glass, EV | 3 |
| Bessette, L | 1 |
| Hill, CD | 1 |
| Gold, DT | 6 |
| Horne, R | 2 |
| Varon, SF | 2 |
| Borenstein, J | 4 |
| Man, HS | 1 |
| Macarios, D | 4 |
| Abelson, A | 2 |
| Ishijima, M | 1 |
| Sakamoto, Y | 1 |
| Yamanaka, M | 1 |
| Tokita, A | 1 |
| Kitahara, K | 1 |
| Kaneko, H | 1 |
| Kurosawa, H | 1 |
| Breart, G | 1 |
| Cooper, C | 2 |
| Meyer, O | 1 |
| Speirs, C | 1 |
| Deltour, N | 1 |
| Faraawi, RY | 1 |
| O'Mahony, MF | 1 |
| Nayar, A | 1 |
| Massaad, R | 1 |
| Evans, JK | 1 |
| Yacik, C | 2 |
| Muñoz-Torres, M | 3 |
| Reyes-García, R | 2 |
| Mezquita-Raya, P | 2 |
| Fernández-García, D | 2 |
| Alonso, G | 1 |
| Luna, Jde D | 1 |
| Ruiz-Requena, ME | 1 |
| Escobar-Jiménez, F | 1 |
| D'Amelio, P | 1 |
| Grimaldi, A | 1 |
| Cristofaro, MA | 1 |
| Ravazzoli, M | 1 |
| Molinatti, PA | 1 |
| Pescarmona, GP | 1 |
| Isaia, GC | 1 |
| Allen, MR | 1 |
| Erickson, AM | 1 |
| Wang, X | 1 |
| Burr, DB | 3 |
| Martin, RB | 1 |
| Hazelwood, SJ | 1 |
| Miyata, A | 1 |
| Mersereau, JE | 1 |
| Khouri, C | 1 |
| Jaffe, RB | 1 |
| Sipos, A | 2 |
| Qin, YJ | 1 |
| Zhang, H | 1 |
| Hu, WW | 1 |
| Liu, YJ | 1 |
| Stovall, DW | 1 |
| Beard, MK | 1 |
| Barbier, S | 1 |
| Chen, E | 4 |
| Howard, E | 1 |
| Tagliarino-Jones, H | 1 |
| Finkelstein, JS | 2 |
| Wyland, JJ | 1 |
| Wu, N | 1 |
| Wang, QP | 1 |
| Wu, XP | 1 |
| Sun, ZQ | 2 |
| Luo, XH | 1 |
| Hori, H | 1 |
| Chen, BL | 1 |
| Xie, DH | 1 |
| Zheng, ZM | 1 |
| Lu, W | 1 |
| Ning, CY | 1 |
| Li, YQ | 1 |
| Li, FB | 1 |
| Liao, WM | 1 |
| McCulloch, CE | 1 |
| Woo, C | 1 |
| Schwartz, K | 1 |
| Pinholt, EM | 1 |
| Rejnmark, L | 1 |
| Mosekilde, L | 3 |
| Grima, DT | 3 |
| Papaioannou, A | 7 |
| Airia, P | 1 |
| Ioannidis, G | 4 |
| Das De, S | 2 |
| Setiobudi, T | 1 |
| Kawate, H | 1 |
| Ohnaka, K | 1 |
| Adachi, M | 1 |
| Kono, S | 1 |
| Ikematsu, H | 1 |
| Matsuo, H | 1 |
| Higuchi, K | 1 |
| Takayama, T | 1 |
| Takayanagi, R | 1 |
| Halse, J | 1 |
| Laroche, M | 1 |
| Krieg, MA | 3 |
| Frieling, I | 2 |
| Delmas, P | 2 |
| Bamrungsong, T | 1 |
| Lee, S | 1 |
| Glendenning, P | 1 |
| Inderjeeth, CA | 1 |
| Freemantle, N | 2 |
| Lillestol, M | 1 |
| Moffett, AH | 2 |
| Satram-Hoang, S | 3 |
| Kaur, P | 2 |
| Rogers, A | 1 |
| Ni, X | 1 |
| Jönsson, B | 4 |
| Siris, ES | 2 |
| Tosteson, A | 1 |
| Delzell, E | 1 |
| Chen, L | 3 |
| Judd, S | 1 |
| Safford, MM | 1 |
| McKague, M | 1 |
| Jorgenson, D | 1 |
| Buxton, KA | 1 |
| Giner, M | 1 |
| Rios, MJ | 1 |
| Montoya, MJ | 1 |
| Vázquez, MA | 1 |
| Miranda, C | 1 |
| Pérez-Cano, R | 1 |
| Makita, K | 1 |
| Katahira, G | 1 |
| Yoshizaki, T | 1 |
| Osugi, K | 1 |
| Miwa, S | 1 |
| Marukawa, S | 1 |
| Marukawa, K | 1 |
| Kawaguchi, Y | 1 |
| Nakato, S | 1 |
| Peacock, M | 2 |
| Weinstein, RL | 1 |
| Ding, B | 1 |
| San Martin, J | 2 |
| Moen, MD | 1 |
| Keam, SJ | 1 |
| Sanad, Z | 1 |
| Ellakwa, H | 1 |
| Desouky, B | 1 |
| Eslami, B | 1 |
| Zhou, S | 1 |
| Van Eekeren, I | 1 |
| Glowacki, J | 1 |
| Kučukalić-Selimović, E | 1 |
| Valjevac, A | 1 |
| Hadžović-Džuvo, A | 1 |
| Skopljak-Beganović, A | 1 |
| Alimanovic-Alagić, R | 1 |
| Brković, A | 1 |
| Bock, O | 3 |
| Börst, H | 1 |
| Armbrecht, G | 1 |
| Beller, G | 1 |
| Degner, C | 1 |
| Stephan-Oelkers, M | 1 |
| Schacht, E | 2 |
| Mazor, Z | 1 |
| Roth, HJ | 1 |
| Martus, P | 1 |
| Runge, M | 1 |
| Gomberg, SJ | 1 |
| Wustrack, RL | 1 |
| Arnaud, CD | 1 |
| Gamerdinger, D | 2 |
| Spieler, W | 2 |
| Kann, PH | 2 |
| Loeffler, H | 1 |
| Articus, K | 2 |
| Möricke, R | 1 |
| Ziller, V | 2 |
| Shapses, SA | 1 |
| Robson, R | 1 |
| Hansen, KE | 1 |
| Sherrell, RM | 1 |
| Field, MP | 1 |
| Woolf, E | 1 |
| Berd, Y | 1 |
| Mantz, AM | 2 |
| Cheen, MH | 1 |
| Kong, MC | 1 |
| Zhang, RF | 1 |
| Tee, FM | 1 |
| Chandran, M | 1 |
| Chouha, F | 1 |
| Djandji, M | 1 |
| Sampalis, JS | 1 |
| Hanley, DA | 7 |
| Uzawa, M | 9 |
| de Boer, T | 1 |
| Wieling, J | 1 |
| Dabrowski, CE | 1 |
| Cicconetti, G | 1 |
| Gordon, DN | 1 |
| Creatsa, M | 1 |
| Pliatsika, P | 1 |
| Kaparos, G | 1 |
| Antoniou, A | 1 |
| Armeni, E | 1 |
| Tsakonas, E | 1 |
| Panoulis, C | 1 |
| Alexandrou, A | 1 |
| Dimitraki, E | 1 |
| Christodoulakos, G | 2 |
| Lambrinoudaki, I | 2 |
| Sheng, ZY | 1 |
| Chen, JY | 1 |
| Pan, L | 1 |
| Fitzpatrick, SG | 1 |
| Stavropoulos, MF | 1 |
| Bowers, LM | 1 |
| Neuman, AN | 1 |
| Hinkson, DW | 1 |
| Green, JG | 1 |
| Bhattacharyya, I | 1 |
| Cohen, DM | 1 |
| Ashfaq, K | 1 |
| Ton, QV | 1 |
| Kleimeyer, JP | 1 |
| Silva, AG | 1 |
| Vieira, JG | 1 |
| Kunii, IS | 1 |
| Lana, JM | 1 |
| Lazaretti-Castro, M | 1 |
| Lupoli, R | 1 |
| Cacciapuoti, M | 1 |
| Granieri, L | 1 |
| Iacono, D | 1 |
| Jain, SK | 1 |
| Roy, SP | 1 |
| Nagi, ON | 1 |
| Bala, Y | 1 |
| Chapurlat, RD | 5 |
| Bogado, CE | 1 |
| Boailchuk, JA | 1 |
| Zanchetta, MB | 1 |
| Massari, FE | 1 |
| Buchinger, B | 1 |
| Zoehrer, R | 1 |
| Laroche, JM | 1 |
| Boutroy, S | 1 |
| Laib, A | 1 |
| Lai, PS | 3 |
| Chua, SS | 3 |
| Chew, YY | 1 |
| Chan, SP | 3 |
| Roddam, A | 1 |
| Gitlin, M | 1 |
| Taylor, A | 1 |
| Shepherd, S | 1 |
| Shearer, A | 1 |
| Jick, S | 1 |
| Neyro, JL | 1 |
| Ferrer, J | 1 |
| Villero, J | 1 |
| Cañada, E | 1 |
| Redondo, E | 1 |
| Caloto, MT | 1 |
| Nocea, G | 1 |
| Mokuda, S | 1 |
| Okuda, Y | 1 |
| Onishi, M | 1 |
| Sawada, N | 1 |
| Matoba, K | 1 |
| Yamada, A | 1 |
| Jouyama, K | 1 |
| Takasugi, K | 1 |
| Sebastián-Ochoa, A | 1 |
| Rozas-Moreno, P | 1 |
| Alonso-Garcia, G | 1 |
| Duhan, N | 1 |
| Siwach, RC | 1 |
| Yadav, K | 1 |
| Dahiya, K | 1 |
| Nanda, S | 1 |
| Sirohiwal, D | 1 |
| Siddique, M | 1 |
| Blake, GM | 1 |
| Moore, AE | 1 |
| Marsden, PK | 1 |
| Schleyer, PJ | 1 |
| Schafer, AL | 1 |
| Rosen, CJ | 10 |
| Shoback, DM | 1 |
| Koh, JS | 4 |
| Ng, AC | 2 |
| Png, MA | 2 |
| Howe, TS | 4 |
| Kopperdahl, DL | 1 |
| Mitlak, BH | 2 |
| Lee, YH | 1 |
| Song, GG | 1 |
| Baier, M | 1 |
| Moericke, R | 1 |
| Coon, CD | 1 |
| Price, MA | 1 |
| Lin, T | 1 |
| Cai, XZ | 1 |
| Zhao, X | 1 |
| Shi, MM | 1 |
| Ying, ZM | 1 |
| Yuan, FZ | 1 |
| Guo, C | 1 |
| Yan, SG | 1 |
| Diaz-Curiel, M | 2 |
| Lorenc, RS | 1 |
| Alzahouri, K | 1 |
| Bahrami, S | 1 |
| Durand-Zaleski, I | 1 |
| Guillemin, F | 1 |
| Pazianas, M | 1 |
| Russell, RG | 1 |
| Chiang, CH | 1 |
| Huang, CC | 1 |
| Chan, WL | 1 |
| Huang, PH | 1 |
| Chen, TJ | 1 |
| Chung, CM | 1 |
| Chen, JW | 1 |
| Leu, HB | 1 |
| Bae, SJ | 1 |
| Kim, BJ | 1 |
| Lim, KH | 1 |
| Lee, SH | 1 |
| Kim, HK | 1 |
| Kim, GS | 1 |
| Ibáñez, L | 1 |
| Alcaraz, MJ | 1 |
| Maicas, N | 1 |
| Guede, D | 1 |
| Caeiro, JR | 1 |
| Motterlini, R | 1 |
| Ferrándiz, ML | 1 |
| Huber, J | 1 |
| Preisinger, E | 1 |
| Kudlacek, S | 1 |
| Suzuki, K | 1 |
| Tsuji, S | 1 |
| Fukushima, Y | 1 |
| Nakase, T | 1 |
| Hamada, M | 1 |
| Tomita, T | 1 |
| Cross, MB | 1 |
| Nam, D | 1 |
| van der Meulen, MC | 1 |
| Bostrom, MP | 1 |
| Horlait, S | 1 |
| Atlan, P | 1 |
| Chong, YH | 1 |
| Bratengeier, C | 1 |
| Woloszczuk, W | 1 |
| Tancredi, A | 1 |
| Uihlein, AV | 1 |
| Bryl, N | 1 |
| Horst-Sikorska, W | 1 |
| Ignaszak-Szczepaniak, M | 1 |
| Marcinkowska, M | 1 |
| Michalak, M | 1 |
| Sewerynek, E | 1 |
| Ang, BF | 1 |
| Robinson, PJ | 1 |
| Bell, RJ | 1 |
| Lanzafame, A | 1 |
| Segal, L | 1 |
| Kirby, C | 1 |
| Piterman, L | 1 |
| Davis, SR | 1 |
| Yang, HI | 1 |
| Lim, KJ | 1 |
| Jeon, YE | 1 |
| Huang, HT | 1 |
| Huang, PJ | 1 |
| Fu, YC | 1 |
| Lin, SY | 1 |
| Hsieh, CH | 1 |
| Chen, JC | 1 |
| Cheng, YM | 1 |
| Chen, CH | 1 |
| Tao, TZ | 1 |
| Lu, YJ | 1 |
| Lu, CY | 1 |
| Meng, GL | 1 |
| Zhang, WJ | 1 |
| Hu, YY | 1 |
| Komaba, H | 1 |
| Yanagisawa, S | 1 |
| Inoue, H | 1 |
| Toujo, T | 1 |
| Fukagawa, M | 2 |
| Takahashi, HE | 1 |
| Chau, D | 1 |
| Becker, DL | 1 |
| Coombes, ME | 1 |
| Olmos, JM | 1 |
| Hernández, JL | 1 |
| Llorca, J | 1 |
| Nan, D | 1 |
| Valero, C | 1 |
| González-Macías, J | 1 |
| Song, K | 1 |
| Park, S | 1 |
| Park, BW | 1 |
| Yoshioka, T | 1 |
| Okimoto, N | 1 |
| Okamoto, K | 1 |
| Sakai, A | 1 |
| Yates, J | 5 |
| Brask-Lindemann, D | 1 |
| Eskildsen, P | 1 |
| Zafeiris, CP | 1 |
| Stathopoulos, IP | 1 |
| Kourkoumelis, G | 1 |
| Gkikas, E | 1 |
| Lyritis, GP | 1 |
| Kopperdahl, D | 1 |
| Krohn, KD | 1 |
| Josse, R | 4 |
| Khan, A | 1 |
| Ngui, D | 1 |
| Shapiro, M | 1 |
| Chen, B | 1 |
| Yang, X | 1 |
| Xu, H | 1 |
| Karch, AM | 1 |
| Karch, FE | 1 |
| Rubin, MR | 1 |
| Arko, B | 1 |
| Prezelj, J | 1 |
| Komel, R | 1 |
| Kocijancic, A | 1 |
| Marc, J | 1 |
| Malnick, SD | 1 |
| Gottesfeld, F | 1 |
| Walpart, A | 1 |
| Keter, D | 1 |
| Lurie, Y | 1 |
| Beergabel, M | 1 |
| Posaci, C | 2 |
| Altunyurt, S | 1 |
| Islekel, H | 1 |
| Saygili, U | 1 |
| Altekin, E | 1 |
| Onvural, A | 1 |
| Onvural, B | 1 |
| Cranney, A | 3 |
| Wells, G | 1 |
| Willan, A | 1 |
| Griffith, L | 1 |
| Zytaruk, N | 1 |
| Robinson, V | 2 |
| Shea, B | 2 |
| Tugwell, P | 3 |
| Guyatt, G | 1 |
| Elliott, ME | 1 |
| Kherani, RB | 1 |
| Thomson, AB | 2 |
| Marshall, JK | 2 |
| Hunt, RH | 2 |
| Provenza, JM | 2 |
| Lanza, FL | 2 |
| Royer, MG | 1 |
| Blank, MA | 2 |
| Body, JJ | 2 |
| Gaich, GA | 1 |
| Scheele, WH | 2 |
| Kulkarni, PM | 4 |
| Peretz, A | 2 |
| Correa-Rotter, R | 3 |
| Cumming, DC | 2 |
| Hodsman, AB | 3 |
| Tremaine, WJ | 1 |
| Khosla, S | 1 |
| Greenspan, S | 3 |
| Field-Munves, E | 1 |
| Tonino, R | 1 |
| Smith, M | 1 |
| Petruschke, R | 1 |
| Palmisano, J | 1 |
| Bone, G | 1 |
| Schnitzer, TJ | 2 |
| Levine, MA | 2 |
| Uebelhart, B | 1 |
| Kaur, A | 6 |
| Peverly, CA | 2 |
| Orloff, JJ | 3 |
| Srivastava, M | 1 |
| Tian, J | 1 |
| Meng, X | 1 |
| Zhou, X | 1 |
| Emkey, RD | 4 |
| Weiss, SR | 3 |
| Bell, NH | 6 |
| Downs, RW | 6 |
| McKeever, C | 1 |
| Miller, SS | 1 |
| Davidson, M | 1 |
| Mulloy, AL | 1 |
| Heyden, N | 1 |
| Maclsaac, RJ | 1 |
| Jerums, G | 1 |
| Andersson, N | 1 |
| Surve, VV | 1 |
| Lehto-Axtelius, D | 1 |
| Ohlsson, C | 1 |
| Håkanson, R | 1 |
| Andersson, K | 1 |
| Ryberg, B | 1 |
| Heijckmann, AC | 1 |
| Juttmann, JR | 1 |
| Wolffenbuttel, BH | 1 |
| Meunier, PJ | 6 |
| Minne, HW | 3 |
| Pollähne, W | 2 |
| Pfeifer, M | 3 |
| Begerow, B | 2 |
| Hinz, C | 1 |
| Simon, JA | 1 |
| Smith, ME | 3 |
| Petruschke, RA | 4 |
| Palmisano, JJ | 1 |
| Deal, CL | 1 |
| Nelson, DB | 1 |
| Kerani, RP | 1 |
| Schreiner, PJ | 1 |
| Nevitt, MC | 6 |
| Yaniv, I | 1 |
| Siderova, V | 1 |
| Dumon, JC | 1 |
| Rozenberg, S | 1 |
| Fellemans, C | 1 |
| Fuss, M | 1 |
| Bergmann, P | 1 |
| Bartl, R | 3 |
| Palomba, S | 4 |
| Numis, FG | 1 |
| Mossetti, G | 1 |
| Rendina, D | 1 |
| Vuotto, P | 1 |
| Russo, T | 3 |
| Zullo, F | 4 |
| Nappi, C | 2 |
| Nunziata, V | 2 |
| Gür, A | 2 |
| Denli, A | 1 |
| Cevik, R | 2 |
| Nas, K | 2 |
| Karakoc, M | 1 |
| Saraç, AJ | 1 |
| Johnell, O | 3 |
| Jönsson, L | 2 |
| Inaoui, R | 1 |
| Petit, B | 1 |
| Jaccard, A | 1 |
| Bertin, P | 1 |
| Trèves, R | 1 |
| Hosking, DJ | 5 |
| Favus, M | 2 |
| Yates, AJ | 11 |
| Thompson, DE | 12 |
| Watts, N | 1 |
| Freedholm, D | 3 |
| Daifotis, A | 5 |
| Luckey, MM | 2 |
| Gilchrist, N | 1 |
| Davie, MW | 1 |
| de Villiers, TJ | 1 |
| Daifotis, AG | 1 |
| Kimura, M | 1 |
| Kawada, A | 1 |
| Murayama, Y | 1 |
| Murayama, M | 1 |
| Pines, A | 2 |
| Eckstein, N | 1 |
| Kopernik, G | 1 |
| Ayalon, D | 2 |
| Comaneshter, D | 1 |
| Frenkel, Y | 1 |
| Srivastava, AK | 2 |
| Oberrauch, W | 1 |
| Leenings, J | 1 |
| Baylink, DJ | 2 |
| Biswas, PN | 1 |
| Wilton, LV | 2 |
| Shakir, SA | 1 |
| Derman, R | 1 |
| Resnick, NM | 3 |
| Parker, RA | 4 |
| Blümel, JE | 1 |
| Castelo-Branco, C | 1 |
| de la Cuadra, G | 1 |
| Maciver, L | 1 |
| Moreno, M | 1 |
| Haya, J | 1 |
| Ichimura, S | 1 |
| Brixen, KT | 2 |
| Cheng, ZQ | 1 |
| Yin, W | 1 |
| Fan, JY | 1 |
| Ma, TJ | 1 |
| Ravn, P | 14 |
| Ross, PD | 8 |
| Davas, I | 1 |
| Altintas, A | 1 |
| Yoldemir, T | 1 |
| Varolan, A | 1 |
| Yazgan, A | 1 |
| Baksu, B | 1 |
| Ylikorkala, O | 3 |
| Eviö, S | 3 |
| Välimäki, M | 3 |
| Tiitinen, A | 3 |
| Hosking, D | 9 |
| Andia, JC | 1 |
| Benhamou, L | 2 |
| Rybak-Feglin, A | 1 |
| Zaru, L | 1 |
| Bagger, YZ | 1 |
| Tankó, LB | 2 |
| Alexandersen, P | 2 |
| McGowan, JA | 2 |
| Garnero, P | 7 |
| Bouxsein, ML | 2 |
| Yood, RA | 3 |
| Emani, S | 1 |
| Reed, JI | 1 |
| Lewis, BE | 1 |
| Charpentier, M | 1 |
| Lydick, E | 1 |
| Weiss, M | 2 |
| Koren-Michowitz, M | 1 |
| Segal, E | 2 |
| Ish-Shalom, S | 3 |
| Sebaldt, RJ | 3 |
| Ferko, N | 1 |
| Puglia, M | 1 |
| Brown, J | 1 |
| Tenenhouse, A | 2 |
| Olszynski, WP | 3 |
| Boulos, P | 1 |
| Murray, TM | 1 |
| Petrie, A | 2 |
| Goldsmith, CH | 2 |
| Ettinger, MP | 3 |
| Ros, I | 1 |
| Alvarez, L | 1 |
| Pons, F | 1 |
| Caballería, L | 1 |
| Martínez de Osaba, MJ | 1 |
| Roca, M | 1 |
| Rodés, J | 1 |
| Chailurkit, LO | 2 |
| Jongjaroenprasert, W | 2 |
| Rungbunnapun, S | 1 |
| Ongphiphadhanakul, B | 2 |
| Sae-tung, S | 2 |
| Rajatanavin, R | 2 |
| Zethraeus, N | 2 |
| Cryer, B | 2 |
| Ragi, S | 1 |
| Walliser, J | 1 |
| Chow, J | 1 |
| Johnson, MA | 1 |
| Leyes, AE | 1 |
| Tamir, A | 1 |
| Fuller, KE | 1 |
| Sugiyama, T | 1 |
| Tanaka, H | 1 |
| Kawai, S | 1 |
| Sawka, AM | 1 |
| Murray, T | 1 |
| Waltman, NL | 1 |
| Twiss, JJ | 1 |
| Ott, CD | 1 |
| Gross, GJ | 1 |
| Lindsey, AM | 1 |
| Moore, TE | 1 |
| Berg, K | 1 |
| DeHart, RM | 1 |
| Gonzalez, EH | 1 |
| Laitinen, K | 1 |
| Välimäki, MJ | 2 |
| Orio, F | 3 |
| Colao, A | 2 |
| Lombardi, G | 3 |
| Kessenich, C | 1 |
| Sapuła, RA | 1 |
| Ostrowski, T | 1 |
| Bojar, I | 1 |
| Wei, GS | 1 |
| Jackson, JL | 1 |
| Hatzigeorgiou, C | 1 |
| Tofferi, JK | 1 |
| Lufkin, EG | 1 |
| Sarkar, S | 1 |
| Ciaccia, AV | 1 |
| Plouffe, L | 2 |
| Strewler, GJ | 1 |
| Devogelaer, JP | 2 |
| Tucci, JR | 4 |
| Tonino, RP | 5 |
| Rodriguez-Portales, JA | 3 |
| Gupta, J | 1 |
| Liberman, UA | 3 |
| Okabe, R | 1 |
| Turbí, C | 1 |
| Herrero-Beaumont, G | 1 |
| Acebes, JC | 1 |
| Torrijos, A | 1 |
| Graña, J | 1 |
| Miguélez, R | 1 |
| Sacristán, J | 1 |
| Sambrook, PN | 3 |
| Ribot, C | 1 |
| Solimano, JA | 1 |
| Ferrer-Barriendos, J | 1 |
| Gaines, K | 1 |
| Verbruggen, N | 4 |
| Melton, ME | 7 |
| Rozkydal, Z | 1 |
| Janicek, P | 1 |
| Crans, G | 1 |
| Gerster, JH | 1 |
| Curković, B | 1 |
| Aunphongpuwanart, S | 1 |
| Doggrell, SA | 2 |
| Alenfeld, F | 2 |
| Feyen, JH | 1 |
| Lakatos, P | 1 |
| Rollins, G | 1 |
| Wehren, LE | 3 |
| Mazanec, D | 1 |
| Chen, YT | 1 |
| Abbott, TA | 1 |
| Berger, ML | 1 |
| Gutteridge, DH | 1 |
| Rodriguez, JP | 1 |
| Wasnich, RD | 9 |
| Meng, L | 1 |
| Pérez-López, FR | 1 |
| Kung, AW | 4 |
| Fuleihan, Gel-H | 1 |
| González González, JG | 1 |
| Gaines, KA | 2 |
| Keegan, TH | 1 |
| Kelsey, JL | 1 |
| Bjarnason, NH | 3 |
| Ruggiero, SL | 1 |
| Mehrotra, B | 1 |
| Ott, SM | 4 |
| Chan, AS | 1 |
| Ghose, R | 1 |
| Kushida, K | 2 |
| Kishimoto, H | 2 |
| Yamamoto, K | 1 |
| Kaneda, K | 2 |
| Nakashima, M | 2 |
| Uusi-Rasi, K | 1 |
| Sievänen, H | 1 |
| Heinonen, A | 1 |
| Kannus, P | 1 |
| Vuori, I | 1 |
| Marx, J | 1 |
| Papapoulos, SE | 2 |
| Quandt, SA | 4 |
| Zizic, TM | 1 |
| Ikeda, T | 1 |
| Manabe, H | 1 |
| Iwata, K | 1 |
| Keller, MI | 1 |
| Brecht, JG | 1 |
| Kruse, HP | 3 |
| Möhrke, W | 1 |
| Oestreich, A | 1 |
| Huppertz, E | 1 |
| Sarioglu, M | 1 |
| Tuzun, C | 1 |
| Unlu, Z | 1 |
| Tikiz, C | 1 |
| Taneli, F | 1 |
| Uyanik, BS | 1 |
| Ramsay, P | 1 |
| Colpan, L | 1 |
| Jale Sarac, A | 1 |
| Young-Min, SA | 1 |
| Herbert, L | 1 |
| Dick, M | 1 |
| Fordham, J | 1 |
| Miller, P | 3 |
| Broy, S | 2 |
| Kagan, R | 2 |
| Jones, DG | 1 |
| Savage, R | 1 |
| Highton, J | 2 |
| Woo, A | 1 |
| Hittell, J | 1 |
| Beardsley, C | 1 |
| Noh, C | 1 |
| Stoukides, CA | 1 |
| Kaul, AF | 1 |
| Tascioglu, F | 1 |
| Colak, O | 1 |
| Armagan, O | 1 |
| Alatas, O | 1 |
| Oner, C | 1 |
| Falbo, A | 1 |
| Tolino, A | 1 |
| Manguso, F | 1 |
| Mastrantonio, P | 2 |
| Kaplan, RJ | 1 |
| Vo, AN | 1 |
| Stitik, TP | 1 |
| Kamen, LB | 1 |
| Bitar, AA | 1 |
| Shih, VC | 1 |
| Hillier, TA | 1 |
| Pressman, A | 1 |
| Che, M | 1 |
| Ozdemir, F | 1 |
| Rodoplu, M | 1 |
| Wallace, DJ | 1 |
| Bhutta, MF | 1 |
| Rance, M | 1 |
| Gillett, D | 1 |
| Weighill, JS | 1 |
| Nendaz, M | 1 |
| Christensen, PM | 1 |
| Brixen, K | 1 |
| Gyrd-Hansen, D | 1 |
| Kristiansen, IS | 2 |
| Cauley, J | 1 |
| Baran, D | 2 |
| Høiseth, A | 3 |
| Scharla, S | 1 |
| Reichenhall, B | 1 |
| Yalçin, F | 1 |
| Gurgan, S | 1 |
| Gurgan, T | 1 |
| Stevenson, M | 1 |
| Jones, ML | 1 |
| De Nigris, E | 1 |
| Brewer, N | 1 |
| Davis, S | 1 |
| Oakley, J | 1 |
| Arlot, M | 1 |
| Haddock, L | 1 |
| Tamayo, J | 1 |
| Jasqui, S | 1 |
| Donley, DW | 2 |
| Dalsky, GP | 1 |
| Martin, JS | 1 |
| Eriksen, EF | 2 |
| Weisman, Y | 1 |
| Shapira, I | 1 |
| Vered, I | 1 |
| Cohen, YC | 1 |
| Shamir-Elron, Y | 1 |
| Api, M | 1 |
| Pande, I | 1 |
| Hu, YF | 1 |
| Rackoff, PJ | 1 |
| Sebba, A | 2 |
| Wong, M | 2 |
| Stock, JL | 4 |
| Ingle, BM | 1 |
| Machado, AB | 1 |
| Pereda, CA | 1 |
| Bhattacharya, R | 1 |
| Ho, AY | 1 |
| Hue, T | 1 |
| Nieves, J | 2 |
| Woelfert, L | 2 |
| Heaney, RP | 2 |
| Köşüş, A | 1 |
| Capar, M | 1 |
| Köşüş, N | 1 |
| Leung, S | 1 |
| Ashar, BH | 1 |
| Miller, RG | 1 |
| Musialik, J | 1 |
| Petelenz, M | 1 |
| Gonciarz, Z | 1 |
| Nyman, JA | 2 |
| Kane, RL | 2 |
| Melton, LJ | 2 |
| Cramer, JA | 1 |
| Amonkar, MM | 2 |
| Hebborn, A | 1 |
| Altman, R | 1 |
| Chattopadhyay, A | 1 |
| Liberman, U | 2 |
| Simonelli, C | 1 |
| Lanza, F | 1 |
| Mullen, C | 1 |
| Hamdy, RC | 3 |
| Chesnut, CH | 5 |
| Gass, ML | 1 |
| Holick, MF | 1 |
| Leib, ES | 1 |
| Lewiecki, ME | 1 |
| McKinney, J | 1 |
| Christoffersen, H | 1 |
| Holmegaard, SN | 1 |
| Terauchi, M | 1 |
| Obayashi, S | 1 |
| Aso, T | 1 |
| Basson, BR | 1 |
| Muldowney, FP | 1 |
| Koltun, W | 1 |
| Beusterien, K | 1 |
| Seidman, L | 1 |
| Kivitz, A | 1 |
| Devas, V | 2 |
| Masanauskaite, D | 2 |
| Hoefert, S | 1 |
| Eufinger, H | 1 |
| Sarlet, N | 1 |
| Kim, SW | 1 |
| Park, DJ | 1 |
| Park, KS | 1 |
| Kim, SY | 1 |
| Cho, BY | 1 |
| Lee, HK | 1 |
| Ewing, SK | 1 |
| Delaney, MF | 1 |
| Tarkkila, L | 1 |
| Sorsa, T | 1 |
| Furuholm, J | 1 |
| Meurman, JH | 1 |
| Cohen, SB | 2 |
| Woodson, GC | 1 |
| Lederman, SN | 1 |
| Lain, D | 1 |
| Kivitz, AJ | 1 |
| Holloway, DL | 1 |
| Peterson, MC | 1 |
| Bekker, PJ | 1 |
| Bayram, M | 1 |
| Soyer, C | 1 |
| Kadioglu, E | 1 |
| Sardas, S | 1 |
| Wilson, KM | 1 |
| Hiltbrunner, V | 1 |
| Schimmer, RC | 1 |
| Lee, E | 1 |
| Wutoh, AK | 1 |
| Xue, Z | 1 |
| Hillman, JJ | 1 |
| Zuckerman, IH | 1 |
| Kanoko, T | 1 |
| Satoh, K | 1 |
| Gass, M | 1 |
| Dawson-Hughes, B | 1 |
| Lo, JC | 1 |
| Pressman, AR | 1 |
| Omar, MA | 1 |
| Hochberg, M | 3 |
| Burnett, SM | 1 |
| de Vernejoul, MC | 1 |
| Gol, M | 1 |
| Baris, N | 1 |
| Guneri, S | 1 |
| Penning-van Beest, FJ | 2 |
| Goettsch, WG | 1 |
| Erkens, JA | 2 |
| Herings, RM | 2 |
| Tseng, LN | 1 |
| Sheu, WH | 1 |
| Ho, ES | 1 |
| Lan, HH | 1 |
| Hu, CC | 1 |
| Kao, CH | 1 |
| Masaryk, P | 2 |
| Stancíková, M | 1 |
| Letkovská, A | 1 |
| Rovenský, J | 1 |
| Rifkin, WD | 1 |
| Götte, S | 1 |
| Hammerschmidt, T | 1 |
| Cooper, A | 2 |
| Drake, J | 1 |
| Brankin, E | 1 |
| Wong, P | 1 |
| Anpalahan, M | 1 |
| Blackhouse, G | 1 |
| Nase, JB | 1 |
| Suzuki, JB | 1 |
| Chen, P | 1 |
| Misurski, DA | 1 |
| Marcus, R | 4 |
| Kurato, S | 1 |
| Iwase, T | 1 |
| Inoue, K | 1 |
| Sasaki, Y | 1 |
| Tanaka, T | 1 |
| Fujita, M | 1 |
| Ando, F | 1 |
| Asaba, Y | 1 |
| Hiramatsu, K | 2 |
| Matsui, Y | 1 |
| Nimura, Y | 1 |
| Katagiri, N | 1 |
| Kobayashi, T | 1 |
| Takewaka, T | 1 |
| Niida, S | 1 |
| Ikeda, K | 1 |
| Recker, R | 3 |
| Lips, P | 2 |
| Lippuner, K | 2 |
| Rosen, C | 2 |
| Salzmann, G | 1 |
| He, W | 1 |
| Kang, M | 1 |
| Min, Y | 1 |
| Byun, D | 1 |
| Chung, Y | 1 |
| Ahn, C | 1 |
| Baek, K | 1 |
| Mok, J | 1 |
| Kim, D | 3 |
| Kim, H | 1 |
| Kim, Y | 1 |
| Myoung, S | 1 |
| Briot, K | 2 |
| Dumarcet, N | 1 |
| Bourgoin, M | 1 |
| Christin-Maitre, S | 1 |
| Costagliola, D | 1 |
| Diebolt, V | 1 |
| Lacoin, F | 1 |
| Letombe, B | 1 |
| Oberlin, F | 1 |
| Orcel, P | 1 |
| Ravaud, P | 1 |
| Seret, P | 1 |
| Vogel, JY | 1 |
| Barna, A | 1 |
| Nouyrigat, E | 1 |
| Veyries, ML | 1 |
| Yoldjian, I | 1 |
| Hoffmann, PF | 1 |
| San Martin, JA | 1 |
| Zhang, XZ | 1 |
| Song, LG | 1 |
| Han, JF | 1 |
| Qian, GF | 1 |
| He, M | 1 |
| Gu, L | 1 |
| Richards, JC | 1 |
| Wiffen, SJ | 1 |
| Reid, DM | 2 |
| Weryha, G | 2 |
| Marques-Neto, JF | 2 |
| Recknor, CP | 2 |
| Rooney, TW | 1 |
| Utian, WH | 1 |
| Cauley, JA | 5 |
| Lorraine, J | 1 |
| Qu, Y | 1 |
| Gaich, CL | 1 |
| Levis, S | 1 |
| Satterfield, S | 2 |
| Wallace, RB | 2 |
| Colón-Emeric, CS | 1 |
| Farahmand, P | 1 |
| Rozehnal, A | 1 |
| Trémollières, F | 2 |
| Yanik, B | 2 |
| Turkay, C | 1 |
| Atalar, H | 1 |
| Jamal, SA | 1 |
| Ishani, A | 1 |
| Keen, R | 1 |
| Jodar, E | 1 |
| Iolascon, G | 1 |
| Varbanov, A | 1 |
| Mann, B | 1 |
| Botsis, D | 1 |
| d'Arailh, AS | 1 |
| Lopes, P | 1 |
| Pasion, EG | 1 |
| Sivananthan, SK | 1 |
| Chen, SH | 1 |
| Chen, YJ | 1 |
| Mirasol, R | 1 |
| Tay, BK | 1 |
| Shah, GA | 1 |
| Khan, MA | 1 |
| Tam, F | 1 |
| Hall, BJ | 1 |
| Thiebaud, D | 1 |
| Imoto, K | 1 |
| Sen, SS | 1 |
| Haentjens, P | 1 |
| Bilezikian, J | 1 |
| Brookhart, MA | 2 |
| Avorn, J | 1 |
| Katz, JN | 2 |
| Arnold, M | 1 |
| Polinski, JM | 1 |
| Patrick, AR | 1 |
| Mogun, H | 1 |
| Solmon, DH | 1 |
| Martin, BC | 1 |
| Frytak, JR | 1 |
| Goh, SK | 2 |
| Yang, KY | 1 |
| Wong, MK | 1 |
| Chua, SY | 1 |
| Chua, DT | 1 |
| Terashima, T | 1 |
| Shimatani, A | 1 |
| Matsuda, M | 1 |
| Ogino, H | 1 |
| Satomura, Y | 1 |
| Noda, Y | 1 |
| Takata, S | 1 |
| Abbaspour, A | 1 |
| Yonezu, H | 1 |
| Yasui, N | 1 |
| Letonturier, P | 1 |
| Fiske, D | 1 |
| Minkoff, J | 1 |
| Kriegman, A | 1 |
| Zhou, W | 1 |
| Adera, M | 1 |
| Davis, J | 1 |
| Frederiksen, L | 1 |
| Junker, P | 1 |
| Erviti, J | 1 |
| Gorricho, J | 1 |
| Razzano, M | 1 |
| Pizzonia, M | 1 |
| Bavbek, N | 1 |
| Yanik, T | 1 |
| Inegöl, I | 1 |
| Kanbay, M | 1 |
| Turgut, FH | 1 |
| Uz, E | 1 |
| Akçay, A | 1 |
| Schwenkglenks, M | 1 |
| Anić, B | 1 |
| Grazio, S | 2 |
| Kaiser, F | 1 |
| Teutsch, C | 1 |
| DeLucca, P | 2 |
| Melton, M | 1 |
| Westmore, M | 1 |
| Michalsky, D | 1 |
| Sato, M | 1 |
| Moro Alvarez, MJ | 1 |
| Brinkmeier, T | 1 |
| Kügler, K | 1 |
| Lepoittevin, JP | 1 |
| Frosch, PJ | 1 |
| Weiss, TW | 1 |
| McHorney, CA | 1 |
| Løkken, P | 1 |
| Skoglund, LA | 1 |
| Skjelbred, P | 1 |
| Karam, R | 1 |
| Camm, J | 1 |
| Wang, A | 1 |
| Strampel, W | 1 |
| Mamdani, M | 1 |
| Kopp, A | 1 |
| Hawker, G | 1 |
| Byrjalsen, I | 1 |
| Leeming, DJ | 1 |
| Qvist, P | 1 |
| Karsdal, MA | 1 |
| Uchida, S | 1 |
| Azuma, Y | 1 |
| Taniguchi, T | 1 |
| Arizono, H | 1 |
| Shimizu, T | 1 |
| Okaniwa, M | 1 |
| Ohta, T | 1 |
| Zuber, MA | 1 |
| Drueke, T | 1 |
| Elder, G | 1 |
| Jorgetti, V | 1 |
| Langman, CB | 1 |
| Moe, S | 1 |
| McCann, L | 1 |
| Wang, AY | 1 |
| Weisinger, J | 1 |
| Wheeler, D | 1 |
| Vergnaud, P | 1 |
| Hoyle, N | 1 |
| Thompson, MF | 1 |
| Pasquale, MK | 1 |
| Wada, S | 1 |
| Fukawa, T | 1 |
| Kamiya, S | 1 |
| Minne, H | 1 |
| Bourgeois, P | 1 |
| Fardellone, P | 1 |
| Licata, A | 2 |
| Iozzino, M | 1 |
| Alva, D | 1 |
| Napolitano, C | 1 |
| De Rosa, B | 1 |
| Contini, S | 1 |
| Mallardo, L | 1 |
| Lauria, A | 1 |
| Reda, G | 1 |
| Orsini, A | 1 |
| Tanaka, I | 1 |
| Oshima, H | 1 |
| Gwynne Jones, DP | 1 |
| Savage, RL | 1 |
| Kwek, EB | 1 |
| Wells, GA | 1 |
| Peterson, J | 1 |
| Boucher, M | 1 |
| Coyle, D | 2 |
| Katayama, K | 1 |
| Matsuno, T | 1 |
| Isaia, G | 1 |
| Luisetto, G | 1 |
| Silvestri, S | 1 |
| Agnusdei, D | 1 |
| Gentilella, R | 1 |
| Nuti, R | 1 |
| Cohen, A | 1 |
| Fleischer, JB | 1 |
| Johnson, MK | 1 |
| Brown, IN | 1 |
| Joe, AK | 1 |
| Hershman, DL | 1 |
| McMahon, DJ | 1 |
| Silverberg, SJ | 1 |
| Hustad, CM | 1 |
| Mahlis, EM | 1 |
| Morović-Vergles, J | 1 |
| Olson, M | 1 |
| Guney, E | 1 |
| Kisakol, G | 1 |
| Ozgen, AG | 1 |
| Yilmaz, C | 1 |
| Kabalak, T | 1 |
| Torres, J | 1 |
| Tamimi, F | 1 |
| García, I | 1 |
| Cebrian, JL | 1 |
| López-Cabarcos, E | 1 |
| Lopez, A | 1 |
| Mareau, E | 1 |
| Engroff, SL | 1 |
| Coletti, D | 1 |
| Heckbert, SR | 1 |
| Li, G | 1 |
| Smith, NL | 1 |
| Psaty, BM | 1 |
| Stürmer, T | 1 |
| Stedman, MR | 1 |
| Solomon, DH | 1 |
| Ryder, KM | 1 |
| Feldstein, AC | 1 |
| Bröll, J | 1 |
| Quan, H | 4 |
| Rodriguez-Portales, J | 1 |
| Dequeker, J | 1 |
| Gertz, BJ | 8 |
| Holland, SD | 5 |
| Kline, WF | 3 |
| Matuszewski, BK | 3 |
| Freeman, A | 1 |
| Lasseter, KC | 1 |
| Mucklow, JC | 1 |
| Porras, AG | 4 |
| Genant, HK | 7 |
| Harris, ST | 8 |
| Singer, FR | 2 |
| Vasikaran, SD | 2 |
| O'Doherty, DP | 1 |
| Gertz, B | 1 |
| Kahn, S | 1 |
| Zamberlan, N | 2 |
| Braga, V | 3 |
| Dorizzi, R | 1 |
| Shih, WJ | 1 |
| Gineyts, E | 1 |
| Karpf, DB | 5 |
| Shao, P | 1 |
| Hanson, DA | 1 |
| Eyre, DR | 1 |
| Baroni, MC | 2 |
| Broggini, M | 1 |
| Carratelli, L | 1 |
| Caruso, I | 1 |
| Gnessi, L | 1 |
| Laurenzi, M | 1 |
| Norbiato, G | 1 |
| Ortolani, S | 1 |
| Hirsch, LJ | 5 |
| Pryor-Tillotson, S | 3 |
| Liedholm, H | 1 |
| Linné, AB | 1 |
| McGrath, H | 1 |
| Busi, S | 1 |
| Shinkai, I | 1 |
| Ohta, Y | 1 |
| Keen, RW | 1 |
| Spector, TD | 1 |
| Bellantoni, MF | 1 |
| de Groen, PC | 1 |
| Lubbe, DF | 1 |
| Stephenson, W | 1 |
| Seleznick, MJ | 1 |
| Pinkas, H | 1 |
| Wang, KK | 1 |
| Castell, DO | 1 |
| Liberman, UI | 1 |
| Frolik, CA | 1 |
| Bryant, HU | 1 |
| Black, EC | 1 |
| Magee, DE | 1 |
| Chandrasekhar, S | 1 |
| Broll, H | 1 |
| De Deuxchaisnes, CN | 1 |
| Jaeger, P | 1 |
| Leite, M | 1 |
| Leon, J | 1 |
| Menkes, CJ | 2 |
| Reid, I | 1 |
| Rodriguez, J | 1 |
| Romanowicz, A | 1 |
| Vermeulen, A | 1 |
| Plezia, K | 1 |
| Yuan, W | 2 |
| Khan, S | 1 |
| Naylor, G | 1 |
| Davies, MH | 1 |
| Overgaard, K | 1 |
| Huang, C | 1 |
| Green, D | 1 |
| Gloth, FM | 1 |
| Kirk, JK | 1 |
| Spangler, JG | 1 |
| Crepaldi, G | 2 |
| Nuzzo, V | 1 |
| Di Carlo, C | 2 |
| Affinito, P | 1 |
| Vollery, M | 1 |
| Vitale, G | 1 |
| Cascone, E | 1 |
| Arlotta, F | 1 |
| Buffo, L | 1 |
| Buoncristiano, A | 1 |
| Girardello, S | 2 |
| Diani, F | 1 |
| Kher, U | 1 |
| Haskell, WL | 1 |
| Torner, JC | 1 |
| Reiss, TF | 1 |
| Sankaran, SK | 1 |
| Weinstein, RS | 2 |
| Licata, AA | 4 |
| Kimmel, DB | 1 |
| Hale, E | 1 |
| Polvino, WJ | 1 |
| Phillips, A | 1 |
| Rubin, BR | 1 |
| Jeal, W | 1 |
| Barradell, LB | 1 |
| McTavish, D | 1 |
| Shapiro, DR | 1 |
| Johnston, CC | 1 |
| Oppenheimer, L | 1 |
| Thompson, D | 6 |
| Englund, L | 1 |
| Maughan, KL | 1 |
| Häuselmann, HJ | 1 |
| Levine, J | 1 |
| Nelson, D | 1 |
| Pizzani, E | 1 |
| Valenzuela, G | 1 |
| Girelli, CM | 1 |
| Reguzzoni, G | 1 |
| Rocca, F | 1 |
| Lilley, LL | 1 |
| Guanci, R | 1 |
| Dempster, DW | 1 |
| Hambro, S | 1 |
| Ross, SD | 1 |
| Prostko, M | 1 |
| Weihrauch, TR | 1 |
| Falch, JA | 1 |
| Andersen, L | 1 |
| Aursnes, I | 1 |
| Khan, SA | 1 |
| Vasikaran, S | 1 |
| Beneton, MN | 1 |
| Sciberras, DG | 1 |
| Orgee, J | 1 |
| Coombes, GM | 1 |
| Rogers, SR | 1 |
| Wei, L | 1 |
| Myers, ER | 1 |
| Wilson, SE | 1 |
| Cameron, RB | 1 |
| Chilvers, CE | 2 |
| Wasnich, R | 1 |
| Ross, P | 1 |
| Balske, A | 2 |
| Daley, M | 3 |
| Ryan, JM | 1 |
| Kelsey, P | 1 |
| Ryan, BM | 1 |
| Mueller, PR | 1 |
| Brager, R | 1 |
| Clemmesen, B | 2 |
| Gilchrist, NL | 2 |
| Eisman, J | 1 |
| Reda, C | 1 |
| Gibaldi, M | 1 |
| Atkinson, H | 1 |
| Kopjar, B | 3 |
| Bjørndal, A | 3 |
| Jilka, RL | 1 |
| Munshi, M | 1 |
| Williams, DC | 1 |
| Roberson, PK | 1 |
| Manolagas, SC | 1 |
| Chase, JL | 1 |
| Sørensen, HA | 1 |
| Hyldstrup, L | 2 |
| Shen, V | 1 |
| Scheen, AJ | 1 |
| Zaidi, M | 1 |
| Mackay, FJ | 1 |
| Pearce, GL | 1 |
| Freemantle, SN | 1 |
| Mann, RD | 1 |
| Clemens, JD | 1 |
| Earnshaw, SA | 1 |
| Keating, N | 1 |
| Minaguchi, H | 1 |
| Tomita, A | 1 |
| Nagata, Y | 1 |
| Meier, CA | 1 |
| Tóth, E | 1 |
| Fork, FT | 1 |
| Lindelöw, K | 1 |
| Lindström, E | 1 |
| Verbaan, H | 1 |
| Veress, B | 1 |
| Fradinger, EE | 1 |
| Rodriguez, G | 1 |
| Bogado, C | 1 |
| Andrews, WC | 1 |
| Lindberg, M | 1 |
| Gennari, C | 3 |
| Yue, QY | 1 |
| Mortimer, O | 1 |
| Lieverse, RJ | 1 |
| Becker, P | 1 |
| Hammermeister, C | 1 |
| Gowan, W | 1 |
| Braga de Castro Machado, A | 1 |
| Hannon, R | 1 |
| McIlwain, H | 1 |
| Baker, MZ | 1 |
| Krupa, D | 3 |
| Harning, R | 1 |
| Rosner, AJ | 1 |
| Torrance, GW | 1 |
| Bradley, C | 1 |
| Willison, DJ | 1 |
| Haugeberg, G | 1 |
| Musliner, T | 4 |
| Beauchesne, MF | 1 |
| Miller, PF | 1 |
| Darte, C | 1 |
| Kress, BC | 1 |
| Mizrahi, IA | 1 |
| Armour, KW | 1 |
| Col, NF | 1 |
| Pauker, SG | 1 |
| Goldberg, RJ | 1 |
| Eckman, MH | 1 |
| Orr, RK | 1 |
| Ross, EM | 1 |
| Wong, JB | 1 |
| Cizza, G | 4 |
| el Maghraoui, A | 1 |
| Lecoules, S | 1 |
| Lechevalier, D | 1 |
| Magnin, J | 1 |
| Eulry, F | 1 |
| Ullom-Minnich, P | 1 |
| Cole, RP | 1 |
| Palushock, S | 1 |
| Haboubi, A | 1 |
| Kleerekoper, M | 3 |
| Scott, J | 1 |
| Riancho, JA | 1 |
| Goldstein, MR | 1 |
| Lobo, RA | 1 |
| Walsh, BW | 2 |
| Reagan, JE | 1 |
| Liss, CL | 1 |
| Byrnes, CA | 1 |
| Ritzmann, P | 1 |
| Gonnelli, S | 2 |
| Cepollaro, C | 2 |
| Pondrelli, C | 1 |
| Martini, S | 2 |
| Montagnani, A | 2 |
| Monaco, R | 1 |
| Møllgaard, A | 1 |
| Pols, HA | 1 |
| Stepán, J | 1 |
| Wilkin, TJ | 2 |
| Qin-sheng, G | 1 |
| Galich, AM | 1 |
| Vandormael, K | 2 |
| Stych, B | 1 |
| Chapman, B | 1 |
| Malavolta, N | 1 |
| Zanardi, M | 1 |
| Veronesi, M | 1 |
| Ripamonti, C | 1 |
| Gnudi, S | 1 |
| Rodríguez Escolar, C | 1 |
| Fidalgo García, ML | 1 |
| Rubio Cebrián, S | 1 |
| Alhava, E | 1 |
| Bidstrup, M | 1 |
| Davis, JW | 1 |
| Coupland, C | 1 |
| Abraham, SC | 1 |
| Cruz-Correa, M | 1 |
| Lee, LA | 1 |
| Yardley, JH | 1 |
| Wu, TT | 1 |
| Rubin, SR | 1 |
| Bettembuk, P | 1 |
| Balogh, A | 1 |
| Nevitt, M | 1 |
| Lowe, CE | 1 |
| Depew, WT | 1 |
| Vanner, SJ | 1 |
| Paterson, WG | 1 |
| Meddings, JB | 1 |
| Browner, W | 1 |
| Wallace, R | 1 |
| Pearson, J | 1 |
| Blackwell, T | 1 |
| Eckert, S | 1 |
| Baran, DT | 1 |
| Schnitzer, T | 2 |
| Kiel, D | 1 |
| Pinchera, A | 1 |
| van der Poest Clement, E | 1 |
| Patka, P | 1 |
| Haarman, H | 1 |
| Guidi, G | 1 |
| Gerardi, D | 1 |
| Fracassi, E | 1 |
| Sambrook, P | 1 |
| Fuleihan, GE | 1 |
| Ho, YV | 1 |
| Frauman, AG | 1 |
| Thomson, W | 1 |
| Bone, H | 1 |
| Orwoll, ES | 1 |
| Favus, MJ | 1 |
| Mako, B | 1 |
| Gormley, GJ | 2 |
| Horwitz, M | 1 |
| Rittmaster, RS | 1 |
| James, G | 1 |
| Klovning, A | 1 |
| Norheim, OF | 1 |
| Lesser, GT | 1 |
| Kashyap, AS | 1 |
| Kashyap, S | 1 |
| Arboleya, LR | 1 |
| Morales, A | 1 |
| Fiter, J | 1 |
| Fink, E | 1 |
| Cormier, C | 1 |
| Steinmetz, P | 1 |
| Kindermans, C | 1 |
| Le Bouc, Y | 1 |
| Souberbielle, JC | 1 |
| Halabe, A | 1 |
| Lifschitz, BM | 1 |
| Azuri, J | 1 |
| Mincey, BA | 1 |
| Moraghan, TJ | 1 |
| Perez, EA | 1 |
| del Puente, A | 1 |
| Scognamiglio, A | 1 |
| Itto, E | 1 |
| Ferrara, G | 1 |
| Oriente, P | 1 |
| Burger, HG | 1 |
| Kronenberg, HM | 1 |
| Buist, DS | 1 |
| LaCroix, AZ | 2 |
| Harris, F | 2 |
| Blank, J | 1 |
| Edgerton, D | 1 |
| Rubin, S | 1 |
| Fox, KM | 1 |
| Desai, R | 1 |
| Yeung, SS | 1 |
| Chu, LW | 1 |
| McGarry, KA | 1 |
| Tiraş, MB | 1 |
| Noyan, V | 1 |
| Yildiz, A | 1 |
| Yildirim, M | 1 |
| Daya, S | 1 |
| Sahin, FI | 1 |
| Sahin, I | 1 |
| Ergün, MA | 1 |
| Saraçoğlu, OF | 1 |
| Dijkmans, BA | 1 |
| Lau, EM | 1 |
| Woo, J | 1 |
| Chan, YH | 1 |
| Griffith, J | 1 |
| Yen, ML | 1 |
| Yen, BL | 1 |
| Jang, MH | 1 |
| Hsu, SH | 1 |
| Cheng, WC | 1 |
| Boivin, GY | 1 |
| Chavassieux, PM | 1 |
| Fairney, A | 1 |
| Kyd, P | 1 |
| Thomas, E | 1 |
| Wilson, J | 1 |
| Suryawanshi, S | 1 |
| Compston, JE | 1 |
| Hamerman, D | 1 |
| Fowler, I | 1 |
| Blackwell, PJ | 1 |
| Lawson, N | 1 |
| Cawte, SA | 1 |
| San, P | 1 |
| Masud, T | 1 |
| Da Silva LLibre, R | 1 |
| Murillo, K | 1 |
| Chú, D | 1 |
| Murphy, MG | 1 |
| Weiss, S | 1 |
| Cerchio, K | 1 |
| Connor, J | 1 |
| Rolnick, SJ | 1 |
| Kopher, R | 1 |
| Jackson, J | 1 |
| Fischer, LR | 1 |
| Compo, R | 1 |
| Yilmaz, L | 1 |
| Ozoran, K | 1 |
| Gündüz, OH | 1 |
| Uçan, H | 1 |
| Yücel, M | 1 |
| Jeffcoat, MK | 1 |
| Lewis, CE | 1 |
| Reddy, MS | 1 |
| Wang, CY | 1 |
| Redford, M | 1 |
| Irani, M | 1 |
| Lenchik, L | 1 |
| Capizzi, T | 1 |
| Payer, J | 1 |
| Killinger, Z | 1 |
| Tomková, S | 1 |
| Kmecová, Z | 1 |
| Ondrejková, J | 1 |
| Necas, L | 1 |
| Smoterová, J | 1 |
| Ondrejka, P | 1 |
| Kratochvilová, H | 1 |
| Sarno, M | 1 |
| Sarno, L | 1 |
| Baylink, D | 1 |
| Drinkwater, B | 1 |
| Farley, S | 1 |
| Lang, R | 1 |
| Lappe, J | 1 |
| Nattrass, S | 1 |
| Schwartz, EN | 1 |
| Wolf, S | 1 |
| Powell, H | 1 |
| Tjersland, G | 1 |
| Warnick, GR | 1 |
| Jørgensen, JT | 1 |
| Sørensen, TK | 1 |
| Baeksgaard, L | 1 |
| McCormack, J | 1 |
| Pavlic, M | 1 |
| Brand, RJ | 1 |
| de La Serna Higuera, C | 1 |
| Pérez Villoria, A | 1 |
| Rodríguez Gómez, S | 1 |
| Martínez Moreno, J | 1 |
| Betancourt González, A | 1 |
| Martín Arribas, M | 1 |
| Jenkins, DK | 1 |
| Visor, JM | 1 |
| Casal, DC | 1 |
| Sharpe, M | 1 |
| Noble, S | 1 |
| Spencer, CM | 1 |
| Slagle, MA | 1 |
| Meissner, T | 1 |
| Lee, KM | 1 |
| Welch, V | 1 |
| Luciani, J | 1 |
| Pigatto, V | 1 |
| Naves, A | 1 |
| Fay, M | 1 |
| Silvestre Begnis, M | 1 |
| Piola, JC | 1 |
| Prada, DB | 1 |
| Pedrana, R | 1 |
| Netelenbos, JC | 1 |
| Chrischilles, EA | 1 |
| Dasbach, EJ | 1 |
| Rubenstein, LM | 1 |
| Cook, JR | 1 |
| Tabor, HK | 1 |
| Umland, EM | 1 |
| Boyce, EG | 1 |
| Dursun, N | 1 |
| Dursun, E | 1 |
| Yalçin, S | 1 |
| Béra-Louville, A | 1 |
| Gauthier, P | 1 |
| Gauthier, A | 1 |
| Marchandise, X | 1 |
| Delcambre, B | 1 |
| Peters, ML | 1 |
| Leonard, M | 1 |
| Prizzi, R | 1 |
| Colapietro, F | 1 |
| Frenkel, SR | 1 |
| Jaffe, WL | 1 |
| Valle, CD | 1 |
| Jazrawi, L | 1 |
| Maurer, S | 1 |
| Baitner, A | 1 |
| Wright, K | 1 |
| Sala, D | 1 |
| Hawkins, M | 1 |
| Di Cesare, PE | 1 |
| Sun, JS | 1 |
| Huang, YC | 1 |
| Tsuang, YH | 1 |
| Chen, LT | 1 |
| Lin, FH | 1 |
| Crandall, C | 2 |
| Chaudhry, MU | 1 |
| Meunie, PJ | 1 |
| Kolarov, G | 1 |
| MacFarlane, G | 1 |
| Srivastava, VP | 1 |
| Mohan, S | 1 |
| Gomez-Panzani, E | 1 |
| Lu, Y | 1 |
| Need, AG | 1 |
| Sena, T | 1 |
| Carrère, C | 1 |
| Duval, JL | 1 |
| Godard, B | 1 |
| De Jaureguiberry, JP | 1 |
| Ciribilli, JM | 1 |
| Sosa, M | 1 |
| Hernández, D | 1 |
| Segarra, MC | 1 |
| Gómez, A | 1 |
| de la Peña, E | 1 |
| Betancor, P | 1 |
| Grady, D | 1 |
| Orwoll, E | 1 |
| Drake, WM | 1 |
| Banville, C | 1 |
| Schneider, DL | 1 |
| Bonin, R | 1 |
| Maragoto, A | 1 |
| Gennari, L | 1 |
| Mangeri, M | 1 |
| Thompson, DD | 1 |
| Seedor, JG | 1 |
| Quartuccio, H | 1 |
| Solomon, H | 1 |
| Fioravanti, C | 1 |
| Davidson, J | 1 |
| Klein, H | 1 |
| Jackson, R | 1 |
| Clair, J | 1 |
| Frankenfield, D | 1 |
| Passeri, M | 1 |
| Pedrazzoni, M | 1 |
| Barbagallo, M | 1 |
| Costi, D | 1 |
| Biondi, M | 1 |
| Arlunno, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis[NCT01575834] | Phase 3 | 7,180 participants (Actual) | Interventional | 2012-03-15 | Completed | ||
| A Multicenter, Randomized, Cross-Over, Open-label Study to Evaluate the Adherence, Preference, and Satisfaction of Denosumab and Alendronate in Postmenopausal Women With Low Bone Mineral Density[NCT00518531] | Phase 3 | 250 participants (Actual) | Interventional | 2007-09-01 | Completed | ||
| A Randomized, Double-blind, Placebo-Controlled, Comparative Multicenter Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women With Severe Osteoporosis and at [NCT01343004] | Phase 3 | 2,463 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 or Placebo Treatment in Protocol BA058-05-003[NCT01657162] | Phase 3 | 1,139 participants (Actual) | Interventional | 2012-11-20 | Completed | ||
| Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients[NCT05346419] | 33 participants (Actual) | Interventional | 2021-07-01 | Completed | |||
| A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis[NCT01631214] | Phase 3 | 4,093 participants (Actual) | Interventional | 2012-05-04 | Completed | ||
| Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate[NCT03051620] | 142 participants (Actual) | Observational | 2017-02-01 | Completed | |||
| 5 Year Follow-Up of Migration of a Cementless Total Knee Replacement[NCT05877261] | 33 participants (Anticipated) | Observational | 2023-05-25 | Recruiting | |||
| Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment[NCT02371252] | Phase 4 | 140 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Effects of Romosozumab on Bone Health in Women With Spinal Cord Injury and Osteoporosis[NCT04708886] | Phase 2 | 12 participants (Anticipated) | Interventional | 2021-03-01 | Active, not recruiting | ||
| Vitamin D Improves Osteoporosis in Postmenopausal Women With Denosumab Failure[NCT05372224] | 55 participants (Actual) | Interventional | 2020-06-22 | Completed | |||
| Effect of Anti-osteoporotic Medications on Hepatic Steatosis and Fibrosis of Women With Postmenopausal Osteoporosis and Nonalcoholic Fatty Liver Disease[NCT05493761] | Phase 4 | 70 participants (Anticipated) | Interventional | 2022-12-23 | Recruiting | ||
| Alendronate in an Weekly Effervescent Tablet Formulation for Preservation of Bone Mass After Denosumab Discontinuation in Postmenopausal Women With Low Bone Mass. An Observational Study (Binosto After Denosumab - The BAD Study)[NCT04338529] | 92 participants (Actual) | Observational | 2020-04-01 | Active, not recruiting | |||
| A Multi-centre, Randomized, Double Blind, Parallel Group Study to Investigate Efficacy and Safety of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis[NCT00532337] | Phase 2 | 285 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Phase IIa Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate[NCT00885170] | Phase 2 | 246 participants (Actual) | Interventional | 2009-04-13 | Completed | ||
| A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel® Therapies in Postmenopausal Women Transitioned From Weekly or Daily Alendronate Therapy[NCT00919711] | Phase 3 | 870 participants (Actual) | Interventional | 2009-09-01 | Completed | ||
| Re-establishment of Ovarian Hormonal Function, Delay of Menopause, or Reversal of Early Menopause With High Density (HD PRP), tSVF + PRP, or Cell Enriched tSVF + PRP by Ultrasound Guided Ovarian Injection[NCT04444245] | Phase 1 | 100 participants (Anticipated) | Interventional | 2022-07-15 | Active, not recruiting | ||
| Study on the Molecular Mechanism in Postmenopausal Osteoporosis With Kidney Yin Deficiency Syndrome Based on miRNA Mediated Gene Translation Regulation Function by Targeting CLCF1[NCT02128009] | 60 participants (Actual) | Observational [Patient Registry] | 2014-02-28 | Completed | |||
| A Randomised, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women With Low Bone Mineral Density[NCT00896532] | Phase 2 | 419 participants (Actual) | Interventional | 2009-06-03 | Completed | ||
| Phase IV Study Teriparatide and Antiresorptive Combination Treatment Subsequent to 9 Months of Teriparatide Monotherapy[NCT01535027] | Phase 4 | 125 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of Denosumab in Japanese Osteoporotic Subjects With Prevalent Fragility Vertebral Fracture(s)[NCT00680953] | Phase 3 | 1,262 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women[NCT00729651] | Phase 4 | 343 participants (Actual) | Interventional | 2008-03-20 | Completed | ||
| Resolution of Hyperparathyroidism With High-dose Vitamin D Improves Osteoporosis in Multi-treated Postmenopausal Women[NCT05347082] | 47 participants (Actual) | Interventional | 2021-04-29 | Completed | |||
| A 6-Month, Randomized, Open-Label, Active-Comparator Controlled, Parallel-Group Study With a 6-Month Extension to Evaluate the Safety and Efficacy of Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination Tablets Versus Calcitriol in the Treatment of O[NCT01350934] | Phase 4 | 219 participants (Actual) | Interventional | 2011-06-19 | Completed | ||
| Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption[NCT01750086] | Phase 4 | 27 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| An Open-Label, Single-Arm, Multicenter Study to Evaluate the Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption[NCT03710889] | Phase 3 | 23 participants (Actual) | Interventional | 2018-09-20 | Completed | ||
| Open-Label Study to Determine How Prior Therapy With Alendronate or Risedronate in Postmenopausal Women With Osteoporosis Influences the Clinical Effectiveness of Teriparatide[NCT00130403] | Phase 4 | 290 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan[NCT00212719] | Phase 3 | 250 participants | Interventional | 2003-05-31 | Completed | ||
| Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene[NCT00079924] | Phase 4 | 200 participants | Interventional | 2004-11-30 | Completed | ||
| Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone[NCT04467983] | Phase 4 | 70 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | ||
| An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density[NCT00325468] | Phase 3 | 200 participants (Actual) | Interventional | 2006-05-01 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled, Multicenter 4-Week Study to Assess the Effect of Alendronate 70 mg and Vitamin D3 2800 IU Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women[NCT00641771] | Phase 1 | 56 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| A Phase III (Phase V Program), Open-Label, Randomized, Referred-Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK -0217A/Alendronate Sodium-70 mg/Vitamin D3 5600 I.U. Combination Tablet on Vitamin D Inadequacy in the Treatment of O[NCT00692913] | Phase 3 | 515 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Study CR9108963: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis[NCT00471237] | Phase 2 | 564 participants (Actual) | Interventional | 2007-05-14 | Terminated (stopped due to Terminated for futility by sponsor after a pre-planned interim review of data) | ||
| Bisphosphonates for Prevention of Post-Denosumab Bone Loss in Premenopausal Women With Idiopathic Osteoporosis[NCT03396315] | Phase 2 | 27 participants (Actual) | Interventional | 2018-01-29 | Active, not recruiting | ||
| The Use of Buffered Soluble Alendronate 70 mg (Steovess/Binosto) After Denosumab Discontinuation to Prevent Increase in Bone Turnover[NCT04403698] | Phase 2 | 30 participants (Actual) | Interventional | 2019-11-13 | Completed | ||
| A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Denisty[NCT00330460] | Phase 3 | 1,189 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women With Low Bone Mineral Density[NCT00377819] | Phase 3 | 504 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Efficacy and Safety of Minodronate in the Treatment of Postmenopausal Osteoporosis With Low Back Pain: a Single-centre and Randomized Controlled Trial[NCT05645289] | Phase 4 | 72 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | ||
| A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)[NCT00089791] | Phase 3 | 7,808 participants (Actual) | Interventional | 2004-08-01 | Completed | ||
| Clinical Trial of Parathyroid Hormone (PTH) and Alendronate in Combination in the Treatment of Osteoporosis[NCT00005005] | Phase 2 | 238 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
| The Denosumab And Teriparatide Administration Study (DATA)[NCT00926380] | Phase 2 | 94 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial[NCT00398931] | Phase 3 | 1,099 participants (Actual) | Interventional | 1998-02-28 | Completed | ||
| A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis[NCT00092014] | Phase 3 | 1,053 participants (Actual) | Interventional | 2002-09-01 | Completed | ||
| Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday: Data From a Single Outpatient Endocrine Clinic.[NCT01854086] | 150 participants (Anticipated) | Observational [Patient Registry] | 2013-09-30 | Not yet recruiting | |||
| A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Compare the Safety and Tolerability of an Oral Buffered Solution of Alendronate Sodium 70 mg Once-Weekly Versus Placebo for the Treatment of Osteoporosis in Postmenopausal Women[NCT00092027] | Phase 3 | 454 participants (Actual) | Interventional | 2003-03-19 | Completed | ||
| A Randomized, Double-Blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Postmenopausal Women With Low Bone Mineral Density[NCT00043186] | Phase 2 | 412 participants (Actual) | Interventional | 2002-05-31 | Completed | ||
| A Phase III, Randomized, Two-armed, Parallel, Double-blind, Active-controlled, Non-inferiority Clinical Trial to Determine the Non-inferior Therapeutic Efficacy and Safety Between Arylia (60 mg, Denosumab, Produced by AryoGen Pharmed) Compared With Prolia[NCT03293108] | Phase 3 | 190 participants (Anticipated) | Interventional | 2017-04-29 | Active, not recruiting | ||
| A 15-Week, Double-Blind, Randomized, Active-Controlled, Multi-Center Study With 24-Week Extension to Evaluate the Safety, Tolerability, Efficacy of Alendronate 70 mg Plus Vitamin D3 2800 IU Combination Tablet in Men and Postmenopausal Women With Osteoporo[NCT00092079] | Phase 3 | 652 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A 15-Week, Double-Blind, Randomized, Active-Controlled, Multi-Center Study With 24-Week Extension to Evaluate the Safety, Tolerability, Efficacy of Alendronate 70 mg Plus Vitamin D3 2800 IU Combination Tablet in Men and Postmenopausal Women With Osteoporo[NCT00092066] | Phase 3 | 717 participants (Actual) | Interventional | 2003-09-24 | Completed | ||
| Genetic Analysis of Familial Cases of Premature Ovarian Failure[NCT01177891] | 110 participants (Actual) | Observational | 2010-10-31 | Completed | |||
| A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis; A 12 Month Extension to: A Randomized, Double[NCT00092040] | Phase 3 | 936 participants (Actual) | Interventional | 2003-03-18 | Completed | ||
| [NCT00035971] | Phase 4 | 0 participants | Interventional | Completed | |||
| A Triple-Blind, Randomized, Active-Controlled, Parallel-Group, Multicenter Study to Evaluate and Compare the Efficacy and Tolerability of Alendronate Sodium With Calcium Supplementation in the Treatment of Osteoporosis in Postmenopausal Women[NCT00398606] | Phase 3 | 650 participants | Interventional | 1995-04-30 | Completed | ||
| Comparison of 3 Month PTHrP(1-36) and PTH(1-34) on Post-Menopausal Osteoporosis[NCT00853723] | Phase 2 | 105 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203] | Phase 2 | 120 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Assessing the Efficacy of Melatonin on Bone Health in Peri-menopausal Women[NCT01152580] | Phase 1 | 19 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Changes in Bone Density, Radiographic Texture Analysis and Bone Turnover During Two Years of Antiresorptive Therapy for Postmenopausal Osteoporosis[NCT00145977] | 36 participants (Actual) | Interventional | 2001-07-31 | Completed | |||
| A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Once-Weekly Alendronate in HIV-Infected Subjects With Decreased Bone Mineral Density Receiving Calcium and Vitamin D[NCT00061256] | Phase 2 | 80 participants | Interventional | Completed | |||
| Comparison of Skeletal and Mineral Metabolism Responses in Healthy African-Americans and Caucasians Using a Continuous Seven-Day Parathyroid Hormone (PTH) or Parathyroid Hormone-related Protein (PTHrP) Infusion[NCT01333267] | Phase 1 | 0 participants (Actual) | Interventional | 2015-01-31 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.4 |
| Romosozumab | 13.1 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo/Denosumab | 5.5 |
| Romosozumab/Denosumab | 16.6 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.3 |
| Romosozumab | 5.5 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo/Denosumab | 2.3 |
| Romosozumab/Denosumab | 7.3 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.3 |
| Romosozumab | 6.0 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo/Denosumab | 3.2 |
| Romosozumab/Denosumab | 8.5 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 2.5 |
| Romosozumab | 1.6 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 4.1 |
| Romosozumab/Denosumab | 2.8 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.4 |
| Romosozumab | 0.2 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 0.6 |
| Romosozumab/Denosumab | 0.3 |
A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.5 |
| Romosozumab | 1.0 |
A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 2.8 |
| Romosozumab/Denosumab | 1.9 |
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.8 |
| Romosozumab | 1.1 |
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 3.1 |
| Romosozumab/Denosumab | 1.9 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.8 |
| Romosozumab | 0.5 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 2.5 |
| Romosozumab/Denosumab | 0.7 |
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 2.1 |
| Romosozumab | 1.6 |
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date as recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 3.6 |
| Romosozumab/Denosumab | 2.7 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.3 |
| Romosozumab | 0.03 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 0.5 |
| Romosozumab/Denosumab | 0.03 |
"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.~The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height." (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.8 |
| Romosozumab | 0.5 |
"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.~The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height." (NCT01575834)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 2.5 |
| Romosozumab/Denosumab | 0.6 |
Time to treatment non-adherence for alendronate is defined for each treatment period as the time to treatment non-compliance or time to treatment non-persistence, whichever occurs earliest, for participants with uncensored values. Participants who had both censored time to non-compliance and censored time to non-persistence values were censored in the analysis at the end of treatment period visit. (NCT00518531)
Timeframe: Treatment Period 1 (Month 1 to Month 12)
| Intervention | weeks (Mean) |
|---|---|
| Alendronate | 43.29 |
Time to treatment non-adherence for alendronate is defined for each treatment period as the time to treatment non-compliance or time to treatment non-persistence, whichever occurs earliest, for participants with uncensored values. Participants who had both censored time to non-compliance and censored time to non-persistence values were censored in the analysis at the end of treatment period visit. (NCT00518531)
Timeframe: Treatment Period 2 (Month 13 to Month 24)
| Intervention | weeks (Mean) |
|---|---|
| Alendronate | 39.45 |
Time to treatment non-compliance for alendronate is based on the percent of QW tablets taken and is defined for each treatment period as the first week since Study Day 1 of the treatment period to the week where the percent of QW tablets taken falls below the threshold of ≥ 80% and where the participant can not reach this threshold again during the treatment period. (NCT00518531)
Timeframe: Treatment period 1 (Month 1 to Month 12)
| Intervention | weeks (Mean) |
|---|---|
| Alendronate | 43.75 |
Time to treatment non-compliance for alendronate is based on the percent of QW tablets taken and is defined for each treatment period as the first week since Study Day 1 of the treatment period to the week where the percent of QW tablets taken falls below the threshold of ≥ 80% and where the participant can not reach this threshold again during the treatment period. (NCT00518531)
Timeframe: Treatment period 2 (Month 13 to Month 24)
| Intervention | weeks (Mean) |
|---|---|
| Alendronate | 39.97 |
Time to non-persistence for alendronate is defined for each treatment period as the first time <2 tablets were taken in a rolling 4-week time period (e.g. study weeks 1-4, 2-5, 3-6 etc) and where the participant never reaches this threshold again during the treatment period. Tablet intake was tracked using a Medication Event Monitoring System. (NCT00518531)
Timeframe: Treatment period 1 (Month 1 to Month 12)
| Intervention | weeks (Mean) |
|---|---|
| Alendronate | 44.59 |
Time to non-persistence for alendronate is defined for each treatment period as the first time <2 tablets were taken in a rolling 4-week time period (e.g. study weeks 1-4, 2-5, 3-6 etc) and where the participant never reaches this threshold again during the treatment period. Tablet intake was tracked using a Medication Event Monitoring System. (NCT00518531)
Timeframe: Treatment period 2 (Month 13 to Month 24)
| Intervention | weeks (Mean) |
|---|---|
| Alendronate | 42.76 |
A participant was considered adherent to denosumab treatment if the participant: - received 2 denosumab injections (overall treatment compliance); - took each injection 6 months (± 4 weeks) apart (treatment compliance over time); - completed the relevant treatment period (treatment persistence). A participant was considered adherent to alendronate treatment if the participant: - took ≥ 80% QW tablets (overall treatment compliance); - took at least 2 tablets in the last month and completed the relevant treatment period (treatment persistence). Participants who did not meet all criteria for their assigned treatment were deemed non-adherent to treatment. (NCT00518531)
Timeframe: Treatment period 1 (Month 1 to Month 12)
| Intervention | Participants (Number) | |
|---|---|---|
| Yes | No | |
| Alendronate | 95 | 29 |
| Denosumab | 111 | 15 |
A participant was considered adherent to denosumab treatment if the participant: - received 2 denosumab injections (overall treatment compliance); - took each injection 6 months (± 4 weeks) apart (treatment compliance over time); - completed the relevant treatment period (treatment persistence). A participant was considered adherent to alendronate treatment if the participant: - took ≥ 80% QW tablets (overall treatment compliance); - took at least 2 tablets in the last month and completed the relevant treatment period (treatment persistence). Participants who did not meet all criteria for their assigned treatment were deemed nonadherent to treatment. (NCT00518531)
Timeframe: Treatment period 2 (Months 13 to 24)
| Intervention | Participants (Number) | |
|---|---|---|
| Yes | No | |
| Alendronate | 73 | 42 |
| Denosumab | 98 | 8 |
The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. Participants' concern about the adverse consequences of taking the medication for controlling osteoporosis was based on the average of 10 items from the BMQ that form the concern score. The concern score ranges from 1 to 5, with higher scores indicating stronger concerns about the adverse consequences of taking the prescribed medication for controlling osteoporosis. (NCT00518531)
Timeframe: Baseline and Month 6, Month 12, Month 18, and Month 24
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (n=104, 117) | Month 6 (n=106, 114) | Month 12 (n=103, 95) | Month 18 (n=98, 98) | Month 24 (n=91, 100) | |
| Alendronate | 2.33 | 2.22 | 2.57 | 2.43 | 2.39 |
| Denosumab | 2.43 | 2.12 | 2.51 | 2.24 | 2.18 |
The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. The BMQ preference score, which measures a participant's overall evaluation of a medication, is based on the average of 7 items in the BMQ. The preference score ranges from 1 to 5, with higher scores indicating stronger preference for one medication over the other. (NCT00518531)
Timeframe: Baseline and Month 6, Month 12, Month 18, and Month 24
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (n=104, 117) | Month 6 (n=106, 114) | Month 12 (n=103, 95) | Month 18 (n=98, 98) | Month 24 (n=91, 100) | |
| Alendronate | 2.97 | 3.01 | 2.62 | 2.55 | 2.57 |
| Denosumab | 3.47 | 3.72 | 3.43 | 3.77 | 3.80 |
"The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other.~Participants' beliefs about the necessity of the prescribed medication to treat osteoporosis were based on the average of 5 items from the BMQ that form the necessity score. The necessity score ranges from 1 to 5, with higher scores indicating stronger beliefs about the necessity of the prescribed medication for controlling osteoporosis." (NCT00518531)
Timeframe: Baseline, Month 6, Month 12, Month 18 and Month 24
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (n=104, 117) | Month 6 (n=106, 114) | Month 12 (n=103, 95) | Month 18 (n=98, 98) | Month 24 (n=91, 100) | |
| Alendronate | 3.32 | 3.14 | 3.21 | 3.20 | 3.21 |
| Denosumab | 3.26 | 3.31 | 3.17 | 3.28 | 3.22 |
Participants were considered compliant to denosumab treatment if they received 2 denosumab injections (overall treatment compliance) and if they took each injection 6 months (± 4 weeks) apart (treatment compliance over time). Participants were considered compliant to alendronate treatment if they took ≥ 80% QW tablets (overall treatment compliance). (NCT00518531)
Timeframe: Treatment period 1 (Month 1 to Month 12)
| Intervention | Participants (Number) | |
|---|---|---|
| Yes | No | |
| Alendronate | 97 | 27 |
| Denosumab | 114 | 12 |
Participants were considered compliant to denosumab treatment if they received 2 denosumab injections (overall treatment compliance) and if they took each injection 6 months (± 4 weeks) apart (treatment compliance over time). Participants were considered compliant to alendronate treatment if they took ≥ 80% QW tablets (overall treatment compliance). (NCT00518531)
Timeframe: Treatment period 2 (Month 13 to Month 24)
| Intervention | Participants (Number) | |
|---|---|---|
| Yes | No | |
| Alendronate | 78 | 37 |
| Denosumab | 99 | 7 |
The MARs questionnaire is a validated, self-reported instrument for assessing treatment adherence. Participants report how often they engage in each of 5 aspects of non-adherent behavior (forgetting to take a dose, changing the dose, stop taking them for a while, deciding to not take a dose, or taking less than instructed). Scores are summed over the 5 items, the total score ranges from 5 to 25 with higher scores indicating greater self-reported adherence. The MARS was collected at the month 6 and month 12 visits of each treatment period only for those participants receiving oral alendronate during that period. (NCT00518531)
Timeframe: Month 6, Month 12 (treatment period 1)
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Month 6 (n=109) | Month 12 (n= 100) | |
| Alendronate | 24.3 | 24.4 |
The MARs questionnaire is a validated, self-reported instrument for assessing treatment adherence. Participants report how often they engage in each of 5 aspects of non-adherent behavior (forgetting to take a dose, changing the dose, stop taking them for a while, deciding to not take a dose, or taking less than instructed). Scores are summed over the 5 items, the total score ranges from 5 to 25 with higher scores indicating greater self-reported adherence. The MARS was collected at the month 6 and month 12 visits of each treatment period only for those participants receiving oral alendronate during that period. (NCT00518531)
Timeframe: Month 18, Month 24 (treatment period 2)
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Treatment period 2 Month 6 (n=98) | Treatment period 2 Month 12 (n= 90) | |
| Alendronate | 23.4 | 23.8 |
"Participant satisfaction with their treatment was assessed using question 7 (ie, Please rate your satisfaction with the weekly pill on the following: frequency of administration; mode of administration [taking a pill]; convenience; overall satisfaction) and question 8 (ie, Please rate your satisfaction with the six month injection on the following: frequency of administration; mode of administration [receiving an injection]; convenience; overall satisfaction) from the Preference Satisfaction Questionnaire (PSQ) at the end of each treatment period. The PSQ is a 34 item, self-report questionnaire of participants' preference and satisfaction for each of the two study treatments. Possible answers include: Not at all Satisfied, A Little Satisfied, Moderately Satisfied, Quite Satisfied, and Very Satisfied." (NCT00518531)
Timeframe: End of treatment period 1 (Month 12)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all satisfied | A little satisfied | Moderately satisfied | Quite satisfied | Very satisfied | |
| Alendronate | 3 | 1 | 17 | 34 | 59 |
| Denosumab | 3 | 3 | 2 | 18 | 95 |
Denosumab-treated participants were considered persistent to treatment if they completed the relevant treatment period and alendronate-treated participants were considered persistent to treatment if they completed the relevant treatment period and took at least 2 tablets in the last month of the treatment period. (NCT00518531)
Timeframe: Treatment period 1 (Month 1 to Month 12)
| Intervention | Participants (Number) | |
|---|---|---|
| Yes | No | |
| Alendronate | 99 | 25 |
| Denosumab | 114 | 12 |
Denosumab-treated participants were considered persistent to treatment if they completed the relevant treatment period and alendronate-treated participants were considered persistent to treatment if they completed the relevant treatment period and took at least 2 tablets in the last month of the treatment period. (NCT00518531)
Timeframe: Treatment period 2 (Month 13 to Month 24)
| Intervention | Participants (Number) | |
|---|---|---|
| Yes | No | |
| Alendronate | 82 | 33 |
| Denosumab | 103 | 3 |
(NCT01343004)
Timeframe: 18 months
| Intervention | participants (Number) |
|---|---|
| Placebo | 30 |
| BA058 80 mcg (Abaloparatide) | 4 |
| Teriparatide | 6 |
(NCT01343004)
Timeframe: 18 months
| Intervention | Participants (Number) |
|---|---|
| Placebo | 33 |
| BA058 80 mcg (Abaloparatide) | 18 |
| Teriparatide | 24 |
(NCT01343004)
Timeframe: 18 months
| Intervention | Hypercalcemic events (Number) |
|---|---|
| Placebo | 5 |
| BA058 80 mcg (Abaloparatide) | 15 |
| Teriparatide | 34 |
(NCT01343004)
Timeframe: Baseline and 18 months
| Intervention | percent change (Mean) |
|---|---|
| Placebo | -0.44 |
| BA058 80 mcg (Abaloparatide) | 2.90 |
| Teriparatide | 2.26 |
(NCT01343004)
Timeframe: Basline and 18 months
| Intervention | percent change from baseline (Mean) |
|---|---|
| Placebo | 0.48 |
| BA058 80 mcg (Abaloparatide) | 9.20 |
| Teriparatide | 9.12 |
(NCT01343004)
Timeframe: Baseline and 18 months
| Intervention | percent change (Mean) |
|---|---|
| Placebo | -0.08 |
| BA058 80 mcg (Abaloparatide) | 3.44 |
| Teriparatide | 2.81 |
Nonvertebral fractures were defined as clinical fractures that included: 1) those of the hip, wrist, forearm, shoulder, collar bone, upper arm, ribs, upper leg (not hip), knee, lower leg (not knee or ankle), foot, ankle, hand, pelvis (not hip), tailbone, and other; and 2) those associated with low trauma, defined as a fall from standing height or less; a fall on stairs, steps or curbs; a minimal trauma other than a fall; or moderate trauma other than a fall. Complete results for Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417. (NCT01657162)
Timeframe: Study BA058-05-003 Baseline (Day 1) up to Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)
| Intervention | percentage of events (Number) |
|---|---|
| Abaloparatide-SC/Alendronate | 2.7 |
| Placebo/Alendronate | 5.6 |
Vertebral fractures were determined clinically and via protocol directed radiograph evaluation. Complete results for Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417. (NCT01657162)
Timeframe: Study BA058-05-003 Baseline (Day 1) up to Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)
| Intervention | Participants (Count of Participants) |
|---|---|
| Abaloparatide-SC/Alendronate | 3 |
| Placebo/Alendronate | 25 |
Coagulation laboratory parameters that were evaluated via notable criteria (presented in parentheses) included: Activated Partial Thromboplastin Time (≥1.41*ULN), Prothrombin Time (≥1.21*ULN). Because the Activated Partial Thromboplastin Time was the only coagulation laboratory parameter with at least 1 participant with a notable laboratory value, this is the only parameter presented below. (NCT01657162)
Timeframe: Study BA058-05-005 Baseline (Day 1) up to Study BA058-05-005 Month 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Abaloparatide-SC/Alendronate | 9 |
| Placebo/Alendronate | 4 |
Nonvertebral fractures were defined as clinical fractures that included: 1) those of the hip, wrist, forearm, shoulder, collar bone, upper arm, ribs, upper leg (not hip), knee, lower leg (not knee or ankle), foot, ankle, hand, pelvis (not hip), tailbone, and other; and 2) those associated with low trauma, defined as a fall from standing height or less; a fall on stairs, steps or curbs; a minimal trauma other than a fall; or moderate trauma other than a fall. Complete results for Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417. (NCT01657162)
Timeframe: Study BA058-05-003 Baseline (Day 1) up to Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)
| Intervention | Participants (Count of Participants) |
|---|---|
| Abaloparatide-SC/Alendronate | 15 |
| Placebo/Alendronate | 32 |
Femoral neck BMD were measured via DXA. Complete results for Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417. (NCT01657162)
Timeframe: Study BA058-05-003 Baseline (Day 1), Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)
| Intervention | percent change (Mean) |
|---|---|
| Abaloparatide-SC/Alendronate | 4.5113 |
| Placebo/Alendronate | 0.4649 |
Lumbar spine BMD were measured via DXA. Complete results for Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417. (NCT01657162)
Timeframe: Study BA058-05-003 Baseline (Day 1), Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)
| Intervention | percent change (Mean) |
|---|---|
| Abaloparatide-SC/Alendronate | 12.7921 |
| Placebo/Alendronate | 3.5133 |
Total hip BMD were measured via DXA. Complete results for Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417. (NCT01657162)
Timeframe: Study BA058-05-003 Baseline (Day 1), Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)
| Intervention | percent change (Mean) |
|---|---|
| Abaloparatide-SC/Alendronate | 5.4737 |
| Placebo/Alendronate | 1.3698 |
Hematology laboratory parameters that were evaluated via notable criteria (presented in parentheses) included: Absolute Eosinophils (>5000 cells/mm^3), Absolute Lymphocytes (≤499 cells/mm^3), Absolute Neutrophils (≤999 cells/mm^3), % Eosinophils (>50%), % Lymphocytes (≤5%), % Neutrophils (≤10%), Hemoglobin (Low: ≤9.4 g/dL; High: change from baseline ≥2.1 g/dL), Platelets (≤99000 cells/mm^3), and White Blood Cells (Low: ≤1499 cells/mm^3; High: ≥20001 cells/mm^3). Only the hematology parameters with at least 1 participant with a notable laboratory value are presented. (NCT01657162)
Timeframe: Study BA058-05-005 Baseline (Day 1) up to Study BA058-05-005 Month 24
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Absolute Lymphocytes | Lymphocytes (Absolute Count or Percentage) | Absolute Neutrophils | Neutrophils (Absolute Count or Percentage) | Hemoglobin (Low) | Hemoglobin (High) | Platelets | |
| Abaloparatide-SC/Alendronate | 15 | 15 | 0 | 0 | 7 | 19 | 1 |
| Placebo/Alendronate | 11 | 11 | 2 | 2 | 2 | 17 | 0 |
Serum Chemistry laboratory parameters that were evaluated via notable criteria (presented in parentheses) included: sodium (Low: ≤129; High: ≥148 milliequivalent per liter [mEq/L]), potassium (Low: ≤3.2; High: ≥5.5 mEq/L), albumin (<2.5 grams [g]/deciliter [dL]), total protein (<5 g/dL), glucose (Low: ≤54; High: >125 mg/dL [fasting] or >200 milligrams [mg]/dL [random]), creatinine (≥2.1 mg/dL), aspartate aminotransferase (AST) (≥5.1*upper limit of normal [ULN]), alanine aminotransferase (ALT) (≥5.1*ULN), alkaline phosphatase (AP) (≥3.1*ULN), total bilirubin (≥1.51*ULN [with any increase in liver function tests] ≥2.0*ULN [with normal liver function tests]), creatine kinase (≥3.1*ULN), total cholesterol (>226 mg/dL), and total calcium (Low: ≤7.4; High: ≥11.6 mg/dL). Only the serum chemistry parameters with at least 1 participant with a notable laboratory value are presented. (NCT01657162)
Timeframe: Study BA058-05-005 Baseline (Day 1) up to Study BA058-05-005 Month 24
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Alkaline Phosphatase | Cholesterol Total | Creatine Kinase | Glucose (Fasting; High) | Glucose (Random) | Potassium (Low) | Potassium (High) | Sodium (Low) | Sodium (High) | |
| Abaloparatide-SC/Alendronate | 1 | 75 | 2 | 22 | 1 | 1 | 4 | 1 | 6 |
| Placebo/Alendronate | 0 | 73 | 1 | 18 | 2 | 3 | 3 | 1 | 2 |
Urine laboratory parameters that were evaluated via notable criteria (presented in parentheses) included: Glucose (2+), Protein (2+), Blood (>50 red blood cells per high-power field [rbc/hpf]). (NCT01657162)
Timeframe: Study BA058-05-005 Baseline (Day 1) up to Study BA058-05-005 Month 24
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Glucose | Protein | Blood | |
| Abaloparatide-SC/Alendronate | 4 | 6 | 77 |
| Placebo/Alendronate | 3 | 6 | 50 |
A TEAE is any untoward medical occurrence or undesirable event(s) experienced in a participant that begins or worsens following administration of study drug, whether or not considered related to study drug by Investigator. A serious adverse event (SAE) was an adverse event (AE) resulting in any of the following outcomes or deemed significant for any other reason, death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), congenital anomaly/birth defect, or persistent or significant disability/incapacity. Intensity for each AE was defined as mild, moderate, or severe. AEs included both SAEs and non-serious AEs. AEs whose causal relation was characterized as Possible or Probable were considered as related to study drug. AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA). A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module. (NCT01657162)
Timeframe: Study BA058-05-005 Baseline (Day 1) up to Study BA058-05-005 Month 24
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| TEAEs | TEAEs Related to Study Treatment | Severe TEAEs | Serious TEAEs | TEAEs Leading to Death | TEAEs Leading to Discontinuation | |
| Abaloparatide-SC/Alendronate | 452 | 85 | 38 | 65 | 0 | 30 |
| Placebo/Alendronate | 466 | 80 | 40 | 58 | 2 | 36 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 1.7 |
| Romosozumab/Alendronate | 4.9 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 5.0 |
| Romosozumab/Alendronate | 13.7 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 7.2 |
| Romosozumab/Alendronate | 15.3 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 2.8 |
| Romosozumab/Alendronate | 6.2 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 2.3 |
| Romosozumab/Alendronate | 6.0 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 36
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 2.4 |
| Romosozumab/Alendronate | 6.0 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 36
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 7.8 |
| Romosozumab/Alendronate | 15.2 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 3.5 |
| Romosozumab/Alendronate | 7.2 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 36
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 3.5 |
| Romosozumab/Alendronate | 7.2 |
All fracture assessments were performed by blinded central imaging readers. Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 13.0 |
| Romosozumab/Alendronate | 9.7 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 5.4 |
| Romosozumab/Alendronate | 3.9 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 9.6 |
| Romosozumab/Alendronate | 7.1 |
A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 0.9 |
| Romosozumab/Alendronate | 0.5 |
A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 2.1 |
| Romosozumab/Alendronate | 0.9 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 3.2 |
| Romosozumab/Alendronate | 2.0 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 1.1 |
| Romosozumab/Alendronate | 0.7 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 2.1 |
| Romosozumab/Alendronate | 1.5 |
Major nonvertebral fractures included a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 9.6 |
| Romosozumab/Alendronate | 7.1 |
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 4.2 |
| Romosozumab/Alendronate | 3.0 |
"A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.~Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method." (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 9.2 |
| Romosozumab/Alendronate | 4.8 |
A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 10.6 |
| Romosozumab/Alendronate | 8.7 |
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 4.6 |
| Romosozumab/Alendronate | 3.4 |
A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 7.8 |
| Romosozumab/Alendronate | 6.3 |
All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 19.1 |
| Romosozumab/Alendronate | 13.0 |
All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 9.2 |
| Romosozumab/Alendronate | 6.5 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. Incident vertebral fractures were confirmed by a second independent reader. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 2.5 |
| Romosozumab/Alendronate | 1.3 |
"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.~Incident vertebral fractures were confirmed by a second independent reader." (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 5.0 |
| Romosozumab/Alendronate | 3.2 |
"All fracture assessments were performed by blinded central imaging readers.~New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.~Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method." (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 8.0 |
| Romosozumab/Alendronate | 4.1 |
"Number of participants in which CTX increased above the least significant change.~The Department of Clinical Biochemistry, Rigshospitalet, Glostrup, Denmark provided the the least significant change for p-CTX > 30%." (NCT03051620)
Timeframe: From baseline to month 24
| Intervention | participants (Number) |
|---|---|
| Study Population | 85 |
We constructed receiver operating characteristic (ROC) curves to evaluate if baseline p-CTX or baseline p-PINP at the time of alendronate discontinuation predicted TH BMD loss above the least significant change at month 12 and/or month 24 at the individual level. (NCT03051620)
Timeframe: Changes in TH BMD after one and two years.
| Intervention | percentage change (Mean) | |
|---|---|---|
| Mean change in TH BMD after one year | Mean change in TH BMD after two years | |
| Study Population | -1.14 | -2.65 |
We constructed receiver operating characteristic (ROC) curves to evaluate if carboxy-terminal collagen crosslinks (CTX) three and six months after stopping alendronate predicted TH BMD loss above the least significant change (LSC) at month 12 at the individual level. (NCT03051620)
Timeframe: Baseline and one year after baseline
| Intervention | percentage change (Mean) | ||
|---|---|---|---|
| Mean change in CTX from baseline to month 3 | Mean change in CTX from baseline to month 6 | Mean change in TH BMD from baseline to month 12 | |
| Study Population | 49 | 64 | 1.14 |
We constructed receiver operating characteristic (ROC) curves to evaluate if changes in p-CTX or p-PINP measured three and six months after stopping alendronate predicted TH BMD loss above the least significant change at month 12 and/or month 24 at the individual level. (NCT03051620)
Timeframe: one and two years after baseline
| Intervention | percentage change (Mean) | |||
|---|---|---|---|---|
| Mean change in PINP from baseline to month 3 | Mean change in PINP from baseline to month 6 | Mean change in TH BMD from baseline to month 12 | Mean change in TH BMD from baseline to month 24 | |
| Study Population | 36 | 54 | -1.14 | -2.65 |
the number of patients who lost BMD beyond the LSC at the lumbar spine (>3%) and total hip (>5%) (NCT03051620)
Timeframe: from baseline to month 24
| Intervention | participants (Number) | |
|---|---|---|
| Spine | Total hip | |
| Study Population | 21 | 26 |
Percent changes of bone mineral density at lumbar spine (L1-L4) from baseline to 1-year after treatment will be compared and analysed between 2 groups. (NCT02371252)
Timeframe: 1 year after treatment
| Intervention | percent (Mean) |
|---|---|
| Original Alendronate (Fosamax) | 5.54 |
| Generic Alendronate (Bonmax) | 5.39 |
Percent changes of bone mineral density at total hip from baseline to 1-year after treatment will be compared and analysed between 2 groups. (NCT02371252)
Timeframe: 1 year after treatment
| Intervention | percent (Mean) |
|---|---|
| Original Alendronate (Fosamax) | 2.48 |
| Generic Alendronate (Bonmax) | 2.52 |
BMD at the 1/3 distal forearm was assessed by DXA at baseline and Month 12. (NCT00885170)
Timeframe: Baseline and 12 Months
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | -0.11 |
| Placebo | -0.49 |
BMD at the 1/3 distal forearm was assessed by DXA at baseline and Month 24. (NCT00885170)
Timeframe: Baseline and 24 Months
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | -0.92 |
| Placebo | -1.14 |
BMD at the femoral neck was assessed by DXA at baseline and Month 12. (NCT00885170)
Timeframe: Baseline and 12 Months
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 0.60 |
| Placebo | -0.28 |
BMD at the femoral neck was assessed by dual-energy X-ray absorptiometry (DXA) at baseline and Month 24. (NCT00885170)
Timeframe: Baseline and Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 1.73 |
| Placebo | -0.94 |
s-CTx is a biochemical marker of bone resorption. (NCT00885170)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 62.27 |
| Placebo | 68.09 |
1,25 dihydroxyvitamin D [1,25(OH)2 D] is the active vitamin D metabolite and stimulates calcium absorption in the intestine. (NCT00885170)
Timeframe: Baseline and Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | -5.23 |
| Placebo | -6.71 |
The 25-hydroxy vitamin D [25(OH)D] test is the most accurate way to measure vitamin D. In the kidney, 25-hydroxy vitamin D is converted into 1,25 di-hydroxyvitamin D, the active vitamin D metabolite. (NCT00885170)
Timeframe: Baseline and Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | -2.57 |
| Placebo | 0.57 |
Bone-Specific Alkaline Phosphatase (BSAP) is a biochemical marker of bone formation. (NCT00885170)
Timeframe: Baseline and Month 24
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 51.62 |
| Placebo | 40.65 |
BSAP is a biochemical marker of bone formation. (NCT00885170)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 30.91 |
| Placebo | 18.10 |
s-CTx is a biochemical marker of bone resorption. (NCT00885170)
Timeframe: Baseline and Month 24
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 93.86 |
| Placebo | 83.70 |
Serum calcium is an index of calcium homeostasis. (NCT00885170)
Timeframe: Baseline and Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | -2.40 |
| Placebo | -2.51 |
s-P1NP is a biochemical marker of bone formation. (NCT00885170)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 80.37 |
| Placebo | 56.37 |
Serum N-terminal propeptide of Type I collagen (s-P1NP) is a biochemical marker of bone formation. (NCT00885170)
Timeframe: Baseline and Month 24
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 90.70 |
| Placebo | 59.53 |
Serum parathyroid hormone (SPH) regulates calcium, phosphorus, and vitamin D levels in the blood. (NCT00885170)
Timeframe: Baseline and Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 4.38 |
| Placebo | 10.28 |
Serum phosphate is an index of mineral homeostasis. (NCT00885170)
Timeframe: Baseline and Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 2.37 |
| Placebo | 0.99 |
u-NTx/Cr is a biochemical marker of bone resorption. (NCT00885170)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | -17.23 |
| Placebo | 29.06 |
N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio (u-NTx/Cr) is a biochemical marker of bone resorption. (NCT00885170)
Timeframe: Baseline and Month 24
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | -15.55 |
| Placebo | 31.48 |
BMD at the lumbar spine was assessed by DXA at baseline and Month 12. (NCT00885170)
Timeframe: Baseline and 12 Months
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 0.69 |
| Placebo | -0.12 |
BMD at the lumbar spine was assessed by DXA at baseline and Month 24. (NCT00885170)
Timeframe: Baseline and 24 Months
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 2.28 |
| Placebo | -0.30 |
BMD at the total hip was assessed by DXA at baseline and Month 12. (NCT00885170)
Timeframe: Baseline and 12 Months
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 0.26 |
| Placebo | -0.80 |
BMD at the total hip was assessed by DXA at baseline and Month 24. (NCT00885170)
Timeframe: Baseline and 24 Months
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 0.83 |
| Placebo | -1.87 |
BMD at the trochanter was assessed by DXA at baseline and Month 12. (NCT00885170)
Timeframe: Baseline and 12 Months
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 0.86 |
| Placebo | -0.14 |
BMD at the trochanter was assessed by DXA at baseline and Month 24. (NCT00885170)
Timeframe: Baseline and 24 Months
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Odanacatib 50 mg | 1.83 |
| Placebo | -1.35 |
An AE was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. (NCT00885170)
Timeframe: Up to 24 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Odanacatib 50 mg | 9.0 |
| Placebo | 3.3 |
An AE was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. (NCT00885170)
Timeframe: Up to 25 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Odanacatib 50 mg | 68.0 |
| Placebo | 73.6 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry (NCT00919711)
Timeframe: Baseline to month 12
| Intervention | Percent Change From Baseline (Mean) |
|---|---|
| Risedronate 150 mg QM | 0.0 |
| Denosumab 60 mg Q6M | 1.4 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry (NCT00919711)
Timeframe: Baseline to month 12
| Intervention | Percent Change From Baseline (Mean) |
|---|---|
| Risedronate 150 mg QM | 1.1 |
| Denosumab 60 mg Q6M | 3.4 |
Serum Type-1 Collagen C-Telopeptide Percent Change From Baseline at Month 1 (NCT00919711)
Timeframe: Baseline to month 1
| Intervention | Percent Change From Baseline (Median) |
|---|---|
| Risedronate 150 mg QM | -17.0 |
| Denosumab 60 mg Q6M | -77.7 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry (NCT00919711)
Timeframe: Baseline to month 12
| Intervention | Percent Change From Baseline (Mean) |
|---|---|
| Risedronate 150 mg QM | 0.5 |
| Denosumab 60 mg Q6M | 2.0 |
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader. (NCT00896532)
Timeframe: Baseline to 12 months
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.1 |
| Alendronate | 4.1 |
| Teriparatide | 7.1 |
| Romosozumab 70 mg QM | 5.4 |
| Romosozumab 140 mg Q3M | 5.4 |
| Romosozumab 140 mg QM | 9.1 |
| Romosozumab 210 mg Q3M | 5.5 |
| Romosozumab 210 mg QM | 11.3 |
| Romosozumab Monthly | 8.6 |
| Romosozumab Every 3 Months | 5.5 |
| Romosozumab 140 mg | 7.3 |
| Romosozumab 210 mg | 8.4 |
"Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.~Percent change from baseline in distal radius BMD was analyzed using an analysis of covariance (ANCOVA) model with the percent change from baseline to Month 12 in DXA BMD as dependent variable, baseline BMD value, machine type, interaction of baseline BMD and machine type, treatment (categorical) and geographic region as the independent class variables." (NCT00896532)
Timeframe: Baseline to 12 months
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.9 |
| Alendronate | -0.3 |
| Teriparatide | -1.7 |
| Romosozumab 70 mg QM | -1.8 |
| Romosozumab 140 mg Q3M | -1.1 |
| Romosozumab 140 mg QM | -1.0 |
| Romosozumab 210 mg Q3M | -0.4 |
| Romosozumab 210 mg QM | -1.2 |
"Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.~Percent change from baseline to 12 months in BMD was analyzed using a linear mixed effects model with the percent change from baseline to month 12 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables." (NCT00896532)
Timeframe: Baseline to 12 months
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.1 |
| Alendronate | 1.2 |
| Teriparatide | 1.1 |
| Romosozumab 70 mg QM | 0.6 |
| Romosozumab 140 mg Q3M | 1.8 |
| Romosozumab 140 mg QM | 4.2 |
| Romosozumab 210 mg Q3M | 1.4 |
| Romosozumab 210 mg QM | 3.7 |
"Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.~Percent change from baseline to 12 months in BMD was analyzed using a linear mixed effects model with the percent change from baseline to month 12 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables." (NCT00896532)
Timeframe: Baseline to 12 months
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.7 |
| Alendronate | 1.9 |
| Teriparatide | 1.3 |
| Romosozumab 70 mg QM | 1.3 |
| Romosozumab 140 mg Q3M | 1.3 |
| Romosozumab 140 mg QM | 3.4 |
| Romosozumab 210 mg Q3M | 1.9 |
| Romosozumab 210 mg QM | 4.1 |
"Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.~Percent change from baseline to month 6 was analyzed using a linear mixed effects model with the percent change from baseline to month 6 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables." (NCT00896532)
Timeframe: Baseline to 6 months
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.3 |
| Alendronate | 2.6 |
| Teriparatide | 4.8 |
| Romosozumab 70 mg QM | 4.1 |
| Romosozumab 140 mg Q3M | 4.2 |
| Romosozumab 140 mg QM | 7.1 |
| Romosozumab 210 mg Q3M | 4.4 |
| Romosozumab 210 mg QM | 8.2 |
"Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.~Percent change from baseline to month 6 was analyzed using a linear mixed effects model with the percent change from baseline to month 6 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables." (NCT00896532)
Timeframe: Baseline to 6 months
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.4 |
| Alendronate | 0.5 |
| Teriparatide | 0.5 |
| Romosozumab 70 mg QM | 0.2 |
| Romosozumab 140 mg Q3M | 0.4 |
| Romosozumab 140 mg QM | 2.1 |
| Romosozumab 210 mg Q3M | 0.9 |
| Romosozumab 210 mg QM | 1.9 |
"Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.~Percent change from baseline to month 6 was analyzed using a linear mixed effects model with the percent change from baseline to month 6 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables." (NCT00896532)
Timeframe: Baseline to 6 months
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.6 |
| Alendronate | 0.9 |
| Teriparatide | 0.5 |
| Romosozumab 70 mg QM | 0.5 |
| Romosozumab 140 mg Q3M | 0.9 |
| Romosozumab 140 mg QM | 2.2 |
| Romosozumab 210 mg Q3M | 1.1 |
| Romosozumab 210 mg QM | 2.9 |
Percent change from baseline in the bone turnover marker (BTM) BSAP was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline. (NCT00896532)
Timeframe: Baseline and months 1, 3, 6, 9, and 12
| Intervention | percent change (Least Squares Mean) | |||
|---|---|---|---|---|
| Month 3 | Month 6 | Month 9 | Month 12 | |
| Alendronate | -30.5 | -35.4 | -32.5 | -31.2 |
| Teriparatide | 21.8 | 29.8 | 41.8 | 45.7 |
Percent change from baseline in the bone turnover marker (BTM) BSAP was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline. (NCT00896532)
Timeframe: Baseline and months 1, 3, 6, 9, and 12
| Intervention | percent change (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 9 | Month 12 | |
| Placebo | -1.1 | -7.6 | -4.1 | 3.5 | 9.2 |
| Romosozumab 140 mg Q3M | 35.1 | -18.0 | -18.2 | -12.5 | -10.8 |
| Romosozumab 140 mg QM | 29.3 | 1.3 | -6.6 | -5.5 | -5.0 |
| Romosozumab 210 mg Q3M | 47.5 | -17.3 | -20.0 | -17.7 | -12.4 |
| Romosozumab 210 mg QM | 60.9 | 27.4 | 13.1 | 10.4 | 9.2 |
| Romosozumab 70 mg QM | 11.7 | -8.5 | -8.7 | -4.9 | -2.6 |
Percent change from baseline in the bone turnover marker (BTM) osteocalcin was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline. (NCT00896532)
Timeframe: Baseline and months 1, 3, 6, 9, and 12
| Intervention | percent change (Least Squares Mean) | |||
|---|---|---|---|---|
| Month 3 | Month 6 | Month 9 | Month 12 | |
| Alendronate | -28.7 | -40.6 | -50.9 | -50.3 |
| Teriparatide | 104.7 | 106.7 | 99.9 | 91.6 |
Percent change from baseline in the bone turnover marker (BTM) osteocalcin was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline. (NCT00896532)
Timeframe: Baseline and months 1, 3, 6, 9, and 12
| Intervention | percent change (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 9 | Month 12 | |
| Placebo | -1.6 | 4.1 | -7.1 | -6.0 | -14.1 |
| Romosozumab 140 mg Q3M | 60.1 | -5.6 | -16.5 | -29.0 | -24.7 |
| Romosozumab 140 mg QM | 53.1 | 15.6 | -7.4 | -27.7 | -31.1 |
| Romosozumab 210 mg Q3M | 77.9 | -3.7 | -23.2 | -30.7 | -26.2 |
| Romosozumab 210 mg QM | 78.6 | 41.6 | 10.0 | -4.0 | -12.5 |
| Romosozumab 70 mg QM | 28.1 | -0.3 | -11.8 | -26.9 | -27.3 |
Percent change from baseline in the bone turnover marker (BTM) P1NP was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline. (NCT00896532)
Timeframe: Baseline and months 1, 3, 6, 9, and 12
| Intervention | percent change (Least Squares Mean) | |||
|---|---|---|---|---|
| Month 3 | Month 6 | Month 9 | Month 12 | |
| Alendronate | -50.8 | -57.0 | -60.8 | -60.8 |
| Teriparatide | 97.1 | 138.0 | 116.8 | 98.3 |
Percent change from baseline in the bone turnover marker (BTM) P1NP was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline. (NCT00896532)
Timeframe: Baseline and months 1, 3, 6, 9, and 12
| Intervention | percent change (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 9 | Month 12 | |
| Placebo | -0.7 | -5.4 | -5.9 | -10.6 | -8.7 |
| Romosozumab 140 mg Q3M | 61.4 | -15.5 | -22.8 | -23.8 | -23.3 |
| Romosozumab 140 mg QM | 55.0 | 3.8 | -18.6 | -26.1 | -31.2 |
| Romosozumab 210 mg Q3M | 75.8 | -19.5 | -25.5 | -30.1 | -29.7 |
| Romosozumab 210 mg QM | 92.2 | 25.6 | 6.9 | -5.8 | -17.2 |
| Romosozumab 70 mg QM | 24.2 | -9.1 | -20.0 | -26.9 | -23.0 |
Percent change from baseline in the bone turnover marker (BTM) CTX was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline. (NCT00896532)
Timeframe: Baseline and months 1, 3, 6, 9, and 12
| Intervention | percent change (Least Squares Mean) | |||
|---|---|---|---|---|
| Month 3 | Month 6 | Month 9 | Month 12 | |
| Alendronate | -65.0 | -64.2 | -64.4 | -66.7 |
| Teriparatide | 69.4 | 93.5 | 81.3 | 77.0 |
Percent change from baseline in the bone turnover marker (BTM) CTX was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline. (NCT00896532)
Timeframe: Baseline and months 1, 3, 6, 9, and 12
| Intervention | percent change (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 9 | Month 12 | |
| Romosozumab 140 mg Q3M | -19.2 | -6.2 | -8.4 | 1.3 | 12.2 |
| Romosozumab 140 mg QM | -35.4 | -26.5 | -24.6 | -27.7 | -33.0 |
| Romosozumab 210 mg Q3M | -33.0 | -12.6 | -10.5 | -11.7 | -6.6 |
| Romosozumab 210 mg QM | -28.5 | -3.7 | -8.7 | -17.2 | -22.5 |
| Romosozumab 70 mg QM | -22.1 | -21.5 | -18.1 | -15.1 | -20.3 |
| Placebo | -3.9 | -2.4 | 2.7 | 1.0 | 9.8 |
(NCT00680953)
Timeframe: Baseline to 24 months
| Intervention | Vertebral fractures (Mean) |
|---|---|
| Denosumab | 3.6 |
| Placebo | 10.3 |
| Alendronate | 7.2 |
The results are expressed as a percentage by Kaplan-Meier estimate. (NCT00680953)
Timeframe: Baseline to 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Denosumab | 0.0 |
| Placebo | 0.5 |
| Alendronate | 0.0 |
The results are expressed as percentage by Kaplan-Meier estimate the percentage of participants with non-vertebral fractures (NCT00680953)
Timeframe: Baseline to 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Denosumab | 4.1 |
| Placebo | 4.1 |
| Alendronate | 2.7 |
(NCT00729651)
Timeframe: 16 weeks
| Intervention | ng/ml (Mean) |
|---|---|
| Fosamax Plus D | 30.08 |
| Fosamax | 17.14 |
(NCT00729651)
Timeframe: Baseline and 16 weeks
| Intervention | Percentage Change Serum PTH (Least Squares Mean) |
|---|---|
| Fosamax Plus D | 8.17 |
| Fosamax | 29.98 |
(NCT00729651)
Timeframe: 16 weeks
| Intervention | participants (Number) | |
|---|---|---|
| With Vitamin D Deficiency | Without Vitamin D Deficiency | |
| Fosamax | 55 | 77 |
| Fosamax Plus D | 2 | 134 |
(NCT00729651)
Timeframe: 16 weeks
| Intervention | participants (Number) | |
|---|---|---|
| With 25 OHD < 20ng/ml at 16 weeks of treatment | With 25 OHD >= 20ng/ml at 16 weeks of treatment | |
| Fosamax | 93 | 39 |
| Fosamax Plus D | 7 | 129 |
BMD at the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA) at baseline and Month 6. (NCT01350934)
Timeframe: Baseline and Month 6
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Fosamax Plus | 3.54 |
| Calcitriol | 1.59 |
s-CTx is a biochemical marker for bone turnover that has been shown to detect increased bone resorption, a process by which bone is broken down within the body. s-CTx was measured at baseline and Month 6. (NCT01350934)
Timeframe: Baseline and Month 6
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Fosamax Plus | -79.23 |
| Calcitriol | -27.20 |
s-P1NP is a biochemical marker of bone turnover that is particularly useful in monitoring bone resorption, a process by which bone is broken down within the body. s-P1NP was measured at baseline and Month 6. (NCT01350934)
Timeframe: Baseline and Month 6
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Fosamax Plus | -59.12 |
| Calcitriol | -16.75 |
BMD at the lumbar spine was assessed by DXA at baseline and Month 12. (NCT01350934)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Fosamax Plus | 5.17 |
| Calcitriol | 2.26 |
s-CTx is a biochemical marker for bone turnover that has been shown to detect increased bone resorption, a process by which bone is broken down within the body. s-CTx was measured at baseline and Month 12. (NCT01350934)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Fosamax Plus | -76.15 |
| Calcitriol | -24.19 |
s-P1NP is a biochemical marker of bone turnover that is particularly useful in monitoring bone resorption, a process by which bone is broken down within the body. s-P1NP was measured at baseline and Month 12. (NCT01350934)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Fosamax Plus | -68.07 |
| Calcitriol | -17.00 |
"The term vitamin D insufficiency is used to describe vitamin D levels that are low enough to cause secondary hyperparathyroidism, bone loss, and increased risk of skeletal fracture. In this study, a threshold for vitamin D insufficiency was a level of serum 25(OH) D <20 ng/mL." (NCT01350934)
Timeframe: Baseline and Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosamax Plus | 4.1 |
| Calcitriol | 47.1 |
The primary outcome was the between-group difference in the teriparatide-induced change in serum c-telopeptide from baseline to week 8. (NCT01750086)
Timeframe: 8 weeks
| Intervention | percentage of change in CTX (Mean) |
|---|---|
| Denosumab 60mg Subcutaneous Injection | -7 |
| Alendronate 70mg Weekly x 8 Weeks | 43 |
Change in dynamic histomorphometry indices was assessed in the cancellous envelope. BFR/BS was reported as cubic millimeter/square millimeter/year (mm^3/mm^2/year). (NCT03710889)
Timeframe: Baseline (Day 1), Month 3
| Intervention | mm^3/mm^2/year (Mean) | |
|---|---|---|
| Baseline | Change at Month 3 | |
| Abaloparatide | 0.011 | 0.034 |
Change in dynamic histomorphometry indices was assessed in the cancellous envelope. (NCT03710889)
Timeframe: Baseline (Day 1), Month 3
| Intervention | percentage of MS/BS (Mean) | |
|---|---|---|
| Baseline | Change at Month 3 | |
| Abaloparatide | 5.74 | 18.66 |
Blood samples were taken to measure efficacy-related markers of bone metabolism at Day 1, Month 1, and Month 3. (NCT03710889)
Timeframe: Baseline (Day 1), Months 1 and 3
| Intervention | ng/mL (Median) | ||
|---|---|---|---|
| Baseline | Change at Month 1 | Change at Month 3 | |
| Abaloparatide | 0.460 | 0.052 | 0.311 |
Blood samples were taken to measure efficacy related markers of bone metabolism at Day 1, Month 1, and Month 3. (NCT03710889)
Timeframe: Baseline (Day 1), Months 1 and 3
| Intervention | nanograms (ng)/milliliter (mL) (Median) | ||
|---|---|---|---|
| Baseline | Change at Month 1 | Change at Month 3 | |
| Abaloparatide | 54.990 | 119.155 | 141.130 |
(NCT00325468)
Timeframe: 8 years
| Intervention | percent (Median) |
|---|---|
| Placebo | -55.8 |
| Denosumab 210 mg Q6M | -44.7 |
| Denosumab 30 mg Q3M | -52.5 |
| Denosumab Continuous Treatment | -44.4 |
| Alendronate 70mg QW | -54.2 |
(NCT00325468)
Timeframe: 8 years
| Intervention | percent (Least Squares Mean) |
|---|---|
| Placebo | -5.2 |
| Denosumab 210 mg Q6M | 1.4 |
| Denosumab 30 mg Q3M | 0.6 |
| Denosumab Continuous Treatment | 1.3 |
| Alendronate 70mg QW | -2.2 |
(NCT00325468)
Timeframe: 8 years
| Intervention | percent (Least Squares Mean) |
|---|---|
| Placebo | 8.4 |
| Denosumab 210 mg Q6M | 11.2 |
| Denosumab 30 mg Q3M | 11.0 |
| Denosumab Continuous Treatment | 16.5 |
| Alendronate 70mg QW | 12.4 |
(NCT00325468)
Timeframe: 8 years
| Intervention | percent (Median) |
|---|---|
| Placebo | -66.4 |
| Denosumab 210 mg Q6M | -72.0 |
| Denosumab 30 mg Q3M | -48.0 |
| Denosumab Continuous Treatment | -64.6 |
| Alendronate 70mg QW | -49.8 |
(NCT00325468)
Timeframe: 8 years
| Intervention | percent (Least Squares Mean) |
|---|---|
| Placebo | 1.1 |
| Denosumab 210 mg Q6M | 4.3 |
| Denosumab 30 mg Q3M | 2.3 |
| Denosumab Continuous Treatment | 6.8 |
| Alendronate 70mg QW | 3.4 |
"Number of falls per participant was measured.~The fall event rate during the study period was defined as the number of adjudicated falls during the study period divided by the total patient-years in the study. Each participant was to be in the study for approximately one year.~In order to guide and standardize all procedures during the fall adjudication process, a Standard Operating Procedure for Fall Adjudication was created by the~SPONSOR and served as a guideline to standardize operational procedures for fall adjudication." (NCT00692913)
Timeframe: Up to Week 52
| Intervention | Number of Falls (Mean) |
|---|---|
| FOSAVANCE 5600 | 0.51 |
| Referred-Care | 0.45 |
Bone-Specific Alkaline Phosphatase (BSAP) is a serum biochemical marker of bone formation and measured in micrograms/Liter (mcg/L). The percent change was calculated as: [100 * ((Week 26/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy. (NCT00692913)
Timeframe: Baseline and Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| FOSAVANCE 5600 | -46.67 |
| Referred-Care | -39.60 |
N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio (NTx) is a urine biochemical marker of bone resorption and measured in nanomoles (nmol) Bone Collagen Equivalents (BCE)/millimoles (mmol) creatinine. The percent change was calculated as: [100 * ((Week 26/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy. (NCT00692913)
Timeframe: Baseline and Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| FOSAVANCE 5600 | -57.06 |
| Referred-Care | -47.36 |
BSAP is a serum biochemical marker of bone formation and measured in micrograms/Liter (mcg/L). The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy. (NCT00692913)
Timeframe: Baseline and Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| FOSAVANCE 5600 | -51.21 |
| Referred-Care | -43.13 |
NTx is a urine biochemical marker of bone resorption and measured in nanomoles (nmol) Bone Collagen Equivalents (BCE)/millimoles (mmol) creatinine. The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy. (NCT00692913)
Timeframe: Baseline and Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| FOSAVANCE 5600 | -58.42 |
| Referred-Care | -50.07 |
"Percentage of participants with serum levels of 25-hydroxyvitamin D below~20 nanograms/milliliter (ng/mL) after 26 weeks of treatment with FOSAVANCE 5600 once weekly versus Referred-Care in postmenopausal women with osteoporosis and at increased risk of falls." (NCT00692913)
Timeframe: Week 26
| Intervention | Percentage of Participants (Number) |
|---|---|
| FOSAVANCE 5600 | 8.6 |
| Referred-Care | 31.0 |
"Percentage of participants with serum levels of 25-hydroxyvitamin D below~20 ng/mL after 52 weeks of treatment (6 month extension study) with FOSAVANCE 5600 once weekly versus Referred-Care in postmenopausal women with osteoporosis and at increased risk of falls." (NCT00692913)
Timeframe: Week 52
| Intervention | Percentage of Participants (Number) |
|---|---|
| FOSAVANCE 5600 | 11.3 |
| Referred-Care | 36.9 |
Bone Mineral Density (BMD) as measured by Dual Energy X-Ray Absorptiometry (DEXA) and measured in g/cm^2 was obtained at baseline (visit 1) and Week 52 (visit 13) or at early study discontinuation visit. The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent change from baseline, the greater the response to therapy. (NCT00692913)
Timeframe: Baseline and Week 52
| Intervention | Percent Change (Least Squares Mean) | |
|---|---|---|
| Lumbar Spine (n= 226/ n=219) | Total Hip (n=227/ n=218) | |
| FOSAVANCE 5600 | 4.92 | 2.22 |
| Referred-Care | 3.91 | 1.40 |
Full 12-lead ECGs pre-dose at screening and visits 6, 8, 11, 12 and 14 were recorded. Participants rested supine or seated for at least 10 minutes before each reading. All ECGs were transmitted to a central reviewer for blinded assessment. The central reviewer measured the following parameters and provide a clinical interpretation: heart rate, RR interval, PR interval, QRS interval, QT (uncorrected) interval, QTcB (Bazett's correction) interval, QTcF (Fridericia's correction) interval. The central reviewer was provided the investigator or designated qualified site physician with a central ECG report or confirmatory report to assist them in identifying any clinically significant abnormalities that would preclude the participant from further participation in the study. (NCT00471237)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 1 |
| Ronacaleret, 100 mg Tablet, OD | 5 |
| Ronacaleret, 200 mg Tablet, OD | 4 |
| Ronacaleret, 300 mg Tablet, OD | 3 |
| Ronacaleret, 400 mg Tablet, OD | 3 |
| Alendronate, 70 mg, Capsule, OW | 5 |
| Teriparatide, 20 mcg, SC Injection, OD | 0 |
Participants with albumin-adjusted serum calcium pre-dose values of >11.0 mg/ deciliter (dL) or post-dose values of >12.0 mg/dL were recorded as participants with hypercalcemia. Number of participant with hypercalcemia were reported. (NCT00471237)
Timeframe: Up to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| Ronacaleret, 100 mg Tablet, OD | 1 |
| Ronacaleret, 200 mg Tablet, OD | 1 |
| Ronacaleret, 300 mg Tablet, OD | 4 |
| Ronacaleret, 400 mg Tablet, OD | 11 |
| Alendronate, 70 mg, Capsule, OW | 0 |
| Teriparatide, 20 mcg, SC Injection, OD | 1 |
A confirmed albumin-adjusted serum calcium pre-dose value of >11.0 mg/dL or post-dose value of >12.0 mg/dL was set as a withdrawal criteria for the study. Number of participants who met this pre-defined stopping criteria were reported. (NCT00471237)
Timeframe: Up to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| Ronacaleret, 100 mg Tablet, OD | 0 |
| Ronacaleret, 200 mg Tablet, OD | 0 |
| Ronacaleret, 300 mg Tablet, OD | 0 |
| Ronacaleret, 400 mg Tablet, OD | 0 |
| Alendronate, 70 mg, Capsule, OW | 0 |
| Teriparatide, 20 mcg, SC Injection, OD | 0 |
DXA scanners from Hologic and GE Lunar was used to measure BMD by a DXA scan. At least two vertebrae (L1-L4) that were suitable for measurement of BMD were evaluated. The same scanner was used throughout the study for all measurements for a given participant. DXA scans were sent to a central reading facility for quality control and central analysis. Assessments performed on Day 0 were considered as Baseline. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from Baseline in areal bone mineral density (aBMD) was reported. (NCT00471237)
Timeframe: Baseline (Day 0) and 12 Months
| Intervention | Percent change in BMD (Least Squares Mean) |
|---|---|
| Placebo | 0.03 |
| Ronacaleret, 100 mg Tablet, OD | 0.32 |
| Ronacaleret, 200 mg Tablet, OD | 1.39 |
| Ronacaleret, 300 mg Tablet, OD | 1.61 |
| Ronacaleret, 400 mg Tablet, OD | 1.62 |
| Alendronate, 70 mg, Capsule, OW | 4.54 |
QCT is a three-dimensional non-projectional technique to quantify BMD with a number of advantages to other densitometric techniques. Cortical and trabecular bone can be separated, trabecular VOI are largely independent of degenerative changes in the spine and 3 dimensional geometric parameters can be determined. BMD as measured by QCT is a true density measured in g/cm^3 in contrast to DXA Which determines an areal density measured in g/cm^2. Baseline values were assessed on Day 0. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%. (NCT00471237)
Timeframe: Baseline (Day 0) and Month 12
| Intervention | Percent change in VOI (Mean) |
|---|---|
| Placebo | 0.04 |
| Ronacaleret, 100 mg Tablet, OD | 0.85 |
| Ronacaleret, 200 mg Tablet, OD | 3.01 |
| Ronacaleret, 300 mg Tablet, OD | 3.58 |
| Ronacaleret, 400 mg Tablet, OD | 3.54 |
| Alendronate, 70 mg, Capsule, OW | 5.39 |
| Teriparatide, 20 mcg, SC Injection, OD | 12.23 |
DXA scanners from Hologic and GE Lunar was used to measure BMD by a DXA scan. At least two vertebrae (L1-L4) that were suitable for measurement of BMD were evaluated. The same scanner was used throughout the study for all measurements for a given participant. DXA scans were sent to a central reading facility for quality control and central analysis. Baseline values were assessed on Day 0. Percent Change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from baseline to month 6 in aBMD was reported. (NCT00471237)
Timeframe: Baseline (Day 0) and Month 6
| Intervention | percent change in BMD (Least Squares Mean) |
|---|---|
| Placebo | 0.66 |
| Ronacaleret, 100 mg Tablet, OD | 0.21 |
| Ronacaleret, 200 mg Tablet, OD | 1.61 |
| Ronacaleret, 300 mg Tablet, OD | 0.47 |
| Ronacaleret, 400 mg Tablet, OD | 1.01 |
| Alendronate, 70 mg, Capsule, OW | 3.42 |
Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive pharmacokinetic and pharmacodynamics subgroup of participants were analyzed by standard noncompartmental methods. Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive PK-PD subgroup of participants were analyzed by standard noncompartmental methods. Following log transformation, AUC(0-t) and AUC(0-τ) of ronacaleret were separately analyzed by ANOVA using mixed effects model, fitting treatment and country/region as fixed effects. (NCT00471237)
Timeframe: Pre-dose (0.0 h) and 12 h post dose at Week 4, 20, 40 min, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 1-4, 8-12, and 24 h at Month 3, 6 and 12
| Intervention | nanogram*hour per millilitre (ng*hr/mL) (Geometric Mean) | |||
|---|---|---|---|---|
| AUC 0-t, Month 6 | AUC 0-t, Month 12 | AUC 0-tau, Month 6 | AUC 0-tau, Month 12 | |
| Ronacaleret, 100 mg Tablet, OD | 2495.8751 | 2766.6822 | 3628.0901 | 3922.9369 |
| Ronacaleret, 200 mg Tablet, OD | 4575.8746 | 4548.6490 | 6428.5540 | 6455.1756 |
| Ronacaleret, 300 mg Tablet, OD | 7545.3302 | 9259.3127 | 10825.9083 | 14827.6940 |
| Ronacaleret, 400 mg Tablet, OD | 6712.0537 | 6798.4219 | 9810.4614 | 10079.2847 |
Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of BALP. (NCT00471237)
Timeframe: Baseline (Day 0), Week 4, Month 3, 6, and 12
| Intervention | mcg/L (Least Squares Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Baseline, Placebo contrast | Week 4 | Week 4, Placebo contrast | Month 3 | Month 3, Placebo contrast | Month 6 | Month 6, Placebo contrast | Month 12 | Month 12, Placebo contrast | |
| Alendronate, 70 mg, Capsule, OW | 14.31 | 0.99 | 13.68 | 0.98 | 9.44 | 0.75 | 8.36 | 0.65 | 8.42 | 0.64 |
| Ronacaleret, 100 mg Tablet, OD | 14.96 | 1.03 | 14.72 | 1.05 | 15.23 | 1.20 | 16.31 | 1.27 | 16.64 | 1.26 |
| Ronacaleret, 200 mg Tablet, OD | 14.24 | 0.98 | 14.51 | 1.03 | 15.44 | 1.22 | 17.43 | 1.36 | 18.80 | 1.42 |
| Ronacaleret, 300 mg Tablet, OD | 15.06 | 1.04 | 15.97 | 1.14 | 18.77 | 1.48 | 22.18 | 1.73 | 23.36 | 1.76 |
| Ronacaleret, 400 mg Tablet, OD | 14.12 | 0.98 | 15.72 | 1.12 | 17.85 | 1.41 | 21.47 | 1.68 | 23.28 | 1.76 |
| Teriparatide, 20 mcg, SC Injection, OD | 14.50 | 1.00 | 16.19 | 1.15 | 16.53 | 1.31 | 17.63 | 1.38 | 19.08 | 1.44 |
Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of BALP. (NCT00471237)
Timeframe: Baseline (Day 0), Week 4, Month 3, 6, and 12
| Intervention | mcg/L (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 4 | Month 3 | Month 6 | Month 12 | |
| Placebo | 14.46 | 14.02 | 12.66 | 12.81 | 13.25 |
Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of CTX1. (NCT00471237)
Timeframe: Baseline (Day 0), Week 4, Month 3, 6, and 12
| Intervention | nanogram per litre (ng/L) (Least Squares Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Baseline, Placebo contrast | Week 4 | Week 4, Placebo contrast | Month 3 | Month 3, Placebo contrast | Month 6 | Month 6, Placebo contrast | Month 12 | Month 12, Placebo contrast | |
| Alendronate, 70 mg, Capsule, OW | 630.4 | 1.01 | 288.0 | 0.54 | 257.1 | 0.49 | 235.9 | 0.46 | 158.3 | 0.30 |
| Ronacaleret, 100 mg Tablet, OD | 635.3 | 1.02 | 515.2 | 0.97 | 598.5 | 1.14 | 648.2 | 1.25 | 695.2 | 1.32 |
| Ronacaleret, 200 mg Tablet, OD | 632.0 | 1.01 | 525.4 | 0.99 | 688.9 | 1.32 | 777.1 | 1.50 | 806.1 | 1.54 |
| Ronacaleret, 300 mg Tablet, OD | 587.9 | 0.94 | 506.1 | 0.95 | 723.2 | 1.38 | 859.6 | 1.66 | 852.8 | 1.62 |
| Ronacaleret, 400 mg Tablet, OD | 645.5 | 1.03 | 529.2 | 1.00 | 818.9 | 1.56 | 964.3 | 1.86 | 991.9 | 1.89 |
| Teriparatide, 20 mcg, SC Injection, OD | 564.0 | 0.90 | 576.1 | 1.09 | 864.1 | 1.65 | 1112 | 2.15 | 1071 | 2.04 |
Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of CTX1. (NCT00471237)
Timeframe: Baseline (Day 0), Week 4, Month 3, 6, and 12
| Intervention | nanogram per litre (ng/L) (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 4 | Month 3 | Month 6 | Month 12 | |
| Placebo | 625.2 | 530.7 | 523.5 | 517.6 | 525.1 |
Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of P1NP. (NCT00471237)
Timeframe: Baseline (Day 0), Week 4, Month 3, 6, and 12
| Intervention | Microgram per Litre (mcg/L) (Least Squares Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Baseline, Placebo contrast | Week 4 | Week 4, Placebo contrast | Month 3 | Month 3, Placebo contrast | Month 6 | Month 6, Placebo contrast | Month 12 | Month 12, Placebo contrast | |
| Alendronate, 70 mg, Capsule, OW | 47.71 | 1.00 | 43.66 | 0.96 | 20.15 | 0.51 | 16.41 | 0.43 | 16.98 | 0.42 |
| Teriparatide, 20 mcg, SC Injection, OD | 48.57 | 1.02 | 92.74 | 2.05 | 99.74 | 2.52 | 117.8 | 3.07 | 119.0 | 2.92 |
| Ronacaleret, 100 mg Tablet, OD | 45.59 | 0.96 | 49.67 | 1.10 | 49.99 | 1.26 | 56.37 | 1.47 | 61.43 | 1.51 |
| Ronacaleret, 200 mg Tablet, OD | 47.70 | 1.00 | 57.36 | 1.27 | 65.21 | 1.65 | 75.73 | 1.97 | 82.69 | 2.03 |
| Ronacaleret, 300 mg Tablet, OD | 46.62 | 0.98 | 60.27 | 1.33 | 73.68 | 1.86 | 90.55 | 2.36 | 98.04 | 2.41 |
| Ronacaleret, 400 mg Tablet, OD | 46.19 | 0.97 | 63.46 | 1.40 | 86.84 | 2.20 | 104.6 | 2.72 | 112.6 | 2.76 |
Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of P1NP. (NCT00471237)
Timeframe: Baseline (Day 0), Week 4, Month 3, 6, and 12
| Intervention | Microgram per Litre (mcg/L) (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 4 | Month 3 | Month 6 | Month 12 | |
| Placebo | 47.66 | 45.32 | 39.53 | 38.41 | 40.74 |
Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive PK-PD subgroup of participants were analyzed by standard noncompartmental methods. Blood concentrations of ronacaleret were reported. (NCT00471237)
Timeframe: Pre-dose (0.0 hour [h]) and 12 h post dose at Week 4, 20, 40 min, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 1-4, 8-12, and 24 h at Month 3, 6 and 12
| Intervention | nanograms per millilitre (ng/mL) (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 4, Pre-dose | Week 4, 8-12 h post dose | Month 6, Pre-dose | Month 6, 1-4 h post dose | Month 6, 8-12 h post dose | Month 6, 24 h post dose | Month 12, Pre-dose | Month 12, 1-4 h post dose | Month 12, 8-12 h post dose | Month 12, 24 h post dose | |
| Ronacaleret, 100 mg Tablet, OD | 41.22 | 204.82 | 21.37 | 644.90 | 186.69 | 186.21 | 20.68 | 779.92 | 203.39 | 187.23 |
| Ronacaleret, 200 mg Tablet, OD | 37.24 | 328.33 | 65.94 | 1308.35 | 385.03 | 290.74 | 33.47 | 999.63 | 262.20 | 297.20 |
| Ronacaleret, 300 mg Tablet, OD | 85.44 | 581.08 | 74.12 | 1610.74 | 576.35 | 578.63 | 147.63 | 1819.53 | 651.95 | 626.72 |
| Ronacaleret, 400 mg Tablet, OD | 79.40 | 685.14 | 117.94 | 2054.71 | 796.99 | 473.41 | 114.83 | 2128.24 | 740.18 | 512.65 |
Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive pharmacokinetic and pharmacodynamics subgroup of participants were analyzed by standard noncompartmental methods. Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive PK-PD subgroup of participants were analyzed by standard noncompartmental methods. Following log transformation, Cmax of ronacaleret were separately analyzed by ANOVA using mixed effects model, fitting treatment and country/region as fixed effects. (NCT00471237)
Timeframe: Pre-dose (0.0 h) and 12 h post dose at Week 4, 20, 40 min, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 1-4, 8-12, and 24 h at Month 3, 6 and 12
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| Cmax. Month 6 | Cmax. Month 12 | |
| Ronacaleret, 100 mg Tablet, OD | 572.10 | 661.70 |
| Ronacaleret, 200 mg Tablet, OD | 1050.42 | 999.91 |
| Ronacaleret, 300 mg Tablet, OD | 1756.45 | 2254.26 |
| Ronacaleret, 400 mg Tablet, OD | 1556.58 | 1506.45 |
Assessments performed on Day 0 were considered as Baseline. Change from Baseline was computed as values at post baseline visit minus Baseline value. Mean change from baseline in height at Month 6 and 12 and early withdrawal were reported. (NCT00471237)
Timeframe: Baseline (Day 0), Month 6, 12 and early withdrawal
| Intervention | Centimeter (Mean) | ||
|---|---|---|---|
| Month 6 | Month 12 | Early withdrawal | |
| Alendronate, 70 mg, Capsule, OW | -0.07 | -0.08 | -0.37 |
| Placebo | -0.04 | -0.14 | 0.03 |
| Ronacaleret, 100 mg Tablet, OD | 0.17 | 0.04 | 0.17 |
| Ronacaleret, 200 mg Tablet, OD | 0.72 | 0.02 | -0.13 |
| Ronacaleret, 300 mg Tablet, OD | 0.05 | -0.09 | -0.16 |
| Ronacaleret, 400 mg Tablet, OD | -0.04 | -0.17 | -0.16 |
| Teriparatide, 20 mcg, SC Injection, OD | 0.11 | 0.11 | 0 |
Baseline values were assessed on Day 0. Change from Baseline was computed as values at post baseline visit minus Baseline value. Mean change from baseline in weight at Month 6, 12 and early withdrawal were reported. (NCT00471237)
Timeframe: Baseline (Day 0), Month 6, 12 and early withdrawal
| Intervention | Kilogram (Mean) | ||
|---|---|---|---|
| Month 6 | Month 12 | Early withdrawal | |
| Alendronate, 70 mg, Capsule, OW | 0.29 | 0.57 | -0.12 |
| Placebo | -0.02 | 0.32 | -0.45 |
| Ronacaleret, 100 mg Tablet, OD | 0.27 | -0.72 | 0.40 |
| Ronacaleret, 200 mg Tablet, OD | 0.45 | 1.18 | -0.34 |
| Ronacaleret, 300 mg Tablet, OD | -0.24 | -0.22 | 0.37 |
| Ronacaleret, 400 mg Tablet, OD | 0.11 | -0.48 | 0.00 |
| Teriparatide, 20 mcg, SC Injection, OD | 0.51 | 0.09 | -2.15 |
The hematology parameters analyzed were white blood cells (WBC) count with differential WBC count, red blood cells, haemoglobin, haematocrit, mean corpuscular volume and platelet count. The clinical chemistry parameters analyzed were sodium, potassium, calcium, calcium (albumin adjusted), phosphate, bicarbonate, creatinine, bilirubin (total), alanine amino transferase, aspartate amino transferase, glucose, albumin, alkaline phosphatase, creatine phosphokinase, urea, uric acid, total protein, 25-OH vitamin D, 1,25-2(OH) vitamin D, whole parathyroid hormone (PTH 1-84)) and intact PTH (1-84 and 7-84). Only those parameters for which at least one value of potential clinical importance was reported are summarized. The number of participants with potential clinical important laboratory findings at any visit were reported. (NCT00471237)
Timeframe: Up to Month 12
| Intervention | Participants (Count of Participants) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monocytes- high | Total neutrophils- high | Total neutrophils- low | Eosinophils- high | Glucose- high | Glucose- low | Basophils- high | Hematocrit- low | Hemoglobin- high | Hemoglobin- low | Platelets- high | White Blood Cell- high | White Blood Cell- low | Calcium- high | Phosphorus- high | Alkaline Phosphatase- high | Total bilirubin- high | |
| Alendronate, 70 mg, Capsule, OW | 28 | 6 | 13 | 11 | 5 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Placebo | 17 | 9 | 16 | 12 | 10 | 3 | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 0 | 1 | 0 | 0 |
| Ronacaleret, 100 mg Tablet, OD | 14 | 11 | 5 | 8 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| Ronacaleret, 200 mg Tablet, OD | 19 | 10 | 8 | 11 | 9 | 4 | 1 | 0 | 1 | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 2 |
| Ronacaleret, 300 mg Tablet, OD | 17 | 10 | 8 | 18 | 5 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 2 | 1 | 1 | 3 | 1 |
| Ronacaleret, 400 mg Tablet, OD | 18 | 4 | 14 | 19 | 4 | 3 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 3 | 1 |
| Teriparatide, 20 mcg, SC Injection, OD | 6 | 4 | 4 | 6 | 3 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
The potential clinical importance ranges (low and high) of the vital sign parameters-systolic blood pressure (> 30 millimeter of mercury [mmHg] decrease from Baseline, > 30 mmHg increase from Baseline), diastolic blood pressure (> 20 mmHg decrease from Baseline and > 20 mmHg increase from Baseline) and heart rate (<45 and >120 beats per minute). Only those parameters for which at least one value of potential clinical importance was reported are summarized. The number of participants with potential clinical important vital parameter findings at any visit were reported. (NCT00471237)
Timeframe: Up to 12 Months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Systolic Blood Pressure, High | Systolic Blood Pressure, Low | Diastolic Blood Pressure, High | Diastolic Blood Pressure, Low | Heart Rate, Low | |
| Alendronate, 70 mg, Capsule, OW | 8 | 8 | 3 | 10 | 0 |
| Placebo | 5 | 6 | 2 | 8 | 2 |
| Ronacaleret, 100 mg Tablet, OD | 10 | 8 | 6 | 9 | 0 |
| Ronacaleret, 200 mg Tablet, OD | 8 | 10 | 5 | 4 | 1 |
| Ronacaleret, 300 mg Tablet, OD | 9 | 6 | 1 | 12 | 1 |
| Ronacaleret, 400 mg Tablet, OD | 11 | 4 | 6 | 10 | 1 |
| Teriparatide, 20 mcg, SC Injection, OD | 1 | 3 | 1 | 2 | 0 |
Responder rate of participants who remained the same or had any improvement as compared to baseline in DXA BMD of vertebra, femur and vertebra plus femur were reported. Baseline values were assessed on Day 0. Percent change (improvement) from Baseline was computed as (change from baseline / baseline value) * 100%. (NCT00471237)
Timeframe: Baseline (Day 0), Month 5, 6 and 12
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Month 5, Vertebra, BMD % change >=0 | Month 5, Femur, BMD % change >=0 | Month 5, Vertebra + Femur, BMD % change >=0 | Month 6, Vertebra, BMD % change >=0 | Month 6, Femur, BMD % change >=0 | Month 6, Vertebra + Femur, BMD % change >=0 | Month 12, Vertebra, BMD % change >=0 | Month 12, Femur, BMD % change >=0 | Month 12, Vertebra + Femur, BMD % change >=0 | Early Withdrawal, Vertebra, BMD % change >=0 | Early Withdrawal, Femur, BMD % change >=0 | Early Withdrawal, Vertebra + Femur, BMD %change>=0 | |
| Alendronate, 70 mg, Capsule, OW | 0 | 0 | 0 | 1 | 1 | 1 | 44 | 40 | 35 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 20 | 10 | 1 | 1 | 1 |
| Ronacaleret, 100 mg Tablet, OD | 0 | 0 | 0 | 0 | 0 | 0 | 29 | 23 | 19 | 1 | 1 | 1 |
| Ronacaleret, 200 mg Tablet, OD | 1 | 1 | 1 | 0 | 0 | 0 | 32 | 14 | 12 | 1 | 0 | 0 |
| Ronacaleret, 300 mg Tablet, OD | 0 | 0 | 0 | 0 | 0 | 0 | 35 | 19 | 17 | 2 | 1 | 1 |
| Ronacaleret, 400 mg Tablet, OD | 1 | 0 | 0 | 0 | 0 | 0 | 31 | 16 | 16 | 1 | 1 | 1 |
| Teriparatide, 20 mcg, SC Injection, OD | 0 | 0 | 0 | 0 | 0 | 0 | 34 | 25 | 24 | 1 | 1 | 1 |
Percent change in thickness of femur neck cortical VOI thickness and trochanter cortical VOI thickness were at Month 12 measured by QCT were reported. Assessments performed on Day 0 were considered as Baseline. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%. (NCT00471237)
Timeframe: Baseline (Day 0) and Month 12
| Intervention | Percent change in cortical thickness (Mean) | |
|---|---|---|
| Neck cortical VOI Thickness | Trochanter cortical VOI Thickness | |
| Alendronate, 70 mg, Capsule, OW | -0.13 | 0.81 |
| Placebo | -0.85 | -1.00 |
| Ronacaleret, 100 mg Tablet, OD | -0.13 | 0.76 |
| Ronacaleret, 200 mg Tablet, OD | 1.12 | 1.01 |
| Ronacaleret, 300 mg Tablet, OD | -0.88 | -0.82 |
| Ronacaleret, 400 mg Tablet, OD | 0.32 | 1.60 |
| Teriparatide, 20 mcg, SC Injection, OD | 0.39 | 0.76 |
QCT is a three-dimensional non-projectional technique to quantify BMD with a number of advantages to other densitometric techniques. Cortical and trabecular bone can be separated, trabecular volume of interest (VOI) are largely independent of degenerative changes in the spine and 3 dimensional geometric parameters can be determined. BMD as measured by QCT is a true density measured in g/cm^3 in contrast to DXA Which determines an areal density measured in g/cm^2. Baseline values were assessed on Day 0. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from Baseline to month 12 in the volumetric integral, cortical, and trabecular density (BMD) at the hip and lumbar spine measured by QCT were reported. (NCT00471237)
Timeframe: Baseline (Day 0) and Month 12
| Intervention | Percent change in BMD (Mean) | |||||
|---|---|---|---|---|---|---|
| Total vertebra integral VOI BMD | Mid vertebra integral VOI BMD | Mid Cylinder trabecular VOI BMD | Mid Osteo trabecular VOI BMD | Total vertebra trabecular VOI BMD | Mid Osteo cortical VOI BMD | |
| Alendronate, 70 mg, Capsule, OW | 5.04 | 4.85 | 4.88 | 5.15 | 4.97 | 4.98 |
| Placebo | -0.98 | -1.31 | -2.45 | -2.21 | -2.46 | -0.30 |
| Ronacaleret, 100 mg Tablet, OD | 1.09 | 1.20 | 1.75 | 1.81 | 1.67 | 0.63 |
| Ronacaleret, 200 mg Tablet, OD | 3.00 | 4.65 | 6.17 | 7.06 | 5.81 | 2.37 |
| Ronacaleret, 300 mg Tablet, OD | 3.91 | 6.06 | 8.99 | 9.54 | 8.52 | 2.57 |
| Ronacaleret, 400 mg Tablet, OD | 4.83 | 7.33 | 13.29 | 13.21 | 11.40 | 1.22 |
| Teriparatide, 20 mcg, SC Injection, OD | 14.80 | 17.97 | 24.37 | 24.21 | 23.82 | 9.25 |
QCT is a three-dimensional non-projectional technique to quantify BMD with a number of advantages to other densitometric techniques. Cortical and trabecular bone can be separated, trabecular VOI are largely independent of degenerative changes in the spine and 3 dimensional geometric parameters can be determined. BMD as measured by QCT is a true density measured in mg/cm^3 in contrast to DXA Which determines an areal density measured in g/cm^2. Baseline values were assessed on Day 0. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%. (NCT00471237)
Timeframe: Baseline (Day 0) and Month 12
| Intervention | Percent change in BMD (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Femur integral VOI BMD | Femur trabecular VOI BMD | Femur cortical VOI BMD | Neck integral VOI BMD | Neck trabecular VOI BMD | Neck cortical VOI BMD | Trochanter integral VOI BMD | Trochanter trabecular VOI BMD | Trochanter cortical VOI BMD | |
| Alendronate, 70 mg, Capsule, OW | 2.70 | 3.05 | 2.44 | 1.65 | 2.77 | 1.10 | 3.15 | 3.55 | 3.33 |
| Placebo | 0.02 | -0.36 | 1.11 | -0.10 | -0.95 | 1.23 | -0.58 | -1.62 | 0.56 |
| Ronacaleret, 100 mg Tablet, OD | -0.05 | -0.40 | -0.32 | 0.16 | -2.19 | 0.44 | -0.16 | -1.34 | -0.70 |
| Ronacaleret, 200 mg Tablet, OD | -0.81 | -2.16 | -1.46 | -0.94 | -2.68 | -1.67 | -1.53 | -2.54 | -1.53 |
| Ronacaleret, 300 mg Tablet, OD | -0.53 | 1.16 | -1.06 | -1.20 | 1.35 | -1.85 | -1.16 | 2.12 | -1.48 |
| Ronacaleret, 400 mg Tablet, OD | -0.15 | 2.81 | -1.79 | -1.45 | 3.05 | -2.80 | -0.98 | 2.10 | -2.59 |
| Teriparatide, 20 mcg, SC Injection, OD | 3.92 | 13.19 | 0.22 | 2.06 | 11.27 | -0.69 | 4.96 | 14.12 | 1.99 |
DXA scanners from Hologic and GE Lunar was used to measure BMD by a DXA scan. At least two vertebrae (L1-L4) that were suitable for measurement of BMD were evaluated. The same scanner was used throughout the study for all measurements for a given participant. DXA scans were sent to a central reading facility for quality control and central analysis. Baseline values were assessed on Day 0. Percent Change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from baseline to month 6 and 12 in aBMD of hip (total hip, femoral neck and trochanter) were reported. (NCT00471237)
Timeframe: Baseline (Day 0), Month 6 and Month 12
| Intervention | Percent change in BMD (Least Squares Mean) | |
|---|---|---|
| Total Hip aBMD, Month 6 | Total Hip aBMD, Month 12 | |
| Alendronate, 70 mg, Capsule, OW | 1.84 | 2.70 |
| Placebo | 0.42 | 0.27 |
| Ronacaleret, 100 mg Tablet, OD | -0.26 | -0.62 |
| Ronacaleret, 200 mg Tablet, OD | -0.37 | -0.75 |
| Ronacaleret, 300 mg Tablet, OD | -0.86 | -1.07 |
| Ronacaleret, 400 mg Tablet, OD | -0.88 | -1.31 |
Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive pharmacokinetic and pharmacodynamics subgroup of participants were analyzed by standard noncompartmental methods. (NCT00471237)
Timeframe: Pre-dose (0.0 h) and 12 h post dose at Week 4, 20, 40 min, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 1-4, 8-12, and 24 h at Month 3, 6 and 12
| Intervention | h (Median) | |
|---|---|---|
| Tmax, Month 6 | Tmax, Month 12 | |
| Ronacaleret, 100 mg Tablet, OD | 1.483 | 1.000 |
| Ronacaleret, 200 mg Tablet, OD | 1.250 | 1.500 |
| Ronacaleret, 300 mg Tablet, OD | 1.700 | 1.500 |
| Ronacaleret, 400 mg Tablet, OD | 1.500 | 1.500 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. (NCT00330460)
Timeframe: 12 months
| Intervention | Percent Change from Baseline (Least Squares Mean) |
|---|---|
| Alendronate 70 mg QW | 0.6 |
| Denosumab 60 mg Q6M | 1.1 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. (NCT00330460)
Timeframe: 12 months
| Intervention | Percent Change from Baseline (Least Squares Mean) |
|---|---|
| Alendronate 70 mg QW | 1.8 |
| Denosumab 60 mg Q6M | 2.4 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. (NCT00330460)
Timeframe: 12 months
| Intervention | Percent Change from Baseline (Least Squares Mean) |
|---|---|
| Alendronate 70 mg QW | 4.2 |
| Denosumab 60 mg Q6M | 5.3 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. (NCT00330460)
Timeframe: 12 months
| Intervention | Percent Change from Baseline (Least Squares Mean) |
|---|---|
| Alendronate 70 mg QW | 2.6 |
| Denosumab 60 mg Q6M | 3.5 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. (NCT00330460)
Timeframe: 12 months
| Intervention | Percent Change from Baseline (Least Squares Mean) |
|---|---|
| Alendronate 70 mg QW | 3.4 |
| Denosumab 60 mg Q6M | 4.5 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using [(12 month value - baseline value) / baseline value]*100. (NCT00377819)
Timeframe: Baseline, 12 months
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Alendronate 70 mg QW | 1.85 |
| Denosumab 60 mg Q6M | 3.03 |
Percent Change From Baseline to Month 3 in Serum CTX-I. Percent change calculated using [(3 month value - baseline value) / baseline value]*100. (NCT00377819)
Timeframe: Baseline, 3 months
| Intervention | Percent Change (Median) |
|---|---|
| Alendronate 70 mg QW | -4.2 |
| Denosumab 60 mg Q6M | -63.3 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using [(12 month value - baseline value) / baseline value]*100. (NCT00377819)
Timeframe: Baseline, 12 months
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Alendronate 70 mg QW | 1.05 |
| Denosumab 60 mg Q6M | 1.9 |
Hip fractures are a subset of nonvertebral fractures including femur neck, femur intertrochanter, and femur subtrochanter. (NCT00089791)
Timeframe: 36 months
| Intervention | Participants (Number) |
|---|---|
| Placebo | 43 |
| Denosumab 60 mg Q6M | 26 |
A new vertebral fracture, assessed by lateral spine X-ray using Genant semiquantitative scoring method, was identified as an ≥ 1 grade increase from the Baseline grade of 0 in any vertebra from T4 to L4. New vertebral fractures included morphometric vertebral fractures (assessed at scheduled visits and not associated with signs or symptoms [or both] indicative of a fracture) and clinical vertebral fractures (assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms indicative of a fracture, excluding any fracture associated with high trauma severity or a pathologic fracture). (NCT00089791)
Timeframe: 36 months
| Intervention | Participants (Number) |
|---|---|
| Placebo | 264 |
| Denosumab 60 mg Q6M | 86 |
Nonvertebral fractures (osteoporotic) were those occurring on study excluding those of the vertebrae (cervical, thoracic, and lumbar), skull, facial, mandible, metacarpus, finger phalanges, and toe phalanges. Fractures associated with high trauma severity (fractures that were the result of a fall from higher than the height of a stool, chair, first rung on a ladder or equivalent (> 20 inches) or was the result of severe trauma other than a fall) and pathologic fractures were excluded from this category. Nonvertebral fractures were required to be confirmed either by radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging (MRI), or by documentation in a radiology report, surgical report, or discharge summary. (NCT00089791)
Timeframe: 36 months
| Intervention | Participants (Number) |
|---|---|
| Placebo | 293 |
| Denosumab 60 mg Q6M | 238 |
(NCT00926380)
Timeframe: Baseline and 2 years
| Intervention | percent change (Mean) |
|---|---|
| Denosumab ONLY | 8.3 |
| Teriparatide (Forteo®) ONLY | 9.5 |
| Denosumab and Teriparatide (Forteo®) | 12.9 |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 12 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -4.609 |
| Denosumab 6 mg Q3M | -62.716 |
| Denosumab 14 mg Q3M | -60.098 |
| Denosumab 30 mg Q3M | -70.256 |
| Denosumab 14 mg Q6M | -39.474 |
| Denosumab 60 mg Q6M | -65.215 |
| Denosumab 100 mg Q6M | -61.979 |
| Denosumab 210 mg Q6M | -67.634 |
| Alendronate 70 mg | -61.059 |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 24 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 16.464 |
| Denosumab 6 mg Q3M | -41.225 |
| Denosumab 14 mg Q3M | -47.597 |
| Denosumab 30 mg Q3M | -57.905 |
| Denosumab 14 mg Q6M | -22.350 |
| Denosumab 60 mg Q6M | -43.448 |
| Denosumab 100 mg Q6M | -50.176 |
| Denosumab 210 mg Q6M | -48.833 |
| Alendronate 70 mg | -48.778 |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 36 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 1.955 |
| Denosumab 6 mg Q3M | -39.012 |
| Denosumab 14 mg Q3M | -56.021 |
| Denosumab 30 mg Q3M | 22.343 |
| Denosumab 14 mg Q6M | -47.500 |
| Denosumab 60 mg Q6M | -42.541 |
| Denosumab 100 mg Q6M | -47.418 |
| Denosumab 210 mg Q6M | 61.747 |
| Alendronate 70 mg | -8.209 |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 42 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 1.288 |
| Denosumab 6 mg Q3M | -40.182 |
| Denosumab 14 mg Q3M | -40.819 |
| Denosumab 30 mg Q3M | -52.684 |
| Denosumab 14 mg Q6M | -53.763 |
| Denosumab 60 mg Q6M | -44.892 |
| Denosumab 100 mg Q6M | -48.303 |
| Denosumab 210 mg Q6M | 17.841 |
| Alendronate 70 mg | -22.069 |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 48 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 18.122 |
| Denosumab 6 mg Q3M | -34.727 |
| Denosumab 14 mg Q3M | -45.779 |
| Denosumab 30 mg Q3M | -47.770 |
| Denosumab 14 mg Q6M | -46.286 |
| Denosumab 60 mg Q6M | -34.361 |
| Denosumab 100 mg Q6M | -42.653 |
| Denosumab 210 mg Q6M | 21.053 |
| Alendronate 70 mg | -17.891 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 12 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.97 |
| Denosumab 6 mg Q3M | 0.89 |
| Denosumab 14 mg Q3M | 0.40 |
| Denosumab 30 mg Q3M | 1.10 |
| Denosumab 14 mg Q6M | 0.94 |
| Denosumab 60 mg Q6M | 1.29 |
| Denosumab 100 mg Q6M | 1.07 |
| Denosumab 210 mg Q6M | 1.09 |
| Alendronate 70 mg | -0.53 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 24 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -2.78 |
| Denosumab 6 mg Q3M | 1.31 |
| Denosumab 14 mg Q3M | 0.62 |
| Denosumab 30 mg Q3M | 1.30 |
| Denosumab 14 mg Q6M | 2.48 |
| Denosumab 60 mg Q6M | 1.89 |
| Denosumab 100 mg Q6M | 1.48 |
| Denosumab 210 mg Q6M | 0.81 |
| Alendronate 70 mg | -0.78 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 36 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -3.64 |
| Denosumab 6 mg Q3M | 1.99 |
| Denosumab 14 mg Q3M | 1.06 |
| Denosumab 30 mg Q3M | 1.05 |
| Denosumab 14 mg Q6M | 2.08 |
| Denosumab 60 mg Q6M | 2.69 |
| Denosumab 100 mg Q6M | 1.92 |
| Denosumab 210 mg Q6M | 0.12 |
| Alendronate 70 mg | -0.95 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 42 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -6.59 |
| Denosumab 6 mg Q3M | 1.00 |
| Denosumab 14 mg Q3M | 0.82 |
| Denosumab 30 mg Q3M | -3.91 |
| Denosumab 14 mg Q6M | 1.29 |
| Denosumab 60 mg Q6M | -0.87 |
| Denosumab 100 mg Q6M | 0.02 |
| Denosumab 210 mg Q6M | 0.59 |
| Alendronate 70 mg | -3.32 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 48 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -4.67 |
| Denosumab 6 mg Q3M | 1.04 |
| Denosumab 14 mg Q3M | 1.42 |
| Denosumab 30 mg Q3M | 1.77 |
| Denosumab 14 mg Q6M | 1.74 |
| Denosumab 60 mg Q6M | 1.71 |
| Denosumab 100 mg Q6M | 1.37 |
| Denosumab 210 mg Q6M | -0.94 |
| Alendronate 70 mg | -2.67 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Alendronate 70 mg | 4.59 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.81 |
| Denosumab 6 mg Q3M | 4.41 |
| Denosumab 14 mg Q3M | 4.71 |
| Denosumab 30 mg Q3M | 6.69 |
| Denosumab 14 mg Q6M | 3.03 |
| Denosumab 60 mg Q6M | 4.55 |
| Denosumab 100 mg Q6M | 5.52 |
| Denosumab 210 mg Q6M | 5.07 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 24 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.25 |
| Denosumab 6 mg Q3M | 7.42 |
| Denosumab 14 mg Q3M | 7.21 |
| Denosumab 30 mg Q3M | 8.83 |
| Denosumab 14 mg Q6M | 3.94 |
| Denosumab 60 mg Q6M | 7.19 |
| Denosumab 100 mg Q6M | 7.31 |
| Denosumab 210 mg Q6M | 7.86 |
| Alendronate 70 mg | 6.09 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 36 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.80 |
| Denosumab 6 mg Q3M | 8.57 |
| Denosumab 14 mg Q3M | 9.17 |
| Denosumab 30 mg Q3M | 1.94 |
| Denosumab 14 mg Q6M | 7.99 |
| Denosumab 60 mg Q6M | 9.04 |
| Denosumab 100 mg Q6M | 10.63 |
| Denosumab 210 mg Q6M | 0.85 |
| Alendronate 70 mg | 4.70 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 42 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | 1.09 |
| Denosumab 6 mg Q3M | 7.21 |
| Denosumab 14 mg Q3M | 10.04 |
| Denosumab 30 mg Q3M | 5.06 |
| Denosumab 14 mg Q6M | 9.46 |
| Denosumab 60 mg Q6M | 9.59 |
| Denosumab 100 mg Q6M | 9.99 |
| Denosumab 210 mg Q6M | 1.06 |
| Alendronate 70 mg | 6.51 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 48 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -2.39 |
| Denosumab 6 mg Q3M | 9.35 |
| Denosumab 14 mg Q3M | 9.93 |
| Denosumab 30 mg Q3M | 9.03 |
| Denosumab 14 mg Q6M | 10.10 |
| Denosumab 60 mg Q6M | 10.34 |
| Denosumab 100 mg Q6M | 11.76 |
| Denosumab 210 mg Q6M | 2.50 |
| Alendronate 70 mg | 4.54 |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -4.699 |
| Denosumab 6 mg Q3M | -61.366 |
| Denosumab 14 mg Q3M | -77.989 |
| Denosumab 30 mg Q3M | -87.238 |
| Denosumab 14 mg Q6M | -12.054 |
| Denosumab 60 mg Q6M | -70.757 |
| Denosumab 100 mg Q6M | -78.617 |
| Denosumab 210 mg Q6M | -84.107 |
| Alendronate 70 mg | -72.603 |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 24 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -5.940 |
| Denosumab 6 mg Q3M | -50.687 |
| Denosumab 14 mg Q3M | -74.078 |
| Denosumab 30 mg Q3M | -83.985 |
| Denosumab 14 mg Q6M | -8.467 |
| Denosumab 60 mg Q6M | -68.437 |
| Denosumab 100 mg Q6M | -80.460 |
| Denosumab 210 mg Q6M | -85.680 |
| Alendronate 70 mg | -69.386 |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 36 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -16.577 |
| Denosumab 6 mg Q3M | -62.298 |
| Denosumab 14 mg Q3M | -53.643 |
| Denosumab 30 mg Q3M | 56.286 |
| Denosumab 14 mg Q6M | -57.500 |
| Denosumab 60 mg Q6M | -54.418 |
| Denosumab 100 mg Q6M | -45.057 |
| Denosumab 210 mg Q6M | 72.135 |
| Alendronate 70 mg | -33.982 |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 42 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -16.279 |
| Denosumab 6 mg Q3M | -63.543 |
| Denosumab 14 mg Q3M | -40.827 |
| Denosumab 30 mg Q3M | -62.334 |
| Denosumab 14 mg Q6M | -46.408 |
| Denosumab 60 mg Q6M | -57.255 |
| Denosumab 100 mg Q6M | -56.377 |
| Denosumab 210 mg Q6M | 33.999 |
| Alendronate 70 mg | -46.743 |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 48 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -14.561 |
| Denosumab 6 mg Q3M | -40.016 |
| Denosumab 14 mg Q3M | -34.999 |
| Denosumab 30 mg Q3M | -52.656 |
| Denosumab 14 mg Q6M | -39.899 |
| Denosumab 60 mg Q6M | -51.494 |
| Denosumab 100 mg Q6M | -36.480 |
| Denosumab 210 mg Q6M | 7.067 |
| Alendronate 70 mg | -43.724 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 12 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.21 |
| Denosumab 6 mg Q3M | 1.82 |
| Denosumab 14 mg Q3M | 1.80 |
| Denosumab 30 mg Q3M | 2.74 |
| Denosumab 14 mg Q6M | 0.55 |
| Denosumab 60 mg Q6M | 2.51 |
| Denosumab 100 mg Q6M | 1.78 |
| Denosumab 210 mg Q6M | 2.08 |
| Alendronate 70 mg | 1.51 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 24 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.64 |
| Denosumab 6 mg Q3M | 2.59 |
| Denosumab 14 mg Q3M | 2.91 |
| Denosumab 30 mg Q3M | 4.44 |
| Denosumab 14 mg Q6M | 0.89 |
| Denosumab 60 mg Q6M | 2.57 |
| Denosumab 100 mg Q6M | 3.00 |
| Denosumab 210 mg Q6M | 2.75 |
| Alendronate 70 mg | 1.50 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 36 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.61 |
| Denosumab 6 mg Q3M | 3.14 |
| Denosumab 14 mg Q3M | 3.04 |
| Denosumab 30 mg Q3M | 2.34 |
| Denosumab 14 mg Q6M | 2.04 |
| Denosumab 60 mg Q6M | 2.80 |
| Denosumab 100 mg Q6M | 2.59 |
| Denosumab 210 mg Q6M | -0.29 |
| Alendronate 70 mg | 4.55 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 42 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | 1.61 |
| Denosumab 6 mg Q3M | 1.90 |
| Denosumab 14 mg Q3M | 4.05 |
| Denosumab 30 mg Q3M | 8.85 |
| Denosumab 14 mg Q6M | 3.72 |
| Denosumab 60 mg Q6M | 4.92 |
| Denosumab 100 mg Q6M | 3.79 |
| Denosumab 210 mg Q6M | -0.75 |
| Alendronate 70 mg | 2.85 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 48 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -2.54 |
| Denosumab 6 mg Q3M | 3.68 |
| Denosumab 14 mg Q3M | 3.38 |
| Denosumab 30 mg Q3M | 3.76 |
| Denosumab 14 mg Q6M | 3.42 |
| Denosumab 60 mg Q6M | 3.43 |
| Denosumab 100 mg Q6M | 3.68 |
| Denosumab 210 mg Q6M | -0.29 |
| Alendronate 70 mg | 4.49 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 12 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.56 |
| Denosumab 6 mg Q3M | 2.89 |
| Denosumab 14 mg Q3M | 2.45 |
| Denosumab 30 mg Q3M | 3.32 |
| Denosumab 14 mg Q6M | 1.94 |
| Denosumab 60 mg Q6M | 3.56 |
| Denosumab 100 mg Q6M | 2.53 |
| Denosumab 210 mg Q6M | 2.33 |
| Alendronate 70 mg | 2.11 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 24 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.92 |
| Denosumab 6 mg Q3M | 4.04 |
| Denosumab 14 mg Q3M | 3.55 |
| Denosumab 30 mg Q3M | 5.03 |
| Denosumab 14 mg Q6M | 2.62 |
| Denosumab 60 mg Q6M | 4.96 |
| Denosumab 100 mg Q6M | 3.67 |
| Denosumab 210 mg Q6M | 4.18 |
| Alendronate 70 mg | 3.27 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 36 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -2.84 |
| Denosumab 6 mg Q3M | 4.79 |
| Denosumab 14 mg Q3M | 4.41 |
| Denosumab 30 mg Q3M | -1.23 |
| Denosumab 14 mg Q6M | 4.31 |
| Denosumab 60 mg Q6M | 5.83 |
| Denosumab 100 mg Q6M | 4.33 |
| Denosumab 210 mg Q6M | -1.43 |
| Alendronate 70 mg | 0.93 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 42 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.96 |
| Denosumab 6 mg Q3M | 5.01 |
| Denosumab 14 mg Q3M | 3.98 |
| Denosumab 30 mg Q3M | 2.37 |
| Denosumab 14 mg Q6M | 4.54 |
| Denosumab 60 mg Q6M | 6.34 |
| Denosumab 100 mg Q6M | 4.70 |
| Denosumab 210 mg Q6M | -2.67 |
| Alendronate 70 mg | 2.98 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 48 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -3.52 |
| Denosumab 6 mg Q3M | 5.45 |
| Denosumab 14 mg Q3M | 4.03 |
| Denosumab 30 mg Q3M | 3.86 |
| Denosumab 14 mg Q6M | 4.82 |
| Denosumab 60 mg Q6M | 6.06 |
| Denosumab 100 mg Q6M | 4.99 |
| Denosumab 210 mg Q6M | -1.37 |
| Alendronate 70 mg | 1.17 |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 24.300 |
| Denosumab 6 mg Q3M | -40.018 |
| Denosumab 14 mg Q3M | -54.688 |
| Denosumab 30 mg Q3M | -60.652 |
| Denosumab 14 mg Q6M | -2.027 |
| Denosumab 60 mg Q6M | -36.523 |
| Denosumab 100 mg Q6M | -51.256 |
| Denosumab 210 mg Q6M | -58.502 |
| Alendronate 70 mg | -45.409 |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 24 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 14.422 |
| Denosumab 6 mg Q3M | -19.699 |
| Denosumab 14 mg Q3M | -37.691 |
| Denosumab 30 mg Q3M | -49.907 |
| Denosumab 14 mg Q6M | 2.134 |
| Denosumab 60 mg Q6M | -32.303 |
| Denosumab 100 mg Q6M | -37.001 |
| Denosumab 210 mg Q6M | -47.105 |
| Alendronate 70 mg | -44.482 |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 36 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 0.508 |
| Denosumab 6 mg Q3M | -33.294 |
| Denosumab 14 mg Q3M | -47.752 |
| Denosumab 30 mg Q3M | 82.910 |
| Denosumab 14 mg Q6M | -44.301 |
| Denosumab 60 mg Q6M | -36.874 |
| Denosumab 100 mg Q6M | -27.174 |
| Denosumab 210 mg Q6M | 70.997 |
| Alendronate 70 mg | -15.627 |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 42 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -18.102 |
| Denosumab 6 mg Q3M | -40.741 |
| Denosumab 14 mg Q3M | -40.043 |
| Denosumab 30 mg Q3M | -58.893 |
| Denosumab 14 mg Q6M | -47.188 |
| Denosumab 60 mg Q6M | -39.269 |
| Denosumab 100 mg Q6M | -46.674 |
| Denosumab 210 mg Q6M | 26.277 |
| Alendronate 70 mg | -33.102 |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 48 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -21.064 |
| Denosumab 6 mg Q3M | -23.311 |
| Denosumab 14 mg Q3M | -38.002 |
| Denosumab 30 mg Q3M | -50.864 |
| Denosumab 14 mg Q6M | -46.128 |
| Denosumab 60 mg Q6M | -40.375 |
| Denosumab 100 mg Q6M | -41.998 |
| Denosumab 210 mg Q6M | 7.884 |
| Alendronate 70 mg | -32.198 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | -0.35 |
| PTHrP 600 mcg/Day | -0.34 |
| PTH 20 mcg/Day | -0.82 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | 0.91 |
| PTHrP 600 mcg/Day | 0.54 |
| PTH 20 mcg/Day | 0.61 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | -0.48 |
| PTHrP 600 mcg/Day | -0.99 |
| PTH 20 mcg/Day | -0.97 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | 1.89 |
| PTHrP 600 mcg/Day | 1.52 |
| PTH 20 mcg/Day | 2.17 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | 0.68 |
| PTHrP 600 mcg/Day | 0.72 |
| PTH 20 mcg/Day | 0.54 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | pg/ml (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 42.51 | 65.25 | 67.29 | 58.15 | 53.73 |
| PTHrP 400 mcg/Day | 49.06 | 84.92 | 76.04 | 67.85 | 64.36 |
| PTHrP 600 mcg/Day | 42.49 | 63.07 | 65.15 | 57.02 | 55.08 |
(NCT00853723)
Timeframe: 90 days
| Intervention | mg/gm creatinine (Mean) | |
|---|---|---|
| Baseline | Day 90 | |
| PTH 20 mcg/Day | 209.99 | 232.48 |
| PTHrP 400 mcg/Day | 206.37 | 260.46 |
| PTHrP 600 mcg/Day | 213.07 | 235.25 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | percentage change from baseline (Mean) | |||
|---|---|---|---|---|
| Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 4.87 | 13.89 | 52.98 | 92.46 |
| PTHrP 400 mcg/Day | -12.40 | 1.60 | 4.13 | 32.65 |
| PTHrP 600 mcg/Day | 10.25 | 9.59 | 14.38 | 25.65 |
(Serum Creatinine X Urine Calcium)/(Serum Calcium X Urine Creatinine) (NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | % excreted (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 2.30 | 2.55 | 2.92 | 2.95 | 3.37 |
| PTHrP 400 mcg/Day | 2.38 | 3.42 | 3.27 | 3.38 | 3.10 |
| PTHrP 600 mcg/Day | 2.71 | 4.18 | 3.74 | 2.89 | 2.89 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | percentage change from baseline (Mean) | |||
|---|---|---|---|---|
| Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 60.67 | 97.27 | 125.46 | 171.49 |
| PTHrP 400 mcg/Day | 32.54 | 48.89 | 34.71 | 46.07 |
| PTHrP 600 mcg/Day | 23.51 | 83.14 | 87.39 | 84.09 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | mg/dl (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 4.09 | 4.13 | 4.19 | 4.28 | 4.10 |
| PTHrP 400 mcg/Day | 4.0 | 3.78 | 3.87 | 4.02 | 4.05 |
| PTHrP 600 mcg/Day | 3.93 | 3.68 | 3.71 | 3.97 | 3.98 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | mg/dl (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90, time 0 | Day 90, time 3 hours | day 90, time 6 hours | |
| PTH 20 mcg/Day | 9.49 | 9.57 | 9.55 | 9.58 | 9.44 | 9.75 | 9.78 |
| PTHrP 400 mcg/Day | 9.48 | 9.95 | 9.73 | 9.71 | 9.56 | 9.90 | 9.90 |
| PTHrP 600 mcg/Day | 9.51 | 9.87 | 9.67 | 9.61 | 9.45 | 9.76 | 9.81 |
"Fractional tubular reabsorption of phosphate (TRP) = 1-{(U phos/P phos) x ( P creat/U creat)} if TRP < or = 0.86 then TMP/GFR = TRP x P phos if TRP > 0.86 then TMP/GFR = 0.3 x TRP/{1-(0.8 x TRP)} x P phos~U= urine, P = plasma" (NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | mg/dl (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 3.96 | 4.18 | 4.03 | 4.28 | 4.00 |
| PTHrP 400 mcg/Day | 3.80 | 3.78 | 3.88 | 4.02 | 4.11 |
| PTHrP 600 mcg/Day | 3.71 | 3.47 | 3.61 | 3.84 | 3.90 |
The mean change in bone mineral density (BMD), represented by T-scores, was assessed by calcaneal ultrasound in women taking melatonin (3 mg) or placebo nightly at baseline and after 6 months. A T-score is a comparison of a subject's BMD to that of a healthy 30 year old female of the same ethnicity. The more negative the T-score, the worse the BMD. Osteoporosis or brittle bone disease is defined as a T-score -2.5 or less. A more negative mean change in a T-score would indicate a worsening of BMD. A more positive mean change in a T-score would indicate an improvement of BMD. (NCT01152580)
Timeframe: Baseline and 6 months
| Intervention | T-score (Mean) |
|---|---|
| Sugar Pill | -0.02 |
| Melatonin | 0.05 |
"Menopause-Specific Quality of Life (MENQOL) questionnaires were administered to women at baseline and after 6 months of taking placebo or melatonin nightly. The MENQOL is a validated questionnaire that measures 4 domains of menopause quality of life in women: physical, vasomotor, psychosocial and sexual with each domain having a scale of not bothered (score 0) or bothered ranging from 1(not too bothered) to 6 (really bothered). A more negative mean change for each of the MENQOL domain scores indicates an improvement of these symptoms and a more positive value a worsening of symptoms." (NCT01152580)
Timeframe: Baseline and 6 mos
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | 0.1 |
| Melatonin | -0.6 |
"Menopause-Specific Quality of Life (MENQOL) questionnaires were administered to women at baseline and after 6 months of taking placebo or melatonin nightly. The MENQOL is a validated questionnaire that measures 4 domains of menopause quality of life in women: physical, vasomotor, psychosocial and sexual with each domain having a scale of not bothered (score 0) or bothered ranging from 1(not too bothered) to 6 (really bothered). A more negative mean change for each of the MENQOL domain scores indicates an improvement of these symptoms and a more positive value a worsening of symptoms." (NCT01152580)
Timeframe: Baseline and 6 mos
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | -0.2 |
| Melatonin | -0.4 |
"Menopause-Specific Quality of Life (MENQOL) questionnaires were administered to women at baseline and after 6 months of taking placebo or melatonin nightly. The MENQOL is a validated questionnaire that measures 4 domains of menopause quality of life in women: physical, vasomotor, psychosocial and sexual with each domain having a scale of not bothered (score 0) or bothered ranging from 1(not too bothered) to 6 (really bothered). A more negative mean change for each of the MENQOL domain scores indicates an improvement of these symptoms and a more positive value a worsening of symptoms." (NCT01152580)
Timeframe: Baseline and 6 mos
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | -0.7 |
| Melatonin | -0.4 |
"Menopause-Specific Quality of Life (MENQOL) questionnaires were administered to women at baseline and after 6 months of taking placebo or melatonin nightly. The MENQOL is a validated questionnaire that measures 4 domains of menopause quality of life in women: physical, vasomotor, psychosocial and sexual with each domain having a scale of not bothered (score 0) or bothered ranging from 1(not too bothered) to 6 (really bothered). A more negative mean change for each of the MENQOL domain scores indicates an improvement of these symptoms and a more positive value a worsening of symptoms." (NCT01152580)
Timeframe: Baseline and 6 mos
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | -0.2 |
| Melatonin | 0.4 |
Osteocalcin is a measure of osteoblast activity because it is secreted from osteoblasts. Osteocalcin levels were measured in the serum of women at baseline and after 6 months of taking placebo or melatonin (3 mg) and the data are reported as ng/mL. Osteoblasts are bone-forming cells so a more positive mean change in osteoblast activity over time (6 months - baseline) could indicate an improvement in bone mineral density. A more negative mean change in osteocalcin levels over time (6 months - baseline) could indicate a worsening of bone mineral density. (NCT01152580)
Timeframe: Baseline and 6 months
| Intervention | ng/mL (Mean) |
|---|---|
| Sugar Pill | -0.6 |
| Melatonin | 1.83 |
Type-1 collagen cross-linked N-telopeptide (NTX) levels were measured in the serum of women at baseline and after taking placebo or melatonin (3 mg) nightly for 6 months. NTX, reported as bone collagen equivalents (BCE), is released from bone due to the actions of osteoclasts or bone breakdown cells. A more positive mean change in NTX levels (6 months - baseline) could result in a worsening of bone mineral density due to an increase in bone breakdown whereas a more negative mean change in NTX levels could result in an improvement in bone mineral density due to a decrease in bone breakdown. (NCT01152580)
Timeframe: Baseline and 6 months
| Intervention | nM BCE (Mean) |
|---|---|
| Sugar Pill | -0.36 |
| Melatonin | -0.32 |
"Pittsburgh Sleep Quality Index (PSQI) Questionnaire is a validated questionnaire that assesses the quality and quantity of sleep and sleep disorders.This survey is designed to identify good and poor sleepers and has a score scale that ranges from 0-21 with 0 being good quality of sleep and 21 being poor quality of sleep and/or indicating as having a sleep disorder. A more positive mean change in the PSQI over time indicates a worsening of sleep. A more negative mean change in the PSQI over time indicates an improvement in sleep." (NCT01152580)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | -1.0 |
| Melatonin | -0.5 |
Percent Change in femoral neck BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -4.21 |
| Control | 0.04 |
Percent Change in lumbar spine BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 5.28 |
| Control | -1.48 |
Percent Change in peripheral heel BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 1.02 |
| Control | -1.99 |
To derive a measure of variability and directionality in the first moment of the power spectrum (FMP) in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and FMP is calculated for each segment. We use iFMP (integrated FMP) as a measure of overall special frequency of the radiographic pattern. FMP characterizes spatial frequency in the radiographic pattern and the underlying trabecular structure. This corresponds to the coarseness or fineness of the radiographic texture pattern. A high level of FMP indicates thin and closely spaced trabecular structure. Low FMP indicates widely spaced dark areas usually corresponding to a strong, thick trabecular structure. (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 0.09 |
| Control | 1.04 |
"Root Mean Square (RMS) is a measure of the variability in the radiographic texture pattern, the relative difference in the contrast between light and dark areas is expressed in a grayscale level. In practical terms, a bone image with a washed-out appearance due to loss of trabecular structure such as that seen in osteoporosis, will have a low value for RMS because there will be relatively little contrast between lighter and darker areas of the image. An image of a bone with strong trabecular structure will have a high RMS value because the contrast between the lighter and darker areas of the image will be greater.~To derive a measure of variability in the RMS in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and RMS is calculated for each segment. We use sdRMS (standard deviation of the RMS across the segments) as a measure of the direction dependence (anisotropy) of the trabeculae in the bone image." (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 6.85 |
| Control | 1.08 |
"Root Mean Square (RMS) is a measure of the variability in the radiographic texture pattern, the relative difference in the contrast between light and dark areas is expressed in a grayscale level. In practical terms, a bone image with a washed-out appearance due to loss of trabecular structure such as that seen in osteoporosis, will have a low value for RMS because there will be relatively little contrast between lighter and darker areas of the image. An image of a bone with strong trabecular structure will have a high RMS value because the contrast between the lighter and darker areas of the image will be greater.~To derive a measure of variability in the RMS in the region of interest in the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and RMS is calculated for each segment. The iRMS (integrated RMS) roughly corresponds to RMS averaged across all 24 angular sectors" (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -3.70 |
| Control | -0.53 |
To derive a measure of variability and directionality in the first moment of the power spectrum (FMP) in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals and FMP is calculated for each segment. We use minFMP (minimum FMP) to represent the lowest value of FMP across the 24 angular sectors corresponding to the special frequency in the most washed-out direction. FMP characterizes spatial frequency in the radiographic pattern and the underlying trabecular structure. This corresponds to the coarseness or fineness of the radiographic texture pattern. A high level of FMP indicates thin and closely spaced trabecular structure. Low FMP indicates widely spaced dark areas usually corresponding to a strong, thick trabecular structure. (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -3.61 |
| Control | -0.18 |
The Percent Change in Radiographic Texture Analysis (RTA) Minkowski Fractal Dimension (MINK) from Baseline to Month 24 is a description of the similarity of texture of the images at different magnifications. The Minkowski fractal dimension is calculated from the slope of the least -square fitted line relating log volume and log magnification. (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -0.06 |
| Control | 0.12 |
The Percent Change in Radiographic Texture Analysis (RTA) spectral density coefficient beta (BETA) from Baseline to Month 24 is an analysis of spectral density vs. the spacial frequency on a log-log plot. BETA is the coefficient (slope) of this plot. Higher values of beta correspond to rougher (strong bone) and lower values to smoother, higher-frequency texture pattern (washed out bone). (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 3.09 |
| Control | 6.53 |
Percent Change in total hip BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -3.68 |
| Control | -0.77 |
173 reviews available for alendronate and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus.
Topics: Alendronate; Alkaline Phosphatase; Atorvastatin; Bone Density; Bone Density Conservation Agents; Dia | 2022 |
Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denos | 2022 |
Aminobisphosphonates: Reconsideration 25 years after their approval for the treatment of osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Hydroxyapa | 2022 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Fract | 2023 |
Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cost-Benefit Analy | 2023 |
Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J).
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fractures, Compression; Humans; | 2023 |
Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures: A Systematic Review of Experimental and Observational Studies.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Obse | 2023 |
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Huma | 2023 |
Long-term consequences of osteoporosis therapy with bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Oste | 2023 |
Cumulative network meta-analyses, practice guidelines, and actual prescriptions for postmenopausal osteoporosis: a meta-epidemiological study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcium, Dietary; Diphosphon | 2020 |
The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Iban | 2020 |
History of risedronate.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; | 2020 |
Quantitative prediction of bone mineral density by using bone turnover markers in response to antiresorptive agents in postmenopausal osteoporosis: A model-based meta-analysis.
Topics: Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Female; Hu | 2021 |
Romosozumab: A Review in Postmenopausal Osteoporosis.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Clinical Trials | 2020 |
Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diab | 2020 |
Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Female; Humans; Italy; M | 2021 |
Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis.
Topics: Alendronate; Bayes Theorem; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Human | 2021 |
CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Dru | 2017 |
Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials.
Topics: Alendronate; Bone Density Conservation Agents; Humans; Osteoporosis, Postmenopausal; Randomized Cont | 2017 |
A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Female; Humans; Hypoglycemic Agents; Osteoporosis, Postmenopausal; Random | 2018 |
THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Hum | 2018 |
THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Hum | 2018 |
THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Hum | 2018 |
THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Hum | 2018 |
Comparative Efficacy of Alendronate upon Vertebral Bone Mineral Density and Fracture Rates in East Asians Versus Non-East Asians with Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis.
Topics: Alendronate; Asian People; Bone Density; Female; Humans; Osteoporosis, Postmenopausal; Randomized Co | 2018 |
Fractures related to bone fragility: prevention First-choice treatments.
Topics: Accidental Falls; Alendronate; Bone Density Conservation Agents; Calcium, Dietary; Exercise; Humans; | 2017 |
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonate | 2019 |
[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
Topics: Aged; Alendronate; Animals; Bone Density; Disease Models, Animal; Drug Combinations; Drug Interactio | 2012 |
Controversies in osteoporosis management: antiresorptive therapy for preventing bone loss: when to use one or two antiresorptive agents?
Topics: Alendronate; Bone Density Conservation Agents; Calcitriol; Calcium, Dietary; Diphosphonates; Drug Th | 2013 |
Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosp | 2013 |
Postmenopausal osteoporosis.
Topics: Accidental Falls; Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density C | 2013 |
Prevention and treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Remodeli | 2014 |
A review of osteoporosis management in younger premenopausal women.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Evidence-Based Medicine; Female; | 2014 |
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosp | 2014 |
Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointesti | 2015 |
Alendronate: new formulations of an old and effective drug to improve adherence avoiding upper gastrointestinal side effects.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Female; Fractures | 2014 |
The use of bisphosphonates in women: when to use and when to stop.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Iban | 2015 |
Treatment of osteoporosis after alendronate or risedronate.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Female; Humans; Im | 2016 |
Bisphosphonate-Mediated Oral Ulcers: A Rare Differential Diagnosis of Erosive Oral Lesions.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Female; Humans; Oral U | 2016 |
Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substituti | 2016 |
Alendronate for fracture prevention in postmenopause.
Topics: Alendronate; Bone Density Conservation Agents; Female; Fractures, Spontaneous; Humans; Middle Aged; | 2008 |
Treatment of postmenopausal osteoporosis in women: a systematic review.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone | 2008 |
Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature.
Topics: Alendronate; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Osteoporosis, Postmeno | 2008 |
Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Estrogens; Female; Fertility | 2008 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Sp | 2009 |
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Frac | 2009 |
[Alendronate for the prevention and treatment of postmenopausal osteoporosis. A survey of a Cochrane review].
Topics: Alendronate; Bone Density Conservation Agents; Evidence-Based Medicine; Female; Fractures, Spontaneo | 2009 |
Denosumab update.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Bone | 2009 |
[Effects of SERMs on bone health. Combination therapy with raloxifene].
Topics: Alendronate; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Fractures, Spontan | 2010 |
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; | 2011 |
Ocular side effects of bisphosphonates: A case report and literature review.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Conjunctivitis; Diphosphonates; Female; Humans; | 2010 |
Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.
Topics: Alendronate; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone | 2011 |
Vertebral fracture risk and alendronate effects on osteoporosis assessed by a computed tomography-based nonlinear finite element method.
Topics: Alendronate; Female; Finite Element Analysis; Humans; Osteoporosis, Postmenopausal; Spinal Fractures | 2011 |
Denosumab: an update.
Topics: Alendronate; Androgen Antagonists; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aromat | 2011 |
Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; D | 2011 |
Denosumab for postmenopausal osteoporosis?
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bon | 2012 |
Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bon | 2012 |
Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; | 2012 |
Update on denosumab in postmenopausal osteoporosis--recent clinical data.
Topics: Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents | 2012 |
Anabolic therapies for osteoporosis.
Topics: Alendronate; Anabolic Agents; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agent | 2012 |
A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation | 2013 |
Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density; Bone Density Con | 2013 |
New anabolic therapies in osteoporosis.
Topics: Alendronate; Bone and Bones; Bone Resorption; Drug Therapy, Combination; Female; Fluorides; Human Gr | 2002 |
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.
Topics: Alendronate; Bone Density; Female; Humans; Osteoporosis, Postmenopausal; Randomized Controlled Trial | 2002 |
Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
Topics: Alendronate; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Osteoporosis, | 2002 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Estrogen Replacement Therapy; Etidronic A | 2002 |
Osteoporosis in elderly: prevention and treatment.
Topics: Aged; Alendronate; Etidronic Acid; Exercise; Female; Fractures, Bone; Hormone Replacement Therapy; H | 2002 |
[Osteoporosis: prevention of bone loss and fractures].
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Diseases, Metabolic; Diagnosis, D | 2002 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etid | 2002 |
[Osteoporosis].
Topics: Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; | 2002 |
The clinical tolerability profile of alendronate.
Topics: Alendronate; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Gastrointestinal Dise | 1999 |
Results of special studies with alendronate.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Clinical Trials, Phase III as Topic; Dose-Response Rela | 1999 |
Canadian consensus on osteoporosis. Preventing osteoporosis among postmenopausal women.
Topics: Aged; Alendronate; Calcium Channel Blockers; Canada; Estrogen Replacement Therapy; Etidronic Acid; F | 2003 |
Identifying the osteopenic patient and preventing worsening of the disease.
Topics: Alendronate; Body Mass Index; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Calcitonin; Es | 2003 |
The gastrointestinal tolerability and safety of oral bisphosphonates.
Topics: Administration, Oral; Alendronate; Biological Availability; Clinical Trials as Topic; Diphosphonates | 2002 |
Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Topics: Aged; Alendronate; Calcium Channel Blockers; Diphosphonates; Estrogen Replacement Therapy; Etidronic | 2003 |
What predicts early fracture or bone loss on bisphosphonate therapy?
Topics: Alendronate; Etidronic Acid; Female; Forecasting; Fractures, Bone; Humans; Middle Aged; Osteoporosis | 2003 |
Osteoporosis: point-of-care testing.
Topics: Absorptiometry, Photon; Alendronate; Calcitonin; Female; Humans; Osteoporosis, Postmenopausal; Point | 2004 |
An approach to postmenopausal osteoporosis treatment: a case study review.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement | 2003 |
Osteoporosis management in the new millennium.
Topics: Alendronate; Bone Density; Calcitonin; Calcium; Estrogens; Etidronic Acid; Exercise; Humans; Middle | 2003 |
Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial.
Topics: Alendronate; Biomarkers; Bone Density; Calcitonin; Diphosphonates; Estrogens; Female; Fractures, Bon | 2004 |
[Serum beta-CTx(beta-CrossLaps)].
Topics: Alendronate; Biomarkers; Bone Density; Bone Resorption; Collagen; Collagen Type I; Fractures, Bone; | 2004 |
Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis?
Topics: Alendronate; Drug Therapy, Combination; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopa | 2004 |
Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Remodeling; Bone Resorption; Calcitonin; Diphosphonates; Estrogen Re | 2003 |
Postmenopausal osteoporosis and alendronate.
Topics: Aged; Alendronate; Bone Density; Bone Resorption; Female; Femur Neck; Fractures, Bone; Humans; Lumba | 2004 |
Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Hip Fractures; Human | 2005 |
Pharmacologic prevention of osteoporotic fractures.
Topics: Aged; Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; | 2004 |
Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.
Topics: Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; | 2004 |
Treating osteoporosis in post-menopausal women: a case approach.
Topics: Aged; Alendronate; Densitometry; Diphosphonates; Etidronic Acid; Female; Humans; Mass Screening; Mid | 2004 |
[Who are the candidates for the treatment by raloxifen ?].
Topics: Age Factors; Alendronate; Bone and Bones; Bone Density; Diet Therapy; Drug Therapy, Combination; Exe | 2004 |
Rapid prevention of vertebral fractures associated with osteoporosis.
Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogens; Female; Glucocor | 2005 |
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysi | 2005 |
The use of bisphosphonates in the treatment of osteoporosis.
Topics: Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Male; Osteogenesi | 2005 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosp | 2003 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; | 2004 |
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Humans; | 2005 |
Bisphosphonate-associated scleritis: a case report and review.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Female; Humans; Osteoporosis, Postmenopausal; | 2005 |
Review of treatment modalities for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Die | 2005 |
The treatment of severe postmenopausal osteoporosis : a review of current and emerging therapeutic options.
Topics: Alendronate; Bone Density; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochlor | 2006 |
Strategies for the prevention and treatment of osteoporosis during early postmenopause.
Topics: Accidental Falls; Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Est | 2006 |
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administra | 2006 |
Preventing osteoporosis-related fractures: an overview.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone D | 2006 |
Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; | 2006 |
Long-term experience with alendronate in the treatment of osteoporosis.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Drug | 2006 |
Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic A | 2006 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphon | 2006 |
[Drug treatment of postmenopausal osteoporosis. What's New in 2006].
Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Body Mass Index; B | 2006 |
[Osteoporosis: Optimizing treatment strategy].
Topics: Age Factors; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcium, | 2006 |
How long should patients take medications for postmenopausal osteoporosis?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Dr | 2007 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandroni | 2006 |
[Menopause].
Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Densitometry; Estrog | 2006 |
[Practical guidelines for the management of osteoporosis--evidence-based and cost-effective].
Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone | 2007 |
[Current osteoporosis treatment: reasons for adding vitamin D to alendronate].
Topics: Alendronate; Bone Density Conservation Agents; Drug Combinations; Female; Fractures, Bone; Humans; O | 2006 |
Pharmacological treatment of osteoporosis for people over 70.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium; Diphosphonates; Etidronic Acid; Female; Fractu | 2007 |
[Diphosphonate therapy and osteonecrosis of the jaw].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Dental Care; Diphosphonates; Female; Humans; Ja | 2007 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphospho | 2007 |
Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
Topics: Alendronate; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone | 2007 |
Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2007 |
[Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trial | 2007 |
[Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials as Top | 2007 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosph | 2007 |
[FACT study].
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double- | 2007 |
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Fractures, Spontaneous; Hip | 2008 |
[Alendronate and vitamin D (Fosavance): persistence, adherence and importance of vitamin D].
Topics: Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Osteoporosis, Postme | 2007 |
An overview of the results of clinical trials with alendronate, a promising treatment of osteoporosis in postmenopausal women.
Topics: Adult; Aged; Alendronate; Bone Density; Clinical Trials as Topic; Diphosphonates; Female; Humans; Mi | 1995 |
Osteoporosis prevention and treatment.
Topics: Absorptiometry, Photon; Alendronate; Calcitonin; Diphosphonates; Exercise; Female; Fluorides; Humans | 1996 |
Esophagitis associated with the use of alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Esophagitis; Female; Humans; Osteoporosis, Pos | 1996 |
Osteoporosis treatment: focusing the target.
Topics: Aged; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; O | 1996 |
[Diphosphonates: and alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate].
Topics: Aged; Alendronate; Diphosphonates; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteop | 1996 |
Osteoporosis prevention and treatment. Pharmacological management and treatment implications.
Topics: Aged; Alendronate; Calcitonin; Estrogen Replacement Therapy; Female; Humans; Male; Osteoporosis, Pos | 1996 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; | 1997 |
Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis.
Topics: Alendronate; Animals; Female; Humans; Osteoporosis, Postmenopausal | 1997 |
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Middle A | 1997 |
[Alendronate-induced esophagitis. A report of 2 cases].
Topics: Alendronate; Esophagitis; Female; Humans; Middle Aged; Omeprazole; Osteoporosis, Postmenopausal; Suc | 1997 |
Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis.
Topics: Alendronate; Bone Density; Bone Remodeling; Bone Resorption; Female; Humans; Osteoporosis, Postmenop | 1997 |
Osteoporosis: trials and tribulations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Estrogen Replaceme | 1997 |
Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications.
Topics: Absorptiometry, Photon; Alendronate; Animals; Bone and Bones; Bone Density; Bone Remodeling; Calcifi | 1997 |
Biomechanics of osteoporosis and vertebral fracture.
Topics: Aged; Aged, 80 and over; Aging; Alendronate; Animals; Bone Density; Female; Humans; Middle Aged; Ost | 1997 |
Alendronate treatment for osteoporosis.
Topics: Alendronate; Bone Density; Calcium, Dietary; Female; Humans; Middle Aged; Osteoporosis, Postmenopaus | 1997 |
Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy?
Topics: Alendronate; Alzheimer Disease; Calcitonin; Calcium; Coronary Disease; Diphosphonates; Endometrial N | 1997 |
Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
Topics: Adult; Aged; Alendronate; Bone and Bones; Bone Density; Calcification, Physiologic; Clinical Trials, | 1998 |
Lowering the risk of esophagitis from alendronate therapy.
Topics: Alendronate; Esophagitis; Female; Humans; Osteoporosis, Postmenopausal | 1998 |
Ultrasound and alendronate: new tools for osteoporosis screening and treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Calcium; Clinical Trials as Topic; Estrogen Antagonists; | 1998 |
What's new in preventing and treating osteoporosis?
Topics: Alendronate; Bone Density; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Ost | 1998 |
Bisphosphonates and osteoporosis treatment in Italy.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Fem | 1998 |
Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
Topics: Aging; Alendronate; Bone Density; Clinical Trials as Topic; Data Collection; Etidronic Acid; Female; | 1999 |
Pharmacokinetics of alendronate.
Topics: Alendronate; Animals; Biological Availability; Bone and Bones; Female; Humans; Intestinal Absorption | 1999 |
Prevention of osteoporosis and fractures.
Topics: Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Female; | 1999 |
Sequential parathyroid hormone/alendronate therapy for osteoporosis--robbing Peter to pay Paul?
Topics: Adult; Alendronate; Bone Density; Clinical Trials as Topic; Drug Therapy, Combination; Female; Human | 2000 |
[Alendronate also for women without established osteoporosis?].
Topics: Aged; Alendronate; Bone Density; Diphosphonates; Double-Blind Method; Evidence-Based Medicine; Femal | 2000 |
[Effect of alendronate on bone mineral density and incidence of fractures in postmenopausal women with osteoporosis. A meta-analysis of published studies].
Topics: Alendronate; Bone Density; Calcification, Physiologic; Female; Hip Fractures; Humans; Middle Aged; O | 2000 |
Prevention and treatment of osteoporosis in women with breast cancer.
Topics: Aged; Alendronate; Bone Density; Breast Neoplasms; Calcitonin; Diphosphonates; Female; Fractures, Bo | 2000 |
Gastroenterologists and choosing the right bisphosphonate.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Gastroenterology; Glucocorticoids; Humans; Oste | 2000 |
Postmenopausal osteoporosis. Strategies for preventing bone loss, avoiding fracture.
Topics: Aged; Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Female; Fractures, Bone; Hum | 2000 |
[Effect of anti-osteoporosis agents on the incidence of vertebral fractures].
Topics: Alendronate; Bone Density; Calcitonin; Calcium Channel Blockers; Densitometry; Etidronic Acid; Femal | 2000 |
[Therapeutic strategies for osteoporosis].
Topics: Accidental Falls; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calci | 2000 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; | 2000 |
Considerations of osteoporosis prevention in an aging society.
Topics: Aging; Alendronate; Bone Density; Estrogens; Female; Humans; Osteoporosis, Postmenopausal | 2000 |
Post-menopausal bone loss and its relationship to oral bone loss.
Topics: Absorptiometry, Photon; Alendronate; Alveolar Bone Loss; Bone Density; Calcium; Estrogen Replacement | 2000 |
Treatment of osteoporosis with bisphosphonates.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Fem | 2001 |
Evidence-based medicine: putting theory into practice.
Topics: Alendronate; Calcium Channel Blockers; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based | 2001 |
[Alendronate-induced hepatocellular lesion].
Topics: Aged; Alendronate; Chemical and Drug Induced Liver Injury; Female; Humans; Liver Function Tests; Ost | 2001 |
Alendronate: an update of its use in osteoporosis.
Topics: Adult; Aged; Alendronate; Biological Availability; Bone and Bones; Cost-Benefit Analysis; Female; Hu | 2001 |
Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation.
Topics: Aged; Aged, 80 and over; Alendronate; Calcitonin; Cost-Benefit Analysis; Female; Fractures, Bone; Hu | 2001 |
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
Topics: Age Factors; Aged; Alendronate; Bone Density; Calcium Channel Blockers; Diphosphonates; Etidronic Ac | 2001 |
Bisphosphonates for osteoporosis.
Topics: Aged; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; | 2001 |
Risedronate: a new oral bisphosphonate.
Topics: Administration, Oral; Alendronate; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; | 2001 |
Role of alendronate and risedronate in preventing and treating osteoporosis.
Topics: Alendronate; Cost-Benefit Analysis; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid | 2001 |
[Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates].
Topics: Aging; Alendronate; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Mi | 2001 |
[New aspects and opportunities in the clinical use of fosamax].
Topics: Administration, Oral; Aged; Alendronate; Bulgaria; Female; Fractures, Bone; Humans; Middle Aged; Ost | 2001 |
Bisphosphonates for the treatment of postmenopausal osteoporosis: clinical studies of etidronate and alendronate.
Topics: Aged; Alendronate; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmeno | 2001 |
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.
Topics: Alendronate; Bone Density; Bone Resorption; Female; Fractures, Spontaneous; Humans; Logistic Models; | 2002 |
Bisphosphonates for prevention of postmenopausal osteoporosis.
Topics: Alendronate; Biomarkers; Bone Density; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis | 2002 |
Combination treatment of osteoporosis: a clinical review.
Topics: Alendronate; Bone Density; Clinical Trials as Topic; Drug Therapy, Combination; Estrogens, Conjugate | 2002 |
Treatment of male osteoporosis: recent advances with alendronate.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Resorption; Calcium; Female; Fractures, Bone; Humans; H | 2002 |
327 trials available for alendronate and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
The effects of alendronate treatment in the diagnosis and management of proximal femur osteoporosis: A real-life scenario.
Topics: Alendronate; Bone Density Conservation Agents; Female; Femur Head; Humans; Middle Aged; Osteoporosis | 2021 |
Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Female; Femur N | 2022 |
Efficacy of Raloxifene as Add-on Therapy on Disease Activity of Postmenopausal Women with Rheumatoid Arthritis: A Double-blind, Randomized, Placebo-controlled Clinical Trial.
Topics: Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Female; Humans; | 2023 |
Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; China; Female; Humans; Osteoporosis; Os | 2022 |
Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; East Asian People; Female; Humans; Oste | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
The Effect of Effervescent and Buffered Alendronate Compared to Conventional Alendronate on Markers of Bone Turnover: A Randomized Non-inferiority Trial.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Female; Humans; Osteop | 2023 |
Bone Mineral Density After Transitioning From Denosumab to Alendronate.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cross-Over Studies; Denosumab; Fe | 2020 |
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Female | 2020 |
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Female | 2020 |
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Female | 2020 |
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Female | 2020 |
Effect of bisphosphonate on the prevention of bone loss in patients with gastric cancer after gastrectomy: A randomized controlled trial.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Fe | 2020 |
The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Fema | 2020 |
Zoledronate Slows Weight Loss and Maintains Fat Mass in Osteopenic Older Women: Secondary Analysis of a Randomized Controlled Trial.
Topics: Age Distribution; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, | 2020 |
Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Female; F | 2020 |
Assessment of eldecalcitol and alendronate effect on postural balance control in aged women with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Female; Humans; Ost | 2020 |
Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Female; Fore | 2021 |
Impact of bone mineral density in reducing fracture risk in patients receiving alendronate plus alfacalcidol therapy.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Hydroxycholecalciferols | 2021 |
The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study.
Topics: Administration, Oral; Aged; Alendronate; Arthroplasty, Replacement, Knee; Biomarkers; Bone Density; | 2021 |
A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Japan; Osteoporosis; Os | 2021 |
Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Female; Humans; | 2021 |
Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial.
Topics: Aged; Alendronate; Amino Acids; Asian People; Bone Density; Bone Density Conservation Agents; Drug T | 2017 |
Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bone Density; Bone Density | 2017 |
Short-term effects of extracorporeal shock wave therapy on bone mineral density in postmenopausal osteoporotic patients.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Combined | 2017 |
Baseline mineralizing surface determines the magnitude of the bisphosphonate effect on cortical bone mineralization in postmenopausal osteoporotic patients.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcification, Physiologic; Diphosphonates; Fem | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Comparative adherence to weekly oral and quarterly intravenous bisphosphonates among patients with limited heath literacy who sustained distal radius fractures.
Topics: Administration, Intravenous; Administration, Oral; Alendronate; Bone Density Conservation Agents; De | 2018 |
Insights into the bisphosphonate holiday: a preliminary FTIRI study.
Topics: Aged; Alendronate; Biopsy; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Fema | 2018 |
Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis.
Topics: Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Drug Administration Schedul | 2018 |
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; | 2018 |
Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Biomarker | 2018 |
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Drug Administr | 2018 |
Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Ca | 2018 |
Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitriol; China; Cholecalcifero | 2018 |
Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Bone Remode | 2018 |
A prospective comparative study of intravenous alendronate and ibandronate for the treatment of osteoporosis.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conser | 2019 |
Effects of adding alendronate to ongoing hormone therapy on bone mineral density in postmenopausal Korean women: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Aged; Alendronate; Amino Acids; Bone Density; Bone Density Conservation Agents; Double-Blind Method; | 2013 |
BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate.
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; F | 2013 |
Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women.
Topics: Alendronate; Calcitriol; Dosage Forms; Drug Combinations; Female; Humans; Middle Aged; Osteoporosis, | 2013 |
Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Diphosphonates; Drug Administration Schedule; | 2013 |
Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Cath | 2014 |
Actions of osteoporosis treatments on bone histomorphometric remodeling: a two-fold principal component analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Bone Resorp | 2013 |
A negative feedback model for a mechanism based description of longitudinal observations. Application for bone turnover biomarkers.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone | 2013 |
Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Dietary Supple | 2014 |
Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Topics: Aged; Alendronate; Biomarkers; Biphenyl Compounds; Bone and Bones; Bone Density; Bone Density Conser | 2013 |
Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Female; Humans; Hyperpar | 2013 |
The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Analgesics; Bone Density Conservation Ag | 2014 |
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Topics: Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents | 2014 |
Comparing tolerability and efficacy of generic versus brand alendronate: a randomized clinical study in postmenopausal women with a recent fracture.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cross-Over Studies; Double-Blind Method; Drugs, | 2013 |
Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment.
Topics: Aged; Alendronate; Calcification, Physiologic; Female; Humans; Osteogenesis; Osteoporosis, Postmenop | 2014 |
Romosozumab in postmenopausal women with low bone mineral density.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Biomarkers; Bone Density; Bone Density | 2014 |
Romosozumab in postmenopausal women with low bone mineral density.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Biomarkers; Bone Density; Bone Density | 2014 |
Romosozumab in postmenopausal women with low bone mineral density.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Biomarkers; Bone Density; Bone Density | 2014 |
Romosozumab in postmenopausal women with low bone mineral density.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Biomarkers; Bone Density; Bone Density | 2014 |
Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Ankle Brachial Index; Atherosclerosis; Bone Density Conserv | 2014 |
Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis, Pos | 2014 |
Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT).
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Denosumab; Female; Humans; | 2014 |
Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trial.
Topics: Adult; Aged; Alendronate; Cholecalciferol; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal | 2014 |
[Curative effects of pulsed electromagnetic fields on postmenopausal osteoporosis].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Electromagnetic Fields; Female; Humans; | 2014 |
Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.
Topics: Aged; Alendronate; Biopsy; Bone Density; Bone Density Conservation Agents; Bone Matrix; Calcificatio | 2014 |
Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Dens | 2014 |
A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femur | 2014 |
Effects of long-term alendronate treatment on bone mineralisation, resorption parameters and biomechanics of single human vertebral trabeculae.
Topics: Aged; Aged, 80 and over; Alendronate; Biomechanical Phenomena; Bone Density Conservation Agents; Bon | 2014 |
Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties.
Topics: Alendronate; Biopsy; Bone Density Conservation Agents; Bone Remodeling; Drug Administration Schedule | 2015 |
The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells.
Topics: Alendronate; Angiopoietin-1; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, | 2015 |
Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.
Topics: Administration, Oral; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Cholecal | 2015 |
Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
Topics: Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Calcitriol; Cholec | 2015 |
Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density | 2015 |
Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Drug | 2015 |
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone De | 2016 |
Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate.
Topics: Alendronate; Bone Density; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausa | 2016 |
Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Cancellous Bone; | 2016 |
Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; | 2016 |
Disease Systems Analysis of Bone Mineral Density and Bone Turnover Markers in Response to Alendronate, Placebo, and Washout in Postmenopausal Women.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Collagen Type I; Double | 2016 |
Association Between Geranylgeranyl Pyrophosphate Synthase Gene Polymorphisms and Bone Phenotypes and Response to Alendronate Treatment in Chinese Osteoporotic Women.
Topics: Alendronate; Asian People; Biomarkers; Bone Density; Female; Geranylgeranyl-Diphosphate Geranylgeran | 2016 |
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans | 2017 |
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans | 2017 |
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans | 2017 |
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans | 2017 |
Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female | 2017 |
Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Topics: Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Collagen Type I; | 2008 |
Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Asian People; Biomarkers; Bone and Bo | 2008 |
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Anabolic Agents; Bone Density Conservation Agents; | 2008 |
Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Density Conservation Agents; Confidence Inte | 2008 |
Vitamin D insufficiency does not affect response of bone mineral density to alendronate.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; | 2009 |
Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Diuretics; Dose-Response | 2009 |
Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
Topics: Aged; Aged, 80 and over; Alendronate; Area Under Curve; Biomarkers; Bone Density Conservation Agents | 2009 |
A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Meth | 2009 |
The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone and Bones; Bone Density; China; Collagen Type I; Doubl | 2009 |
Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
Topics: Adult; Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind | 2009 |
Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; | 2009 |
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Collagen Type | 2009 |
Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Calcification, | 2010 |
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calc | 2009 |
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calc | 2009 |
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calc | 2009 |
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calc | 2009 |
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; | 2009 |
Alendronate reduces osteoclast precursors in osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcium; Cells, Cultured; Cyto | 2010 |
The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Double-Blind Method; F | 2010 |
Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
Topics: Adult; Aged; Alendronate; Biomarkers; Biopsy; Bone Density; Bone Density Conservation Agents; Bone R | 2010 |
Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
Topics: Adult; Age Factors; Aged; Alendronate; Analysis of Variance; Bone Density; Bone Density Conservation | 2010 |
Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Anabolic Agents; Biomarkers; Bone and | 2010 |
Relationships between serum adiponectin, leptin concentrations and bone mineral density, and bone biochemical markers in Chinese women.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Blood; B | 2010 |
Alendronate improves QOL of postmenopausal women with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Humans; Japan; Middl | 2010 |
Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femur Neck; Fractures, Bone; Hi | 2010 |
Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Drug Admini | 2010 |
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2011 |
Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone Remo | 2011 |
The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Confounding Factors, Epidemiologic; Diphosphonat | 2011 |
Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Back Pain; Calcitonin; Collagen Type I; | 2011 |
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Antibodies, Monoclonal; Antibodies, Mono | 2011 |
Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Cholesterol, HDL; Collagen Type I; Drug Administration | 2011 |
Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; | 2011 |
Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone and Bones; Bone Density | 2012 |
Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcium; Cholecalciferol; Do | 2011 |
Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density; Bone Density Conse | 2011 |
The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
Topics: Administration, Oral; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; | 2011 |
The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femur Neck; Genotype; Hum | 2011 |
The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in chinese post-menopausal women at risk of osteoporosis.
Topics: Adult; Aged; Alendronate; Alkaline Phosphatase; Asian People; Biomarkers; Bone Density; Bone Density | 2011 |
Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.
Topics: Aged; Alendronate; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cohor | 2011 |
Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Double-Blind Meth | 2012 |
Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Topics: Alendronate; Biomarkers, Pharmacological; Bone and Bones; Bone Density; Bone Density Conservation Ag | 2011 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Comparative evaluation of isosorbide mononitrate and alendronate in management of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Female | 2012 |
Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density | 2012 |
Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study).
Topics: Adiponectin; Adiposity; Aged; Aged, 80 and over; Alendronate; Body Weight; Bone Density; Bone Densit | 2011 |
Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.
Topics: Activities of Daily Living; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density | 2012 |
Development, reliability, and validity of a new Preference and Satisfaction Questionnaire.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservat | 2011 |
Development, reliability, and validity of a new Preference and Satisfaction Questionnaire.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservat | 2011 |
Development, reliability, and validity of a new Preference and Satisfaction Questionnaire.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservat | 2011 |
Development, reliability, and validity of a new Preference and Satisfaction Questionnaire.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservat | 2011 |
Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosp | 2012 |
Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone.
Topics: Adaptor Proteins, Signal Transducing; Aged; Alendronate; Bone Density; Bone Density Conservation Age | 2012 |
Comparison of plain vertebral X-ray and dual-energy X-ray absorptiometry for the identification of older women for fracture prevention in primary care.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Australia; Bone Density; Bone Density | 2013 |
Whole body vibration exercise improves body balance and walking velocity in postmenopausal osteoporotic women treated with alendronate: Galileo and Alendronate Intervention Trail (GAIT).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Exercise Therapy; Female; Hu | 2012 |
Changes in serum levels of cartilage oligomeric matrix protein after estrogen and alendronate therapy in postmenopausal women.
Topics: Aged; Alendronate; Androstenes; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metab | 2012 |
Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Re | 2013 |
Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calc | 2012 |
Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.
Topics: Alendronate; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone and Bones; Bone Density; | 2013 |
A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.
Topics: Aged; Alendronate; Back Pain; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remod | 2013 |
Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Finite | 2013 |
14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
Topics: Aged; Alendronate; Analysis of Variance; Confidence Intervals; Dose-Response Relationship, Drug; Dru | 2002 |
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Body Height; Bone and | 2002 |
Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
Topics: Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Double-Blind Method; Female; Gastr | 2002 |
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bone Resorption; Co | 2002 |
[Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density; Bone Diseases, Metabolic; Calcium Carbonate; | 2002 |
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Double-Blind Method; Drug The | 2002 |
Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study.
Topics: Administration, Oral; Adult; Aged; Alendronate; Cross-Over Studies; Female; Humans; Middle Aged; Ost | 2002 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etid | 2002 |
Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT).
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alendronate; Disability Evaluation; Female; Fol | 2003 |
Response to alendronate in osteoporotic women previously treated with pamidronate.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Bone Density; Calcium; Collagen; Diet | 2003 |
Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes.
Topics: Aged; Alendronate; Amino Acids; Biomarkers; Bone Density; Creatinine; Female; Humans; Lumbar Vertebr | 2003 |
The effects of alendronate and calcitonin on cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
Topics: Aged; Alendronate; Calcitonin; Cytokines; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; | 2003 |
Alendronate in the treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Dose-Response Relationship, Drug; Female; Hip Jo | 1999 |
The effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention Trial.
Topics: Aged; Aged, 80 and over; Alendronate; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Po | 1999 |
The antifracture efficacy of alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Double-Blind Method; Female; Fractures, Bone; Hu | 1999 |
Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Alendronate; Bone Density; Diphosphonates | 2003 |
Month 3 and month 6 measurements of bone mineral density predict the annual outcome in postmenopausal women with osteoporosis in whom alendronate was added to long-term HRT.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Replacement T | 2003 |
Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Double-Blind Method; Drug Therapy, Combination; | 2003 |
Alendronate daily, weekly in conventional tablets and weekly in enteric tablets: preliminary study on the effects in bone turnover markers and incidence of side effects.
Topics: Administration, Oral; Adult; Alendronate; Bone Density; Collagen Type I; Drug Administration Schedul | 2003 |
Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Back Pain; Bone Density; Calcium; Collagen; Collagen Type I; E | 2003 |
[The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Female; Humans; Middle Aged; Osteoporosis, | 2002 |
Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women.
Topics: Absorptiometry, Photon; Administration, Cutaneous; Administration, Oral; Alendronate; Bone Density; | 2003 |
Effects of hormone therapy and alendronate on C-reactive protein, E-selectin, and sex hormone-binding globulin in osteoporotic women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; C-Reactive Protein; Double-Blind Method; | 2003 |
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Calcium C | 2003 |
Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal.
Topics: Adult; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Denmark; Female; Follow-Up Studies; H | 2003 |
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodel | 2003 |
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodel | 2003 |
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodel | 2003 |
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodel | 2003 |
Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Remodeling; Densitometry; Dose-Response Relationship, D | 2003 |
Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Drug Tolerance; Female; Humans; Middle | 2003 |
Compliance of osteoporotic patients with different treatment regimens.
Topics: Aged; Alendronate; Attitude to Health; Comorbidity; Female; Humans; Israel; Logistic Models; Osteopo | 2003 |
Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Collagen; Collagen Type I; Drug Therap | 2004 |
Dose reduction and discontinuation of alendronate in postmenopausal osteoporotic women who were receiving estrogen therapy.
Topics: Alendronate; Bone Density; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administratio | 2004 |
Ten years' experience with alendronate for osteoporosis in postmenopausal women.
Topics: Aged; Alendronate; Body Height; Bone Density; Bone Remodeling; Double-Blind Method; Female; Fracture | 2004 |
Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
Topics: Aged; Alendronate; Female; Humans; Logistic Models; Middle Aged; Osteoporosis, Postmenopausal; Patie | 2004 |
Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Resorption; Double-Blind Method; F | 2004 |
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Collagen; Coll | 2004 |
Alendronate in the prevention of osteoporosis: 7-year follow-up.
Topics: Adult; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Collagen; Collagen Type I; Dipho | 2004 |
Patients with osteoporosis prefer once weekly to once daily dosing with alendronate.
Topics: Aged; Alendronate; Cross-Over Studies; Drug Administration Schedule; Female; Humans; Middle Aged; Os | 2004 |
Recent important clinical trials of drugs in osteoporosis.
Topics: Aged; Alendronate; Animals; Calcitriol; Drug Therapy, Combination; Exercise Therapy; Female; Heart T | 2004 |
Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Body Mass Index; Bone Density; Diabetes Mellitus, | 2004 |
Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Back Pain; Biomarkers; Bone Density; B | 2004 |
Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density; Calcium; Female; Follow-Up Studies; Humans; I | 2004 |
Effect of discontinuation of alendronate treatment and exercise on bone mass and physical fitness: 15-month follow-up of a randomized, controlled trial.
Topics: Alendronate; Bone Density; Confidence Intervals; Exercise; Female; Follow-Up Studies; Humans; Middle | 2004 |
Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Ca | 2004 |
Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study.
Topics: Alendronate; Biomarkers; Bone Density; Cohort Studies; Female; Humans; Middle Aged; Osteoporosis, Po | 2004 |
Clinical significance of alendronate in postmenopausal type 2 diabetes mellitus.
Topics: Aged; Alendronate; Bone Density; Collagen; Collagen Type I; Diabetes Mellitus, Type 2; Female; Human | 2004 |
Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conserv | 2006 |
Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Remodeling; Female; Fractures, Bone; H | 2005 |
Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis.
Topics: Alendronate; Biomarkers; Bone and Bones; Calcitonin; Female; Humans; Middle Aged; Osteocalcin; Osteo | 2005 |
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Topics: Aged; Alendronate; Biomarkers; Bone Remodeling; Calcium Channel Blockers; Diphosphonates; Double-Bli | 2005 |
The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Topics: Absorptiometry, Photon; Administration, Inhalation; Administration, Intranasal; Alendronate; Alkalin | 2005 |
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorp | 2005 |
Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Double-Blind Method; Female; Fractu | 2005 |
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.
Topics: Absorptiometry, Photon; Aged; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Calcification, | 2005 |
Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Back Pain; Bone Densit | 2005 |
[Quality of life in the treatment assessment of postmenopausal osteoporosis].
Topics: Absorptiometry, Photon; Alendronate; Estrogen Replacement Therapy; Female; Follow-Up Studies; Humans | 2005 |
Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind Me | 2005 |
Monitoring alendronate and estradiol therapy with quantitative ultrasound and bone mineral density.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium Carbonate; Double-Blind M | 2005 |
Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial.
Topics: Aged; Aging; Alendronate; Body Weight; Bone and Bones; Bone Density; Densitometry; Diphosphonates; D | 2005 |
Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women.
Topics: Aged; Alendronate; Alkaline Phosphatase; Asian People; Bone Density; Collagen; Collagen Type I; Fema | 2005 |
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Calcium Carbonate; | 2005 |
Daily and cyclic parathyroid hormone in women receiving alendronate.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Drug Administration Schedule; Drug The | 2005 |
Cyclical alendronate treatment in postmenopausal women with osteoporosis.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density; Bone Density Conservation Agents; Calc | 2005 |
A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Collagen; | 2005 |
The effect of hormone replacement on physical performance in community-dwelling elderly women.
Topics: Accidental Falls; Activities of Daily Living; Aged; Alendronate; Bone Density Conservation Agents; B | 2005 |
The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Double-Blind Method; Drug Administration Schedule; Fe | 2006 |
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Cross-Over Studies; Diphosphonates; Drug Administration | 2005 |
Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Back Pain; Biomarkers; Bone Density; Bone Density Conservation | 2005 |
Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone and Bones; Bon | 2005 |
Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodel | 2006 |
Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone and Bones; Bone Densi | 2006 |
Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind M | 2006 |
Denosumab in postmenopausal women with low bone mineral density.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bo | 2006 |
Denosumab in postmenopausal women with low bone mineral density.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bo | 2006 |
Denosumab in postmenopausal women with low bone mineral density.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bo | 2006 |
Denosumab in postmenopausal women with low bone mineral density.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bo | 2006 |
Assessment of DNA damage in postmenopausal women under osteoporosis therapy.
Topics: Alendronate; Bone Density Conservation Agents; Comet Assay; DNA; DNA Damage; Drug Therapy, Combinati | 2006 |
Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alendronate; Amino Acids; Bone Density; Bone Resorption; Calcium; Drug Ther | 2006 |
Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Dens | 2007 |
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
Topics: Aged; Alendronate; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Femur | 2006 |
The effect of raloxifene on cardiac autonomic regulation in osteoporotic women.
Topics: Alendronate; Autonomic Nervous System; Bone Density Conservation Agents; Female; Heart; Heart Rate; | 2006 |
Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women.
Topics: Aged; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Collagen Type I; Dr | 2006 |
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; F | 2006 |
Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Female; Frac | 2006 |
[Should bisphosphonate treatment be used for super-old patients with osteoporosis?].
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; F | 2006 |
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
Topics: Aged; Alendronate; Bone and Bones; Cholecalciferol; Double-Blind Method; Drug Combinations; Female; | 2006 |
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
Topics: Aged; Alendronate; Bone and Bones; Cholecalciferol; Double-Blind Method; Drug Combinations; Female; | 2006 |
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
Topics: Aged; Alendronate; Bone and Bones; Cholecalciferol; Double-Blind Method; Drug Combinations; Female; | 2006 |
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
Topics: Aged; Alendronate; Bone and Bones; Cholecalciferol; Double-Blind Method; Drug Combinations; Female; | 2006 |
Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Calci | 2006 |
Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Female; Huma | 2007 |
[Effects of alendronate on bone mineral density, cytokines and indices of bone metabolism in postmenopausal osteoporotic patients].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Cytokines; Female; Humans; Insulin-Like | 2006 |
Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Topics: Aged; Alendronate; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Human | 2006 |
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Calcium; Double-Blind Method; Drug | 2007 |
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Calcium; Double-Blind Method; Drug | 2007 |
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Calcium; Double-Blind Method; Drug | 2007 |
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Calcium; Double-Blind Method; Drug | 2007 |
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; Female; | 2007 |
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; Female; | 2007 |
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; Female; | 2007 |
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; Female; | 2007 |
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Topics: Aged; Alendronate; Biomarkers; Biopsy; Bone Density; Bone Density Conservation Agents; Bone Remodeli | 2006 |
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Topics: Aged; Alendronate; Biomarkers; Biopsy; Bone Density; Bone Density Conservation Agents; Bone Remodeli | 2006 |
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Topics: Aged; Alendronate; Biomarkers; Biopsy; Bone Density; Bone Density Conservation Agents; Bone Remodeli | 2006 |
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Topics: Aged; Alendronate; Biomarkers; Biopsy; Bone Density; Bone Density Conservation Agents; Bone Remodeli | 2006 |
Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Female | 2007 |
Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Creatinine; Fe | 2007 |
Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women.
Topics: Aged; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fem | 2007 |
Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Collagen Type I; Etidronic Acid; Female; Humans | 2007 |
Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Fe | 2007 |
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
Topics: Administration, Oral; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation Age | 2007 |
Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitrio | 2007 |
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Etidronic Acid; Fe | 2007 |
Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Topics: Absorptiometry, Photon; Aged; Alendronate; Analysis of Variance; Bone Density; Bone Density Conserva | 2007 |
Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cros | 2007 |
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Densi | 2007 |
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Collagen; Collagen Type I; Diphos | 2008 |
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density; Bone Density C | 2008 |
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; | 2008 |
Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density Con | 2008 |
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcium; Drug Combinations; Female; Humans; Hyp | 2008 |
Prevention of bone loss after withdrawal of tamoxifen.
Topics: Absorptiometry, Photon; Administration, Oral; Alendronate; Alkaline Phosphatase; Bone Density; Bone | 2008 |
A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bo | 2008 |
Effects of bisphosphonates on lipid metabolism.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Lipid Metabolism; Lip | 2008 |
Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone and Bones; Collagen Type I; Female; Humans; I | 2008 |
Does a history of non-vertebral fracture identify women without osteoporosis for treatment?
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Chi-Square Dis | 2008 |
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Topics: Aged; Aged, 80 and over; Alendronate; Body Height; Bone Density; Calcium Carbonate; Diphosphonates; | 1995 |
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Topics: Aged; Aged, 80 and over; Alendronate; Body Height; Bone Density; Calcium Carbonate; Diphosphonates; | 1995 |
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Topics: Aged; Aged, 80 and over; Alendronate; Body Height; Bone Density; Calcium Carbonate; Diphosphonates; | 1995 |
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Topics: Aged; Aged, 80 and over; Alendronate; Body Height; Bone Density; Calcium Carbonate; Diphosphonates; | 1995 |
Studies of the oral bioavailability of alendronate.
Topics: Achlorhydria; Administration, Oral; Adult; Aged; Alendronate; Analysis of Variance; Beverages; Biolo | 1995 |
Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.
Topics: Adult; Aged; Alendronate; Analysis of Variance; Bone Density; Bone Remodeling; Calcium; Diphosphonat | 1995 |
Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Alendronate; Analysis of Variance; Bone Density; | 1994 |
Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Rem | 1994 |
Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.
Topics: Alendronate; Amino Acids; Biomarkers; Bone Density; Bone Resorption; Calcium; Diphosphonates; Enzyme | 1994 |
Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.
Topics: Administration, Intranasal; Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Bone Dens | 1993 |
Esophagitis and alendronate.
Topics: Alendronate; Diphosphonates; Esophageal Diseases; Esophagitis; Female; Humans; Osteoporosis, Postmen | 1996 |
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Double-Blind M | 1996 |
Comparison of bone densitometry of the phalanges, distal forearm and axial skeleton in early postmenopausal women participating in the EPIC Study.
Topics: Absorptiometry, Photon; Adult; Alendronate; Asian People; Bone and Bones; Bone Density; Cohort Studi | 1996 |
[Diphosphonates: and alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate].
Topics: Aged; Alendronate; Diphosphonates; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteop | 1996 |
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Resorption; Double- | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
Topics: Aged; Aged, 80 and over; Alendronate; Biopsy; Bone and Bones; Bone Density; Dose-Response Relationsh | 1997 |
Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density; Calcium; Female; Half-Life; Humans; Hydroxypr | 1997 |
Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Remodeling; Female; Humans; Lumbar Vertebrae; Middle Ag | 1997 |
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
Topics: Alendronate; Bone Density; Double-Blind Method; Drug Combinations; Estrogen Replacement Therapy; Est | 1998 |
Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group.
Topics: Adult; Alendronate; Anthropometry; Bone Density; Bone Resorption; Double-Blind Method; Drug Administ | 1998 |
Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
Topics: Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Bone Remodeling; Collagen; Collagen Type I; Dr | 1998 |
Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment.
Topics: Aged; Alendronate; Biomarkers; Bone and Bones; Bone Resorption; Circadian Rhythm; Collagen; Collagen | 1998 |
Tooth counts do not predict bone mineral density in early postmenopausal Caucasian women. EPIC study group.
Topics: Alendronate; Bone Density; Cohort Studies; Double-Blind Method; Female; Humans; Middle Aged; Osteopo | 1998 |
A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group.
Topics: Adult; Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density; Bone Diseases, Metabolic; | 1998 |
Effect of antiresorptive therapy on day-to-day variation of urinary free deoxypyridinoline excretion.
Topics: Aged; Alendronate; Amino Acids; Biomarkers; Bone Resorption; Enzyme-Linked Immunosorbent Assay; Fema | 1998 |
Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Amino Acids; Bon | 1999 |
Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Alendronate; Area Under Curve; Biomarkers; Bone | 1999 |
Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Analysis of Variance; Bone Density; Diph | 1998 |
Monitoring alendronate therapy for osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Remodeling; Bon | 1999 |
An open-label extension study of alendronate treatment in elderly women with osteoporosis.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density; Do | 1999 |
Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Fractures, Spontaneous; Huma | 1999 |
A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Double-Blind Method; Female; Huma | 1999 |
Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone and Bones; Bone Density; Drug Monit | 1999 |
Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study.
Topics: Alendronate; Biomarkers; Bone Density; Cohort Studies; Collagen; Collagen Type I; Dose-Response Rela | 1999 |
Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group.
Topics: Alendronate; Body Mass Index; Bone Density; Collagen; Collagen Type I; Female; Humans; Middle Aged; | 1999 |
Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.
Topics: Adult; Aged; Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; Fem | 1999 |
Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Bone Density; Bone Remodeling; Calcium; Female; Hu | 1999 |
Bone densitometry: a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Analysis of Variance; Bone Resorption; Diphosphona | 1999 |
Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women.
Topics: Alendronate; Alkaline Phosphatase; Asia; Biomarkers; Bone Density; Bone Resorption; Collagen; Collag | 1999 |
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Analysis of Variance; Biomarkers; | 1999 |
Calcitriol and alendronate combination treatment in menopausal women with low bone mass.
Topics: Aged; Alendronate; Calcitriol; Calcium; Calcium Channel Agonists; Calcium, Dietary; Drug Therapy, Co | 1999 |
Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Resorption; Female; Humans; Incidence; Lumb | 1999 |
Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.
Topics: Alendronate; Bone Density; Data Interpretation, Statistical; Double-Blind Method; Drug Therapy, Comb | 1999 |
Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Activities of Daily Living; Aged; Alendronate; Back Pain; Bed Rest; Bone Density; Double-Blind Metho | 2000 |
[The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungary of an international multicenter clinical study)].
Topics: Aged; Alendronate; Female; Humans; Hungary; Middle Aged; Osteoporosis, Postmenopausal; Placebos | 1999 |
Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Double-Blind Method; Female; Femur Neck; Hu | 1999 |
Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Digestive System; Double-Blind Method; Duodenal | 2000 |
Upper gastrointestinal toxicity of alendronate.
Topics: Adult; Aged; Alendronate; Double-Blind Method; Dyspepsia; Female; Gastric Mucosa; Gastritis; Gastros | 2000 |
Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Female; Humans; Multicenter Studies as Topic; Ost | 2000 |
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Dose-Response Relat | 2000 |
The effect of alendronate on bone mass after distal forearm fracture.
Topics: Absorptiometry, Photon; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Reso | 2000 |
Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; | 2000 |
Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.
Topics: Absorptiometry, Photon; Adult; Alendronate; Bone Density; Collagen; Collagen Type I; Double-Blind Me | 2000 |
Effects of alendronate on bone density in men with primary and secondary osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Antimetabolites; Bone Density; | 2000 |
Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
Topics: Absorptiometry, Photon; Administration, Intranasal; Alendronate; Alkaline Phosphatase; Biomarkers; B | 2000 |
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Collagen; Collagen Type I; Dose-R | 2000 |
Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Female; Humans; Middle Aged; Osteoporosis, Po | 2000 |
Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Analgesics, N | 2000 |
Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.
Topics: Adult; Alendronate; Duodenoscopy; Duodenum; Endoscopy; Esophagoscopy; Esophagus; Etidronic Acid; Fem | 2000 |
Inclusion of older women in randomized clinical trials: factors associated with taking study medication in the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Comorbidity; Depression; Female; Follow-Up Studies; Fractures, | 2000 |
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone and Bones; Bone Density; Double-Blind Method; Female | 2000 |
The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study.
Topics: Absorptiometry, Photon; Aged; Alendronate; Alkaline Phosphatase; Asian People; Bone Density; China; | 2000 |
Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study.
Topics: Alendronate; Alkaline Phosphatase; Bone Density; Estradiol; Female; Hormone Replacement Therapy; Hum | 2000 |
Effects of estrogen and alendronate on sister chromatid exchange (SCE) frequencies in postmenopausal osteoporosis patients.
Topics: Adult; Alendronate; Estrogen Replacement Therapy; Female; Gene Frequency; Humans; Middle Aged; Mutag | 2000 |
Alendronate prevents bone loss in Chinese women with osteoporosis.
Topics: Aged; Alendronate; Bone Density; Calcium Carbonate; China; Female; Humans; Middle Aged; Osteoporosis | 2000 |
Effects of alendronate on osteopenic postmenopausal Chinese women.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Double-Blind Method; Female; Humans; Middle Aged; Osteo | 2000 |
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Female; Humans; Middle Aged; Osteoporosis, Postme | 2000 |
Response to alendronate in osteoporosis after previous treatment with etidronate.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Cohort Studies; Etidronic Acid; Female; Hum | 2000 |
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.
Topics: Aged; Alendronate; Cohort Studies; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Os | 2000 |
A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodelin | 2000 |
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; | 2001 |
What is the impact of osteoporosis education and bone mineral density testing for postmenopausal women in a managed care setting?
Topics: Aged; Alendronate; Bone Density; Calcium, Dietary; Estrogen Replacement Therapy; Female; Humans; Man | 2001 |
Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Calc | 2001 |
[Effect of alendronate therapy on bone turnover--results of a multicenter study].
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Remodeling; Bone Resorption; Calcium; Collagen; Collagen | 2000 |
Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease.
Topics: Adult; Aged; Alendronate; Amino Acids; Area Under Curve; Biomarkers; Bone Diseases, Metabolic; Cross | 2001 |
Response of cortical bone to antiresorptive treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone and Bones; Bone Density; Etidronic Acid; Female; Hor | 2001 |
Estimating probability of non-response to treatment using mixture distributions.
Topics: Aged; Alendronate; Bone Density; Computer Simulation; Female; Hip Fractures; Humans; Likelihood Func | 2001 |
Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density | 2001 |
The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Chi-Square Distribution; Confidence Intervals; Cost Savings; D | 2001 |
Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis.
Topics: Alendronate; Analysis of Variance; Bone Density; Calcitonin; Calcium; Female; Follow-Up Studies; Hum | 2001 |
Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.
Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Densitometry; Drug Therapy, Combination; Etid | 2001 |
Tolerability of risedronate in postmenopausal women intolerant of alendronate.
Topics: Alendronate; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Gastrointestinal | 2001 |
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Collagen; Collagen Type I; Double-Blin | 2002 |
Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis.
Topics: Alendronate; Biomarkers; Bone and Bones; Bone Density; Dose-Response Relationship, Drug; Double-Blin | 2002 |
Effect of two forms of alendronate administration upon bone mass after two years of treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Remodeling; Female; Humans; Middle Age | 2002 |
Use of phalangeal bone mineral density and multi-site speed of sound conduction to monitor therapy with alendronate in postmenopausal women.
Topics: Administration, Oral; Alendronate; Bone and Bones; Bone Density; Drug Administration Schedule; Femal | 2002 |
Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium; Dietary Supplements; Double-Blind Metho | 2002 |
Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women.
Topics: Aged; Alendronate; Biomarkers; Black or African American; Black People; Bone and Bones; Bone Density | 2002 |
Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Calcaneus; Calcium, Dietary; Drug Monitoring; Fem | 2002 |
Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis.
Topics: Aged; Alendronate; Diphosphonates; Drug Administration Schedule; Female; Humans; Middle Aged; Osteop | 1991 |
504 other studies available for alendronate and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Topics: Alendronate; Bone Density Conservation Agents; Data Analysis; Diphosphonates; Etidronic Acid; Female | 2022 |
Analysis of the Efficacy and Safety of Teriparatide and Alendronate in the Treatment of Osteoporosis After Renal Transplantation.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Kidney Transplantation; | 2021 |
Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy : A Propensity Score-Matched Cohort Study.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Canada; Cohort Studies; Female; Hu | 2022 |
Anti-osteoporosis Effect of Fisetin against Ovariectomy Induced Osteoporosis in Rats: In silico, in vitro and in vivo Activity.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Antioxidants; Bone Density; Cell Line; Cell Prolifer | 2022 |
Romosozumab and antiresorptive treatment: the importance of treatment sequence.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Denosumab; Fema | 2022 |
Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine.
Topics: Alendronate; Bone Density Conservation Agents; Cross-Sectional Studies; Female; Humans; Osteoporosis | 2022 |
Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density Conservation Agents; Cost-Benefit Analysis; Female | 2022 |
The potential anti-osteoporotic effect of exercise-induced increased preptin level in ovariectomized rats.
Topics: Alendronate; Animals; Biomarkers; Body Weight; Bone Density; Estradiol; Female; Humans; Osteopontin; | 2023 |
Denosumab and Risk of Community-acquired Pneumonia: A Population-based Cohort Study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Female; Humans; Male | 2022 |
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Iban | 2022 |
Denosumab treatment is associated with decreased cortical porosity and increased bone density and strength at the proximal humerus of ovariectomized cynomolgus monkeys.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Denosumab; Epiphyses; Female; | 2022 |
Changes in osteoporosis therapy in postmenopausal women from the RAC‑OST‑POL study: a 10‑year follow‑up.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Female; Follow-Up Studie | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Di | 2023 |
Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Female; Huma | 2023 |
Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fractures, Compression; Humans; | 2023 |
Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bo | 2023 |
Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Female; Humans; Male; Middle A | 2023 |
Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Fractures, B | 2023 |
Drug utilization analysis of osteoporosis medications in seven European electronic health databases.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Dru | 2023 |
Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Cost-Effectiveness Analy | 2023 |
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Fema | 2023 |
Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Etidronic Acid | 2023 |
Clinicians' views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Oste | 2023 |
A Case Report of Oral Bisphosphonate Treatment for Osteoporosis Leading to Atypical Femoral Fracture and Pathologic Mandibular Fracture.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Fractures, | 2023 |
Unexpected rapid increase in bone mineral density by bisphosphonate therapy after multiple spinal fractures: a case report.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Colla | 2019 |
Simple methods for the estimation and sensitivity analysis of principal strata effects using marginal structural models: Application to a bone fracture prevention trial.
Topics: Aged; Alendronate; Biometry; Clinical Trials as Topic; Drug Interactions; Female; Fractures, Bone; H | 2019 |
Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Asian People; Bone Density; Calcium; Col | 2020 |
Response to: Effects of Alendronic Acid on Fracture Healing.
Topics: Alendronate; Female; Fracture Healing; Humans; Osteoporosis, Postmenopausal | 2020 |
Effects of alendronate and calcifediol compared to alendronate and cholecalciferol in osteoporotic patients.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Calcifediol | 2019 |
Cost-effectiveness of five versus ten years of alendronate treatment prior to drug holiday for women with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Femal | 2020 |
Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denos | 2020 |
Immunohistochemical Femoral Nerve Study Following Bisphosphonates Administration.
Topics: Administration, Oral; Alendronate; Animals; Antigens, Nuclear; Bone Density Conservation Agents; Cas | 2020 |
Practical guidance for the use of bisphosphonates in osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; M | 2020 |
Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Cardiovascular | 2020 |
Alendronate or Zoledronic acid do not impair wound healing after tooth extraction in postmenopausal women with osteoporosis.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2020 |
History of alendronate.
Topics: Aged; Alendronate; Bone Density; Bone Remodeling; Female; Humans; Medicare; Osteoporosis, Postmenopa | 2020 |
T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Female; Fractur | 2020 |
Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend.
Topics: Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind Method; | 2020 |
Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteoporosis, Postmen | 2020 |
Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Bone Density Conservation Agents; Cost | 2021 |
Fracture rates in patients discontinuing alendronate treatment in real life: a population-based cohort study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Cohort Studies; Female; Humans; Osteopo | 2021 |
A novel effervescent formulation of oral weekly alendronate (70 mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2021 |
Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Female; Humans; | 2020 |
The predictive value of bone turnover markers during discontinuation of alendronate: the PROSA study.
Topics: Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Cohort Stu | 2021 |
The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: A protocol for systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphos | 2021 |
Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Cost-Bene | 2021 |
Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Femal | 2021 |
Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis.
Topics: Aged; Alendronate; Bone Density; Drug Administration Schedule; Female; Humans; Middle Aged; Osteopor | 2021 |
Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Female; Humans; Male | 2022 |
Bone matrix quality in paired iliac bone biopsies from postmenopausal women treated for 12 months with strontium ranelate or alendronate.
Topics: Alendronate; Biopsy; Bone Density; Bone Density Conservation Agents; Bone Matrix; Female; Humans; Il | 2021 |
Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Female; Human | 2021 |
BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD.
Topics: Administration, Intravenous; Administration, Oral; Aged; Alendronate; Amino Acids; Bone Density Cons | 2017 |
Intermittent Parathyroid Hormone After Prolonged Alendronate Treatment Induces Substantial New Bone Formation and Increases Bone Tissue Heterogeneity in Ovariectomized Rats.
Topics: Alendronate; Animals; Female; Humans; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; Parat | 2017 |
One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Databases, Factual; Denosuma | 2017 |
Potassium citrate prevents increased osteoclastogenesis resulting from acidic conditions: Implication for the treatment of postmenopausal bone loss.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone Density Conservation Agents; Cell Proliferation; Cu | 2017 |
Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Con | 2017 |
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Etidronic | 2017 |
Alendronate and Hip Fracture in Patients Using Glucocorticoids.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Glucocorticoids; Hip Fractures; Humans; | 2017 |
Alendronate and Hip Fracture in Patients Using Glucocorticoids-Reply.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Glucocorticoids; Hip Fractures; Humans; | 2017 |
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Female; Fractur | 2018 |
In postmenopausal women with osteoporosis, romosozumab followed by alendronate reduced fractures vs alendronate alone.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density Conservation Agents; Drug Therapy, Combinati | 2018 |
An elderly woman with progressive odynophagia, epigastralgia and nausea.
Topics: Abdominal Pain; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Endoscopy, Digesti | 2018 |
Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substit | 2018 |
Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model.
Topics: Alendronate; Animals; Biomarkers; Bone Density; Bone Remodeling; Collagen Type I; Diabetes Mellitus, | 2018 |
How Would You Manage This Patient With Osteoporosis?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Clinical | 2018 |
VISUAL VIGNETTE.
Topics: Alendronate; Bone Density Conservation Agents; Calcium Carbonate; Female; Femoral Fractures; Humans; | 2018 |
Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit A | 2018 |
Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Drug | 2019 |
Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Becaplermin; Bone Density; Bone Density Conservation Agents | 2018 |
Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysi | 2019 |
Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Drug Administration Schedule; Drug S | 2019 |
Effects of Intermittent Parathyroid Hormone 1-34 Administration on Circulating Mesenchymal Stem Cells in Postmenopausal Osteoporotic Women.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Resorption; China; Female; H | 2019 |
Multiple severe vertebral fractures during the 3-month period following a missed dose of denosumab in a postmenopausal woman with osteoporosis previously treated with alendronate
.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Humans; Middle Aged; | 2019 |
Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-B | 2019 |
Raman spectroscopy as a predictive tool for monitoring osteoporosis therapy in a rat model of postmenopausal osteoporosis.
Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Disease Models, A | 2019 |
Patients' reasons for adhering to long-term alendronate therapy.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Drug Administration Schedu | 2019 |
The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Female; Fractures, Bone; Human | 2013 |
Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Huma | 2013 |
Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcitriol; Drug Therapy, Combination; | 2013 |
Fractures in women treated with raloxifene or alendronate: a retrospective database analysis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Cohort Studies; | 2013 |
Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; E | 2013 |
Serum sclerostin levels following treatment with parathyroid hormone.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Female; Hu | 2013 |
Pseudoarthrosis in atypical femoral fracture: case report.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Fracture Fixation, I | 2013 |
Bilateral low-energy sequential femoral shaft fractures in patients on long-term bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Early Diagn | 2013 |
Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases.
Topics: Administration, Oral; Adrenal Cortex Hormones; Age Factors; Aged; Aged, 80 and over; Alendronate; Bi | 2013 |
Pure and hybrid causal effects on variables associated with an incident event.
Topics: Alendronate; Bone Density Conservation Agents; Causality; Computer Simulation; Fracture Healing; Fra | 2013 |
Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation A | 2013 |
Submandibular cutaneous fistula.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Con | 2013 |
Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation | 2014 |
[Public spending on drugs for the treatment of osteoporosis in post-menopause].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Ag | 2013 |
Menopause practitioner perspective on the American Society of Bone and Mineral Research Task Force report on atypical femoral fracture.
Topics: Advisory Committees; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; | 2013 |
Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Case-Control Stu | 2013 |
Atypical femoral fractures bilaterally in a patient receiving denosumab.
Topics: Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; D | 2014 |
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone | 2014 |
Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.
Topics: Alendronate; Asian People; Bone Density Conservation Agents; Female; Geranyltranstransferase; Humans | 2014 |
Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Femoral | 2014 |
Investigation of responsiveness indices of generic and specific measures of health related quality of life in patients with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcium; Dietary Supplements | 2014 |
Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Coh | 2014 |
Chemical injury caused by acute alendronic acid aspiration.
Topics: Aged; Alendronate; Bronchoscopy; Female; Foreign Bodies; Humans; Osteoporosis, Postmenopausal; Respi | 2014 |
Stress fracture of the ulna associated with bisphosphonate therapy and use of walking aid.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Fractures, Stress; Humans; Magnetic Res | 2014 |
Atypical ulnar fracture associated with long-term bisphosphonate use.
Topics: Accidental Falls; Aged, 80 and over; Alendronate; Bone Nails; Bone Plates; Dose-Response Relationshi | 2015 |
Ask the doctor. I've had osteoporosis for several years, and I've been taking alendronate (Fosamax) once a week. I wasn't very good at remembering to take it regularly, so my doctor recently recommended that I start on once-a-year infusions of zoledronic
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Sch | 2014 |
A prospective analytical study of the effects and adverse events of alendronate (Aldren70) treatment in Thai postmenopausal women.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabo | 2014 |
Alterations in collagen and mineral nanostructure observed in osteoporosis and pharmaceutical treatments using simultaneous small- and wide-angle X-ray scattering.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Collagen; Disease Models, An | 2014 |
Alendronate-induced unmasking or deterioration of coeliac disease: a case series.
Topics: Alendronate; Bone Density Conservation Agents; Celiac Disease; Disease Progression; Female; Humans; | 2015 |
An unusual adverse event from a common medication in an individual with dementia.
Topics: Administration, Oral; Aged, 80 and over; Alendronate; Alzheimer Disease; Deglutition Disorders; Fema | 2014 |
Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density | 2015 |
Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Female; Fract | 2015 |
Dental implants treatment outcomes in patient under active therapy with alendronate: 3-year follow-up results of a multicenter prospective observational study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Dental Prosthesis, Implant-Supported; Female; F | 2016 |
Results of a national multicentric study on compliance to treatment with various disphosphonate formulations in patients with postmenopausal osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid | 2015 |
In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Disease Model | 2016 |
OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.
Topics: Alendronate; Bone Density; Bone Diseases, Metabolic; China; Female; Femur Neck; Humans; Lumbar Verte | 2016 |
Bisphosphonate-Related Osteonecrosis of the Jaw After Tooth Extraction.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bispho | 2015 |
Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Biomarke | 2016 |
Effect of a Short-Term Treatment with Once-A-Week Medication of Alendronate 70 Mg on Bone Turnover Markers in Postmenopausal Women with Osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Collag | 2015 |
Bilateral distal fibula fractures in a woman on long-term bisphosphonate therapy.
Topics: Alendronate; Ankle Injuries; Bone Density Conservation Agents; Diphosphonates; Female; Fibula; Fract | 2016 |
Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Topics: Aged; Alendronate; Body Weight; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fema | 2016 |
An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cohort Stud | 2017 |
The analysis of DKK1 polymorphisms in relation to skeletal phenotypes and bone response to alendronate treatment in Chinese postmenopausal women.
Topics: Alanine Transaminase; Alendronate; Alkaline Phosphatase; Asian People; Biomarkers; Bone Density; Bon | 2016 |
Metabolite Profiling Reveals the Effect of Dietary Rubus coreanus Vinegar on Ovariectomy-Induced Osteoporosis in a Rat Model.
Topics: Acetic Acid; Alendronate; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; | 2016 |
Management after first-line antiresorptive treatment for postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Dose-Respons | 2016 |
Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analys | 2016 |
Alendronate- and risedronate-induced acute polyarthritis.
Topics: Alendronate; Arthritis; Bone Density Conservation Agents; Female; Humans; Middle Aged; Osteoporosis, | 2016 |
A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
Topics: Absorptiometry, Photon; Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agen | 2017 |
Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Con | 2017 |
Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-B | 2017 |
Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Diphosphonates; Drug Adm | 2017 |
Effects of alendronate on lumbar intervertebral disc degeneration with bone loss in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Cartilage; Collagen Type II; Female; Humans; | 2017 |
The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Calci | 2008 |
Osteodensitometry in healthy postmenopausal women.
Topics: Absorptiometry, Photon; Age Factors; Aged; Alendronate; Bone Density; Calcium; Clinical Trials as To | 2008 |
Vitamin D status and response to treatment in post-menopausal osteoporosis.
Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation A | 2009 |
Calcium, vitamin D supplements with or without alendronate and supragingival calculus formation in osteoporotic women: a preliminary study.
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Cross-Sectional Studies; Dental Calculus; De | 2008 |
Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy--a case report.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fracture Healing; Hip Fra | 2008 |
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Budgets; Cost-Benefit Analys | 2008 |
Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method.
Topics: Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; | 2009 |
Low incidence of anti-osteoporosis treatment after hip fracture.
Topics: Aged; Alendronate; Belgium; Bone Density Conservation Agents; Cohort Studies; Databases, Factual; Di | 2008 |
DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Diphosphonates; Etidronic Acid; Female; Femur; Fr | 2009 |
Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Collagen Type I; Diph | 2008 |
Prolyl-hydroxyproline dipeptide in non-hydrolyzed morning urine and its value in postmenopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone and Bones; Bone Resorption; Dipeptides | 2008 |
Quantitative ultrasound at the phalanges in monitoring alendronate therapy.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calibration; Case-Control Studies | 2009 |
[Treatment of osteoporosis in the elderly: what is the evidence?].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Ag | 2008 |
Differences in persistence among different weekly oral bisphosphonate medications.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2009 |
What's the story with Fosamax? Recent reports have women wondering if they should stop taking this widely prescribed osteoporosis drug.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Osteogenesis; | 2008 |
Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female | 2009 |
Is your knowledge up-to-date? Bisphosphonate-related osteonecrosis of the jaw.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denture, Complete, Upper; Diphosphonates; Femal | 2008 |
[Osteoporotic fracture in menopausal women: alendronate reduces the risk].
Topics: Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Hip Fractures; Humans; Middl | 2008 |
Case reports: two femoral insufficiency fractures after long-term alendronate therapy.
Topics: Aged; Alendronate; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Bone Nails; Bon | 2009 |
Evidence-based dentistry and the concept of harm.
Topics: Alendronate; Bone Density Conservation Agents; Chronic Periodontitis; Clinical Competence; Databases | 2009 |
Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone and Bones; Bone Density; Bone Den | 2008 |
Alendronate-induced asthma.
Topics: Alendronate; Asthma; Bone Density Conservation Agents; Drug Hypersensitivity; Female; Humans; Middle | 2009 |
The prognosis for dental implants placed in patients taking oral bisphosphonates.
Topics: Administration, Oral; Adult; Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studi | 2009 |
Oral bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Female; Humans; Jaw Diseases; Osteonecrosis; Osteopor | 2009 |
Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; | 2009 |
Oral bisphosphonate-related osteonecrosis of the jaws: favorable outcome after bisphosphonate holiday.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Collagen Type I; Drug Adm | 2009 |
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates | 2009 |
Why are physicians reluctant to use estrogens for anything--or do they prefer 'PROFOX'?
Topics: Alendronate; Attitude of Health Personnel; Bone Density Conservation Agents; Depression; England; Es | 2009 |
[Postmenopausal osteoporosis. Bisphosphonates are not all equal].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drugs, Gene | 2009 |
[Patient compliance program aids therapy success].
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Cholecalciferol; Clinical Trials as Topic; D | 2009 |
[Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
Topics: Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Clinical Trials as Topic; Diphos | 2009 |
Bisphosphonates and atrial fibrillation.
Topics: Aged; Alendronate; Atrial Fibrillation; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Ost | 2008 |
Do not use bisphosphonate therapy indefinitely for fracture prevention.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Diphosphonates; Female; Fractures, Bone; Fractur | 2008 |
By the way, doctor. I'm 69 and have taking Fosamax for 10 years. My doctor has approved a "drug holiday," provided we use a CTX test to monitor my bones. Can you explain?
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; | 2009 |
Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density; Bone Resorption; Collagen Type I; Cross-Secti | 2009 |
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Meth | 2010 |
Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Collagen Type I; Female; Humans; | 2009 |
Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Epidemiologic Methods; Femal | 2010 |
Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Case-Control | 2009 |
Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Cell Aggreg | 2010 |
Factors affecting discontinuation of alendronate treatment in postmenopausal Japanese women with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation | 2009 |
[Osteoprotegerin gene polymorphism and therapeutic response to alendronate in postmenopausal women with osteoporosis].
Topics: Aged; Alendronate; Alleles; Bone Density; Female; Genotype; Humans; Middle Aged; Osteoporosis, Postm | 2009 |
FPIN's clinical inquiries. Combination therapy for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Synergism; Drug Therapy, Combina | 2010 |
Comparison of the effects of alendronate sodium and calcitonin on bone-prosthesis osseointegration in osteoporotic rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Calcitonin; Disease Models, An | 2011 |
Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins.
Topics: Alendronate; Bone Density Conservation Agents; Computer Simulation; Humans; Models, Statistical; Mon | 2010 |
Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
Topics: Aged; Alendronate; Atrial Fibrillation; Atrial Flutter; Bone Density Conservation Agents; Cohort Stu | 2010 |
Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents | 2010 |
A rational approach to management of alendronate-related subtrochanteric fractures.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density; Bone Density Conservation A | 2010 |
[New proposal concerning alendronate reimbursement].
Topics: Alendronate; Bone Density Conservation Agents; Female; Humans; Norway; Osteoporosis, Postmenopausal; | 2010 |
Bilateral atypical femoral fractures after long-term alendronate therapy: a case report.
Topics: Aged; Alendronate; Asian People; Bone Density Conservation Agents; Female; Femoral Fractures; Humans | 2010 |
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bon | 2011 |
Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Cells, Cult | 2011 |
Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Asian People; Diphosphonates; Etidronic Acid; Female; Hip; Humans; Japan; Osteopo | 2011 |
Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy - 3 more cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Femoral Fractures; Frac | 2011 |
Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate.
Topics: Aged, 80 and over; Alendronate; Bone Marrow Cells; Case-Control Studies; Cell Differentiation; Dipho | 2011 |
Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone | 2011 |
Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Female; Femoral Fractures; Fra | 2011 |
Adherence to osteoporosis medications amongst Singaporean patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosph | 2012 |
Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Cholecalciferol; Cohort Studies; Dietar | 2011 |
RETRACTED: Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes.
Topics: Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density Conservation Agents; Case-Control S | 2011 |
Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan.
Topics: Aged; Alendronate; Analysis of Variance; Asian People; Bone Density Conservation Agents; Cohort Stud | 2011 |
Incurred sample accuracy assessment: design of experiments based on standard addition.
Topics: Alendronate; Artifacts; Calibration; Chromatography, Liquid; Female; Guidelines as Topic; Humans; Ma | 2011 |
Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2011 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2012 |
The effect of long-term alendronate treatment on cortical thickness of the proximal femur.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Densitometr | 2012 |
The effects of discontinuing long term alendronate therapy in a clinical practice setting.
Topics: Aged; Alendronate; Analysis of Variance; Biomarkers; Bone Density; Bone Density Conservation Agents; | 2011 |
Alendronate induced femur fracture complicated with secondary hyperparathyroidism.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Humans; Hyperparathy | 2011 |
Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate.
Topics: Aged; Alendronate; Biomechanical Phenomena; Biopsy; Bone and Bones; Bone Density Conservation Agents | 2011 |
Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Topics: Aged; Alendronate; Analysis of Variance; Bone and Bones; Bone Density; Bone Density Conservation Age | 2011 |
Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Databases, Factual; Diphosph | 2012 |
Reduction of urinary levels of N-telopeptide correlates with treatment compliance in women with postmenopausal osteoporosis receiving alendronate.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Collage | 2012 |
Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels.
Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Biomarkers; Bone and Bones; Bone Densit | 2012 |
Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate.
Topics: Adiponectin; Aged; Alendronate; Body Mass Index; Bone Density; Bone Density Conservation Agents; Fem | 2012 |
Letter to the editor: the effect of long-term alendronate treatment on cortical thickness of the proximal femur.
Topics: Alendronate; Bone Density Conservation Agents; Female; Femur; Humans; Osteoporosis, Postmenopausal | 2011 |
Femoral strength in osteoporotic women treated with teriparatide or alendronate.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Fe | 2012 |
Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without renal dysfunction: a retrospective study.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Fe | 2012 |
Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX™ thresholds for decision.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Female; Hip Fractures; H | 2013 |
Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Colore | 2012 |
Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study.
Topics: Administration, Oral; Aged; Alendronate; Case-Control Studies; Female; Follow-Up Studies; Humans; In | 2012 |
Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Asian Peopl | 2012 |
Downregulation of the inflammatory response by CORM-3 results in protective effects in a model of postmenopausal arthritis.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Arthritis; Biomarkers; Disease Models, Animal; Down- | 2012 |
Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK₂) in postmenopausal RA patients.
Topics: Aged; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Drug Thera | 2013 |
A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture.
Topics: Aged, 80 and over; Alendronate; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Dr | 2012 |
Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic | 2013 |
The effect of mandatory generic substitution on the safety of alendronate and patients' adherence.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Data Collection; Drug Substi | 2012 |
Influence of social competence of physicians on patient compliance with osteoporosis medications--a study on Polish postmenopausal women.
Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density Conservation Agents; Drug Adm | 2012 |
Bilateral ulna fractures associated with bisphosphonate therapy.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Fractures, Stress; Humans; | 2013 |
Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.
Topics: Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Fractures, Stress; Humans; | 2012 |
Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Diseases, Metabolic; Cost-Benefit An | 2013 |
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation A | 2012 |
Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Denmark; Drug Prescriptio | 2013 |
Simultaneous bilateral atypical femoral fractures after alendronate therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Humans; Osteoporosis | 2012 |
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Antibodies, Monoclonal, Humanized; Bone Density Co | 2013 |
Zoledronic acid enhances bone-implant osseointegration more than alendronate and strontium ranelate in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Evaluatio | 2013 |
When the patient knows best.
Topics: Alendronate; Esophagitis; Female; Fractures, Bone; Hospitalization; Humans; Leg Injuries; Middle Age | 2001 |
No major effect of estrogen receptor beta gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis.
Topics: Adult; Alendronate; Amino Acids; Base Sequence; Bone Density; Deoxyribonucleases, Type II Site-Speci | 2002 |
[Long-term insurance for the bones. Effective and safe over 7 years].
Topics: Alendronate; Bone Density; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Follo | 2002 |
Nonhealing gastric ulcer caused by chronic alendronate administration.
Topics: Abdominal Pain; Aged; Alendronate; Anti-Ulcer Agents; Bone Resorption; Drug Administration Schedule; | 2002 |
The values of urinary NTx in postmenopausal women undergoing HRT; the role of additional alendronate therapy.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Alendronate; Bone Density; Collagen; Collage | 2002 |
[Osteoporosis therapy. A comparison of bisphosphonates].
Topics: Aged; Alendronate; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Random | 2002 |
Osteoporotic fractures in older women.
Topics: Age Factors; Aged; Alendronate; Calcium, Dietary; Combined Modality Therapy; Female; Humans; Osteopo | 2002 |
Bisphosphonates and the upper gastrointestinal tract: skeletal gain without visceral pain?
Topics: Alendronate; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Osteoporosis, Postmenopausal | 2002 |
[Patients evaluate osteoporosis therapy. Once a week is preferred].
Topics: Alendronate; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fem | 2002 |
Summaries for patients. Bone loss after stopping estrogen or alendronate therapy.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Repla | 2002 |
Seizures after alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Drug Administration Schedule; Female; Humans; Hypocalcemia; Os | 2002 |
Drug-induced prevention of gastrectomy- and ovariectomy-induced osteopaenia in the young female rat.
Topics: Alendronate; Analysis of Variance; Animals; Biomarkers; Bone Density; Bone Diseases, Metabolic; Estr | 2002 |
Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Diphosphonates; Female; Fractures, Spontaneou | 2002 |
Insufficiency fracture of the femoral neck during osteoporosis treatment: a case report.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Resorption; Dose-Response Relationship, | 2002 |
Changes in bone remodeling rate influence the degree of mineralization of bone.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Calcification, Physiolog | 2002 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, | 2002 |
Medications for postmenopausal osteoporosis prevention.
Topics: Alendronate; Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated | 2002 |
[Convenient, effective and well accepted. The weekly pill against osteoporosis].
Topics: Alendronate; Cross-Over Studies; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Post | 2002 |
The effects of alendronate in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Drug Monitoring; Female; Humans; Osteoporosis, Postmenopausal; Research D | 2003 |
Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.
Topics: Age Factors; Aged; Alendronate; Cohort Studies; Cost-Benefit Analysis; Female; Fractures, Bone; Huma | 2003 |
Efficacy of teriparatide and alendronate on nonvertebral fractures.
Topics: Aged; Alendronate; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Terip | 2003 |
Aggressive systemic mastocytosis.
Topics: Aged; Alendronate; Bone Marrow Cells; Fatal Outcome; Female; Humans; Interferon-alpha; Leukemia, Mye | 2003 |
Drug eruption due to alendronate sodium hydrate.
Topics: Aged; Alendronate; Drug Eruptions; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; | 2003 |
Analytical and clinical evaluation of the Bio-Rad HPLC kit for measurement of type I collagen cross links.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Amino Acids; Bone Density; Bone Resorption; Chromatogra | 2003 |
Pharmacovigilance study of alendronate in England.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Angioedema; Cohort Studies; Erythema Multiforme; Family | 2003 |
[Fragility fracture and its control].
Topics: Accidental Falls; Aged; Alendronate; Female; Fractures, Spontaneous; Hip Fractures; Humans; Male; Os | 2003 |
[When do men's bones become brittle. A cause can be found only in every second patient].
Topics: Alendronate; Clinical Trials as Topic; Humans; Hydroxycholecalciferols; Male; Osteoporosis; Osteopor | 2003 |
[Alendronate once a week].
Topics: Alendronate; Bone Density; Female; Fractures, Spontaneous; Gastrointestinal Diseases; Humans; Male; | 2003 |
Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis.
Topics: Alendronate; Area Under Curve; Biomarkers; Bone Density; Cohort Studies; Female; Hip Joint; Humans; | 2003 |
Compliance with pharmacologic therapy for osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitonin; Estrogens; Etidronic | 2003 |
Monitoring response to osteoporosis therapy with alendronate by a multisite ultrasound device: a prospective study.
Topics: Aged; Alendronate; Bone Density; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prospect | 2003 |
Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database.
Topics: Aged; Alendronate; Analysis of Variance; Canada; Diphosphonates; Drug Therapy, Combination; Etidroni | 2003 |
[Osteoporosis therapy compared. More solid bones with bisphosphonates].
Topics: Alendronate; Bone Density; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans | 2003 |
[Evidence-based assessment of therapeutic agents of osteoporosis. Bisphosphonates, SERM and basic therapy in front].
Topics: Age Factors; Aged; Alendronate; Calcium; Cholecalciferol; Diphosphonates; Drug Therapy, Combination; | 2003 |
[Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial].
Topics: Aged; Alendronate; Cost of Illness; Cost-Benefit Analysis; Denmark; Drug Costs; Female; Fractures, S | 2003 |
[Osteoporosis medications. Bisphosphonates exceed the others].
Topics: Alendronate; Bone Density; Controlled Clinical Trials as Topic; Diphosphonates; Humans; Meta-Analysi | 2003 |
Disintegration/dissolution profiles of copies of Fosamax (alendronate).
Topics: Alendronate; Biological Availability; Drugs, Generic; Esophagitis; Humans; Latin America; Osteoporos | 2003 |
Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis.
Topics: Alendronate; Bone Remodeling; Drug Therapy, Combination; Female; Humans; Osteoporosis, Postmenopausa | 2004 |
Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis.
Topics: Alendronate; Bone Density; Bone Remodeling; Drug Therapy, Combination; Female; Hip Fractures; Humans | 2004 |
Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis.
Topics: Alendronate; Bone Remodeling; Drug Therapy, Combination; Female; Humans; Osteoporosis, Postmenopausa | 2004 |
Testing an intervention for preventing osteoporosis in postmenopausal breast cancer survivors.
Topics: Adult; Aged; Alendronate; Bone Density; Breast Neoplasms; Calcium; Combined Modality Therapy; Contra | 2003 |
[Quality of life of patients suffering from osteoporosis treated with alendronate and salmon calcitonin].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Female; Follo | 2002 |
Decimal point--osteoporosis therapy at the 10-year mark.
Topics: Alendronate; Bone Density; Bone Remodeling; Diphosphonates; Female; Fractures, Bone; Humans; Osteopo | 2004 |
The effect of alendronate in the treatment of postmenopausal osteoporosis.
Topics: Aged; Alendronate; Bone Density; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal | 2003 |
[Effects of different treatments for osteoporosis on prevention of fractures: toward and individualized and economic approach].
Topics: Aged; Aged, 80 and over; Alendronate; Calcitonin; Calcium; Cost-Benefit Analysis; Diphosphonates; Fe | 2004 |
Acute polyarthritis related to once-weekly alendronate in a woman with osteoporosis.
Topics: Acute Disease; Alendronate; Arthralgia; Arthritis; Drug Administration Schedule; Female; Humans; Joi | 2004 |
[Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Os | 2003 |
Efficacy of intermittent low dose alendronate in Thai postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Calcium; Collagen; Cost Savings; Female; Hu | 2004 |
[Osteoporosis therapy. Bisphosphonates compared].
Topics: Alendronate; Bone Density; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Etidronic | 2003 |
Long-term use of Fosamax sustains or continues increases in bone density.
Topics: Alendronate; Bone Density; Female; Humans; Osteoporosis, Postmenopausal; Time Factors; Treatment Out | 2004 |
Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis.
Topics: Alendronate; Bone Resorption; Evidence-Based Medicine; Female; Fractures, Spontaneous; Humans; Meta- | 2004 |
Osteoporosis screening: time to take responsibility.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Calcium Compounds; Female; Follow-Up Studie | 2004 |
Bone mineral density thresholds for pharmacological intervention to prevent fractures.
Topics: Age Distribution; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Compounds; Cohort Stud | 2004 |
Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Resorption; Calcitriol; Drug Therapy, Combination; Estrogens; Humans; Organ Transp | 2004 |
Bone anabolic agents: the unanswered queries.
Topics: Alendronate; Anabolic Agents; Animals; Bone Resorption; Clinical Trials as Topic; Female; Humans; Ma | 2004 |
Ten years of alendronate treatment for osteoporosis in postmenopausal women.
Topics: Alendronate; Bone Remodeling; Female; Humans; Osteoporosis, Postmenopausal | 2004 |
Ten years of alendronate treatment for osteoporosis in postmenopausal women.
Topics: Alendronate; Bone Regeneration; Female; Humans; Jaw; Osteonecrosis; Osteoporosis, Postmenopausal; Ri | 2004 |
Ten years of alendronate treatment for osteoporosis in postmenopausal women.
Topics: Alendronate; Bone Density; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal | 2004 |
Ten years of alendronate treatment for osteoporosis in postmenopausal women.
Topics: Aged; Alendronate; Bone Density; Female; Humans; Osteoporosis, Postmenopausal; Vitamin D; Vitamin D | 2004 |
Osteomalacia: recovery of bone density.
Topics: 25-Hydroxyvitamin D 2; Absorptiometry, Photon; Aged; Alendronate; Alkaline Phosphatase; Back Pain; B | 2004 |
Coming to grips with bone loss.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Remodeling; Carrier Proteins; Estrenes; Est | 2004 |
[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Etidronic Acid; Evidence-Based Medicine; Fr | 2004 |
[Weekly Fosamax tablet is significantly more effective than risedronate daily, as results of the Head-to-Head Study show].
Topics: Alendronate; Bone Density; Drug Administration Schedule; Etidronic Acid; Female; Humans; Multicenter | 2004 |
Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Cohort Studies; Cost-Benefit Analysis; Etidronic | 2004 |
Weekly alendronate-induced acute pseudogout.
Topics: Alendronate; Chondrocalcinosis; Female; Humans; Middle Aged; Osteoarthritis, Knee; Osteoporosis, Pos | 2005 |
Synovitis induced by alendronic acid can present as acute carpal tunnel syndrome.
Topics: Aged; Alendronate; Carpal Tunnel Syndrome; Female; Humans; Osteoporosis, Postmenopausal; Synovitis; | 2005 |
An ongoing six-year innovative osteoporosis disease management program: challenges and success in an IPA physician group environment.
Topics: Absorptiometry, Photon; Age Distribution; Aged; Alendronate; California; Disease Management; Family | 2004 |
[FACT study: benefits of alendronate].
Topics: Aged; Alendronate; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Fema | 2005 |
[Long-term usefulness of alendronate confirmed. Bones still benefit even after 10 years].
Topics: Alendronate; Bone Density; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Rand | 2005 |
[Recent progress in osteoporosis research].
Topics: Aged; Alendronate; Bone Density; Evidence-Based Medicine; Female; Fractures, Spontaneous; Genetic Pr | 2005 |
Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
Topics: Alendronate; Animals; Bone Density; Clinical Trials as Topic; Drug Combinations; Female; Fractures, | 2005 |
Rehabilitation of orthopedic and rheumatologic disorders. 1. Osteoporosis assessment, treatment, and rehabilitation.
Topics: Alendronate; Analgesics, Opioid; Cyclooxygenase Inhibitors; Diagnosis, Differential; Humans; Osteopo | 2005 |
Simple computer model for calculating and reporting 5-year osteoporotic fracture risk in postmenopausal women.
Topics: Aged; Alendronate; Bone Density; Computer Simulation; Female; Fractures, Bone; Humans; Middle Aged; | 2005 |
Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Analysis of Variance; Bone Density; Bone Resorptio | 2005 |
Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporos | 2005 |
Alendronate-induced chemical laryngitis.
Topics: Aged; Alendronate; Female; Humans; Laryngeal Mucosa; Laryngitis; Osteoporosis, Postmenopausal | 2005 |
Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Calcium; Collagen; Collagen Type | 2005 |
Alendronate (Fosamax) and risedronate (Actonel) revisited.
Topics: Alendronate; Bone Density; Bone Remodeling; Dose-Response Relationship, Drug; Etidronic Acid; Female | 2005 |
[The efficacy of a treatment: absolute and relative risk, number of patients to be treated].
Topics: Age Factors; Aged; Alendronate; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Osteoporo | 2005 |
Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women.
Topics: Aged; Aged, 80 and over; Alendronate; Cohort Studies; Cost-Benefit Analysis; Denmark; Female; Fractu | 2005 |
[Calcium gaps in osteoporosis patients close. Blister pack simplifies comedication of calcium and bisphosphonates].
Topics: Alendronate; Calcitonin; Calcium; Clinical Trials as Topic; Cohort Studies; Drug Packaging; Etidroni | 2005 |
[Marketing--alendronate versus risedronate].
Topics: Alendronate; Bone Density; Drug Information Services; Etidronic Acid; Humans; Marketing; Osteoporosi | 2005 |
[Optimal osteoporosis strategy?].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Drug Therapy, Combination; | 2005 |
The effect of menopause, hormone replacement therapy (HRT), alendronate (ALN), and calcium supplements on saliva.
Topics: Adult; Alendronate; Analysis of Variance; Bone Density Conservation Agents; Calcium; Case-Control St | 2005 |
[To increase bone density faster and stronger].
Topics: Alendronate; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Middle Aged; Multicenter | 2005 |
Is there a role for a random measurement of 24-hour urine calcium excretion in the determination of calcium supplementation in osteoporotic postmenopausal women using alendronate?
Topics: Aged; Alendronate; Bone Density; Calcium; Dietary Supplements; Diphosphonates; Female; Femur; Hormon | 2005 |
Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Drug Administration Schedule; Humans; Middle Aged; Oste | 2005 |
Are we treating women with postmenopausal osteoporosis for their low BMD or high fracture risk?
Topics: Alendronate; Bone and Bones; Bone Density; Female; Humans; Osteoporosis, Postmenopausal; Risk Factor | 2005 |
Combination and sequential therapy for osteoporosis.
Topics: Alendronate; Bone Density; Bone Remodeling; Drug Administration Schedule; Drug Therapy, Combination; | 2005 |
Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: preliminary results after one year.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Remodeling; Dose-Response Relationship | 2005 |
Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Femal | 2005 |
Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Ambulatory Care; Bone Density Conserva | 2005 |
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female | 2005 |
Are we treating women with postmenopausal osteoporosis for their low BMD or high fracture risk?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Osteop | 2005 |
The patient's page. Bone health facts.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Dietary Sup | 2005 |
[Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; F | 2005 |
Estriol, conjugated equine estrogens, and alendronate therapy for osteoporosis.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Estriol; Estrogens; Estrogens, Conjugate | 2006 |
Alendronate and parathyroid hormone.
Topics: Alendronate; Bone Remodeling; Drug Therapy, Combination; Female; Humans; Osteoporosis, Postmenopausa | 2005 |
[Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates].
Topics: Aged; Alendronate; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular D | 2005 |
Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Clini | 2005 |
[An advantage for compliance: alendronate once weekly].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Drug Administ | 2005 |
[Treating with what? Therapy for how long?].
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; | 2005 |
Osteoporosis management in a Medicaid population after the Women's Health Initiative study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; | 2006 |
Persistence with weekly alendronate therapy among postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; California; Cohort Studies; Female; Humans; Mid | 2006 |
[New therapeutic approaches to osteoporosis].
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Male; Osteoporo | 2006 |
Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Databases, Factual; Drug Administr | 2006 |
[Prediction of changes in bone density during alendronate treatment in postmenopausal women].
Topics: Absorptiometry, Photon; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Dens | 2002 |
Denosumab in postmenopausal women with low bone mineral density.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density C | 2006 |
[Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment].
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Alendronate; Diphosphonates; D | 2006 |
Osteoporotic fractures and vitamin D deficiency.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractur | 2006 |
Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Cost-Benefit Analysis; Decision Support | 2006 |
[Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
Topics: Aged; Aged, 80 and over; Alendronate; Biological Availability; Bone Density Conservation Agents; Dip | 2006 |
Osteonecrosis of the jaw and oral bisphosphonate treatment.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Debridement; Dental Carie | 2006 |
[FOSAVANCE -- alendronate plus vitamin D in a weekly tablet].
Topics: Alendronate; Bone Density Conservation Agents; Controlled Clinical Trials as Topic; Drug Combination | 2006 |
[Very old patients with osteoporosis should be treated with alendronate].
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; B | 2006 |
Urinary gamma-glutamyltransferase (GGT) as a potential marker of bone resorption.
Topics: Aged; Aged, 80 and over; Alendronate; Amino Acids; Animals; Biomarkers; Bone Density Conservation Ag | 2006 |
Compliance with treatment for osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; | 2006 |
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Evaluation; Etidronic A | 2007 |
Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Graft Rejection; Humans; Keratoplasty, | 2006 |
Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; | 2006 |
Hepatotoxicity induced by alendronate therapy.
Topics: Alendronate; Bone Density Conservation Agents; Chemical and Drug Induced Liver Injury; Female; Human | 2007 |
European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; E | 2006 |
Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Computer Simulation; Cost-Be | 2007 |
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Ag | 2007 |
A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
Topics: Age Distribution; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cohort Studies; | 2007 |
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; F | 2007 |
An esophageal ulcer mimicking advanced esophageal cancer in a patient on alendronate sodium treatment for osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Esophageal Diseases; Esophag | 2006 |
Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density C | 2007 |
[Questions and answers about bisphosphonates].
Topics: Administration, Oral; Age Factors; Alendronate; Bone Density; Bone Density Conservation Agents; Bone | 2007 |
Meds hiatus won't hurt your hips. Five years on, five years off: taking a break from Fosamax won't result in broken bones.
Topics: Alendronate; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Osteoporosis, Postmeno | 2007 |
Alendronate and atrial fibrillation.
Topics: Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Female; Fr | 2007 |
[Persistent polyarticular synovitis after treatment with alendronate].
Topics: Alendronate; Arthritis; Bone Density Conservation Agents; Female; Humans; Middle Aged; Osteoporosis, | 2007 |
Use of alendronate after 5 years of treatment.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Fractures, Bone; Humans; Osteoporosis, | 2007 |
Use of alendronate after 5 years of treatment.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Fractures, Bone; Humans; Osteoporosis, | 2007 |
Use of alendronate after 5 years of treatment.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Fractures, Bone; Humans; Osteoporosis, | 2007 |
Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost | 2007 |
[Correlation between studies and general practice].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Family Practice; Fe | 2006 |
Adverse cutaneous drug reaction to alendronate.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Drug E | 2007 |
[Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Etidronic Acid; Female; Fractures, Sp | 2007 |
Osteoporosis medication profile preference: results from the PREFER-US study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; F | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diph | 2007 |
Hip fractures in users of first- vs. second-generation bisphosphonates.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Diphosphonat | 2007 |
Osteoporosis: non-hormonal treatment.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2007 |
[Pharmacological and clinical profile of once weekly alendronate for the treatment of osteoporosis (Fosamac 35 mg/Bonalon 35 mg)].
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorptio | 2007 |
[Osteoporosis and bisphosphonates].
Topics: Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Dose-Respo | 2007 |
Renal function and bisphosphonate safety.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Creatinine; Fe | 2008 |
Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis.
Topics: Adult; Aged; Alendronate; Autoanalysis; Biomarkers; Bone Density Conservation Agents; Fasting; Femal | 2008 |
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; E | 2008 |
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Canada; Cost-B | 2008 |
The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden.
Topics: Aged; Aged, 80 and over; Alendronate; Antihypertensive Agents; Bone Density Conservation Agents; Cos | 2008 |
Alendronate-induced synovitis.
Topics: Aged; Alendronate; Arthritis; Bone Density Conservation Agents; Female; Humans; Middle Aged; Osteopo | 2008 |
An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femora | 2008 |
[Long term effects of raloxifen on the bones].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Frac | 2008 |
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.
Topics: Adult; Age Factors; Aged; Alendronate; Body Mass Index; Bone Density Conservation Agents; Etidronic | 2008 |
Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Cohort Studies; Databases, Factual; Diphospho | 2008 |
Management of atrophic maxilla in severe osteoporosis treated with bisphosphonates: a case report.
Topics: Alendronate; Alveolar Bone Loss; Bone Density; Bone Density Conservation Agents; Bone Regeneration; | 2008 |
Bisphosphonate related osteonecrosis of the palate: report of a case managed with free tissue transfer.
Topics: Administration, Oral; Aged; Alendronate; Anastomosis, Surgical; Bone Density Conservation Agents; Fe | 2008 |
Considering competing risks . . . Not all black and white.
Topics: Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Decision Making; Diabetes Mellit | 2008 |
Use of alendronate and risk of incident atrial fibrillation in women.
Topics: Aged; Aged, 80 and over; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Case-Co | 2008 |
Summaries for patients. Drug therapy for osteoporosis.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
The treatment of postmenopausal osteoporosis.
Topics: Aged; Alendronate; Bone Density; Diphosphonates; Female; Fractures, Bone; Humans; Middle Aged; Osteo | 1995 |
The effect of alendronate on renal tubular reabsorption of phosphate.
Topics: Absorption; Aged; Alendronate; Calcium; Diphosphonates; Female; Glomerular Filtration Rate; Homeosta | 1994 |
Clinical pharmacology of alendronate sodium.
Topics: Alendronate; Animals; Bone and Bones; Diphosphonates; Female; Half-Life; Humans; Osteoporosis, Postm | 1993 |
Alendronate reaches U.S. market for osteoporosis, Paget's disease.
Topics: Alendronate; Diphosphonates; Female; Humans; Osteitis Deformans; Osteoporosis, Postmenopausal; Unite | 1995 |
Alendronate in postmenopausal osteoporosis.
Topics: Alendronate; Diphosphonates; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Spinal Fra | 1996 |
Alendronate in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Diphosphonates; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopa | 1996 |
[Reduction of the Nordin index after therapy with oral alendronate in patients with postmenopausal osteoporosis].
Topics: Administration, Oral; Adult; Aged; Alendronate; Bone Density; Bone Resorption; Diphosphonates; Femal | 1995 |
New drugs--reports of new drugs recently approved by the FDA. Alendronate.
Topics: Alendronate; Animals; Clinical Trials as Topic; Diphosphonates; Female; Humans; Osteitis Deformans; | 1996 |
Alendronate: a new bisphosphonate for the treatment of osteoporosis.
Topics: Alendronate; Bone Density; Diphosphonates; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopa | 1996 |
"Pill esophagitis"--the case of alendronate.
Topics: Alendronate; Diphosphonates; Esophagitis; Female; Humans; Osteoporosis, Postmenopausal; Ulcer | 1996 |
Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Topics: Alendronate; Amino Acids; Animals; Biomarkers; Body Weight; Bone Resorption; Cholesterol; Disease Mo | 1996 |
Sustained response to intravenous alendronate in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Calcium; Female; Humans | 1995 |
Oesophageal stricture associated with alendronic acid.
Topics: Alendronate; Esophageal Stenosis; Esophagitis; Female; Humans; Middle Aged; Osteoporosis, Postmenopa | 1996 |
Treatment of osteoporosis: brighter horizons.
Topics: Alendronate; Female; Humans; Osteoporosis, Postmenopausal | 1996 |
Alendronate: a bisphosphonate for treatment of osteoporosis.
Topics: Alendronate; Bone Remodeling; Drug Interactions; Female; Humans; Middle Aged; Osteoporosis, Postmeno | 1996 |
Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole.
Topics: Adult; Alendronate; Bone Density; Female; Humans; Hyperthyroidism; Methimazole; Middle Aged; Osteoca | 1996 |
[Alendronate (Fosamax 10 mg). The first amino-bisphosphate for the therapy of osteoporosis in postmenopausal women].
Topics: Aged; Alendronate; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal | 1996 |
[Alendronate (Fosamax 10 mg). The first amino-biphosphate for the treatment of women with postmenopausal osteoporosis].
Topics: Aged; Alendronate; Diphosphonates; Dose-Response Relationship, Drug; Female; Femoral Neck Fractures; | 1996 |
The Fracture Intervention Trial.
Topics: Alendronate; Bone Density; Costs and Cost Analysis; Female; Fractures, Bone; Hip Fractures; Humans; | 1997 |
Alendronate useful in treating osteoporosis.
Topics: Aged; Alendronate; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled | 1997 |
[Careless risk estimation in an advertisement on osteoporosis].
Topics: Advertising; Aged; Alendronate; Cost-Benefit Analysis; Drug Information Services; Female; Humans; Mi | 1997 |
Preventing osteoporotic fractures with alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Double-Blind Method; Female; Fractures, Bone; Humans; Middle A | 1997 |
AACE Clinical Practice Guidelines for the Prevention and Treatment of Postmenopausal Osteoporosis.
Topics: Alendronate; Bone Density; Calcitonin; Calcium; Decision Making; Estrogen Replacement Therapy; Femal | 1996 |
[Does alendronate reduce the risk of fractures in postmenopausal women with osteoporosis?].
Topics: Aged; Alendronate; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal | 1997 |
Esophageal stricture associated with alendronate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Constriction, Pathologic; Esophagoscopy; Esophagus; Female; Hu | 1997 |
Esophagitis associated with alendronate sodium.
Topics: Aged; Aged, 80 and over; Alendronate; Esophagitis; Female; Humans; Osteoporosis, Postmenopausal | 1997 |
Avoiding alendronate-related esophageal irritation.
Topics: Aged; Alendronate; Esophagitis; Female; Humans; Osteoporosis, Postmenopausal; Patient Education as T | 1997 |
[Drugs for osteoporosis].
Topics: Alendronate; Dose-Response Relationship, Drug; Female; Humans; Osteoporosis; Osteoporosis, Postmenop | 1997 |
Meta-analysis of prevention of nonvertebral fractures by alendronate.
Topics: Alendronate; Female; Fractures, Bone; Humans; Meta-Analysis as Topic; Osteoporosis, Postmenopausal | 1997 |
Meta-analysis of prevention of nonvertebral fractures by alendronate.
Topics: Alendronate; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal | 1997 |
[Drug-induced esophagitis: can stringent indications help prevent this disease picture?].
Topics: Aged; Aged, 80 and over; Alendronate; Esophagitis; Female; Humans; Middle Aged; Osteitis Deformans; | 1997 |
[Use of alendronate in osteoporosis--is it cost-effective?].
Topics: Aged; Alendronate; Bone Density; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Models, Econ | 1997 |
A tale of two worlds in prescribing etidronate for osteoporosis.
Topics: Alendronate; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal | 1997 |
Injury prevention.
Topics: Alendronate; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal | 1998 |
Esophagitis dissecans superficialis and alendronate: case report.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Esophageal Stenosis; Esophagitis; Esopha | 1997 |
Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features.
Topics: Administration, Oral; Aged; Alendronate; Dilatation; Esophageal Stenosis; Esophagitis; Female; Human | 1998 |
Bone mass, bone loss, and osteoporosis prophylaxis.
Topics: Alendronate; Bone Density; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal | 1998 |
Preventing osteoporosis.
Topics: Alendronate; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Pos | 1998 |
[Prevention of osteoporosis-related fractures with alendronate].
Topics: Aged; Alendronate; Diphosphonates; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postm | 1998 |
[Etidronate versus alendronate].
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal | 1998 |
Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption.
Topics: Alendronate; Amino Acids; Animals; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Estroge | 1998 |
Drug prevents bone loss in healthy women.
Topics: Alendronate; Bone Density; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause | 1998 |
[Estrogen substitution is better than alendronate (Fosamax)].
Topics: Alendronate; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal | 1998 |
[Alendronate].
Topics: Alendronate; Diphosphonates; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal | 1998 |
[Drug clinics. The drug of the month. Alendronate (Fosamax)].
Topics: Absorption; Alendronate; Biological Availability; Bone and Bones; Bone Density; Fasting; Female; Fra | 1998 |
[Estrogen replacement is better than alendronate].
Topics: Aged; Alendronate; Diphosphonates; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteop | 1998 |
Biological basis of anti-resorptive therapies for osteoporosis.
Topics: Aged; Alendronate; Bone Resorption; Calcitonin; Estrogen Replacement Therapy; Female; Humans; Middle | 1998 |
Alendronate in the treatment of osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Diseases, Metabolic; Calcitonin; Estrogen Replacement Therapy; | 1998 |
United Kingdom experience with alendronate and oesophageal reactions.
Topics: Aged; Alendronate; Esophagitis; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postm | 1998 |
Prevention of hip fractures in older women: a population-based perspective.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Exercise; | 1998 |
Role of novel antiresorptive agents for the prevention and treatment of osteoporosis.
Topics: Alendronate; Bone Density; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Piper | 1998 |
[Alendronate-induced severe esophagitis. A rare and severe reversible side-effect illustrated by three case reports].
Topics: Aged; Alendronate; Burns, Chemical; Diphosphonates; Esophageal Stenosis; Esophagitis; Esophagoscopy; | 1998 |
[Alendronate].
Topics: Aged; Alendronate; Diphosphonates; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal | 1998 |
I am 51 years old, perimenopausal, have irritable bowel syndrome and a family history of breast cancer, and am told my bones are thinning. These conditions would seem to rule out my use of estrogen or Fosamax. I weight train and take 1,500 mg of calcium a
Topics: Alendronate; Colonic Diseases, Functional; Estrogen Antagonists; Estrogens; Female; Humans; Middle A | 1998 |
Combination therapy for osteoporosis.
Topics: Alendronate; Bone Density; Drug Therapy, Combination; Estrogens; Female; Hormone Replacement Therapy | 1998 |
Alendronate--risk for esophageal stricture.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Alendronate; Esophageal Stenosis; | 1998 |
Hepatitis after alendronate.
Topics: Aged; Alendronate; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Female; Follow-U | 1998 |
[New knowledge on alendronate (Fosamax) and fractures].
Topics: Alendronate; Diphosphonates; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal | 1999 |
Alendronic acid: new preparation. Limited efficacy, risk of oesophagitis.
Topics: Alendronate; Clinical Trials as Topic; Diphosphonates; Drug Evaluation; Esophagitis; Female; Fractur | 1998 |
A 73-year-old woman with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Blood Chemical Analysis; Bone Density; Calcium Compounds; | 1999 |
[Fast protection against osteoporotic fractures by using alendronat].
Topics: Alendronate; Diphosphonates; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal | 1999 |
Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Calcium; Cost-Benefit Analysis; Drug Therapy, Combination; Estradiol; Estrogen Re | 1998 |
Spine studies to remain part of bone analysis.
Topics: Aged; Alendronate; Bone Density; Dose-Response Relationship, Drug; Estrogen Replacement Therapy; Fem | 1998 |
[Primary prevention in osteoporosis?].
Topics: Aged; Alendronate; Diphosphonates; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Primar | 1999 |
[Research philosophy and practical research--new knowledge about alendronate and fractures].
Topics: Alendronate; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Research | 1999 |
Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.
Topics: Alendronate; Bone Density; Breast Neoplasms; Coronary Disease; Decision Support Techniques; Estrogen | 1999 |
[A new type of iliac fracture caused by bone insufficiency].
Topics: Alendronate; Bone Density; Calcium; Densitometry; Diphosphonates; Female; Fractures, Spontaneous; Hu | 1999 |
Osteoporosis management: physicians' recommendations and womens' compliance following osteoporosis testing.
Topics: Absorptiometry, Photon; Aged; Alendronate; Analysis of Variance; Bone Density; Calcitonin; Calcium; | 1999 |
Osteoporosis: protecting bone mass with fundamentals and drug therapy.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Calcitonin; Calcium; Decision Trees; Dietar | 1999 |
Alendronate and fracture prevention.
Topics: Alendronate; Bone Density; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Osteoporos | 1999 |
[Number of patients to be treated and number of prevented fractures: clinical efficiency of osteoporosis treatment with diphosphonate alendronate].
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Data Interpretation, Statistical; F | 1999 |
Long-term therapy for postmenopausal osteoporosis: stronger bones but weaker arteries.
Topics: Alendronate; Arteries; Cardiovascular Diseases; Female; Humans; Osteoporosis, Postmenopausal; Time F | 1999 |
[Working title: Will reducing alendronate increase the risk of bone fractures by a decrease in bone density? Benefit from alendronate therapy for women without prior fractures remains uncertain].
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Middle Aged; Os | 1999 |
Biochemical bone markers.
Topics: Alendronate; Biomarkers; Bone Remodeling; Bone Resorption; Diphosphonates; Estrogen Antagonists; Fem | 1999 |
Frequency of bone densitometry for osteoporosis?
Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Resorption; Calcitonin; Estrogen | 1999 |
Alendronate.
Topics: Alendronate; Bone Density; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Spinal Fract | 1999 |
Iatrogenic osteoporosis.
Topics: Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Glucocorticoids; Humans; Osteoporosis | 1999 |
[A cost-effectiveness analysis of alendronate compared to placebo in the prevention of hip fracture].
Topics: Aged; Alendronate; Cost-Benefit Analysis; Decision Support Techniques; Female; Hip Fractures; Humans | 1999 |
[Is osteoporosis a disease?].
Topics: Aged; Alendronate; Bone Density; Calcitonin; Female; Hormone Replacement Therapy; Humans; Incidence; | 1996 |
Alendronate-associated esophageal injury: pathologic and endoscopic features.
Topics: Aged; Aged, 80 and over; Alendronate; Esophageal Diseases; Esophagitis; Esophagoscopy; Esophagus; Fe | 1999 |
Early prevention of fracture in osteoporosis: new developments.
Topics: Aged; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmen | 1999 |
New ways to manage the old problem of osteoporosis.
Topics: Aged; Alendronate; Bone Density; Diagnosis, Differential; Estrogen Replacement Therapy; Female; Huma | 1999 |
Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis.
Topics: Alendronate; Bone Density; Diphosphonates; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausa | 2000 |
How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
Topics: Aged; Alendronate; Bone and Bones; Bone Demineralization, Pathologic; Estrogen Antagonists; Female; | 2000 |
Long-term prevention of bone loss.
Topics: Alendronate; Bone Density; Calcium, Dietary; Cholecalciferol; Dietary Supplements; Female; Fractures | 2000 |
Hypoparathyroidism unmasked by alendronate.
Topics: Aged; Alendronate; Calcitriol; Calcium Carbonate; Calcium Channel Agonists; Female; Humans; Hypocalc | 2000 |
Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
Topics: Adult; Alendronate; Biomarkers; Bone Density; Bone Resorption; Female; Humans; Middle Aged; Osteopor | 2000 |
Liver damage due to alendronate.
Topics: Aged; Alendronate; Chemical and Drug Induced Liver Injury; Female; Humans; Liver; Liver Function Tes | 2000 |
Osteoporosis prevention and treatment.
Topics: Alendronate; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopa | 2000 |
Alendronic acid in primary prevention: new indication. No reduction in fracture risk.
Topics: Alendronate; Clinical Trials as Topic; Cost-Benefit Analysis; Esophagitis; Estrogen Replacement Ther | 2000 |
Drugs for prevention and treatment of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calciton | 2000 |
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagoni | 2000 |
Once-a-week alendronate for postmenopausal osteoporosis is as effective as once-daily dosing.
Topics: Aged; Alendronate; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Osteoporo | 2001 |
[Comparative study in postmenopausal women with osteoporosis (sodium alendronate, calcium and HRT vs sodium alendronate and calcium].
Topics: Alendronate; Calcium; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal | 1998 |
Osteoporosis. Efficacy and safety of a bisphosphonate dosed once weekly.
Topics: Alendronate; Bone Remodeling; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausa | 2001 |
Once-a-week alendronate (Fosamax).
Topics: Alendronate; Bone Resorption; Calcium Channel Blockers; Chemistry, Pharmaceutical; Clinical Trials a | 2001 |
Regression to the mean: what does it mean? Using bone density results to monitor treatment of osteoporosis.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Data Interpretation, Statistical; Female; Humans; | 2001 |
Adjusted regression trend test for a multicenter clinical trial.
Topics: Aged; Alendronate; Biometry; Bone Density; Computer Simulation; Female; Humans; Models, Statistical; | 1999 |
Absolute vs. relative numbers in evaluating drug therapy.
Topics: Alendronate; Data Interpretation, Statistical; Etidronic Acid; Female; Fractures, Bone; Humans; Info | 2001 |
By the way, doctor. I recently heard that I can take Fosamax once a week for osteoporosis, rather than every day. Is it really effective when taken this way? Is there a downside?
Topics: Alendronate; Bone Density; Drug Administration Schedule; Female; Humans; Osteoporosis, Postmenopausa | 2001 |
Medication update.
Topics: Aged; Aged, 80 and over; Alendronate; Calcitonin; Dosage Forms; Drug Interactions; Female; Femur; Hu | 2001 |
[Treatment of osteoporosis. Compliance is significantly enhanced].
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Double-Blind Method; Drug Administration Schedule; Huma | 2001 |
[Esophagitis associated with use of alendronate in 5 postmenopausic patients].
Topics: Aged; Alendronate; Esophagitis; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenop | 2001 |
[Modern osteoporosis therapy. Only once weekly against osteoporosis].
Topics: Aged; Alendronate; Bone Density; Dose-Response Relationship, Drug; Drug Administration Schedule; Hum | 2001 |
[Bisphosphonates once weekly. Osteoporosis therapy becomes more effective].
Topics: Aged; Alendronate; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Mid | 2001 |
Alendronate for the treatment of osteoporosis in men.
Topics: Alendronate; Bone Density; Climacteric; Female; Fractures, Spontaneous; Humans; Lumbar Vertebrae; Ma | 2001 |
The effect of alendronate (Fosamax) and implant surface on bone integration and remodeling in a canine model.
Topics: Alendronate; Animals; Arthroplasty, Replacement, Hip; Bone Plates; Bone Remodeling; Disease Models, | 2001 |
Sintered dicalcium pyrophosphate increases bone mass in ovariectomized rats.
Topics: Administration, Oral; Alendronate; Alkaline Phosphatase; Animals; Bone Density; Calcium Pyrophosphat | 2002 |
The role of serial bone mineral density testing for osteoporosis.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Female; Hormone Replacement Therapy; Humans; Oste | 2001 |
Case of the month. Osteoporosis in a postmenopausal woman.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Alendronate; Bone Density; Female; Follow-Up Stu | 2002 |
Changes in bone remodeling rate influence the degree of mineralization of bone which is a determinant of bone strength: therapeutic implications.
Topics: Adult; Alendronate; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Remodeling; Female; | 2001 |
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
Topics: Aged; Alendronate; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Germany; H | 2001 |
A new monoclonal antibody ELISA for detection and characterization of C-telopeptide fragments of type I collagen in urine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Amino Acid Sequence; Animals; Antibodies, M | 2001 |
[Severe acute hepatitis induced by alendronate].
Topics: Aged; Alendronate; Bone Density; Chemical and Drug Induced Liver Injury; Female; Humans; Osteoporosi | 2002 |
A 60-year-old woman trying to discontinue hormone replacement therapy.
Topics: Alendronate; Breast Neoplasms; Contraindications; Coronary Disease; Decision Making; Estrogen Replac | 2002 |
Summaries for patients. Alendronate improves osteoporosis in elderly women living in long-term care facilities.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium; Dietary Supplements; Double-Blind Metho | 2002 |
[Convenient and well-tolerated therapy of osteoporosis. Preventing fractures only once a week].
Topics: Aged; Alendronate; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Middle Aged | 2002 |
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
Topics: Aged; Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; | 2002 |
The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons.
Topics: Acid Phosphatase; Alendronate; Analysis of Variance; Animals; Bone and Bones; Bone Density; Calcium; | 1992 |